

for 2.25 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, and concentrated. To a solution of the above residue in CHCl_3 (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0 °C and ZnCl_2 (14.4 g, 84.4 mmol) was added below 5 °C. The reaction mixture was stirred at ambient temperature for 16 hr and poured into saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCl_3) to give [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (25.3 g, 91%) as a colorless oil.

ESI MS m/e 385, $\text{M} + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.13-1.31 (m, 2 H), 1.44 (s, 9 H), 1.48-1.75 (m, 7 H), 3.10 (t, $J = 6.4$ Hz, 2 H), 3.72 (brs, 1 H), 4.42-4.76 (m, 1 H), 4.76-4.92 (m, 1 H), 5.09 (s, 2 H), 7.27-7.38 (m, 5 H).

15 Step C: Synthesis of (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtrated, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (five times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and dried under reduced pressure to give (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

ESI MS m/e 263, $\text{M} + \text{H}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.36-1.98 (m, 9 H), 2.96-3.32 (m, 3 H), 5.12 (brs, 3 H), 7.36 (s, 5 H).

25

Step D: Synthesis of [cis-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-quinolin-4-yl)-methyl-amine obtained in step B of example 1 (2.00 g,

10.4 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (3.27 g, 12.5 mmol) in butanol (3 mL) was stirred at 130 °C for 16 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica, 10% MeOH in CHCl₃) to give [*cis*-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid-benzyl ester (2.16 g, 49%) as a white solid.

ESI MS *m/e* 419, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.42-1.99 (m, 9 H), 3.05 (d, *J* = 4.7 Hz, 3 H), 3.08-3.16 (m, 2 H), 3.81 (brs, 1 H), 5.07 (s, 2 H), 5.18-5.28 (m, 1 H), 5.34 (s, 1 H), 7.07-7.18 (m, 1 H), 7.22-7.45 (m, 6 H), 7.56-7.70 (m, 1 H), 8.16 (d, *J* = 8.4 Hz, 1 H), 8.23 (d, *J* = 7.6 Hz, 1 H), 12.76 (brs, 1 H).

Step E: Synthesis of *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-*N*⁴-methyl-quinoline-2,4-diamine dihydrochloride.

To a solution of [*cis*-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid-benzyl ester (2.02 g, 4.83 mmol) in MeOH (20 mL) was added 10% Pd/C (202 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 23.5 hr. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue (500 mg) in methanol (5 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step F of example 1 (497 mg, 1.85 mmol), acetic acid (111 mg, 1.85 mmol), and NaBH₃CN (166 mg, 2.64 mmol). The reaction mixture was stirred at ambient temperature for 23 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) and flash chromatography (silica gel, 2% to 50% MeOH in CHCl₃) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (12 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-

methyl]-cyclohexyl}-*N*⁴-methyl-quinoline-2,4-diamine dihydrochloride (147 mg, 14%) as a white solid.

ESI MS *m/e* 537, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.34-2.15 (m, 9 H), 2.63-3.08 (m, 5 H), 3.41-3.88 (m, 1 H), 4.28 (s, 2 H), 7.00-7.62 (m, 6 H), 7.65-8.38 (m, 3 H), 10.01 (brs, 2 H), 11.76 (brs, 1 H).

Example 4

*N*⁴-Methyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of *N*⁴-methyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride.

To a solution of *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-*N*⁴-methyl-quinoline-2,4-diamine obtained in step E of example 3 (250 mg, 0.465 mmol) in EtOH (2.5 mL) was added 10% Pd/C (75 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 15 hr. The reaction mixture was filtrated through a pad of celite and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended with Et₂O (10 mL) and stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O and dried under reduced pressure to give *N*⁴-methyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride (114 mg, 46%) as a white solid.

ESI MS *m/e* 459, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.46-2.09 (m, 9 H), 2.84 (brs, 3 H), 2.92 (brs, 2 H), 3.60-3.82 (m, 1 H), 4.32 (s, 2 H), 7.05-7.49 (m, 6 H), 7.88 (d, *J* = 7.8 Hz, 1 H), 8.11-8.35 (m, 2 H), 9.91 (brs, 2 H), 11.83 (s, 1 H).

Example 5***N*²-[*cis*-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine dihydrochloride**

5

Step A: Synthesis of (2-chloro-quinolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-quinoline (177 g, 894 mmol) in THF (2.1 L) was added 50% aqueous Me₂NH (234 mL, 2.23 mol). The mixture was stirred at ambient temperature for 68 hr. To the mixture was added 50% aqueous Me₂NH (47 mL, 448 mmol) and stirred at ambient temperature

10 for 3 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 1% to 3% EtOAc in hexane) to give (2-chloro-quinolin-4-yl)-dimethyl-amine (75.9 g, 41%) as a pale yellow oil and (4-chloro-quinolin-2-yl)-dimethyl-amine (28.0 g, 15%) as a pale yellow oil.

15 (2-chloro-quinolin-4-yl)-dimethyl-amine;

ESI MS *m/e* 207, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.06 (s, 6 H), 6.71 (s, 1 H), 7.45 (ddd, *J* = 8.4, 7.0, 1.2 Hz, 1 H), 7.63 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1 H), 7.91-7.93 (m, 1 H), 7.97-8.03 (m, 1 H).

(4-chloro-quinolin-2-yl)-dimethyl-amine;

ESI MS *m/e* 229, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.18 (s, 6 H), 6.97 (brs, 1 H), 7.18-7.31 (m, 1 H), 7.49-7.63 (m, 1 H), 7.66-7.72 (m, 1 H), 7.95-8.00 (m, 1 H).

20

Step B: Synthesis of *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine.

Using the procedure for the step E of example 1, the title compound was obtained.

FAB MS *m/e* 285, *M* + *H*⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.12-2.00 (m, 9 H), 2.81-2.98 (m, 1 H), 2.93 (s, 6 H), 4.09 (brs, 1 H), 4.75 (d, *J* = 7.9 Hz, 1 H), 6.03 (s, 1 H), 7.14 (ddd, *J* = 8.2, 6.7, 1.3 Hz, 1 H), 7.45 (ddd, *J* = 8.4, 6.8, 1.5 Hz, 1 H), 7.62 (m, 1 H), 7.84 (dd, *J* = 8.4, 1.3 Hz, 1 H).

25

Step C: Synthesis of *N*²-[*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-

dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 537, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.73-2.36 (m, 10 H), 3.05-3.31 (m, 2 H), 3.20 (s, 6 H), 4.32 (s, 2 H), 7.30-7.62 (m, 5 H), 7.86 (d, $J = 8.6$ Hz, 1 H), 8.21 (d, $J = 8.4$ Hz, 1 H), 8.53-8.64 (m, 1 H), 13.04 (brs, 1 H).

Example 6

N^2 -{*cis*-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}- N^4,N^4 -dimethyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of N^2 -{*cis*-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}- N^4,N^4 -dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 551, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.69-2.40 (m, 10 H), 3.11-3.46 (m, 10 H), 7.26-7.49 (m, 5 H), 7.59 (t, $J = 7.3$ Hz, 1 H), 7.86 (d, $J = 7.5$ Hz, 1 H), 8.53-8.70 (m, 1 H), 9.75-10.14 (m, 2 H), 13.05 (brs, 1 H).

Example 7

N^2 -{*cis*-4-[(4-Bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}- N^4,N^4 -dimethyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine obtained in step A of example 5 (23.6 g, 114 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3 (36.0 g, 137 mmol) in butanol (31 mL) was stirred at reflux for 14 days. The reaction

mixture was poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (NH-silica, 14% to 66% EtOAc in hexane) to give [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 39%) as a pale yellow solid.

ESI MS m/e 433, $M + H^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.12-1.97 (m, 9 H), 2.94 (s, 6 H), 3.13 (t, $J = 6.4$ Hz, 2 H), 4.06-4.26 (m, 1 H), 4.62-4.94 (m, 2 H), 5.11 (s, 2 H), 6.04 (s, 1 H), 7.14 (ddd, $J = 8.4, 7.0, 1.3$ Hz, 1 H), 7.29-7.40 (m, 5 H), 7.45 (ddd, $J = 8.4, 6.8, 1.5$ Hz, 1 H), 7.57-7.64 (m, 1 H), 7.84 (dd, $J = 8.4, 1.3$ Hz, 1 H).

10

Step B: Synthesis of N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4, N^4 -dimethyl-quinoline-2,4-diamine.

To a solution of [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 44.6 mmol) in MeOH (200 mL) was added 5% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue in methanol (200 mL) was added 10% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 day. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 5% to 14% 7 M NH_3/MeOH in CHCl_3) to give N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4, N^4 -dimethyl-quinoline-2,4-diamine (12.7 g, 95%) as a pale yellow solid.

20

FAB MS m/e 299, $M + H^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.08-1.99 (m, 11 H), 2.60 (d, $J = 6.2$ Hz, 2 H), 2.94 (s, 6 H), 4.04-4.22 (m, 1 H), 4.77-4.93 (m, 1 H), 6.06 (s, 1 H), 7.14 (ddd, $J = 8.4, 7.0, 1.3$ Hz, 1 H), 7.45 (ddd, $J = 8.4, 6.8, 1.5$ Hz, 1 H), 7.61 (m, 1 H), 7.84 (dd, $J = 8.4, 1.3$ Hz, 1 H).

25 Step C: Synthesis of N^2 -{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}- N^4, N^4 -dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 551, $M(\text{free}) + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.50-2.20 (m, 9 H), 2.89 (s, 2 H), 3.20

(s, 6 H), 3.75-4.02 (m, 1 H), 4.23 (s, 2 H), 7.22-7.32 (m, 2 H), 7.40-7.46 (m, 1 H), 7.49-7.62 (m, 2 H), 7.83 (d, $J = 8.7$ Hz, 1 H), 8.17 (d, $J = 8.4$ Hz, 1 H), 8.53-8.69 (m, 1 H), 10.05 (brs, 2 H), 13.00 (brs, 1 H).

5

Example 8

***N*⁴,*N*⁴-Dimethyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride**

10 Step A: Synthesis of *N*⁴,*N*⁴-dimethyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 473, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-2.20 (m, 9 H), 2.87 (brs, 2 H), 3.19 (s, 6 H), 3.70-4.03 (m, 1 H), 4.28 (brs, 2 H), 7.15-7.67 (m, 6 H), 7.81 (d, $J = 8.4$ Hz, 1 H), 8.17 (d, $J = 7.3$ Hz, 1 H), 8.63 (brs, 1 H), 9.92 (brs, 1 H), 13.13 (s, 1 H).

15

Example 9

***N*²-[*cis*-4-(4-Bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-*N*⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

20

Step A: Synthesis of 5,6,7,8-tetrahydro-quinazoline-2,4-diol.

To a solution of 2-oxo-cyclohexanecarboxylic acid ethyl ester (61.5 g, 361 mmol) in EtOH (61.5 mL) was added urea (73.8 g, 1.23 mol). The mixture was stirred at reflux for 10.5 days and
25 stirred at ambient temperature for 30 min. The precipitate was filtrated, washed with acetone, and dried. A suspension of the above solid in H₂O (100 mL) stirred on an ice-bath for 1 hr. The precipitate was filtrated, washed with hexane, and dried under reduced pressure to give 5,6,7,8-tetrahydro-quinazoline-2,4-diol (21.0 g, 35%) as a pale yellow solid.

CI MS m/e 167, $M + H^+$; 1H NMR (300 MHz, DMSO- d_6) δ 1.48-1.71 (m, 4 H), 2.09-2.19 (m, 2 H), 2.24-2.34 (m, 2 H), 10.41-10.98 (m, 2 H).

Step B: Synthesis of 2,4-dichloro-5,6,7,8-tetrahydro-quinazoline.

5 Using the procedure for the step A of example 1, the title compound was obtained.

ESI MS m/e 203, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.83-1.94 (m, 4 H), 2.67-2.79 (m, 2 H), 2.84-2.95 (m, 2 H).

Step C: Synthesis of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine.

10 To a solution of 2,4-dichloro-5,6,7,8-tetrahydro-quinazolin (8.70 g, 42.8 mmol) in THF (87 mL) was added 40% aqueous $MeNH_2$ (8.32 g, 107 mmol). The mixture was stirred at ambient temperature for 8 hr. The solution was poured into saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtrated, concentrated, and purified by flash chromatography (NH-silica, 50% EtOAc in hexane) to give
15 (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine (7.04 g, 83%) as a white solid.

ESI MS m/e 220, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.74-1.92 (m, 4 H), 2.26 (t, $J = 5.5$ Hz, 2 H), 2.67 (t, $J = 5.6$ Hz, 2 H), 3.05 (d, $J = 5.0$ Hz, 3 H), 4.81 (s, 1 H).

Step D: Synthesis of N^2 -(cis-4-amino-cyclohexyl)- N^4 -methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

20 Using the procedure for the step E of example 1, the title compound was obtained.

ESI MS m/e 276, $M + H^+$; 1H NMR (300 MHz, DMSO- d_6) δ 1.33-1.76 (m, 12 H), 2.11-2.21 (m, 2 H), 2.31-2.40 (m, 2 H), 2.70-2.77 (m, 2 H), 2.78 (d, $J = 4.5$ Hz, 3 H), 3.71-3.83 (m, 1 H), 5.50-5.63 (m, 1 H), 6.10-6.22 (m, 1 H).

25

Step E: Synthesis of N^2 -[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]- N^4 -methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 528, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.24 (m, 12 H), 2.41-2.56 (m, 4 H), 3.00 (d, J = 4.5 Hz, 3 H), 3.04 (brs, 1 H), 4.03 (brs, 1 H), 4.30 (brs, 2 H), 7.45-7.48 (m, 1 H), 7.52 (dd, J = 8.3, 1.8 Hz, 1 H), 7.61 (d, J = 5.8 Hz, 1 H), 7.74 (brs, 1 H), 8.14 (d, J = 8.2 Hz, 1 H), 11.84 (brs, 1 H).

5

Example 10

***N*²-{*cis*-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-*N*⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

10

Step A: Synthesis of *N*²-{*cis*-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-*N*⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 542, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.25 (m, 12 H), 2.35-2.60 (m, 4 H), 2.94-3.28 (m, 6 H), 3.32-3.45 (m, 2 H), 4.13 (brs, 1 H), 7.30-7.51 (m, 4 H), 7.72 (d, J = 6.2 Hz, 1 H), 9.86 (brs, 2 H) 11.90 (s, 1 H).

15

Example 11

***N*²-{*cis*-4-[(4-Bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-*N*⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

20

Step A: Synthesis of [*cis*-4-(4-methylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

25

A mixture of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine obtained in step C of example 9 (2.00 g, 10.1 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3 (3.19 g, 12.2 mmol) in butanol (3 mL) was stirred at 130 °C for 16 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous

layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 10% MeOH in CHCl₃) to give [*cis*-4-(4-methylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (1.38 g, 32%) as a pale yellow oil.

- 5 ESI MS *m/e* 424, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.31-2.02 (m, 13 H), 2.22-2.34 (m, 2 H), 2.52-2.64 (m, 2 H), 3.05 (d, *J* = 4.8 Hz, 3 H), 3.11 (t, *J* = 6.1 Hz, 2 H), 5.05-5.23 (m, 1 H), 5.08 (s, 2 H), 6.34-6.47 (m, 1 H), 7.23-7.42 (m, 5 H), 7.99 (d, *J* = 7.3 Hz, 1 H), 12.34 (brs, 1 H).

Step B: Synthesis of *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-*N*⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step E of example 3, the title compound was obtained.

ESI MS *m/e* 542, M (free) + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.50-2.19 (m, 13 H), 2.58-2.61 (m, 2 H), 2.72-2.91 (m, 2 H), 2.83-2.97 (m, 2 H), 3.24 (s, 6 H), 4.15-4.20 (m, 1 H), 4.22-4.38 (m, 2 H), 7.43-7.50 (m, 1 H), 7.56-7.61 (m, 1 H), 8.18-8.29 (m, 2 H), 10.06 (brs, 2 H), 12.30 (brs, 1 H).

15

Example 12

***N*⁴-Methyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

20

Step A: Synthesis of *N*⁴-methyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

- 25 ESI MS *m/e* 464, M (free) + H⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.28-2.04 (m, 15 H), 2.14-2.30 (m, 2 H), 2.83-2.95 (m, 2 H), 2.91 (d, *J* = 4.5 Hz, 3 H), 4.13 (brs, 1 H), 4.22 (brs, 2 H), 7.43-7.62 (m, 3 H), 7.91 (dd, *J* = 7.5, 1.6 Hz, 1 H), 8.09 (d, *J* = 6.7 Hz, 2 H), 9.37 (brs, 2 H), 12.30-12.70 (m, 1 H).

Example 13

***N*²-[*cis*-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

5 Step A: Synthesis of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-5,6,7,8-tetrahydro-quinazolin (7.00 g, 34.5 mmol) in THF (70 mL) was added 50% aqueous MeNH₂ (7.77 g, 86.2 mmol). The mixture was stirred at ambient temperature for 2.25 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄,
10 filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (6.08 g, 83%) as a white solid. ESI MS *m/e* 234, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-1.90 (m, 4 H), 2.59 (t, *J* = 6.0 Hz, 2 H), 2.76 (t, *J* = 6.6 Hz, 2 H), 3.06 (s, 6 H).

15 Step B: Synthesis of *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

Using the procedure for the step E of example 1, the title compound was obtained. FAB MS *m/e* 290, M + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 0.95-1.94 (m, 14 H), 2.49 (t, *J* = 5.9 Hz, 2 H), 2.61 (t, *J* = 7.0 Hz, 2 H), 2.72-2.94 (m, 1 H), 2.94 (s, 6 H), 3.89-4.11 (m, 1 H), 4.73 (d, *J* = 7.5
20 Hz, 1 H).

Step C: Synthesis of *N*²-[*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine-dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.
25 ESI MS *m/e* 542, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.32 (m, 12 H), 2.52-2.60 (m, 2 H), 2.63-2.72 (m, 2 H), 3.11-3.24 (m, 7 H), 4.12-4.23 (m, 1 H), 4.28 (s, 2 H), 7.41 (d, *J* = 10.4 Hz, 1 H), 7.49 (dd, *J* = 8.2, 1.9 Hz, 1 H), 8.19 (d, *J* = 8.4 Hz, 1 H), 8.25 (d, *J* = 8.1 Hz, 1 H), 10.02 (brs, 1 H), 12.43 (brs, 1 H).

Example 14

*N*²-{*cis*-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-5,
5 6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *N*²-{*cis*-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

10 ESI MS *m/e* 556, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.32 (m, 12 H), 2.56 (t, *J* = 5.8 Hz, 2 H), 2.69 (t, *J* = 6.2 Hz, 2 H), 3.14-3.41 (m, 9 H), 4.13-4.25 (m, 1 H), 7.35-7.44 (m, 2 H), 7.49-7.55 (m, 1 H), 8.20 (d, *J* = 7.8 Hz, 1 H).

15 **Example 15**

*N*²-{*cis*-4-[(4-Bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-
5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

**Step A: Synthesis of [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic
20 acid benzyl ester.**

Using the procedure for the step A of example 11, the title compound was obtained.

ESI MS *m/e* 438, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.18-1.39 (m, 2 H), 1.48-1.94 (m, 11 H), 2.49 (t, *J* = 5.9 Hz, 2 H), 2.60 (t, *J* = 6.6 Hz, 2 H), 2.94 (s, 6 H), 3.09 (t, *J* = 6.1 Hz, 2 H), 4.01-4.13 (m, 1 H), 4.70-4.91 (m, 2 H), 5.09 (s, 2 H), 7.27-7.39 (m, 5 H).

25

Step B: Synthesis of *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step E of example 3, the title compound was obtained.

ESI MS m/e 556, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.46-2.17 (m, 12 H), 2.55 (t, $J = 5.8$ Hz, 2 H), 2.69 (t, $J = 6.1$ Hz, 2 H), 2.79-2.92 (m, 2 H), 3.20 (s, 6 H), 4.08-4.18 (m, 1 H), 4.20-4.31 (m, 2 H), 7.43-7.47 (m, 1 H), 7.53 (dd, $J = 8.4, 1.9$ Hz, 1 H), 8.16 (d, $J = 7.8$ Hz, 1 H), 8.22 (d, $J = 8.4$ Hz, 1 H), 10.02 (brs, 2 H), 12.28 (brs, 1 H).

5

Example 16

***N*⁴,*N*⁴-Dimethyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride**

10

Step A: Synthesis of *N*⁴,*N*⁴-dimethyl-*N*²-{*cis*-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 478, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.48-2.15 (m, 13 H), 2.55 (t, $J = 5.4$ Hz, 2 H), 2.71 (t, $J = 6.2$ Hz, 2 H), 2.77-2.89 (m, 2 H), 3.19 (s, 6 H), 4.10 (brs, 1 H), 4.26-4.37 (m, 2 H), 7.27-7.34 (m, 1 H), 7.36-7.47 (m, 2 H), 8.15-8.25 (m, 2 H), 9.90 (s, 2 H), 12.52 (s, 1 H).

15

Example 17

***N*²-[*cis*-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-pyrimidin-2,4-diamine dihydrochloride**

20

Step A: Synthesis of [*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step D of example 1 (6.72 g, 31.4 mmol) in $CHCl_3$ (67 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step F of example 1 (8.44 g, 31.4 mmol), acetic acid (1.88 g, 31.3 mmol), and $NaBH(OAc)_3$ (9.97 g, 47.0 mmol). The reaction mixture was stirred at ambient temperature for

25

4 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give [*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carbamic acid *tert*-butyl ester (10.28 g, 70%) as a pale yellow oil.

ESI MS *m/e* 467, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.78 (m, 17 H), 2.57-2.70 (m, 1 H), 3.62 (brs, 1 H), 3.78 (s, 2 H), 4.60 (brs, 1 H), 7.34-7.54 (m, 3 H).

Step B: Synthesis of (2-chloro-pyrimidin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-pyrimidine (15.0 g, 10.15 mmol) in THF (150 mL) was added 50% aqueous MeNH₂ (22.7 g, 25.2 mmol). The mixture was stirred at ambient temperature for 2 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-dimethyl-amine (8.66 g, 55%) as a white solid and (4-chloro-pyrimidin-2-yl)-dimethyl-amine (0.87 g, 6%) as a white solid.

(2-chloro-pyrimidin-4-yl)-dimethyl-amine;

CI MS *m/e* 158, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 6 H), 6.32 (d, *J* = 6.1 Hz, 1 H), 8.00 (d, *J* = 6.1 Hz, 1 H).

(4-chloro-pyrimidin-2-yl)-dimethyl-amine;

ESI MS *m/e* 157, *M*⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.21 (s, 6 H), 6.50 (d, *J* = 5.1 Hz, 1 H), 8.18 (d, *J* = 5.1 Hz, 1 H).

Step C: Synthesis of *N*²-[*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride.

To a solution of [*cis*-4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (3.00 g, 6.42 mmol) in EtOAc (30 mL) was added 4 M hydrogen chloride in EtOAc (60 mL). The reaction mixture was stirred at ambient temperature for 1 hr and

concentrated. The residue was alkalized with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. The above material (466 mg, 1.27 mmol) and (2-chloro-pyrimidin-4-yl)-dimethyl-amine (200 mg, 1.27 mmol) in butanol (1 mL) was stirred at 130 °C for 13.5 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (12 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to N²-[*cis*-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride (180 mg, 25%) as a white solid.

ESI MS m/e 488, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-1.72 (m, 2 H), 2.01-2.29 (m, 6 H), 3.02 (brs, 1 H), 3.16 (s, 3 H), 3.24 (s, 3 H), 4.13 (brs, 1 H), 4.30 (s, 2 H), 6.02 (d, *J* = 7.5 Hz, 1 H), 7.40-7.43 (m, 1 H), 7.50 (dd, *J* = 8.4, 1.9 Hz, 1 H), 7.99 (d, *J* = 7.3 Hz, 1 H), 8.26 (d, *J* = 8.4 Hz, 1 H), 8.57 (d, *J* = 7.0 Hz, 1 H), 10.25 (s, 2 H).

20 Example 18

N²-{*cis*-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride

Step A: Synthesis of [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step B of example 17 (1.50 g, 9.52 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step D of example 1 (2.24 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130 °C for 22 hr in a sealed tube. The

reaction mixture was poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane) to give [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (1.34 g, 5 42%) as a white solid.

ESI MS m/e 358, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.45 (s, 9 H), 1.48 (s, 8 H), 3.03 (s, 6 H), 3.61 (brs, 1 H), 3.89-4.04 (m, 1 H), 4.47-4.63 (m, 1 H), 4.77-4.89 (m, 1 H), 5.80 (d, $J = 6.1$ Hz, 1 H), 7.84 (d, $J = 6.1$ Hz, 1 H).

10 Step B: Synthesis of N^2 -(cis-4-amino-cyclohexyl)- N^4 , N^4 -dimethyl-pyrimidine-2,4-diamine.

To a solution of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (1.26 g, 3.76 mmol) in EtOAc (15 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was alkalized with 1 M aqueous NaOH. The aqueous layer was extracted 15 with CHCl_3 (six times). The combined organic layer was dried over MgSO_4 , filtrated, and concentrated to give N^2 -(cis-4-amino-cyclohexyl)- N^4 , N^4 -dimethyl-pyrimidine-2,4-diamine (923 mg, quant.) as a pale yellow oil.

ESI MS m/e 250, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.29-1.51 (m, 2 H), 1.61-1.91 (m, 6 H), 2.80-2.92 (m, 1 H), 3.03 (s, 6 H), 3.96-4.04 (m, 1 H), 4.85-4.98 (m, 1 H), 5.79 (d, $J = 6.1$ Hz, 1 H), 20 7.84 (d, $J = 6.1$ Hz, 1 H).

Step C: Synthesis of N^2 -{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}- N^4 , N^4 -dimethyl-pyrimidine-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

25 ESI MS m/e 502, M (free) + H^+ ; ^1H NMR (300 MHz, CDCl_3) δ 1.62-1.82 (m, 2 H), 1.97-2.44 (m, 6 H), 3.16 (s, 3 H), 3.14-3.31 (m, 1 H), 3.25 (s, 3 H), 3.34-3.46 (m, 2 H), 4.18 (brs, 1 H), 6.02 (d, $J = 6.8$ Hz, 1 H), 7.34-7.43 (m, 2 H), 7.45-7.52 (m, 1 H), 7.85-7.97 (m, 1 H), 8.49-8.59 (m, 1 H), 9.95 (brs, 2 H), 12.42 (brs, 1 H).

Example 19

*N*²-{*cis*-4-[(4-Bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-
5 pyrimidine-2,4-diamine dihydrochloride

Step A: Synthesis of [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step B of example 17
10 (1.50 g, 9.52 mmol) and *cis*-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (2.75 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130 °C for 22 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times).

The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane to EtOAc) to give

15 [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (816 mg, 22%) as a pale yellow oil.

ESI MS *m/e* 406, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.22-1.92 (m, 9 H), 3.03 (s, 6 H), 3.11 (t, *J* = 6.2 Hz, 2 H), 4.02-4.15 (m, 1 H), 4.82-4.93 (m, 2 H), 5.10 (s, 2 H), 5.79 (d, *J* = 6.1 Hz, 1 H), 7.28-7.42 (m, 5 H), 7.83 (d, *J* = 6.1 Hz, 1 H).

20

Step B: Synthesis of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine.

Using the procedure for the step B of example 7, the title compound was obtained.

ESI MS *m/e* 250, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.88 (m, 9 H), 2.87 (d, *J* = 5.9 Hz, 2
25 H), 3.03 (s, 6 H), 4.11 (brs, 1 H), 5.63 (brs, 1 H), 5.78 (d, *J* = 6.2 Hz, 1 H), 7.08 (brs, 2 H), 7.82 (d, *J* = 6.2 Hz, 1 H).

Step C: Synthesis of *N*²-{*cis*-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-

cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS *m/e* 502, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.52-2.21 (m, 9 H), 2.85 (d, *J* = 5.8 Hz, 2 H), 3.16 (s, 3 H), 3.24 (s, 3 H), 4.15-4.30 (m, 3 H), 6.00 (d, *J* = 7.6 Hz, 1 H), 7.43-7.47 (m, 1 H), 7.53 (dd, *J* = 8.3, 1.9 Hz, 1 H), 7.66 (d, *J* = 7.5 Hz, 1 H), 8.20 (d, *J* = 8.4 Hz, 1 H), 8.53 (d, *J* = 7.5 Hz, 1 H), 10.07 (brs, 2 H).

Example 20-672

10 To a solution of poly(4-vinylpyridine) (75 μL) in CH₂Cl₂ (200 μL) were added the amines (30 μmol) as shown below in CH₂Cl₂ (200 μL) and acid chloride (60 μmol) in CH₂Cl₂ (200 μL) at ambient temperature. After stirring at the same temperature for 19 hr, the reaction mixture was filtrated and concentrated by a stream of dry N₂. To the residue were added dry CH₂Cl₂ (700 μL) and PSA (300 μL). After the stirring at ambient temperature for 14 hr, the reaction mixture was purified by silica gel
15 chromatography (NH-silica, 50% EtOAc in hexane to EtOAc only) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from

*N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5,
20 *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or
25 *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 673-1084

To a solution of 1-cyclohexyl-3-methylpolystyrene-carbodiimide (150 μL) in CH_2Cl_2 (400 μL) were added the amines (30 μmol) as shown below in CH_2Cl_2 (200 μL) and carboxylic acid (60 μmol) in CH_2Cl_2 (200 μL) at ambient temperature. After stirring at the same temperature for 20 hr, the
 5 reaction mixture was filtrated through NH-silica gel, concentrated by a stream of dry N_2 , and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH_3/MeOH in CHCl_3) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from

- 10 N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N^2 -(*cis*-
 15 4-amino-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

20 **Example 1085-1446**

-method A-

To a solution of the amines (36 μmol) as shown below in MeOH (200 μL) were added aromatic aldehyde (30 μmol) in MeOH (200 μL) and AcOH (90 μmol) at ambient temperature. The reaction mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBH_3CN
 25 (120 μmol) in MeOH (200 μL). After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N_2 . The residue was partitionated between CHCl_3 and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl_3 (500 μL) and EtOAc (300 μL). The combined organic layers were dried over MgSO_4 , concentrated by a stream of dry N_2 , and

purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

-method B-

To a solution of the amines (36 μmol) as shown below in MeOH (200 μL) were added
5 aliphatic aldehyde (30 μmol) in MeOH (200 μL), AcOH (90 μmol), and NaBH₃CN (120 μmol) in MeOH (200 μL) at ambient temperature. After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N₂. The residue was partitioned between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃ (500 μL) and EtOAc (300 μL). The combined organic layers were dried over MgSO₄, concentrated by a stream of dry N₂,
10 and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from

*N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5,
15 *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or
20 *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1457-1462, 1478-1480, 1491-1497, and 1510-1512

25 To a solution of the amide product in THF (200 μl) was added 1 M borane-THF complex in THF (300 μl, 300 μmol). The mixture was stirred at 80 °C for 1 hr, and concentrated by a stream of dry N₂. To the residue were added 1 M aqueous HCl (300 μl) and THF (200 μl). The mixture was stirred at 80 °C for 1 hr and concentrated by a stream of dry N₂. To the residue was partitioned

between CHCl_3 and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl_3 (300 μL , twice) and EtOAc (300 μL). The combined organic layers were dried over MgSO_4 , concentrated by a stream of dry N_2 , and the purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH_3/MeOH in CHCl_3) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Example 1447-1456, 1463-1477, 1481-1490, 1498-1509, and 1513-1538

To a suspension of Dess-Martin periodinane (63 μmol) in CH_2Cl_2 (200 μL) was added alcohol (35 μmol) in CH_2Cl_2 (200 μL) at ambient temperature, and the reaction mixture was stirred at the same temperature for 18 hr. To the reaction mixture were added amines (36 μmol) as shown below in MeOH (200 μL) and AcOH (90 μL). The mixture was stirred at the same temperature for 1 hr, and then NaBH_3CN (120 μmol) in MeOH (200 μL) was added. After stirring at the same temperature for 17 hr, the reaction mixture was concentrated by a stream of dry N_2 . The residue was partitioned between CHCl_3 and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl_3 (500 mL) and EtOAc (300 μL). The combined organic layers were dried over MgSO_4 , concentrated by a stream of dry N_2 , and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH_3/MeOH in CHCl_3) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from

N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1539-1658

To a solution of poly(4-vinylpyridine) (75 μ L) in CH_2Cl_2 (200 μ L) were added the amines (30
5 μ mol) as shown below in CH_2Cl_2 (200 μ L) and chloroformate (60 μ mol) in CH_2Cl_2 (200 μ L) at
ambient temperature. After stirring at the same temperature for 17 hr, the reaction mixture was
filtrated and concentrated by a stream of dry N_2 . To the residue were added CH_2Cl_2 (700 μ L) and PSA
(300 μ L). After the stirring at ambient temperature for 19 hr, the reaction mixture was filtrated and
purified by silica gel chromatography (NH-silica gel, 20% EtOAc in hexane to EtOAc only, and silica
10 gel, 2% to 7% 2 M NH_3/MeOH in CHCl_3) to give the desired product. The product was determined
by ESI-MS or APCI-MS.

Wherein the amines are selected from

- N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of example 5,
15 N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-quinoline-2,4-diamine obtained in step B of
example 7, N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
obtained in step B of example 13, N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-
tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N^2 -(*cis*-4-
amino-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or
20 N^2 -(*cis*-4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-pyrimidine-2,4-diamine obtained in step B of
example 19.

Example 1659-2496

- 25 To a solution of amines (30 μ mol) as shown below in DMSO (300 μ L) were added isocyanate
or isothiocyanate (60 μ mol) in DMSO (200 μ L) at ambient temperature. The mixture was stirred at
the same temperature for 22 hr. To the reaction mixture were added 2 M MeNH_2 in THF (30 μ L, 60
 μ mol) or D-gulcamine (60 μ mol) in DMSO (200 μ L) at ambient temperature. After stirring at the

same temperature for 20 hr, the reaction mixture was filtrated through a SCX, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 10% 2 M NH₃/MeOH in CHCl₃) and silica gel chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give the desired product. The product was determined by ESI-MS or APCI-MS.

5 Wherein the amines are selected from

- N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5,
*N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine obtained in step B of
example 7, *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
obtained in step B of example 13, *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-
10 tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, *N*²-(*cis*-4-
amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or
*N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of
example 19.

Ex. No.	compound name	MS	class
20	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	419 (M + H)	2
21	3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	467 (M + H)	1
22	4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	467 (M + H)	2
23	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide	431 (M + H)	1
24	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	423 (M + H)	1
25	4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	423 (M + H)	1
26	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-phenylacrylamide	415 (M + H)	3
27	4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide	468 (M + H)	1
28	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	437 (M + H)	3
29	3-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	414 (M + H)	2
30	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	457 (M + H)	2
31	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	457 (M + H)	1
32	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide	479 (M + H)	2
33	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	425 (M + H)	1
34	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide	425 (M + H)	2
35	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	463 (M + H)	3
36	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(ethylthio)nicotinamide	450 (M + H)	3
37	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	407 (M + H)	1
38	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide	475 (M + H)	2
39	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-fluorobenzamide	475 (M + H)	3
40	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)hexanamide	383 (M + H)	3
41	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-iodobenzamide	515 (M + H)	3
42	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(methylthio)nicotinamide	436 (M + H)	3
43	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide	448 (M + H)	2

Ex. No.	compound name	MS	class
44	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-nitrobenzamide	434 (M + H)	1
45	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-phenylacetamide	403 (M + H)	3
46	(2R)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-phenylcyclopropanecarboxamide	429 (M + H)	3
47	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-1,3-benzodioxole-5-carboxamide	433 (M + H)	3
48	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-phenoxybutanamide	447 (M + H)	1
49	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-phenoxypropanamide	433 (M + H)	1
50	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-methylbenzamide	403 (M + H)	1
51	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-4-methylbenzamide	403 (M + H)	3
52	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)thiophene-2-carboxamide	395 (M + H)	3
53	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(2-thienyl)acetamide	409 (M + H)	3
54	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-(trifluoromethoxy)benzamide	473 (M + H)	2
55	benzyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)carbamate	419 (M + H)	3
56	4-nitrobenzyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)carbamate	464 (M + H)	3
57	4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-methylbenzamide	481 (M + H)	1
58	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-iodobenzamide	515 (M + H)	2
59	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-fluorobenzamide	441 (M + H)	3
60	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2,3-difluoro-4-methylbenzamide	439 (M + H)	3
61	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-4-fluorobenzamide	441 (M + H)	3
62	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2,4-difluorobenzamide	459 (M + H)	2
63	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(phenylthio)acetamide	435 (M + H)	3
64	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-fluoro-3-(trifluoromethyl)benzamide	475 (M + H)	3
65	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-fluoro-5-(trifluoromethyl)benzamide	475 (M + H)	3
66	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-phenylbutanamide	431 (M + H)	3
67	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(3-methoxyphenyl)acetamide	433 (M + H)	3

Ex. No.	compound name	MS	class
68	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-fluorophenyl)acetamide	421 (M + H)	3
69	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenyl)acetamide	433 (M + H)	3
70	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide	461 (M + H)	3
71	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide	407 (M + H)	1
72	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-ethoxybenzamide	433 (M + H)	3
73	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	441 (M + H)	1
74	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide	421 (M + H)	2
75	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	395 (M + H)	3
76	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide	449 (M + H)	1
77	4-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	414 (M + H)	3
78	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide	525 (M + H)	2
79	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide	460 (M + H)	3
80	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	481 (M + H)	3
81	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	421 (M + H)	1
82	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	471 (M + H)	3
83	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiophene-3-carboxamide	463 (M + H)	2
84	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide	464 (M + H)	3
85	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	525 (M + H)	3
86	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-methyl-1H-pyrazole-5-carboxamide	449 (M + H)	3
87	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide	429 (M + H)	3
88	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)nicotinamide	468 (M + H)	3
89	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide	453 (M + H)	3
90	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methyl-1H-pyrazole-3-carboxamide	449 (M + H)	3
91	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-benzothiophene-3-carboxamide	445 (M + H)	3

Ex. No.	compound name	MS	class
92	2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]-2-oxo-1-phenylethyl acetate	461 (M + H)	3
93	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	389 (M + H)	3
94	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide	445 (M + H)	3
95	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	433 (M + H)	3
96	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	453 (M + H)	1
97	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)cyclohexanecarboxamide	395 (M + H)	3
98	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	504 (M + H)	1
99	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)cyclopentanecarboxamide	491 (M + H)	2
100	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	522 (M + H)	1
101	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)thiophene-2-carboxamide	535 (M + H)	3
102	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	468 (M + H)	3
103	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide	407 (M + H)	3
104	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-dimethoxybenzamide	449 (M + H)	3
105	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluorobenzamide	407 (M + H)	2
106	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide	475 (M + H)	1
107	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide	470 (M + H)	2
108	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide	556 (M + H)	1
109	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-naphthamide	439 (M + H)	3
110	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-naphthamide	439 (M + H)	3
111	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide	424 (M + H)	1
112	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide	419 (M + H)	1
113	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-nitrophenoxy)acetamide	464 (M + H)	3
114	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)quinoxaline-2-carboxamide	441 (M + H)	2

Ex. No.	compound name	MS	class
115	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide	479 (M + H)	3
116	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	457 (M + H)	3
117	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	457 (M + H)	3
118	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(trifluoromethoxy)benzamide	473 (M + H)	3
119	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	524 (M + H)	3
120	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-phenoxybutanamide	447 (M + H)	3
121	2-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methoxybenzamide	497 (M + H)	3
122	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(pentafluorophenoxy)acetamide	509 (M + H)	3
123	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	463 (M + H)	3
124	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide	443 (M + H)	3
125	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)cyclopentanecarboxamide	381 (M + H)	3
126	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide	425 (M + H)	3
127	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-phenylpropanamide	417 (M + H)	3
128	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,3,4,5-tetrafluorobenzamide	461 (M + H)	3
129	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-ethoxy-1-naphthamide	483 (M + H)	3
130	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,3,4,5,6-pentafluorobenzamide	479 (M + H)	3
131	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-[(trifluoromethyl)thio]benzamide	489 (M + H)	3
132	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	497 (M + H)	3
133	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	453 (M + H)	1
134	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	538 (M + H)	1
135	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxy nicotinamide	482 (M + H)	1
136	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(phenylthio)nicotinamide	498 (M + H)	3
137	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide	496 (M + H)	1
138	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide	552 (M + H)	3

Ex. No.	compound name	MS	class
139	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methylpropanamide	481 (M + H)	3
140	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)-3-furamide	557 (M + H)	3
141	2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide	514 (M + H)	3
142	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	593 (M + H)	3
143	6-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide	477 (M + H)	3
144	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	507 (M + H)	3
145	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide	501 (M + H)	3
146	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide	478 (M + H)	1
147	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxybenzamide	433 (M + H)	3
148	3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	481 (M + H)	3
149	4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	481 (M + H)	3
150	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-5-carboxamide	445 (M + H)	3
151	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	437 (M + H)	3
152	4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	437 (M + H)	3
153	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-phenylacrylamide	429 (M + H)	3
154	4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	482 (M + H)	3
155	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	451 (M + H)	3
156	3-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	428 (M + H)	3
157	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	471 (M + H)	3
158	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	471 (M + H)	3
159	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide	493 (M + H)	2
160	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide	439 (M + H)	3

Ex. No.	compound name	MS	class
161	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide	439 (M + H)	3
162	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	477 (M + H)	3
163	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide	464 (M + H)	3
164	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	421 (M + H)	3
165	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-fluoro-5-(trifluoromethyl)benzamide	489 (M + H)	3
166	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide	489 (M + H)	3
167	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]hexanamide	397 (M + H)	3
168	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-iodobenzamide	529 (M + H)	3
169	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide	450 (M + H)	3
170	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide	462 (M + H)	3
171	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	448 (M + H)	3
172	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenylacetamide	417 (M + H)	3
173	(2R)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenylcyclopropanecarboxamide	443 (M + H)	3
174	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide	447 (M + H)	3
175	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide	461 (M + H)	3
176	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide	447 (M + H)	3
177	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	417 (M + H)	3
178	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-methylbenzamide	417 (M + H)	3
179	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	409 (M + H)	3
180	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide	423 (M + H)	3
181	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide	487 (M + H)	3
182	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester	433 (M + H)	3
183	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester	478 (M + H)	3
184	4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	495 (M + H)	3

Ex. No.	compound name	MS	class
185	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-iodobenzamide	529 (M + H)	3
186	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-fluorobenzamide	455 (M + H)	3
187	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide	453 (M + H)	3
188	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	455 (M + H)	3
189	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,4-difluorobenzamide	473 (M + H)	3
190	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide	449 (M + H)	3
191	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2-fluoro-3-(trifluoromethyl)benzamide	489 (M + H)	3
192	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2-fluoro-5-(trifluoromethyl)benzamide	489 (M + H)	3
193	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide	445 (M + H)	3
194	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide	447 (M + H)	3
195	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide	435 (M + H)	3
196	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide	447 (M + H)	3
197	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furamide	475 (M + H)	3
198	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide	421 (M + H)	3
199	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide	447 (M + H)	3
200	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	455 (M + H)	3
201	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide	435 (M + H)	3
202	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	409 (M + H)	3
203	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide	463 (M + H)	3
204	4-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	428 (M + H)	3
205	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide	539 (M + H)	3
206	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide	474 (M + H)	2
207	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	495 (M + H)	3
208	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide	435 (M + H)	3

Ex. No.	compound name	MS	class
209	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	485 (M + H)	3
210	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]thiophene-3-carboxamide	477 (M + H)	3
211	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(propylthio)nicotinamide	478 (M + H)	3
212	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-1H-pyrazole-5-carboxamide	539 (M + H)	3
213	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-1-methyl-1H-pyrazole-5-carboxamide	463 (M + H)	3
214	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-methyl-3-phenylacrylamide	443 (M + H)	3
215	5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]nicotinamide	482 (M + H)	3
216	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide	467 (M + H)	3
217	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-methyl-1H-pyrazole-3-carboxamide	463 (M + H)	3
218	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-1-benzothiophene-3-carboxamide	459 (M + H)	3
219	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide	479 (M + H)	3
220	2-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	481 (M + H)	3
221	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	471 (M + H)	2
222	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-iodobenzamide	529 (M + H)	3
223	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-methylbenzamide	417 (M + H)	3
224	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	471 (M + H)	3
225	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide	455 (M + H)	3
226	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide	505 (M + H)	3
227	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,3,6-trifluorobenzamide	457 (M + H)	3
228	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide	439 (M + H)	3
229	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide	439 (M + H)	3
230	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2-fluoro-6-(trifluoromethyl)benzamide	489 (M + H)	3
231	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide	445 (M + H)	1

Ex. No.	compound name	MS	class
232	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-6-fluorobenzamide	455 (M + H)	3
233	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	505 (M + H)	1
234	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acrylamide	463 (M + H)	2
235	6-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-methylbenzamide	469 (M + H)	3
236	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,6-difluorobenzamide	473 (M + H)	3
237	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide	431 (M + H)	3
238	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	370 (M + H)	2
239	3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	418 (M + H)	1
240	4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	418 (M + H)	3
241	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide	382 (M + H)	1
242	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	374 (M + H)	1
243	4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	374 (M + H)	2
244	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenylacrylamide	366 (M + H)	3
245	4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide	419 (M + H)	1
246	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	388 (M + H)	3
247	3-cyano-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	365 (M + H)	3
248	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	408 (M + H)	1
249	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	408 (M + H)	1
250	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide	430 (M + H)	2
251	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	376 (M + H)	1
252	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide	376 (M + H)	2
253	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	414 (M + H)	3
254	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)nicotinamide	401 (M + H)	3
255	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	358 (M + H)	3

Ex. No.	compound name	MS	class
256	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide	426 (M + H)	2
257	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-5-fluorobenzamide	426 (M + H)	3
258	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)hexanamide	334 (M + H)	3
259	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-4-iodobenzamide	466 (M + H)	3
260	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-(methylthio)nicotinamide	387 (M + H)	3
261	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-4-methyl-3-nitrobenzamide	399 (M + H)	2
262	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-nitrobenzamide	385 (M + H)	1
263	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-phenylacetamide	354 (M + H)	3
264	(2R)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-phenylcyclopropanecarboxamide	380 (M + H)	3
265	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-1,3-benzodioxole-5-carboxamide	384 (M + H)	3
266	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-phenoxybutanamide	398 (M + H)	2
267	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-phenoxypropanamide	384 (M + H)	3
268	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-methylbenzamide	354 (M + H)	2
269	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-4-methylbenzamide	354 (M + H)	3
270	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)thiophene-2-carboxamide	346 (M + H)	3
271	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-(2-thienyl)acetamide	360 (M + H)	3
272	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-(trifluoromethoxy)benzamide	424 (M + H)	1
273	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester	370 (M + H)	3
274	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester	415 (M + H)	3
275	4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-methylbenzamide	432 (M + H)	1
276	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-3-iodobenzamide	466 (M + H)	1
277	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2-fluorobenzamide	392 (M + H)	3
278	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-2,3-difluoro-4-methylbenzamide	390 (M + H)	3
279	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)-4-fluorobenzamide	392 (M + H)	3

Ex. No.	compound name	MS	class
280	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide	410 (M + H)	3
281	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(phenylthio)acetamide	386 (M + H)	3
282	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-fluoro-3-(trifluoromethyl)benzamide	426 (M + H)	3
283	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-fluoro-5-(trifluoromethyl)benzamide	426 (M + H)	3
284	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenylbutanamide	382 (M + H)	3
285	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenyl)acetamide	384 (M + H)	3
286	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenyl)acetamide	372 (M + H)	3
287	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenyl)acetamide	384 (M + H)	3
288	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide	412 (M + H)	3
289	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide	358 (M + H)	2
290	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-ethoxybenzamide	384 (M + H)	3
291	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	392 (M + H)	1
292	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide	372 (M + H)	3
293	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	346 (M + H)	3
294	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide	400 (M + H)	1
295	4-cyano-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	365 (M + H)	3
296	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide	476 (M + H)	1
297	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide	411 (M + H)	3
298	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	432 (M + H)	3
299	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	372 (M + H)	1
300	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	422 (M + H)	3
301	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiophene-3-carboxamide	414 (M + H)	2
302	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide	415 (M + H)	3
303	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	476 (M + H)	2

Ex. No.	compound name	MS	class
304	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-1H-pyrazole-5-carboxamide	400 (M + H)	3
305	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide	380 (M + H)	3
306	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)nicotinamide	419 (M + H)	3
307	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide	404 (M + H)	2
308	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-1H-pyrazole-3-carboxamide	400 (M + H)	3
309	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-benzothiophene-3-carboxamide	396 (M + H)	3
310	2-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]-2-oxo-1-phenylethyl acetate	412 (M + H)	3
311	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	340 (M + H)	3
312	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide	396 (M + H)	3
313	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	384 (M + H)	3
314	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	404 (M + H)	1
315	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)cyclohexanecarboxamide	346 (M + H)	3
316	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	455 (M + H)	3
317	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)cyclopentanecarboxamide	442 (M + H)	2
318	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	473 (M + H)	2
319	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)thiophene-2-carboxamide	486 (M + H)	3
320	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	419 (M + H)	3
321	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide	358 (M + H)	3
322	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-dimethoxybenzamide	400 (M + H)	3
323	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide	358 (M + H)	3
324	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide	426 (M + H)	1
325	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide	421 (M + H)	1
326	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide	507 (M + H)	1

Ex. No.	compound name	MS	class
327	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-naphthamide	390 (M + H)	3
328	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-naphthamide	390 (M + H)	3
329	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide	375 (M + H)	3
330	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide	370 (M + H)	2
331	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-nitrophenoxy)acetamide	415 (M + H)	3
332	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)quinoxaline-2-carboxamide	392 (M + H)	1
333	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide	430 (M + H)	3
334	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	408 (M + H)	2
335	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	408 (M + H)	3
336	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(trifluoromethoxy)benzamide	424 (M + H)	3
337	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	475 (M + H)	3
338	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-phenoxybutanamide	398 (M + H)	3
339	2-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methoxybenzamide	448 (M + H)	3
340	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(pentafluorophenoxy)acetamide	460 (M + H)	2
341	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	414 (M + H)	3
342	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide	394 (M + H)	3
343	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)cyclopentanecarboxamide	332 (M + H)	3
344	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide	376 (M + H)	3
345	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenylpropanamide	368 (M + H)	3
346	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,3,4,5-tetrafluorobenzamide	412 (M + H)	3
347	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-ethoxy-1-naphthamide	434 (M + H)	3
348	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,3,4,5,6-pentafluorobenzamide	430 (M + H)	3
349	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(trifluoromethyl)thio]benzamide	440 (M + H)	3
350	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	448 (M + H)	3

Ex. No.	compound name	MS	class
351	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	404 (M + H)	1
352	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	489 (M + H)	1
353	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxy nicotinamide	433 (M + H)	2
354	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(phenylthio)nicotinamide	449 (M + H)	3
355	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide	447 (M + H)	1
356	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide	503 (M + H)	1
357	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide	432 (M + H)	2
358	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)-3-furamide	508 (M + H)	3
359	2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide	465 (M + H)	1
360	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	544 (M + H)	2
361	6-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide	428 (M + H)	2
362	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	458 (M + H)	3
363	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide	452 (M + H)	3
364	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide	429 (M + H)	1
365	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxybenzamide	384 (M + H)	3
366	3-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	432 (M + H)	3
367	4-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	432 (M + H)	3
368	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-5-carboxamide	396 (M + H)	3
369	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	388 (M + H)	3
370	4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	388 (M + H)	2
371	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-phenylacrylamide	380 (M + H)	2
372	4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	433 (M + H)	2

Ex. No.	compound name	MS	class
373	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	402 (M + H)	2
374	3-cyano-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	379 (M + H)	3
375	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	422 (M + H)	2
376	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	422 (M + H)	2
377	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide	444 (M + H)	1
378	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide	390 (M + H)	3
379	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide	390 (M + H)	3
380	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	428 (M + H)	3
381	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide	415 (M + H)	3
382	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	372 (M + H)	3
383	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-5-(trifluoromethyl)benzamide	440 (M + H)	3
384	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide	440 (M + H)	2
385	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]hexanamide	348 (M + H)	3
386	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-iodobenzamide	480 (M + H)	3
387	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide	401 (M + H)	3
388	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide	413 (M + H)	3
389	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	399 (M + H)	3
390	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylacetamide	368 (M + H)	3
391	(2R)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylcyclopropanecarboxamide	394 (M + H)	3
392	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide	398 (M + H)	3
393	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide	412 (M + H)	2
394	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide	398 (M + H)	3
395	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	368 (M + H)	3
396	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methylbenzamide	368 (M + H)	3

Ex. No.	compound name	MS	class
397	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	360 (M + H)	3
398	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide	374 (M + H)	3
399	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide	438 (M + H)	3
400	benzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	384 (M + H)	3
401	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	429 (M + H)	3
402	4-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	446 (M + H)	3
403	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-iodobenzamide	480 (M + H)	3
404	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-fluorobenzamide	406 (M + H)	3
405	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide	404 (M + H)	3
406	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	406 (M + H)	3
407	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,4-difluorobenzamide	424 (M + H)	3
408	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide	400 (M + H)	3
409	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-(trifluoromethyl)benzamide	440 (M + H)	3
410	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-5-(trifluoromethyl)benzamide	440 (M + H)	3
411	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide	396 (M + H)	1
412	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide	398 (M + H)	2
413	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide	386 (M + H)	3
414	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide	398 (M + H)	2
415	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-methyl-2-(trifluoromethyl)-3-furamide	426 (M + H)	3
416	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide	372 (M + H)	3
417	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide	398 (M + H)	3
418	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	406 (M + H)	3
419	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide	386 (M + H)	3
420	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	360 (M + H)	3

Ex. No.	compound name	MS	class
421	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide	414 (M + H)	3
422	4-cyano-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	379 (M + H)	3
423	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide	490 (M + H)	2
424	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide	425 (M + H)	1
425	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	446 (M + H)	2
426	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide	386 (M + H)	3
427	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	436 (M + H)	3
428	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]thiophene-3-carboxamide	428 (M + H)	3
429	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(propylthio)nicotinamide	429 (M + H)	2
430	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-1H-pyrazole-5-carboxamide	490 (M + H)	3
431	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-1-methyl-1H-pyrazole-5-carboxamide	414 (M + H)	3
432	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-methyl-3-phenylacrylamide	394 (M + H)	3
433	5-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]nicotinamide	433 (M + H)	3
434	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide	418 (M + H)	1
435	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-methyl-1H-pyrazole-3-carboxamide	414 (M + H)	3
436	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-1-benzothiophene-3-carboxamide	410 (M + H)	3
437	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide	430 (M + H)	3
438	2-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	432 (M + H)	3
439	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	422 (M + H)	3
440	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-iodobenzamide	480 (M + H)	3
441	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-methylbenzamide	368 (M + H)	3
442	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	422 (M + H)	3
443	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide	406 (M + H)	3

Ex. No.	compound name	MS	class
444	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide	456 (M + H)	2
445	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3,6-trifluorobenzamide	408 (M + H)	3
446	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide	390 (M + H)	3
447	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide	390 (M + H)	3
448	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-6-(trifluoromethyl)benzamide	440 (M + H)	3
449	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide	396 (M + H)	2
450	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-6-fluorobenzamide	406 (M + H)	3
451	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	456 (M + H)	2
452	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acrylamide	414 (M + H)	2
453	6-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-methylbenzamide	420 (M + H)	3
454	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,6-difluorobenzamide	424 (M + H)	3
455	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide	382 (M + H)	3
456	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	424 (M + H)	1
457	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	472 (M + H)	1
458	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	472 (M + H)	2
459	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide	436 (M + H)	1
460	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	428 (M + H)	1
461	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	428 (M + H)	1
462	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-phenylacrylamide	420 (M + H)	3
463	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide	473 (M + H)	1
464	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	442 (M + H)	1
465	3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	419 (M + H)	1
466	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	462 (M + H)	1
467	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	462 (M + H)	1

Ex. No.	compound name	MS	class
468	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide	484 (M + H)	1
469	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	430 (M + H)	1
470	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide	430 (M + H)	1
471	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	468 (M + H)	3
472	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(ethylthio)nicotinamide	455 (M + H)	3
473	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	412 (M + H)	1
474	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide	480 (M + H)	1
475	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-fluorobenzamide	480 (M + H)	3
476	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)hexanamide	388 (M + H)	2
477	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-iodobenzamide	520 (M + H)	3
478	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(methylthio)nicotinamide	441 (M + H)	3
479	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide	453 (M + H)	1
480	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide	439 (M + H)	1
481	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenylacetamide	408 (M + H)	3
482	(2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide	434 (M + H)	2
483	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide	438 (M + H)	3
484	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide	452 (M + H)	1
485	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenoxypropanamide	438 (M + H)	1
486	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methylbenzamide	408 (M + H)	1
487	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-methylbenzamide	408 (M + H)	2
488	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	400 (M + H)	3
489	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-thienyl)acetamide	414 (M + H)	3
490	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide	478 (M + H)	2
491	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester	424 (M + H)	3

Ex. No.	compound name	MS	class
492	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester	469 (M + H)	3
493	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3-methylbenzamide	486 (M + H)	2
494	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3-iodobenzamide	520 (M + H)	1
495	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-fluorobenzamide	446 (M + H)	3
496	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2,3-difluoro-4-methylbenzamide	444 (M + H)	3
497	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-4-fluorobenzamide	446 (M + H)	2
498	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2,4-difluorobenzamide	464 (M + H)	3
499	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-(phenylthio)acetamide	440 (M + H)	3
500	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-fluoro-3-(trifluoromethyl)benzamide	480 (M + H)	3
501	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-fluoro-5-(trifluoromethyl)benzamide	480 (M + H)	3
502	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-phenylbutanamide	436 (M + H)	3
503	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-(3-methoxyphenyl)acetamide	438 (M + H)	2
504	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-(4-fluorophenyl)acetamide	426 (M + H)	1
505	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-(4-methoxyphenyl)acetamide	438 (M + H)	2
506	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide	466 (M + H)	2
507	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2,5-dimethyl-3-furamide	412 (M + H)	1
508	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-2-ethoxybenzamide	438 (M + H)	3
509	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-4-fluorobenzamide	446 (M + H)	1
510	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3-fluoro-4-methylbenzamide	426 (M + H)	2
511	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)acetamide	400 (M + H)	3
512	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3,5-dimethoxybenzamide	454 (M + H)	1
513	4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)benzamide	419 (M + H)	3
514	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide	530 (M + H)	1
515	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-3-(4-nitrophenyl)acrylamide	465 (M + H)	3

Ex. No.	compound name	MS	class
516	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	486 (M + H)	3
517	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	426 (M + H)	1
518	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	476 (M + H)	3
519	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-3-carboxamide	468 (M + H)	1
520	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide	469 (M + H)	2
521	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	530 (M + H)	2
522	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-methyl-1H-pyrazole-5-carboxamide	454 (M + H)	3
523	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide	434 (M + H)	3
524	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide	473 (M + H)	1
525	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide	458 (M + H)	3
526	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methyl-1H-pyrazole-3-carboxamide	454 (M + H)	3
527	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-benzothiophene-3-carboxamide	450 (M + H)	3
528	2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-2-oxo-1-phenylethyl acetate	466 (M + H)	1
529	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	394 (M + H)	2
530	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide	450 (M + H)	3
531	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	438 (M + H)	2
532	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	458 (M + H)	2
533	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)cyclohexanecarboxamide	400 (M + H)	3
534	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	509 (M + H)	2
535	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-cyclopentanecarboxamide	496 (M + H)	2

Ex. No.	compound name	MS	class
536	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	527 (M + H)	1
537	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)thiophene-2-carboxamide	540 (M + H)	3
538	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	473 (M + H)	3
539	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide	412 (M + H)	2
540	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,4-dimethoxybenzamide	454 (M + H)	3
541	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-fluorobenzamide	412 (M + H)	1
542	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide	480 (M + H)	1
543	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide	475 (M + H)	2
544	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide	561 (M + H)	1
545	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-naphthamide	444 (M + H)	3
546	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-naphthamide	444 (M + H)	3
547	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide	429 (M + H)	1
548	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide	424 (M + H)	1
549	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-nitrophenoxy)acetamide	469 (M + H)	3
550	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)quinoxaline-2-carboxamide	446 (M + H)	1
551	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide	484 (M + H)	3
552	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	462 (M + H)	1
553	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	462 (M + H)	3
554	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(trifluoromethoxy)benzamide	478 (M + H)	3
555	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	529 (M + H)	3
556	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-phenoxybutanamide	452 (M + H)	3
557	2-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methoxybenzamide	502 (M + H)	3

Ex. No.	compound name	MS	class
558	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(pentafluorophenoxy)acetamide	514 (M + H)	3
559	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	468 (M + H)	3
560	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide	448 (M + H)	3
561	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)cyclopentanecarboxamide	386 (M + H)	3
562	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide	430 (M + H)	3
563	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-phenylpropanamide	422 (M + H)	3
564	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,3,4,5-tetrafluorobenzamide	466 (M + H)	3
565	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-ethoxy-1-naphthamide	488 (M + H)	3
566	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,3,4,5,6-pentafluorobenzamide	484 (M + H)	3
567	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-[(trifluoromethyl)thio]benzamide	494 (M + H)	3
568	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	502 (M + H)	3
569	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	458 (M + H)	1
570	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide	543 (M + H)	1
571	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide	487 (M + H)	2
572	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(phenylthio)nicotinamide	503 (M + H)	3
573	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide	501 (M + H)	1
574	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide	557 (M + H)	3
575	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methylpropanamide	486 (M + H)	3
576	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)-3-furamide	562 (M + H)	3
577	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide	598 (M + H)	3
578	6-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide	482 (M + H)	3

Ex. No.	compound name	MS	class
579	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)-benzamide	512 (M + H)	3
580	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide	506 (M + H)	3
581	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide	483 (M + H)	2
582	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-methoxybenzamide	438 (M + H)	3
583	3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	486 (M + H)	2
584	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	486 (M + H)	3
585	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-5-carboxamide	450 (M + H)	3
586	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	442 (M + H)	3
587	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	442 (M + H)	3
588	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-phenylacrylamide	434 (M + H)	3
589	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	487 (M + H)	3
590	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	456 (M + H)	3
591	3-cyano-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	433 (M + H)	3
592	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	476 (M + H)	3
593	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	476 (M + H)	3
594	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide	498 (M + H)	3
595	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide	444 (M + H)	3
596	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide	444 (M + H)	3
597	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	482 (M + H)	3
598	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide	469 (M + H)	1
599	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	426 (M + H)	3

Ex. No.	compound name	MS	class
600	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-5-(trifluoromethyl)benzamide	494 (M + H)	3
601	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide	494 (M + H)	3
602	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]hexanamide	402 (M + H)	3
603	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-iodobenzamide	534 (M + H)	3
604	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide	455 (M + H)	3
605	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide	467 (M + H)	3
606	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide	453 (M + H)	3
607	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-phenylacetamide	422 (M + H)	3
608	(2R)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-phenylcyclopropane-carboxamide	448 (M + H)	3
609	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide	452 (M + H)	3
610	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide	466 (M + H)	3
611	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide	452 (M + H)	3
612	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	422 (M + H)	3
613	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-methylbenzamide	422 (M + H)	3
614	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	414 (M + H)	3
615	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide	428 (M + H)	3
616	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide	492 (M + H)	3
617	benzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate	438 (M + H)	3
618	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate	483 (M + H)	3
619	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	500 (M + H)	3
620	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-iodobenzamide	534 (M + H)	3

Ex. No.	compound name	MS	class
621	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluorobenzamide	460 (M + H)	3
622	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide	458 (M + H)	3
623	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	460 (M + H)	3
624	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,4-difluorobenzamide	478 (M + H)	3
625	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide	454 (M + H)	3
626	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-(trifluoromethyl)benzamide	494 (M + H)	3
627	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-5-(trifluoromethyl)benzamide	494 (M + H)	3
628	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide	450 (M + H)	3
629	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide	452 (M + H)	3
630	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide	440 (M + H)	3
631	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide	452 (M + H)	1
632	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-methyl-2-(trifluoromethyl)-3-furamide	480 (M + H)	1
633	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide	426 (M + H)	3
634	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide	452 (M + H)	3
635	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	460 (M + H)	3
636	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide	440 (M + H)	3
637	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	414 (M + H)	3
638	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide	468 (M + H)	3
639	4-cyano-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	433 (M + H)	3
640	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide	544 (M + H)	3

Ex. No.	compound name	MS	class
641	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide	479 (M + H)	2
642	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]acetamide	500 (M + H)	3
643	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-4-fluoro-3-methylbenzamide	440 (M + H)	2
644	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]benzamide	490 (M + H)	3
645	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]thiophene-3-carboxamide	482 (M + H)	3
646	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2-(propylthio)nicotinamide	483 (M + H)	1
647	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-1H-pyrazole-5-carboxamide	544 (M + H)	3
648	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-1-methyl-1H-pyrazole-5-carboxamide	468 (M + H)	3
649	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2-methyl-3-phenylacrylamide	448 (M + H)	3
650	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-methyl]nicotinamide	487 (M + H)	3
651	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2-(1-naphthyl)acetamide	472 (M + H)	3
652	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-5-methyl-1H-pyrazole-3-carboxamide	468 (M + H)	3
653	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-1-benzothiophene-3-carboxamide	464 (M + H)	3
654	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]biphenyl-4-carboxamide	484 (M + H)	3
655	2-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]benzamide	486 (M + H)	3
656	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]benzamide	476 (M + H)	2
657	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2-iodobenzamide	534 (M + H)	3
658	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2-methylbenzamide	422 (M + H)	3
659	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]benzamide	476 (M + H)	3
660	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-5-fluorobenzamide	460 (M + H)	3
661	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide	510 (M + H)	3
662	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]-2,3,6-trifluorobenzamide	462 (M + H)	3

Ex. No.	compound name	MS	class
663	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide	444 (M + H)	3
664	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide	444 (M + H)	3
665	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-6-(trifluoromethyl)-benzamide	494 (M + H)	3
666	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide	450 (M + H)	2
667	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-6-fluorobenzamide	460 (M + H)	2
668	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	510 (M + H)	1
669	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acrylamide	468 (M + H)	3
670	6-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-methylbenzamide	474 (M + H)	3
671	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,6-difluorobenzamide	478 (M + H)	3
672	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide	436 (M + H)	3
673	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	473 (M + H)	2
674	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide	505 (M + H)	3
675	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	455 (M + H)	3
676	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide	534 (M + H)	2
677	5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	429 (M + H)	2
678	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,3-diphenylpropanamide	493 (M + H)	3
679	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(2-hydroxyphenyl)propanamide	433 (M + H)	3
680	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide	505 (M + H)	1
681	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide	529 (M + H)	2
682	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide	486 (M + H)	2
683	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide	460 (M + H)	2
684	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-oxoindane-1-carboxamide	443 (M + H)	3

Ex. No.	compound name	MS	class
685	2-benzyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	479 (M + H)	3
686	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	547 (M + H)	2
687	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide	514 (M + H)	3
688	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide	440 (M + H)	1
689	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide	448 (M + H)	1
690	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide	464 (M + H)	1
691	1-benzyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide	518 (M + H)	3
692	3-acetyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	431 (M + H)	3
693	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)cyclohexanecarboxamide	499 (M + H)	3
694	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide	457 (M + H)	1
695	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)propanamide	423 (M + H)	3
696	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide	451 (M + H)	3
697	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide	489 (M + H)	3
698	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)propanamide	485 (M + H)	3
699	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	471 (M + H)	3
700	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide	479 (M + H)	3
701	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	551 (M + H)	2
702	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	463 (M + H)	3
703	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	531 (M + H)	3
704	N-2~,N-6~-dibenzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)lysineamide	621 (M + H)	3
705	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	432 (M + H)	3
706	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide	535 (M + H)	1
707	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide	463 (M + H)	3
708	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	511 (M + H)	3

Ex. No.	compound name	MS	class
709	tert-butyl {(1S)-1-[(1-benzyl-1H-imidazol-4-yl)methyl]-2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)amino]-2-oxoethyl} carbamate	612 (M + H)	3
710	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide	548 (M + H)	3
711	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(1H-indol-3-yl)acetamide	442 (M + H)	1
712	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide	500 (M + H)	3
713	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(6-methoxy-3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide	487 (M + H)	3
714	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-{1-[4-methoxybenzyl]thio}cyclohexyl}acetamide	561 (M + H)	3
715	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide	501 (M + H)	3
716	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide	560 (M + H)	2
717	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide	638 (M + H)	3
718	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3,5-dimethyl-2-[(4-(trifluoromethoxy)phenyl)amino]-carbonyl]amino]benzamide	635 (M + H)	3
719	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide	600 (M + H)	3
720	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide	644 (M + H)	3
721	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-oxobutanamide	630 (M + H)	3
722	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide	588 (M + H)	3
723	N-(2,4-dichlorophenyl)-2-{2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)amino]-2-oxoethyl} benzamide	590 (M + H)	3
724	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide	595 (M + H)	3
725	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-4-(4-nitrophenyl)butanamide	476 (M + H)	3
726	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-3-(2-nitrophenyl)acrylamide	460 (M + H)	3
727	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(3-phenoxyphenyl)acetamide	495 (M + H)	3
728	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(4-phenoxyphenyl)acetamide	495 (M + H)	3
729	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide	518 (M + H)	2

Ex. No.	compound name	MS	class
730	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide	601 (M + H)	3
731	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide	481 (M + H)	3
732	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-phenylethyl)benzamide	493 (M + H)	3
733	3-benzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	493 (M + H)	3
734	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide	539 (M + H)	3
735	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)benzamide	522 (M + H)	3
736	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	539 (M + H)	3
737	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-(1-naphthyl)ethyl]phthalamide	586 (M + H)	3
738	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)propanamide	521 (M + H)	3
739	N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide	640 (M + H)	3
740	(2S)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	511 (M + H)	3
741	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-oxobutanamide	635 (M + H)	3
742	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide	615 (M + H)	3
743	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide	623 (M + H)	3
744	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide	527 (M + H)	3
745	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-oxo-4-(2-thienyl)butanamide	451 (M + H)	3
746	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(2-thienyl)butanamide	437 (M + H)	3
747	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,4,6-trichlorophenoxy)acetamide	521 (M + H)	2
748	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	548 (M + H)	3
749	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1-naphthoyl)benzamide	543 (M + H)	3
750	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-methoxybenzamide	525 (M + H)	2
751	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide	544 (M + H)	3

Ex. No.	compound name	MS	class
752	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	670 (M + H)	3
753	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)anthracene-9-carboxamide	489 (M + H)	3
754	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide	481 (M + H)	2
755	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)biphenyl-2-carboxamide	465 (M + H)	3
756	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,3-diphenylpropanamide	493 (M + H)	3
757	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide	516 (M + H)	2
758	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(1S)-1-phenylethyl]phthalamide	536 (M + H)	3
759	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylbenzoyl)benzamide	507 (M + H)	3
760	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(phenoxymethyl)benzamide	495 (M + H)	3
761	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide	596 (M + H)	3
762	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide	532 (M + H)	3
763	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide	500 (M + H)	1
764	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-2-carboxamide	507 (M + H)	3
765	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	581 (M + H)	3
766	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	673 (M + H)	3
767	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide	440 (M + H)	1
768	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide	437 (M + H)	1
769	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-(phenylsulfonyl)-1H-indole-3-carboxamide	568 (M + H)	3
770	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	434 (M + H)	1
771	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methoxy-4-nitrobenzamide	464 (M + H)	2
772	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide	475 (M + H)	1
773	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-fluoro-4-nitrobenzamide	452 (M + H)	3

Ex. No.	compound name	MS	class
774	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide	462 (M + H)	2
775	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide	459 (M + H)	2
776	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)quinoline-3-carboxamide	440 (M + H)	3
777	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methoxy-2-phenylacetamide	433 (M + H)	3
778	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide	443 (M + H)	3
779	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1,3-benzothiazole-6-carboxamide	446 (M + H)	3
780	5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-hydroxybenzamide	439 (M + H)	2
781	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(methylthio)benzamide	469 (M + H)	3
782	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-7-methoxy-1-benzofuran-2-carboxamide	459 (M + H)	3
783	2-amino-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide	418 (M + H)	3
784	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-hydroxy-3,5-dimethoxybenzamide	465 (M + H)	3
785	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)quinoline-4-carboxamide	440 (M + H)	3
786	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)nicotinamide	462 (M + H)	3
787	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-hydroxybenzamide	517 (M + H)	3
788	5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	487 (M + H)	3
789	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide	519 (M + H)	1
790	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]acetamide	469 (M + H)	3
791	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-furamide	548 (M + H)	3
792	5-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	443 (M + H)	3
793	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide	507 (M + H)	3
794	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide	447 (M + H)	3
795	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide	519 (M + H)	3
796	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2-iodophenyl)acetamide	543 (M + H)	3
797	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide	474 (M + H)	2

Ex. No.	compound name	MS	class
798	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide	457 (M + H)	3
799	2-benzyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]benzamide	493 (M + H)	3
800	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	561 (M + H)	3
801	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-5-(4-methyl-2-nitrophenyl)-2-furamide	528 (M + H)	3
802	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide	454 (M + H)	3
803	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide	462 (M + H)	3
804	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide	478 (M + H)	3
805	1-benzyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-1H-indole-3-carboxamide	532 (M + H)	3
806	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	421 (M + H)	3
807	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide	675 (M + H)	3
808	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide	501 (M + H)	3
809	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethylbenzamide	537 (M + H)	3
810	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide	507 (M + H)	3
811	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide	473 (M + H)	3
812	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	424 (M + H)	3
813	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide	456 (M + H)	3
814	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	406 (M + H)	3
815	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide	485 (M + H)	1
816	5-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	380 (M + H)	3
817	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,3-diphenylpropanamide	444 (M + H)	3
818	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(2-hydroxyphenyl)propanamide	384 (M + H)	3
819	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide	456 (M + H)	2
820	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide	480 (M + H)	3

Ex. No.	compound name	MS	class
821	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide	437 (M + H)	3
822	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide	411 (M + H)	3
823	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-oxoindane-1-carboxamide	394 (M + H)	3
824	2-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	430 (M + H)	3
825	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	498 (M + H)	3
826	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide	465 (M + H)	2
827	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide	391 (M + H)	2
828	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide	399 (M + H)	2
829	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide	415 (M + H)	1
830	1-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide	469 (M + H)	2
831	3-acetyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	382 (M + H)	2
832	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)cyclohexanecarboxamide	450 (M + H)	3
833	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide	408 (M + H)	1
834	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)propanamide	374 (M + H)	3
835	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide	402 (M + H)	3
836	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide	440 (M + H)	1
837	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)propanamide	436 (M + H)	3
838	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	422 (M + H)	3
839	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide	430 (M + H)	3
840	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	501 (M + H)	2
841	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	414 (M + H)	3
842	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	482 (M + H)	1
843	N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)lysineamide	572 (M + H)	2
844	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	383 (M + H)	2

Ex. No.	compound name	MS	class
845	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide	486 (M + H)	1
846	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide	414 (M + H)	3
847	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	462 (M + H)	3
848	1-benzyl-N- α -(tert-butoxycarbonyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-L-histidinamide	563 (M + H)	3
849	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide	499 (M + H)	3
850	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)acetamide	393 (M + H)	2
851	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide	451 (M + H)	2
852	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(6-methoxy-3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide	438 (M + H)	3
853	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{1-[(4-methoxybenzyl)thio]cyclohexyl}acetamide	512 (M + H)	3
854	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide	452 (M + H)	3
855	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide	511 (M + H)	1
856	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide	589 (M + H)	2
857	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethyl-2-[(4-(trifluoromethoxy)phenyl)amino]carbonyl]benzamide	586 (M + H)	3
858	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide	551 (M + H)	2
859	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	655 (M + H)	3
860	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide	595 (M + H)	3
861	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-oxobutanamide	581 (M + H)	3
862	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide	539 (M + H)	1
863	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide	546 (M + H)	2
864	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-nitrophenyl)butanamide	427 (M + H)	2
865	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[(3-nitropyridin-2-yl)thio]acetamide	432 (M + H)	-

Ex. No.	compound name	MS	class
866	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(2-nitrophenyl)acrylamide	411 (M + H)	3
867	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(3-phenoxyphenyl)acetamide	446 (M + H)	3
868	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-phenoxyphenyl)acetamide	446 (M + H)	3
869	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide	469 (M + H)	1
870	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide	552 (M + H)	2
871	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide	432 (M + H)	2
872	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenylethyl)benzamide	444 (M + H)	3
873	3-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	444 (M + H)	2
874	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide	490 (M + H)	1
875	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	473 (M + H)	3
876	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	490 (M + H)	3
877	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(1R)-1-(1-naphthyl)ethyl]phthalamide	537 (M + H)	2
878	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)propanamide	472 (M + H)	2
879	N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide	591 (M + H)	1
880	(2S)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	462 (M + H)	3
881	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-oxobutanamide	586 (M + H)	3
882	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide	566 (M + H)	3
883	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl]acetamide	574 (M + H)	2
884	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide	478 (M + H)	2
885	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-oxo-4-(2-thienyl)butanamide	402 (M + H)	3
886	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(2-thienyl)butanamide	388 (M + H)	3
887	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	499 (M + H)	3
888	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-naphthoyl)benzamide	494 (M + H)	3

Ex. No.	compound name	MS	class
889	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-methoxybenzamide	476 (M + H)	1
890	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide	495 (M + H)	1
891	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	621 (M + H)	1
892	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)anthracene-9-carboxamide	440 (M + H)	3
893	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide	432 (M + H)	2
894	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)biphenyl-2-carboxamide	416 (M + H)	3
895	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,3-diphenylpropanamide	444 (M + H)	3
896	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide	467 (M + H)	2
897	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[(1S)-1-phenylethyl]phthalamide	487 (M + H)	3
898	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methylbenzoyl)benzamide	458 (M + H)	3
899	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(phenoxyethyl)benzamide	446 (M + H)	3
900	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide	547 (M + H)	1
901	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-[4-(methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide	483 (M + H)	2
902	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide	451 (M + H)	2
903	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-2-carboxamide	458 (M + H)	3
904	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	532 (M + H)	2
905	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	624 (M + H)	2
906	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide	391 (M + H)	1
907	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide	388 (M + H)	1
908	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-(phenylsulfonyl)-1H-indole-3-carboxamide	519 (M + H)	3
909	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	385 (M + H)	2
910	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methoxy-4-nitrobenzamide	415 (M + H)	3

Ex. No.	compound name	MS	class
911	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide	426 (M + H)	3
912	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-fluoro-4-nitrobenzamide	403 (M + H)	3
913	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide	413 (M + H)	2
914	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide	410 (M + H)	2
915	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)quinoline-3-carboxamide	391 (M + H)	3
916	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methoxy-2-phenylacetamide	384 (M + H)	3
917	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide	394 (M + H)	3
918	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzothiazole-6-carboxamide	397 (M + H)	3
919	5-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-hydroxybenzamide	390 (M + H)	3
920	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(methylthio)benzamide	420 (M + H)	3
921	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-7-methoxy-1-benzofuran-2-carboxamide	410 (M + H)	3
922	2-amino-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	369 (M + H)	3
923	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)nicotinamide	413 (M + H)	3
924	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-hydroxybenzamide	468 (M + H)	1
925	5-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	438 (M + H)	3
926	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide	470 (M + H)	1
927	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]acetamide	420 (M + H)	3
928	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-2-furamide	499 (M + H)	3
929	5-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	394 (M + H)	3
930	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide	458 (M + H)	2
931	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide	398 (M + H)	3
932	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide	470 (M + H)	2
933	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide	451 (M + H)	3
934	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide	425 (M + H)	1

Ex. No.	compound name	MS	class
935	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide	408 (M + H)	1
936	2-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	444 (M + H)	2
937	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	512 (M + H)	1
938	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-(4-methyl-2-nitrophenyl)-2-furamide	479 (M + H)	3
939	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide	405 (M + H)	3
940	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide	413 (M + H)	1
941	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide	429 (M + H)	1
942	1-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-1H-indole-3-carboxamide	483 (M + H)	3
943	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	372 (M + H)	3
944	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide	626 (M + H)	3
945	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide	452 (M + H)	1
946	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethylbenzamide	488 (M + H)	3
947	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide	458 (M + H)	1
948	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide	424 (M + H)	1
949	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiophene-2-carboxamide	478 (M + H)	2
950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide	510 (M + H)	2
951	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	460 (M + H)	1
952	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide	539 (M + H)	1
953	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiophene-2-carboxamide	434 (M + H)	1
954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2,3-diphenylpropanamide	498 (M + H)	2
955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-(2-hydroxyphenyl)propanamide	438 (M + H)	2
956	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide	510 (M + H)	1
957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide	534 (M + H)	2

Ex. No.	compound name	MS	class
958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide	491 (M + H)	2
959	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide	465 (M + H)	3
960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-oxoindane-1-carboxamide	448 (M + H)	2
961	2-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	484 (M + H)	2
962	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	552 (M + H)	1
963	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide	519 (M + H)	2
964	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide	445 (M + H)	1
965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide	453 (M + H)	1
966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide	469 (M + H)	1
967	1-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide	523 (M + H)	3
968	3-acetyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	436 (M + H)	1
969	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-cyclohexanecarboxamide	504 (M + H)	3
970	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide	462 (M + H)	1
971	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide	428 (M + H)	3
972	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide	456 (M + H)	2
973	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide	494 (M + H)	1
974	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide	490 (M + H)	3
975	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	476 (M + H)	1
976	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide	484 (M + H)	1
977	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide	556 (M + H)	2
978	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	468 (M + H)	3

Ex. No.	compound name	MS	class
979	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)acetamide	536 (M + H)	3
980	N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)lysineamide	626 (M + H)	2
981	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	437 (M + H)	2
982	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide	540 (M + H)	1
983	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide	468 (M + H)	2
984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	516 (M + H)	2
985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide	553 (M + H)	2
986	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)acetamide	447 (M + H)	1
987	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide	505 (M + H)	3
988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(6-methoxy-3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide	492 (M + H)	3
989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-{1-[(4-methoxybenzyl)thio]-cyclohexyl}acetamide	566 (M + H)	3
990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide	506 (M + H)	1
991	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide	565 (M + H)	2
992	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide	643 (M + H)	3
993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,5-dimethyl-2-[(4-(trifluoromethoxy)phenyl)amino]carbonyl]amino]benzamide	640 (M + H)	1
994	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide	605 (M + H)	1
995	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	709 (M + H)	3
996	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide	649 (M + H)	1

Ex. No.	compound name	MS	class
997	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-oxobutanamide	635 (M + H)	3
998	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide	593 (M + H)	2
999	N-(2,4-dichlorophenyl)-2-{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-2-oxoethyl}benzamide	595 (M + H)	3
1000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide	600 (M + H)	1
1001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(4-nitrophenyl)butanamide	481 (M + H)	1
1002	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-(2-nitrophenyl)acrylamide	465 (M + H)	3
1003	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(3-phenoxyphenyl)acetamide	500 (M + H)	2
1004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(4-phenoxyphenyl)acetamide	500 (M + H)	2
1005	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide	523 (M + H)	1
1006	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide	606 (M + H)	1
1007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide	486 (M + H)	1
1008	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-phenylethyl)benzamide	498 (M + H)	3
1009	3-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	498 (M + H)	3
1010	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide	544 (M + H)	2
1011	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide	527 (M + H)	3
1012	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	544 (M + H)	3
1013	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-(1-naphthyl)ethyl]phthalamide	591 (M + H)	3
1014	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide	526 (M + H)	3
1015	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide	645 (M + H)	1
1016	(2S)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide	516 (M + H)	2

Ex. No.	compound name	MS	class
1017	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-oxobutanamide	640 (M + H)	3
1018	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide	620 (M + H)	2
1019	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl]acetamide	628 (M + H)	1
1020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide	532 (M + H)	2
1021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-oxo-4-(2-thienyl)butanamide	456 (M + H)	3
1022	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(2-thienyl)butanamide	442 (M + H)	3
1023	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2,4,6-trichlorophenoxy)acetamide	526 (M + H)	3
1024	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	553 (M + H)	3
1025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1-naphthoyl)benzamide	548 (M + H)	3
1026	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-methoxybenzamide	530 (M + H)	1
1027	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide	549 (M + H)	2
1028	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	675 (M + H)	2
1029	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)anthracene-9-carboxamide	494 (M + H)	3
1030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide	486 (M + H)	1
1031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)biphenyl-2-carboxamide	470 (M + H)	3
1032	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,3-diphenylpropanamide	498 (M + H)	3
1033	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide	521 (M + H)	2
1034	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(1S)-1-phenylethyl]phthalamide	541 (M + H)	3
1035	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(4-methylbenzoyl)benzamide	512 (M + H)	3
1036	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(phenoxyethyl)benzamide	500 (M + H)	3

Ex. No.	compound name	MS	class
1037	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide	601 (M + H)	3
1038	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide	537 (M + H)	3
1039	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide	505 (M + H)	2
1040	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-2-carboxamide	512 (M + H)	3
1041	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	586 (M + H)	3
1042	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide	678 (M + H)	3
1043	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide	445 (M + H)	1
1044	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide	442 (M + H)	1
1045	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-(phenylsulfonyl)-1H-indole-3-carboxamide	573 (M + H)	3
1046	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide	439 (M + H)	3
1047	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methoxy-4-nitrobenzamide	469 (M + H)	2
1048	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide	480 (M + H)	3
1049	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-fluoro-4-nitrobenzamide	457 (M + H)	3
1050	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide	467 (M + H)	3
1051	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide	464 (M + H)	3
1052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methoxy-2-phenylacetamide	438 (M + H)	2
1053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide	448 (M + H)	3
1054	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1,3-benzothiazole-6-carboxamide	451 (M + H)	3
1055	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-hydroxybenzamide	444 (M + H)	1
1056	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-(methylthio)-benzamide	474 (M + H)	3

Ex. No.	compound name	MS	class
1057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-7-methoxy-1-benzofuran-2-carboxamide	464 (M + H)	3
1058	2-amino-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methylbenzamide	423 (M + H)	3
1059	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide	467 (M + H)	3
1060	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-hydroxybenzamide	522 (M + H)	3
1061	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	492 (M + H)	3
1062	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide	524 (M + H)	2
1063	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-acetamide	474 (M + H)	3
1064	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-furamide	553 (M + H)	3
1065	5-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide	448 (M + H)	3
1066	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide	512 (M + H)	3
1067	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide	452 (M + H)	3
1068	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide	524 (M + H)	3
1069	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-(2-iodophenyl)acetamide	548 (M + H)	3
1070	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide	479 (M + H)	2
1071	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide	462 (M + H)	3
1072	2-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide	498 (M + H)	3
1073	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	566 (M + H)	3
1074	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-(4-methyl-2-nitrophenyl)-2-furamide	533 (M + H)	3
1075	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide	459 (M + H)	3
1076	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide	467 (M + H)	3
1077	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide	483 (M + H)	3

Ex. No.	compound name	MS	class
1078	1-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-1H-indole-3-carboxamide	537 (M + H)	3
1079	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	426 (M + H)	3
1080	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide	680 (M + H)	3
1081	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]-acetamide	506 (M + H)	3
1082	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethylbenzamide	542 (M + H)	3
1083	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide	512 (M + H)	3
1084	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide	478 (M + H)	3
1085	N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	435 (M + H)	3
1086	N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	419 (M + H)	3
1087	N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	414 (M + H)	3
1088	N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	435 (M + H)	3
1089	N2-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	455 (M + H)	3
1090	N2-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	444 (M + H)	3
1091	N2-(cis-4-{[(2-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	455 (M + H)	3
1092	4-bromo-2-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol	499 (M + H)	3
1093	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	492 (M + H)	3
1094	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	435 (M + H)	3
1095	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-trimethoxybenzyl)amino]cyclohexyl}quinoline-2,4-diamine	465 (M + H)	3
1096	4-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol	451 (M + H)	3
1097	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1098	N4,N4-dimethyl-N2-{cis-4-[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]amino}cyclohexyl}quinoline-2,4-diamine	509 (M + H)	3
1099	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl}quinoline-2,4-diamine	465 (M + H)	3

Ex. No.	compound name	MS	class
1100	N4,N4-dimethyl-N2-{cis-4-[(pentamethylbenzyl)amino]cyclohexyl}quinoline-2,4-diamine	445 (M + H)	3
1101	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	435 (M + H)	3
1102	4-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol	547 (M + H)	3
1103	4-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol	419 (M + H)	3
1104	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	405 (M + H)	3
1105	N2-{cis-4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	471 (M + H)	3
1106	N4,N4-dimethyl-N2-{cis-4-[(3-phenylbutyl)amino]cyclohexyl}quinoline-2,4-diamine	417 (M + H)	3
1107	3-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]methyl}-6-methyl-4H-chromen-4-one	457 (M + H)	3
1108	3-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]methyl}-6,8-dimethyl-4H-chromen-4-one	471 (M + H)	3
1109	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	468 (M + H)	3
1110	N4,N4-dimethyl-N2-{cis-4-[(2-phenylpropyl)amino]cyclohexyl}quinoline-2,4-diamine	403 (M + H)	3
1111	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	471 (M + H)	3
1112	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-yl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	431 (M + H)	3
1113	6-chloro-3-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-4H-chromen-4-one	477 (M + H)	3
1114	N2-[cis-4-{[(5-(4-fluorophenyl)pyridin-3-yl)methyl]amino}-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	470 (M + H)	3
1115	ethyl 4,6-dichloro-3-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate	552 (M - H)	1
1116	methyl 2-[(5-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}imidazo[2,1-b][1,3]thiazol-6-yl)thio]benzoate	587 (M + H)	3
1117	N2-[cis-4-{[(3-(4-fluorophenyl)-1H-pyrazol-4-yl)methyl]amino}-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	459 (M + H)	3
1118	N4,N4-dimethyl-N2-(cis-4-{4-(methylthio)benzyl]amino}cyclohexyl)quinoline-2,4-diamine	421 (M + H)	3
1119	N4,N4-dimethyl-N2-{cis-4-[(1-naphthylmethyl)amino]cyclohexyl}quinoline-2,4-diamine	425 (M + H)	3
1120	4-{[(cis-4-{4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol	421 (M + H)	3
1121	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	427 (M + H)	3
1122	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	2

Ex. No.	compound name	MS	class
1123	N2-(cis-4-(((2-ethoxybenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	433 (M + H)	2
1124	N2-(cis-4-(((1H-indol-3-ylmethyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	428 (M + H)	3
1125	N2-(cis-4-(((2,5-dimethoxybenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1126	N2-[cis-4-(((4-methoxy-1-naphthyl)methyl)amino)methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	469 (M + H)	2
1127	N2-[cis-4-(((5-methoxy-1H-indol-3-yl)methyl)amino)-methyl]cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	458 (M + H)	3
1128	N2-[cis-4-(((2-methoxy-1-naphthyl)methyl)amino)methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	469 (M + H)	3
1129	4-bromo-2-(((cis-4-([4-(dimethylamino)quinolin-2-yl]amino)cyclohexyl)methyl)amino)methyl)-6-methoxyphenol	513 (M + H)	2
1130	N2-[cis-4-(((5-bromo-1H-indol-3-yl)methyl)amino)methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	506 (M + H)	2
1131	N2-(cis-4-(((2,4-dimethoxybenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1132	N4,N4-dimethyl-N2-(cis-4-(((2,3,4-trimethoxybenzyl)amino)methyl)cyclohexyl)-quinoline-2,4-diamine	479 (M + H)	3
1133	4-(((cis-4-([4-(dimethylamino)quinolin-2-yl]amino)cyclohexyl)methyl)amino)methyl)-2,6-dimethoxyphenol	465 (M + H)	3
1134	N2-(cis-4-(((3-ethoxy-4-methoxybenzyl)amino)methyl)-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	463 (M + H)	3
1135	N4,N4-dimethyl-N2-(cis-4-(((3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl)amino)methyl)cyclohexyl)-quinoline-2,4-diamine	523 (M + H)	3
1136	N4,N4-dimethyl-N2-(cis-4-(((3,4,5-trimethoxybenzyl)amino)methyl)cyclohexyl)-quinoline-2,4-diamine	479 (M + H)	3
1137	N4,N4-dimethyl-N2-(cis-4-(((pentamethylbenzyl)amino)methyl)cyclohexyl)-quinoline-2,4-diamine	459 (M + H)	3
1138	N2-(cis-4-(((3,5-dimethoxybenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1139	4-(((cis-4-([4-(dimethylamino)quinolin-2-yl]amino)cyclohexyl)methyl)amino)methyl)-2-iodo-6-methoxyphenol	561 (M + H)	3
1140	4-(((cis-4-([4-(dimethylamino)quinolin-2-yl]amino)cyclohexyl)methyl)amino)methyl)-2,6-dimethylphenol	433 (M + H)	3
1141	N2-(cis-4-(((4-methoxybenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	419 (M + H)	3
1142	N2-(cis-4-(((2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	447 (M + H)	3
1143	N2-(cis-4-(((3-bromobenzyl)amino)methyl)cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	467 (M + H)	3
1144	N2-(cis-4-(((5-bromo-2,4-dimethoxybenzyl)amino)methyl)-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	527 (M + H)	2
1145	N2-(cis-4-(((5-bromo-2-methoxybenzyl)amino)methyl)-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	497 (M + H)	3

Ex. No.	compound name	MS	class
1146	3-chloro-4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	439 (M + H)	3
1147	2-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	414 (M + H)	3
1148	N2-(cis-4-({[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	423 (M + H)	?
1149	N2-(cis-4-({[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	423 (M + H)	3
1150	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	460 (M + H)	3
1151	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	432 (M + H)	3
1152	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	506 (M + H)	3
1153	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	475 (M + H)	3
1154	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	405 (M + H)	3
1155	[5-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol	409 (M + H)	3
1156	N2-(cis-4-({[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	447 (M + H)	3
1157	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	423 (M + H)	3
1158	N2-(cis-4-({[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	491 (M + H)	1
1159	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol	449 (M + H)	3
1160	N2-{cis-4-({[4-(dimethylamino)-1-naphthyl]methyl}amino)-methyl}cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	482 (M + H)	3
1161	N4,N4-dimethyl-N2-(cis-4-({[(2,4,6-trimethoxybenzyl)-amino]methyl}cyclohexyl)quinoline-2,4-diamine	479 (M + H)	2
1162	2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	517 (M + H)	3
1163	3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	414 (M + H)	3
1164	N2-(cis-4-({[(2-fluoro-5-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	437 (M + H)	3
1165	N4,N4-dimethyl-N2-{cis-4-({[2-[(trifluoromethyl)thio]benzyl]-amino}methyl}cyclohexyl]quinoline-2,4-diamine	489 (M + H)	3
1166	N2-(cis-4-({[(5-bromo-2-ethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	511 (M + H)	3
1167	N2-(cis-4-({[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	463 (M + H)	3
1168	N4,N4-dimethyl-N2-[cis-4-({[2-(trifluoromethoxy)benzyl]-amino}methyl)cyclohexyl]-quinoline-2,4-diamine	473 (M + H)	3
1169	N2-(cis-4-({[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	477 (M + H)	2

Ex. No.	compound name	MS	class
1170	N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	477 (M + H)	2
1171	N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	575 (M + H)	2
1172	N2-[cis-4-({[2-(difluoromethoxy)benzyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	455 (M + H)	3
1173	N2-(cis-4-{[(5-fluoro-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	437 (M + H)	3
1174	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	521 (M + H)	2
1175	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}cyclohexyl)-quinoline-2,4-diamine	479 (M + H)	2
1176	N2-(cis-4-{[(2,3-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1177	N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	445 (M + H)	2
1178	N2-(cis-4-{[(1-benzothien-3-ylmethyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	445 (M + H)	3
1179	N4,N4-dimethyl-N2-[cis-4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine	442 (M + H)	3
1180	N4,N4-dimethyl-N2-[cis-4-({[(5-methyl-2-thienyl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine	409 (M + H)	3
1181	N2-(cis-4-{[(mesitylmethyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	431 (M + H)	3
1182	N2-(cis-4-{[(1,3-benzodioxol-5-ylmethyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	433 (M + H)	3
1183	N4,N4-dimethyl-N2-(cis-4-{[(3-thienylmethyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	395 (M + H)	3
1184	N4,N4-dimethyl-N2-(cis-4-{[(3-methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	403 (M + H)	3
1185	N4,N4-dimethyl-N2-(cis-4-{[(2-methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	403 (M + H)	3
1186	N4,N4-dimethyl-N2-(cis-4-{[(4-methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	403 (M + H)	3
1187	N2-(cis-4-{[(3,5-dichlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	457 (M + H)	3
1188	N2-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	463 (M + H)	2
1189	N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	527 (M + H)	3
1190	N2-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	433 (M + H)	3
1191	N2-(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	527 (M + H)	3
1192	N4,N4-dimethyl-N2-[cis-4-({[(2-methyl-5-phenyl-3-furyl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine	469 (M + H)	3
1193	N2-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3

Ex. No.	compound name	MS	class
1194	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-methylphenol	419 (M + H)	3
1195	N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	447 (M + H)	3
1196	2-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol	435 (M + H)	3
1197	N2-[cis-4-({[3-chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	509 (M + H)	3
1198	N2-[cis-4-({[3-fluoro-5-(trifluoromethyl)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	475 (M + H)	3
1199	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-fluoro-6-methoxyphenol	453 (M + H)	3
1200	N2-(cis-4-{[(2-fluoro-4,5-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	467 (M + H)	3
1201	N2-(cis-4-{[(2-ethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	417 (M + H)	3
1202	3-[[4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenyl](methyl)amino]-propanenitrile	471 (M + H)	3
1203	N2-{cis-4-[(4-(4-bromobenzyl)oxy)benzyl]amino}methyl]-cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	573 (M + H)	3
1204	N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	589 (M + H)	3
1205	N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	386 (M + H)	3
1206	N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	370 (M + H)	3
1207	N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	365 (M + H)	3
1208	N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	386 (M + H)	3
1209	N2-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	406 (M + H)	3
1210	N2-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	395 (M + H)	3
1211	N2-(cis-4-{[(2-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	406 (M + H)	3
1212	4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol	450 (M + H)	3
1213	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	443 (M + H)	2
1214	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	386 (M + H)	3
1215	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-trimethoxybenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine	416 (M + H)	3
1216	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol	402 (M + H)	3

Ex. No.	compound name	MS	class
1217	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	3
1218	N4,N4-dimethyl-N2-{cis-4-[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]amino]cyclohexyl}pyrimidine-2,4-diamine	460 (M + H)	3
1219	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine	416 (M + H)	3
1220	N4,N4-dimethyl-N2-{cis-4-[(pentamethylbenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine	396 (M + H)	3
1221	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	386 (M + H)	3
1222	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol	498 (M + H)	3
1223	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol	370 (M + H)	3
1224	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	356 (M + H)	3
1225	N2-{cis-4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	422 (M + H)	3
1226	N4,N4-dimethyl-N2-{cis-4-[(3-phenylbutyl)amino]cyclohexyl}pyrimidine-2,4-diamine	368 (M + H)	3
1227	3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-amino]methyl}-6-methyl-4H-chromen-4-one	408 (M + H)	3
1228	6-chloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-7-methyl-4H-chromen-4-one	442 (M + H)	3
1229	3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-amino]methyl}-6,8-dimethyl-4H-chromen-4-one	422 (M + H)	3
1230	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]-amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	419 (M + H)	3
1231	N4,N4-dimethyl-N2-{cis-4-[(2-phenylpropyl)amino]cyclohexyl}pyrimidine-2,4-diamine	354 (M + H)	3
1232	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	422 (M + H)	3
1233	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-yl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	382 (M + H)	3
1234	6-chloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-4H-chromen-4-one	428 (M + H)	3
1235	N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}-amino)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	421 (M + H)	2
1236	ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate	503 (M - H)	1
1237	methyl 2-[(5-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}imidazo[2,1-b][1,3]thiazol-6-yl)thio]benzoate	538 (M + H)	3
1238	N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}-amino)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	410 (M + H)	3
1239	N4,N4-dimethyl-N2-(cis-4-{[4-(methylthio)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine	372 (M + H)	3

Ex. No.	compound name	MS	class
1240	N4,N4-dimethyl-N2-{cis-4-[(1-naphthylmethyl)amino]cyclohexyl}pyrimidine-2,4-diamine	376 (M + H)	3
1241	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol	372 (M + H)	3
1242	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	378 (M + H)	3
1243	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	2
1244	N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	384 (M + H)	2
1245	N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	379 (M + H)	3
1246	N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	3
1247	N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	420 (M + H)	1
1248	N2-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	407 (M - H)	2
1249	N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	420 (M + H)	1
1250	4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol	462 (M - H)	1
1251	N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	455 (M - H)	1
1252	N2-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	2
1253	N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine	430 (M + H)	1
1254	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethoxyphenol	414 (M - H)	3
1255	N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	414 (M + H)	1
1256	N4,N4-dimethyl-N2-(cis-4-{[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]amino}methyl}cyclohexyl)-pyrimidine-2,4-diamine	474 (M + H)	1
1257	N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine	430 (M + H)	2
1258	N4,N4-dimethyl-N2-(cis-4-{[(pentamethylbenzyl)amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine	410 (M + H)	3
1259	N2-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	3
1260	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol	512 (M + H)	1
1261	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol	382 (M - H)	1
1262	N2-(cis-4-{[(4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	370 (M + H)	3

Ex. No.	compound name	MS	class
1263	N2-(cis-4-{[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino]-methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	398 (M + H)	3
1264	N2-(cis-4-{[(3-bromobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	418 (M + H)	3
1265	N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	478 (M + H)	1
1266	N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	448 (M + H)	1
1267	3-chloro-4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	388 (M - H)	3
1268	2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	365 (M + H)	3
1269	N2-(cis-4-{[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	374 (M + H)	3
1270	N2-(cis-4-{[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	374 (M + H)	3
1271	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	411 (M + H)	2
1272	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	383 (M + H)	3
1273	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}-methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	457 (M + H)	1
1274	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}-methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	426 (M + H)	3
1275	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	354 (M - H)	3
1276	[5-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol	360 (M + H)	3
1277	N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	398 (M + H)	2
1278	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	374 (M + H)	3
1279	N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	442 (M + H)	1
1280	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol	400 (M + H)	2
1281	N2-{cis-4-({[4-(dimethylamino)-1-naphthyl]methyl}amino)-methyl}cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	433 (M + H)	2
1282	N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine	430 (M + H)	1
1283	2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	468 (M + H)	3
1284	3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	365 (M + H)	3
1285	N2-(cis-4-{[(2-fluoro-5-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	388 (M + H)	3
1286	N4,N4-dimethyl-N2-{cis-4-({[2-[(trifluoromethyl)thio]benzyl]-amino}methyl}cyclohexyl}pyrimidine-2,4-diamine	440 (M + H)	3

Ex. No.	compound name	MS	class
1287	N2-(cis-4-{{(5-bromo-2-ethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	462 (M + H)	1
1288	N2-(cis-4-{{(2,4-dimethoxy-3-methylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	414 (M + H)	1
1289	N4,N4-dimethyl-N2-[cis-4-{{[2-(trifluoromethoxy)benzyl]-amino}methyl}cyclohexyl]pyrimidine-2,4-diamine	424 (M + H)	3
1290	N2-(cis-4-{{(2,5-diethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	428 (M + H)	1
1291	N2-(cis-4-{{(2,4-diethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	428 (M + H)	2
1292	N2-(cis-4-{{(3,5-dibromo-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	526 (M + H)	1
1293	N2-[cis-4-{{[2-(difluoromethoxy)benzyl]amino}methyl}-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	406 (M + H)	3
1294	N2-(cis-4-{{(5-fluoro-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	388 (M + H)	3
1295	N4,N4-dimethyl-N2-(cis-4-{{(2,4,5-triethoxybenzyl)-amino}methyl}cyclohexyl)-pyrimidine-2,4-diamine	472 (M + H)	1
1296	N4,N4-dimethyl-N2-(cis-4-{{(2,4,5-trimethoxybenzyl)-amino}methyl}cyclohexyl)-pyrimidine-2,4-diamine	430 (M + H)	2
1297	N2-(cis-4-{{(2,3-dimethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	3
1298	N2-[cis-4-{{[2-(allyloxy)benzyl]amino}methyl}cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	396 (M + H)	1
1299	N2-(cis-4-{{[(1-benzothien-3-yl)methyl]amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	396 (M + H)	3
1300	N4,N4-dimethyl-N2-[cis-4-{{[(1-methyl-1H-indol-3-yl)methyl]amino}methyl}cyclohexyl]pyrimidine-2,4-diamine	393 (M + H)	2
1301	N4,N4-dimethyl-N2-[cis-4-{{[(5-methyl-2-thienyl)methyl]amino}methyl}cyclohexyl]pyrimidine-2,4-diamine	360 (M + H)	3
1302	N2-(cis-4-{{[mesitylmethyl]amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	382 (M + H)	3
1303	N2-(cis-4-{{[(1,3-benzodioxol-5-yl)methyl]amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	384 (M + H)	3
1304	N4,N4-dimethyl-N2-(cis-4-{{[(3-thienyl)methyl]amino}methyl}cyclohexyl)pyrimidine-2,4-diamine	346 (M + H)	3
1305	N4,N4-dimethyl-N2-(cis-4-{{[(3-methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine	354 (M + H)	3
1306	N4,N4-dimethyl-N2-(cis-4-{{[(2-methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine	354 (M + H)	3
1307	N4,N4-dimethyl-N2-(cis-4-{{[(4-methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine	354 (M + H)	3
1308	N2-(cis-4-{{[(3,5-dichlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	408 (M + H)	3
1309	N2-[cis-4-{{[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}-methyl}cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	414 (M + H)	1
1310	N2-(cis-4-{{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	478 (M + H)	1

Ex. No.	compound name	MS	class
1311	N2-(cis-4-{{(4-methoxy-3-methylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	384 (M + H)	2
1312	N2-(cis-4-{{(2-bromo-4,5-dimethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	478 (M + H)	2
1313	N4,N4-dimethyl-N2-[cis-4-{{(2-methyl-5-phenyl-3-furyl)methyl}amino}methyl]cyclohexyl]pyrimidine-2,4-diamine	420 (M + H)	3
1314	N2-(cis-4-{{(3,4-dimethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	400 (M + H)	2
1315	4-{{[(cis-4-{{4-(dimethylamino)pyrimidin-2-yl}amino}cyclohexyl)methyl}amino}methyl)-2-methylphenol	368 (M - H)	3
1316	N2-(cis-4-{{(4-methoxy-2,5-dimethylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	398 (M + H)	2
1317	2-{{[(cis-4-{{4-(dimethylamino)pyrimidin-2-yl}amino}cyclohexyl)methyl}amino}methyl)-6-methoxyphenol	386 (M + H)	3
1318	N2-[cis-4-{{[3-chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino}methyl}cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	460 (M + H)	3
1319	N2-[cis-4-{{[3-fluoro-5-(trifluoromethyl)benzyl]amino}methyl}cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	426 (M + H)	3
1320	4-{{[(cis-4-{{4-(dimethylamino)pyrimidin-2-yl}amino}cyclohexyl)methyl}amino}methyl)-2-fluoro-6-methoxyphenol	402 (M - H)	3
1321	N2-(cis-4-{{(2-fluoro-4,5-dimethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	418 (M + H)	3
1322	N2-(cis-4-{{(2-ethylbenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	368 (M + H)	3
1323	3-[[4-{{[(cis-4-{{4-(dimethylamino)pyrimidin-2-yl}amino}cyclohexyl)methyl}amino}methyl]phenyl}(methyl)amino]-propanenitrile	422 (M + H)	2
1324	N2-{{cis-4-{{[4-(4-bromobenzyl)oxy]benzyl}amino}methyl}-cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	524 (M + H)	2
1325	N2-(cis-4-{{(3,5-dibromo-2-ethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	540 (M + H)	2
1326	N2-{{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	440 (M + H)	3
1327	N2-{{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	424 (M + H)	3
1328	N2-{{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	419 (M + H)	3
1329	N2-{{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	440 (M + H)	3
1330	N2-(cis-4-{{(4-methoxy-1-naphthyl)methyl}amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	460 (M + H)	3
1331	N2-(cis-4-{{(5-methoxy-1H-indol-3-yl)methyl}amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	449 (M + H)	1
1332	N2-(cis-4-{{(2-methoxy-1-naphthyl)methyl}amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	460 (M + H)	3

Ex. No.	compound name	MS	class
1333	4-bromo-2-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol	504 (M + H)	3
1334	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	497 (M + H)	3
1335	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	440 (M + H)	3
1336	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-trimethoxybenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	470 (M + H)	3
1337	4-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol	456 (M + H)	2
1338	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	3
1339	N4,N4-dimethyl-N2-{cis-4-[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	514 (M + H)	3
1340	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	470 (M + H)	3
1341	N4,N4-dimethyl-N2-{cis-4-[(pentamethylbenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	450 (M + H)	2
1342	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	440 (M + H)	2
1343	4-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol	552 (M + H)	2
1344	4-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol	424 (M + H)	3
1345	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	410 (M + H)	3
1346	N2-{cis-4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	476 (M + H)	3
1347	N4,N4-dimethyl-N2-{cis-4-[(3-phenylbutyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	422 (M + H)	3
1348	3-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-6-methyl-4H-chromen-4-one	462 (M + H)	3
1349	6-chloro-3-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-7-methyl-4H-chromen-4-one	496 (M + H)	3
1350	3-{{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-6,8-dimethyl-4H-chromen-4-one	476 (M + H)	2
1351	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	473 (M + H)	3
1352	N4,N4-dimethyl-N2-{cis-4-[(2-phenylpropyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	408 (M + H)	3
1353	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	476 (M + H)	3

Ex. No.	compound name	MS	class
1354	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-yl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	436 (M + H)	3
1355	6-chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-4H-chromen-4-one	482 (M + H)	3
1356	N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}-amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	475 (M + H)	3
1357	ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate	559 (M + H)	1
1358	methyl 2-[(5-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-methyl}imidazo[2,1-b][1,3]thiazol-6-yl)thio]benzoate	592 (M + H)	3
1359	N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	464 (M + H)	1
1360	N4,N4-dimethyl-N2-(cis-4-{[4-(methylthio)benzyl]amino}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	426 (M + H)	3
1361	N4,N4-dimethyl-N2-{cis-4-[(1-naphthylmethyl)amino]-cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine	430 (M + H)	3
1362	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol	426 (M + H)	3
1363	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	432 (M + H)	3
1364	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	1
1365	N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	438 (M + H)	2
1366	N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	433 (M + H)	2
1367	N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	2
1368	N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	474 (M + H)	2
1369	N2-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}-methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	463 (M + H)	1
1370	N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	474 (M + H)	3
1371	4-bromo-2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol	518 (M + H)	2

Ex. No.	compound name	MS	class
1372	N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	511 (M + H)	1
1373	N2-(cis-4-({[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	3
1374	N4,N4-dimethyl-N2-(cis-4-({[(2,3,4-trimethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	484 (M + H)	3
1375	4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethoxyphenol	470 (M + H)	3
1376	N2-(cis-4-({[(3-ethoxy-4-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	468 (M + H)	1
1377	N4,N4-dimethyl-N2-(cis-4-({[(3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]amino}methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	528 (M + H)	2
1378	N4,N4-dimethyl-N2-(cis-4-({[(3,4,5-trimethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	484 (M + H)	2
1379	N4,N4-dimethyl-N2-(cis-4-({[(pentamethylbenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	464 (M + H)	3
1380	N2-(cis-4-({[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	2
1381	4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol	566 (M + H)	1
1382	4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol	438 (M + H)	2
1383	N2-(cis-4-({[(4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	424 (M + H)	3
1384	N2-(cis-4-({[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	452 (M + H)	3
1385	N2-(cis-4-({[(3-bromobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	472 (M + H)	3
1386	N2-(cis-4-({[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	532 (M + H)	3
1387	N2-(cis-4-({[(5-bromo-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	502 (M + H)	3
1388	3-chloro-4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}-methyl)phenol	444 (M + H)	2
1389	2-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	419 (M + H)	3

Ex. No.	compound name	MS	class
1390	N2-(cis-4-{[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	428 (M + H)	3
1391	N2-(cis-4-{[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	428 (M + H)	3
1392	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	465 (M + H)	2
1393	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	437 (M + H)	3
1394	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}-methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	511 (M + H)	3
1395	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}-methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	480 (M + H)	3
1396	4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	410 (M + H)	3
1397	[5-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol	414 (M + H)	3
1398	N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	452 (M + H)	3
1399	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	428 (M + H)	3
1400	N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	496 (M + H)	1
1401	4-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol	454 (M + H)	2
1402	N2-{cis-4-({[4-(dimethylamino)-1-naphthyl]methyl}amino)-methyl}cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	487 (M + H)	2
1403	N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	484 (M + H)	1
1404	2-bromo-4-chloro-6-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol	522 (M + H)	2
1405	3-({[(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile	419 (M + H)	3
1406	N2-(cis-4-{[(2-fluoro-5-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	442 (M + H)	3
1407	N4,N4-dimethyl-N2-{cis-4-({[2-({trifluoromethyl}thio)-benzyl]amino)methyl}cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	494 (M + H)	3

Ex. No.	compound name	MS	class
1408	N2-(cis-4-{{(5-bromo-2-ethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	516 (M + H)	3
1409	N2-(cis-4-{{(2,4-dimethoxy-3-methylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	468 (M + H)	3
1410	N4,N4-dimethyl-N2-[cis-4-{{2-(trifluoromethoxy)benzyl}amino}methyl]cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	478 (M + H)	3
1411	N2-(cis-4-{{(2,5-diethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	482 (M + H)	1
1412	N2-(cis-4-{{(2,4-diethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	482 (M + H)	1
1413	N2-(cis-4-{{(3,5-dibromo-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	580 (M + H)	1
1414	N2-[cis-4-{{2-(difluoromethoxy)benzyl}amino}methyl]-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	460 (M + H)	3
1415	N2-(cis-4-{{(5-fluoro-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	442 (M + H)	3
1416	N4,N4-dimethyl-N2-(cis-4-{{(2,4,5-triethoxybenzyl)amino}methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	526 (M + H)	1
1417	N4,N4-dimethyl-N2-(cis-4-{{(2,4,5-trimethoxybenzyl)amino}methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	484 (M + H)	1
1418	N2-(cis-4-{{(2,3-dimethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	3
1419	N2-[cis-4-{{2-(allyloxy)benzyl}amino}methyl]cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	450 (M + H)	3
1420	N2-(cis-4-{{(1-benzothien-3-ylmethyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	450 (M + H)	3
1421	N4,N4-dimethyl-N2-[cis-4-{{(1-methyl-1H-indol-3-yl)methyl}amino}methyl]cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	447 (M + H)	3
1422	N4,N4-dimethyl-N2-[cis-4-{{(5-methyl-2-thienyl)methyl}amino}methyl]cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	414 (M + H)	3
1423	N2-(cis-4-{{(mesitylmethyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	436 (M + H)	3
1424	N2-(cis-4-{{(1,3-benzodioxol-5-ylmethyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	438 (M + H)	3
1425	N4,N4-dimethyl-N2-(cis-4-{{(3-thienylmethyl)amino}methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	400 (M + H)	3
1426	N4,N4-dimethyl-N2-(cis-4-{{(3-methylbenzyl)amino}methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	408 (M + H)	3

Ex. No.	compound name	MS	class
1427	N4,N4-dimethyl-N2-(cis-4-{{(2-methylbenzyl)amino}methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	408 (M + H)	3
1428	N4,N4-dimethyl-N2-(cis-4-{{(4-methylbenzyl)amino}methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	408 (M + H)	3
1429	N2-(cis-4-{{(3,5-dichlorobenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	462 (M + H)	3
1430	N2-[cis-4-{{(7-methoxy-1,3-benzodioxol-5-yl)methyl}amino}-methyl]cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	468 (M + H)	2
1431	N2-(cis-4-{{(3-bromo-4,5-dimethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	532 (M + H)	3
1432	N2-(cis-4-{{(4-methoxy-3-methylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	438 (M + H)	3
1433	N2-(cis-4-{{(2-bromo-4,5-dimethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	532 (M + H)	3
1434	N4,N4-dimethyl-N2-[cis-4-{{(2-methyl-5-phenyl-3-furyl)methyl}amino}methyl]cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	474 (M + H)	3
1435	N2-(cis-4-{{(3,4-dimethoxybenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	3
1436	4-{{[(cis-4-{{4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl}amino}cyclohexyl)methyl]amino}methyl}-2-methylphenol	424 (M + H)	2
1437	N2-(cis-4-{{(4-methoxy-2,5-dimethylbenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	452 (M + H)	2
1438	2-{{[(cis-4-{{4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl}amino}cyclohexyl)methyl]amino}methyl}-6-methoxyphenol	440 (M + H)	3
1439	N2-[cis-4-{{(3-chloro-2-fluoro-5-(trifluoromethyl)benzyl)amino}methyl}cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	514 (M + H)	3
1440	N2-[cis-4-{{(3-fluoro-5-(trifluoromethyl)benzyl)amino}-methyl}cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	480 (M + H)	3
1441	4-{{[(cis-4-{{4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl}amino}cyclohexyl)methyl]amino}methyl}-2-fluoro-6-methoxyphenol	458 (M + H)	2
1442	N2-(cis-4-{{(2-fluoro-4,5-dimethoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	472 (M + H)	3
1443	N2-(cis-4-{{(2-ethylbenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	422 (M + H)	3
1444	3-[[4-{{[(cis-4-{{4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl}amino}cyclohexyl)methyl]amino}methyl]phenyl](methyl)-amino]propanenitrile	476 (M + H)	3

Ex. No.	compound name	MS	class
1445	N2-{cis-4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	578 (M + H)	3
1446	N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	594 (M + H)	3
1447	N2-(cis-4-{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	467 (M + H)	3
1448	N2-(cis-4-{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	423 (M + H)	-
1449	N2-(cis-4-{[2-(2-chlorophenoxy)ethyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	439 (M + H)	3
1450	N2-{cis-4-[(2-methoxy-2-phenylethyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	419 (M + H)	3
1451	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-cyclohexyl]-quinoline-2,4-diamine	445 (M + H)	3
1452	N2-{cis-4-[(3-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine	419 (M + H)	3
1453	N2-(cis-4-{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	539 (M + H)	3
1454	N2-(cis-4-{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	455 (M + H)	3
1455	3-{[2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]ethyl](phenyl)amino]propanenitrile	457 (M + H)	2
1456	N-{(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide	572 (M + H)	3
1457	(2-{[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylamino]-methyl}-cyclohexyl)-phenyl-methanol	487 (M + H)	3
1458	N2-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	449 (M + H)	3
1459	N4,N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indol-3-yl)ethyl]amino}cyclohexyl)quinoline-2,4-diamine	504 (M + H)	2
1460	N2-(cis-4-{[2,2-bis(4-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	533 (M + H)	3
1461	(3-{(1S)-2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]-1-methylethyl}phenyl)-(phenyl)methanol	509 (M + H)	3
1462	N2-[cis-4-{[1-(diphenylmethyl)azetidin-3-yl]methyl}amino]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	520 (M + H)	1
1463	N2-[cis-4-{[2-(4-bromophenyl)ethyl]amino}methyl]cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	481 (M + H)	3
1464	N2-[cis-4-{[4-(4-methoxyphenyl)butyl]amino}methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	461 (M + H)	3
1465	N4,N4-dimethyl-N2-(cis-4-{[(6-phenylhexyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	459 (M + H)	3
1466	N2-(cis-4-{[(2-mesityl)ethyl]amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	445 (M + H)	3

Ex. No.	compound name	MS	class
1467	N4,N4-dimethyl-N2-(cis-4-{[(8-phenyloctyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	487 (M + H)	3
1468	N2-[cis-4-{[2-(4-tert-butylphenyl)ethyl]amino}methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	459 (M + H)	3
1469	N4,N4-dimethyl-N2-(cis-4-{[(5-phenylpent-4-yn-1-yl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	441 (M + H)	3
1470	N2-[cis-4-{[2-(2-methoxyphenyl)ethyl]amino}methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	433 (M + H)	3
1471	N4,N4-dimethyl-N2-(cis-4-{[(3-phenoxypropyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	433 (M + H)	3
1472	N4,N4-dimethyl-N2-(cis-4-{[(2,3,5,6-tetrafluorobenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine	461 (M + H)	3
1473	N2-(cis-4-{[(2,5-dichlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	457 (M + H)	3
1474	N2-(cis-4-{[(5-chloro-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	453 (M + H)	3
1475	N2-(cis-4-{[(4-chloro-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	453 (M + H)	3
1476	N2-(cis-4-{[(3-iodo-4-methylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine	529 (M + H)	3
1477	N2-[cis-4-{[(2S)-2-(dibenzylamino)propyl]amino}methyl]-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	536 (M + H)	3
1478	N4,N4-dimethyl-N2-[cis-4-{[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino}methyl]cyclohexyl]quinoline-2,4-diamine	497 (M + H)	1
1479	N2-{cis-4-{[(1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-yl)methyl]amino}methyl}cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine	531 (M + H)	1
1480	N4,N4-dimethyl-N2-[cis-4-{[4-(4-nitrophenyl)butyl]amino}methyl]cyclohexyl]quinoline-2,4-diamine	476 (M + H)	3
1481	N2-(cis-4-{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	472 (M + H)	3
1482	N2-(cis-4-{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	428 (M + H)	3
1483	N2-{cis-4-{[2-methoxy-2-phenylethyl]amino}cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	424 (M + H)	3
1484	N2-[4-(2-Methoxy-2-phenyl-ethylamino)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine	424 (M + H)	3
1485	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-cyclohexyl]-5,6,7,8-tetrahydro-quinazoline-2,4-diamine	450 (M + H)	2
1486	N2-{cis-4-{[3-ethoxybenzyl]amino}cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	424 (M + H)	3
1487	N2-(cis-4-{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	544 (M + H)	3
1488	N2-(cis-4-{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	460 (M + H)	3
1489	3-{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]ethyl}(3-methylphenyl)-amino]propanenitrile	476 (M + H)	2

Ex. No.	compound name	MS	class
1490	3-[[2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]ethyl](phenyl)amino]-propanenitrile	462 (M + H)	1
1491	N-[(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]ethyl]-4-methylbenzenesulfonamide	577 (M + H)	1
1492	(2-{[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylamino]-methyl}-cyclohexyl)-phenyl-methanol	490 (M + H)	3
1493	N2-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino} cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	454 (M + H)	2
1494	N4,N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indol-3-yl)ethyl]amino} cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	509 (M + H)	3
1495	N2-(cis-4-{[2,2-bis(4-chlorophenyl)ethyl]amino} cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	538 (M + H)	3
1496	(3-{(1S)-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]-1-methylethyl} phenyl)(phenyl)methanol	512 (M + H)	3
1497	N2-[cis-4-{[1-(diphenylmethyl)azetidin-3-yl]methyl} amino]-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	525 (M + H)	1
1498	N2-[cis-4-{[2-(4-bromophenyl)ethyl]amino} methyl]cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	486 (M + H)	3
1499	N2-[cis-4-{[4-(4-methoxyphenyl)butyl]amino} methyl]-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	466 (M + H)	3
1500	N4,N4-dimethyl-N2-(cis-4-{[(6-phenylhexyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	464 (M + H)	3
1501	N2-(cis-4-{[(2-mesitylethyl)amino]methyl} cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	450 (M + H)	3
1502	N4,N4-dimethyl-N2-(cis-4-{[(8-phenyloctyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	492 (M + H)	3
1503	N2-[cis-4-{[2-(4-tert-butylphenyl)ethyl]amino} methyl]-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	464 (M + H)	3
1504	N2-[cis-4-{[2-(2-methoxyphenyl)ethyl]amino} methyl]-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	438 (M + H)	3
1505	N4,N4-dimethyl-N2-(cis-4-{[(3-phenoxypropyl)amino]methyl} cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine	438 (M + H)	3
1506	N2-(cis-4-{[(5-chloro-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	458 (M + H)	3
1507	N2-(cis-4-{[(4-chloro-2-methoxybenzyl)amino]methyl}-cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	458 (M + H)	3

Ex. No.	compound name	MS	class
1508	N2-(cis-4-{[(3-iodo-4-methylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	534 (M + H)	3
1509	N2-[cis-4-({[(2S)-2-(dibenzylamino)propyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	541 (M + H)	3
1510	N4,N4-dimethyl-N2-[cis-4-({[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino}methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	502 (M + H)	1
1511	N2-{cis-4-([1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-yl]methyl)amino}methylcyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine	536 (M + H)	1
1512	N4,N4-dimethyl-N2-[cis-4-({[4-(4-nitrophenyl)butyl]amino}-methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine	481 (M + H)	3
1513	N2-(cis-4-{{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	418 (M + H)	3
1514	N2-(cis-4-{{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	374 (M + H)	3
1515	N2-(cis-4-{{[2-(2-chlorophenoxy)ethyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	390 (M + H)	3
1516	N2-{cis-4-[(2-methoxy-2-phenylethyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	370 (M + H)	3
1517	N2-[4-(2-Methoxy-2-phenyl-ethylamino)-cyclohexyl]-N4,N4-dimethyl-pyrimidine-2,4-diamine	370 (M + H)	3
1518	N2-(cis-4-{{[2-(4-bromophenoxy)ethyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	434 (M + H)	3
1519	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-cyclohexyl]-pyrimidine-2,4-diamine	396 (M + H)	3
1520	N2-{cis-4-[(3-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine	370 (M + H)	3
1521	N2-(cis-4-{{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	490 (M + H)	3
1522	N2-(cis-4-{{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	406 (M + H)	3
1523	3-[2-[(cis-4-{{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]ethyl}(3-methylphenyl)-amino]propanenitrile	422 (M + H)	3
1524	3-[2-[(cis-4-{{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]propanenitrile	408 (M + H)	3
1525	N2-[cis-4-({[4-(4-methoxyphenyl)butyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	412 (M + H)	3
1526	N4,N4-dimethyl-N2-(cis-4-{{[6-phenylhexyl]amino}methyl}cyclohexyl)pyrimidine-2,4-diamine	410 (M + H)	3
1527	N2-(cis-4-{{[(2-mesitylethyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	396 (M + H)	3
1528	N4,N4-dimethyl-N2-(cis-4-{{[(8-phenyloctyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine	438 (M + H)	3
1529	N2-[cis-4-({[2-(4-tert-butylphenyl)ethyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	410 (M + H)	3

Ex. No.	compound name	MS	class
1530	N4,N4-dimethyl-N2-(cis-4-{{(5-phenylpent-4-yn-1-yl)amino}methyl}cyclohexyl)pyrimidine-2,4-diamine	392 (M + H)	3
1531	N2-[cis-4-{{[2-(2-methoxyphenyl)ethyl]amino}methyl}-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	384 (M + H)	3
1532	N4,N4-dimethyl-N2-(cis-4-{{(3-phenoxypropyl)amino}methyl}cyclohexyl)pyrimidine-2,4-diamine	384 (M + H)	3
1533	N4,N4-dimethyl-N2-(cis-4-{{(2,3,5,6-tetrafluorobenzyl)amino}methyl}cyclohexyl)pyrimidine-2,4-diamine	412 (M + H)	3
1534	N2-(cis-4-{{(2,5-dichlorobenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	408 (M + H)	3
1535	N2-(cis-4-{{(5-chloro-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	404 (M + H)	3
1536	N2-(cis-4-{{(4-chloro-2-methoxybenzyl)amino}methyl}-cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	404 (M + H)	3
1537	N2-(cis-4-{{(3-iodo-4-methylbenzyl)amino}methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine	480 (M + H)	3
1538	N2-[cis-4-{{[(2S)-2-(dibenzylamino)propyl]amino}methyl}-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine	487 (M + H)	3
1539	2-(benzyloxy)ethyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	463 (M + H)	3
1540	2,2-dimethylpropyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	399 (M + H)	3
1541	"[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester	524 (M + H)	2
1542	3-(trifluoromethyl)phenyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	473 (M + H)	3
1543	4-bromophenyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	483 (M + H)	3
1544	2-methoxyphenyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	435 (M + H)	3
1545	2-methoxyethyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	387 (M + H)	3
1546	octyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	441 (M + H)	3
1547	ethyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	357 (M + H)	3
1548	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester	464 (M + H)	3
1549	2-naphthyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	455 (M + H)	3
1550	allyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	369 (M + H)	3
1551	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester	419 (M + H)	3
1552	phenyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	405 (M + H)	3
1553	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl})carbamate	467 (M + H)	3

Ex. No.	compound name	MS	class
1554	4-methylphenyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	419 (M + H)	3
1555	methyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	343 (M + H)	3
1556	2-chlorobenzyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	453 (M + H)	3
1557	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	507 (M + H)	3
1558	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate	459 (M + H)	3
1559	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	477 (M + H)	3
1560	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	413 (M + H)	3
1561	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	538 (M + H)	3
1562	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	487 (M + H)	3
1563	4-bromophenyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	497 (M + H)	3
1564	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	449 (M + H)	3
1565	2-methoxyethyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	401 (M + H)	3
1566	octyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	455 (M + H)	3
1567	ethyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	371 (M + H)	3
1568	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	478 (M + H)	3
1569	2-naphthyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	469 (M + H)	3
1570	allyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	383 (M + H)	3
1571	benzyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	433 (M + H)	3
1572	phenyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	419 (M + H)	3
1573	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-carbamate	481 (M + H)	3
1574	4-methylphenyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	433 (M + H)	3
1575	methyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	357 (M + H)	3
1576	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	467 (M + H)	3

Ex. No.	compound name	MS	class
1577	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	521 (M + H)	3
1578	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]carbamate	473 (M + H)	3
1579	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	468 (M + H)	3
1580	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	404 (M + H)	3
1581	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester	529 (M + H)	2
1582	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	478 (M + H)	3
1583	4-bromophenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	488 (M + H)	3
1584	2-methoxyphenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	440 (M + H)	3
1585	2-methoxyethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	392 (M + H)	3
1586	octyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	446 (M + H)	3
1587	ethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	362 (M + H)	3
1588	4-nitrobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	469 (M + H)	3
1589	2-naphthyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	460 (M + H)	3
1590	allyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	374 (M + H)	3
1591	benzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	424 (M + H)	3
1592	phenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	410 (M + H)	3
1593	(2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	472 (M + H)	3
1594	4-methylphenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	424 (M + H)	3
1595	methyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	348 (M + H)	3
1596	2-chlorobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	458 (M + H)	3
1597	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	512 (M + H)	3
1598	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate	464 (M + H)	3
1599	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate	482 (M + H)	3

Ex. No.	compound name	MS	class
1600	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	418 (M + H)	3
1601	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	543 (M + H)	3
1602	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	492 (M + H)	3
1603	4-bromophenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	502 (M + H)	3
1604	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	454 (M + H)	3
1605	2-methoxyethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	406 (M + H)	3
1606	octyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	460 (M + H)	3
1607	ethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	376 (M + H)	3
1608	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester	483 (M + H)	3
1609	2-naphthyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	474 (M + H)	3
1610	allyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	388 (M + H)	3
1611	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester	438 (M + H)	3
1612	phenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	424 (M + H)	3
1613	(2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	486 (M + H)	3
1614	4-methylphenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	438 (M + H)	3
1615	methyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	362 (M + H)	3
1616	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	472 (M + H)	3
1617	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	526 (M + H)	3
1618	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)methyl]carbamate	478 (M + H)	3
1619	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)carbamate	414 (M + H)	3
1620	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)carbamate	350 (M + H)	3
1621	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester	475 (M + H)	3
1622	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)carbamate	424 (M + H)	3

Ex. No.	compound name	MS	class
1623	4-bromophenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	434 (M + H)	3
1624	2-methoxyphenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	386 (M + H)	3
1625	2-methoxyethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	338 (M + H)	3
1626	octyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	392 (M + H)	3
1627	ethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	308 (M + H)	3
1628	4-nitrobenzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	415 (M + H)	3
1629	2-naphthyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	406 (M + H)	3
1630	allyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	320 (M + H)	3
1631	benzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	370 (M + H)	3
1632	phenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	356 (M + H)	3
1633	(2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	418 (M + H)	3
1634	4-methylphenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	370 (M + H)	3
1635	methyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	294 (M + H)	3
1636	2-chlorobenzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	404 (M + H)	3
1637	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	458 (M + H)	3
1638	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate	410 (M + H)	3
1639	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	428 (M + H)	3
1640	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	364 (M + H)	3
1641	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	489 (M + H)	3
1642	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	438 (M + H)	3
1643	4-bromophenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	448 (M + H)	3
1644	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	400 (M + H)	3
1645	2-methoxyethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	352 (M + H)	3
1646	octyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate	406 (M + H)	3

Ex. No.	compound name	MS	class
1647	ethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	322 (M + H)	3
1648	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester	429 (M + H)	3
1649	2-naphthyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	420 (M + H)	3
1650	allyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	334 (M + H)	3
1651	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester	384 (M + H)	3
1652	phenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	370 (M + H)	3
1653	(2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]-carbamate	432 (M + H)	3
1654	4-methylphenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	384 (M + H)	3
1655	methyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	308 (M + H)	3
1656	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	418 (M + H)	3
1657	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	472 (M + H)	3
1658	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]carbamate	424 (M + H)	3
1659	N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	443 (M + H)	3
1660	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2,6-dimethylphenyl)urea	437 (M + H)	3
1661	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	445 (M + H)	3
1662	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea	451 (M + H)	1
1663	ethyl N-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]carbonyl)leucinate	475 (M + H)	3
1664	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluorophenyl)urea	427 (M + H)	2
1665	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(4-methylthio)phenyl)urea	455 (M + H)	3
1666	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-(trifluoromethyl)phenyl)urea	477 (M + H)	3
1667	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-mesitylurea	451 (M + H)	1
1668	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-methylphenyl)urea	423 (M + H)	3
1669	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea	511 (M + H)	2

Ex. No.	compound name	MS	class
1670	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea	642 (M + H)	1
1671	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	583 (M + H)	2
1672	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	465 (M + H)	1
1673	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	511 (M + H)	3
1674	N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
1675	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	2
1676	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea	479 (M + H)	2
1677	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea	437 (M + H)	2
1678	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea	535 (M + H)	3
1679	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea	465 (M + H)	2
1680	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)urea	451 (M + H)	3
1681	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea	468 (M + H)	3
1682	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea	451 (M + H)	3
1683	N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	479 (M + H)	2
1684	N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	465 (M + H)	3
1685	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
1686	N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	523 (M + H)	3
1687	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	511 (M + H)	3
1688	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	434 (M + H)	3
1689	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea	499 (M + H)	1
1690	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	515 (M + H)	1
1691	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	490 (M + H)	1
1692	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]-urea	481 (M + H)	3

Ex. No.	compound name	MS	class
1693	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	487 (M + H)	3
1694	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	485 (M + H)	3
1695	N-butyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	389 (M + H)	3
1696	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2,3-dimethylphenyl)urea	437 (M + H)	3
1697	ethyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]carbonyl}amino)-benzoate	481 (M + H)	3
1698	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]-urea	491 (M + H)	3
1699	methyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]carbonyl}methioninate	479 (M + H)	3
1700	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-1-naphthylurea	459 (M + H)	2
1701	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea	449 (M + H)	3
1702	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(4-phenoxyphenyl)urea	501 (M + H)	3
1703	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-pentylurea	403 (M + H)	3
1704	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-[1-(1-naphthyl)ethyl]urea	487 (M + H)	1
1705	methyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)amino]carbonyl}-phenylalaninate	495 (M + H)	3
1706	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(1-phenylethyl)urea	437 (M + H)	3
1707	1-[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	437 (M + H)	3
1708	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea	545 (M + H)	3
1709	N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	565 (M + H)	2
1710	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	491 (M + H)	2
1711	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)urea	469 (M + H)	2
1712	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)urea	453 (M + H)	2
1713	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-fluorobenzyl)urea	441 (M + H)	2
1714	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea	468 (M + H)	3

Ex. No.	compound name	MS	class
1715	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea	468 (M + H)	3
1716	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea	437 (M + H)	3
1717	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea	454 (M + H)	3
1718	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	453 (M + H)	3
1719	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea	499 (M + H)	1
1720	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	469 (M + H)	2
1721	N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	473 (M + H)	3
1722	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	555 (M + H)	3
1723	N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	501 (M + H)	3
1724	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	2
1725	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea	441 (M + H)	2
1726	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea	453 (M + H)	2
1727	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	503 (M + H)	1
1728	N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	515 (M + H)	2
1729	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	501 (M + H)	2
1730	ethyl N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl]-phenylalaninate	509 (M + H)	3
1731	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	467 (M + H)	3
1732	N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	607 (M + H)	3
1733	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	523 (M + H)	3
1734	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	481 (M + H)	3
1735	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	479 (M + H)	3
1736	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea	490 (M + H)	1

Ex. No.	compound name	MS	class
1737	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	503 (M + H)	3
1738	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	450 (M + H)	3
1739	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1740	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	485 (M + H)	1
1741	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)thiourea	453 (M + H)	3
1742	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)thiourea	495 (M + H)	3
1743	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)thiourea	455 (M + H)	3
1744	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea	475 (M + H)	3
1745	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea	515 (M + H)	1
1746	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	485 (M + H)	1
1747	N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	518 (M + H)	2
1748	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)thiourea	453 (M + H)	3
1749	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)thiourea	500 (M + H)	3
1750	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)thiourea	469 (M + H)	2
1751	N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	537 (M + H)	1
1752	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)thiourea	551 (M + H)	2
1753	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea	658 (M + H)	1
1754	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)thiourea	527 (M + H)	2
1755	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea	467 (M + H)	1
1756	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)thiourea	453 (M + H)	2
1757	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	481 (M + H)	1
1758	N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	3
1759	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3

Ex. No.	compound name	MS	class
1760	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea	467 (M + H)	3
1761	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)thiourea	467 (M + H)	3
1762	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-benzoate	483 (M + H)	3
1763	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	531 (M + H)	1
1764	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	1
1765	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	571 (M + H)	1
1766	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	1
1767	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)thiourea	489 (M + H)	3
1768	N-(2,3-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	499 (M + H)	3
1769	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea	467 (M + H)	3
1770	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	501 (M + H)	3
1771	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea	482 (M - H)	3
1772	N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
1773	ethyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-benzoate	497 (M + H)	3
1774	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	527 (M + H)	2
1775	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea	457 (M + H)	2
1776	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea	469 (M + H)	2
1777	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	519 (M + H)	1
1778	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(1R)-1-phenylethylthiourea	453 (M + H)	3
1779	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea	453 (M + H)	3
1780	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	599 (M + H)	2

Ex. No.	compound name	MS	class
1781	N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	507 (M + H)	1
1782	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)thiourea	469 (M + H)	2
1783	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea	481 (M + H)	3
1784	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
1785	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	469 (M + H)	3
1786	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
1787	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	587 (M + H)	2
1788	N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	519 (M + H)	2
1789	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea	506 (M + H)	3
1790	1-Bicyclo[2.2.1]hept-2-yl-3-[4-(4-dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)-cyclohexyl]-thiourea	443 (M + H)	3
1791	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4-methylthiophene-2-carboxylate	503 (M + H)	3
1792	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-thiophene-2-carboxylate	489 (M + H)	3
1793	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	495 (M + H)	3
1794	N-(3,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
1795	N-(2,3-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	2
1796	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylphenyl)urea	423 (M + H)	2
1797	N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	493 (M + H)	2
1798	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethyl-6-nitrophenyl)urea	482 (M + H)	3
1799	N-(2,6-dibromo-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	583 (M + H)	3
1800	N-(2,6-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
1801	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)urea	453 (M + H)	3

Ex. No.	compound name	MS	class
1802	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-6-nitrophenyl)urea	468 (M + H)	3
1803	N-(3,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	445 (M + H)	3
1804	N-(3,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	445 (M + H)	3
1805	N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	461 (M + H)	3
1806	N-(3-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	451 (M + H)	3
1807	N-1-adamantyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	467 (M + H)	3
1808	N-(4-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	451 (M + H)	3
1809	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}benzamide	437 (M + H)	3
1810	N-(tert-butyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	389 (M + H)	3
1811	N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	545 (M + H)	3
1812	N-benzyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	423 (M + H)	3
1813	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	487 (M + H)	3
1814	N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	443 (M + H)	3
1815	N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	443 (M + H)	3
1816	N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	415 (M + H)	3
1817	N-(3-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	434 (M + H)	3
1818	N-(3,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
1819	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
1820	N-(2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	445 (M + H)	3
1821	N-(2,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
1822	ethyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}glycinate	419 (M + H)	3
1823	ethyl 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	481 (M + H)	3
1824	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)urea	437 (M + H)	3

Ex. No.	compound name	MS	class
1825	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-ethylurea	361 (M + H)	3
1826	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-3-nitrophenyl)urea	472 (M + H)	3
1827	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorophenyl)urea	427 (M + H)	3
1828	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorophenyl)urea	427 (M + H)	3
1829	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-isopropylphenyl)urea	451 (M + H)	3
1830	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-isopropylurea	375 (M + H)	3
1831	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxyphenyl)urea	439 (M + H)	3
1832	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methyl-2-nitrophenyl)urea	468 (M + H)	3
1833	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)urea	439 (M + H)	3
1834	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxyphenyl)urea	439 (M + H)	3
1835	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybenzyl)urea	453 (M + H)	3
1836	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylbenzyl)urea	437 (M + H)	3
1837	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-propylurea	375 (M + H)	3
1838	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[3-(trifluoromethyl)phenyl]urea	477 (M + H)	3
1839	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[3-(triethoxysilyl)propyl]urea	537 (M + H)	3
1840	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylphenyl)urea	423 (M + H)	3
1841	N-(3-chloro-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
1842	1-[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3-(1-naphthalen-1-yl-ethyl)-urea	487 (M + H)	3
1843	N-[2-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	475 (M + H)	3
1844	methyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	467 (M + H)	3
1845	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(methylthio)phenyl]urea	455 (M + H)	3
1846	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trichlorophenyl)urea	511 (M + H)	2
1847	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)urea	437 (M + H)	3

Ex. No.	compound name	MS	class
1848	N-(2,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	445 (M + H)	3
1849	N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	469 (M + H)	2
1850	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,5-dimethylphenyl)urea	437 (M + H)	3
1851	N-(2-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	499 (M + H)	3
1852	N-(2-bromo-4,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	523 (M + H)	3
1853	N-[2-chloro-4-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-urea	511 (M + H)	3
1854	N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	488 (M + H)	3
1855	N-[2-chloro-5-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-urea	511 (M + H)	3
1856	N-(2-chloro-5-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
1857	ethyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	481 (M + H)	3
1858	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-fluoro-3-(trifluoromethyl)phenyl]-urea	495 (M + H)	3
1859	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-urea	495 (M + H)	3
1860	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluoro-5-methylphenyl)urea	441 (M + H)	3
1861	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)urea	484 (M + H)	3
1862	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-nitrophenyl)urea	484 (M + H)	3
1863	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-2-naphthylurea	459 (M + H)	3
1864	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenoxyphenyl)urea	501 (M + H)	3
1865	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-(methylthio)phenyl)urea	455 (M + H)	3
1866	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-[(trifluoromethyl)thio]phenyl)urea	509 (M + H)	3
1867	N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	491 (M + H)	3
1868	N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	469 (M + H)	3

Ex. No.	compound name	MS	class
1869	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylphenyl)urea	437 (M + H)	3
1870	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	467 (M + H)	3
1871	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)urea	437 (M + H)	3
1872	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[3-fluoro-5-(trifluoromethyl)phenyl]-urea	495 (M + H)	3
1873	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)urea	441 (M + H)	3
1874	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-nitrophenyl)urea	454 (M + H)	3
1875	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-phenoxyphenyl)urea	501 (M + H)	3
1876	N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	475 (M + H)	3
1877	butyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	509 (M + H)	3
1878	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(trifluoromethyl)phenyl]urea	477 (M + H)	3
1879	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-{4-[(trifluoromethyl)thio]phenyl}urea	509 (M + H)	3
1880	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4,5-dimethyl-2-nitrophenyl)urea	482 (M + H)	3
1881	N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	515 (M + H)	3
1882	N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	499 (M + H)	3
1883	N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	521 (M + H)	2
1884	N-(4-bromo-2-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	505 (M + H)	3
1885	N-(4-bromo-3-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	501 (M + H)	3
1886	N-(4-chloro-2-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	488 (M + H)	3
1887	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	511 (M + H)	3
1888	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethoxyphenyl)urea	453 (M + H)	3
1889	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-nitrophenyl)urea	472 (M + H)	3
1890	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-urea	495 (M + H)	3

Ex. No.	compound name	MS	class
1891	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(heptyloxy)phenyl]urea	523 (M + H)	3
1892	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)urea	535 (M + H)	3
1893	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-nitrophenyl)urea	484 (M + H)	3
1894	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methyl-3-nitrophenyl)urea	468 (M + H)	3
1895	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylbenzyl)urea	437 (M + H)	3
1896	N-(4-butoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	481 (M + H)	3
1897	N-(4-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	465 (M + H)	3
1898	N-biphenyl-4-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	485 (M + H)	3
1899	N-(5-chloro-2-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	473 (M + H)	3
1900	N-(5-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
1901	N-(5-chloro-2-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	488 (M + H)	3
1902	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(5-fluoro-2-methylphenyl)urea	441 (M + H)	3
1903	N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	449 (M + H)	3
1904	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-9H-fluoren-2-ylurea	497 (M + H)	3
1905	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-9H-fluoren-9-ylurea	497 (M + H)	3
1906	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenylethyl)urea	437 (M + H)	3
1907	N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	401 (M + H)	3
1908	methyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	467 (M + H)	3
1909	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethoxy)phenyl]urea	493 (M + H)	2
1910	butyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-benzoate	509 (M + H)	3
1911	dimethyl 5-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-isophthalate	525 (M + H)	3
1912	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(trifluoromethoxy)phenyl]urea	493 (M + H)	3

Ex. No.	compound name	MS	class
1913	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea	539 (M + H)	3
1914	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(2-thienyl)ethyl]urea	443 (M + H)	3
1915	N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	434 (M + H)	3
1916	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-2-thienylurea	415 (M + H)	3
1917	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-3-thienylurea	415 (M + H)	3
1918	N-(4-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	465 (M + H)	3
1919	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(5-phenyl-2-thienyl)urea	491 (M + H)	3
1920	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea	485 (M + H)	3
1921	benzyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)-piperidine-1-carboxylate	550 (M + H)	3
1922	N-[4-(dimethylamino)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	452 (M + H)	3
1923	N-(2,6-dichloropyridin-4-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea	478 (M + H)	3
1924	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylisoxazol-4-yl)urea	428 (M + H)	3
1925	N-(3-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	467 (M + H)	3
1926	N-(4-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	465 (M - H)	3
1927	N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	561 (M + H)	3
1928	N-benzyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	439 (M + H)	3
1929	N-(3-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	503 (M + H)	3
1930	N-butyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	405 (M + H)	3
1931	N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	431 (M + H)	3
1932	N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	417 (M + H)	3
1933	N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	459 (M + H)	3
1934	N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	459 (M + H)	3

Ex. No.	compound name	MS	class
1935	N-(2,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	461 (M + H)	3
1936	N-(2,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1937	N-(3,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1938	N-(2,6-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1939	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethoxyphenyl)thiourea	469 (M + H)	3
1940	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-furylmethyl)thiourea	429 (M + H)	3
1941	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorophenyl)thiourea	443 (M + H)	3
1942	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-hexylthiourea	433 (M + H)	3
1943	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(trans-4-propylcyclohexyl)phenyl]-thiourea	549 (M + H)	3
1944	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-isobutylthiourea	405 (M + H)	3
1945	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybiphenyl-3-yl)thiourea	531 (M + H)	3
1946	N-(1,3-benzodioxol-5-ylmethyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
1947	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylphenyl)thiourea	439 (M + H)	3
1948	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(methylthio)phenyl]thiourea	471 (M + H)	3
1949	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxyphenyl)thiourea	453 (M - H)	3
1950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylprop-2-en-1-yl)thiourea	403 (M + H)	3
1951	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-methylthiourea	363 (M + H)	3
1952	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-nitrophenyl)thiourea	470 (M + H)	3
1953	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-nitrophenyl)thiourea	470 (M + H)	3
1954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(1,1,3,3-tetramethylbutyl)thiourea	461 (M + H)	3
1955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-phenylthiourea	425 (M + H)	3
1956	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-propylthiourea	391 (M + H)	3
1957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[3-(trifluoromethyl)phenyl]thiourea	493 (M + H)	3

Ex. No.	compound name	MS	class
1958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(tetrahydrofuran-2-ylmethyl)thiourea	433 (M + H)	3
1959	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylphenyl)thiourea	439 (M + H)	3
1960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)thiourea	439 (M + H)	3
1961	N-(tert-butyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	405 (M + H)	3
1962	N-1-adamantyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
1963	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	503 (M + H)	3
1964	N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	459 (M + H)	3
1965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenylethyl)thiourea	453 (M + H)	3
1966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)thiourea	453 (M + H)	3
1967	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(methylthio)phenyl]thiourea	471 (M + H)	3
1968	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethoxy)phenyl]thiourea	509 (M + H)	3
1969	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethyl)phenyl]thiourea	493 (M + H)	3
1970	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,4-trifluorophenyl)thiourea	479 (M + H)	3
1971	N-(2,3-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1972	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	461 (M + H)	3
1973	N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	485 (M + H)	3
1974	N-(2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	461 (M + H)	3
1975	N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	504 (M + H)	3
1976	N-[2-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	491 (M + H)	3
1977	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-thiourea	511 (M + H)	3
1978	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorophenyl)thiourea	443 (M + H)	3
1979	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)thiourea	551 (M + H)	3
1980	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-{3-[(trifluoromethyl)thio]phenyl}-thiourea	525 (M + H)	3

Ex. No.	compound name	MS	class
1981	N-(3,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	493 (M + H)	3
1982	N-(3,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	461 (M + H)	3
1983	N-(3-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	450 (M + H)	3
1984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorophenyl)thiourea	443 (M + H)	3
1985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-iodophenyl)thiourea	551 (M + H)	3
1986	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxyphenyl)thiourea	455 (M + H)	3
1987	N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	491 (M + H)	3
1988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(trifluoromethoxy)phenyl]thiourea	509 (M + H)	3
1989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(trifluoromethyl)phenyl]thiourea	493 (M + H)	3
1990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-{4-[(trifluoromethyl)thio]phenyl}-thiourea	525 (M + H)	3
1991	N-(4-bromo-2-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	520 (M)	3
1992	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	527 (M + H)	3
1993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-thiourea	511 (M + H)	3
1994	N-(5-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
1995	N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	443 (M + H)	3
1996	tert-butyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-phenyl]carbamate	540 (M + H)	3
1997	N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	513 (M + H)	3
1998	N-[2-(4-chlorophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	487 (M + H)	3
1999	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,4,5-tetrachlorophenyl)thiourea	561 (M + H)	3
2000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trichlorophenyl)thiourea	527 (M + H)	3
2001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trifluorophenyl)thiourea	479 (M + H)	3
2002	N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	509 (M + H)	3

Ex. No.	compound name	MS	class
2003	N-[2-chloro-5-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-thiourea	527 (M + H)	3
2004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[3-(methylthio)phenyl]thiourea	471 (M + H)	3
2005	N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	507 (M + H)	3
2006	N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	485 (M + H)	3
2007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylphenyl)thiourea	453 (M + H)	3
2008	N-[3-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	531 (M + H)	3
2009	3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoic acid	469 (M + H)	3
2010	N-(3-chloro-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
2011	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-phenylpropyl)thiourea	467 (M + H)	3
2012	N-[4-(diethylamino)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	496 (M + H)	3
2013	ethyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-benzoate	497 (M + H)	3
2014	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[1-(4-fluorophenyl)ethyl]thiourea	471 (M + H)	3
2015	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)thiourea	457 (M + H)	3
2016	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-isopropylphenyl)thiourea	466 (M)	3
2017	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-nitrophenyl)thiourea	500 (M + H)	3
2018	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybenzyl)thiourea	469 (M + H)	3
2019	methyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-benzoate	483 (M + H)	3
2020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methyl-2-nitrophenyl)thiourea	484 (M + H)	3
2021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylbenzyl)thiourea	453 (M + H)	3
2022	N-(4-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	481 (M + H)	3
2023	N-(5-chloro-2-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	489 (M + H)	3
2024	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(1-phenylethyl)thiourea	453 (M + H)	3

Ex. No.	compound name	MS	class
2025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)thiourea	515 (M + H)	3
2026	N-cyclododecyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	515 (M + H)	3
2027	N-(cyclohexylmethyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	445 (M + H)	3
2028	N-cyclooctyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	459 (M + H)	3
2029	N-cyclopropyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	389 (M + H)	3
2030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,2-diphenylethyl)thiourea	529 (M)	2
2031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)thiourea	561 (M + H)	3
2032	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	507 (M + H)	3
2033	N-(2,5-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	581 (M + H)	3
2034	N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	513 (M + H)	3
2035	N-(2-chloro-5-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	504 (M + H)	3
2036	N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	450 (M + H)	3
2037	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)thiourea	457 (M + H)	3
2038	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}-2-furamide	443 (M + H)	3
2039	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-nitrophenyl)thiourea	500 (M + H)	3
2040	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)thiourea	453 (M + H)	3
2041	N-(3,4-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	499 (M + H)	3
2042	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)thiourea	453 (M + H)	3
2043	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)thiourea	457 (M + H)	3
2044	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxybenzyl)thiourea	469 (M + H)	3
2045	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylbenzyl)thiourea	453 (M + H)	3
2046	N-(4-bromo-3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	537 (M + H)	3
2047	N-(4-bromo-3-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	3
2048	N-(4-decylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	565 (M + H)	3

Ex. No.	compound name	MS	class
2049	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(4-nitrophenoxy)phenyl]thiourea	562 (M + H)	3
2050	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-{4-[(4-nitrophenyl)thio]phenyl}thiourea	578 (M + H)	3
2051	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-benzenesulfonamide	502 (M - H)	3
2052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[2-(4-methylphenyl)ethyl]thiourea	467 (M + H)	3
2053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)thiourea	517 (M + H)	3
2054	N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	465 (M + H)	3
2055	N-cycloheptyl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	445 (M + H)	3
2056	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-prop-2-yn-1-ylthiourea	387 (M + H)	3
2057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(piperidin-1-ylsulfonyl)phenyl]thiourea	572 (M + H)	3
2058	N-(2-cyclohex-1-en-1-ylethyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	457 (M + H)	3
2059	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2,5-dimethylphenyl)thiourea	453 (M + H)	3
2060	N-(2-bromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	545 (M + H)	3
2061	N-(2-bromo-5-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	521 (M + H)	3
2062	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxybenzyl)thiourea	469 (M + H)	3
2063	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,4-dimethylphenyl)thiourea	453 (M + H)	3
2064	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenylbutyl)thiourea	481 (M + H)	3
2065	N-(4-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	481 (M + H)	3
2066	N-(5-chloro-2-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	477 (M + H)	3
2067	N-bicyclo[2.2.1]hept-5-en-2-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	441 (M + H)	3
2068	N-(cyclopropylmethyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	403 (M + H)	3
2069	ethyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	557 (M + H)	3
2070	N-(2-bromo-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	521 (M + H)	3

Ex. No.	compound name	MS	class
2071	N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	477 (M + H)	3
2072	N-[4-(dimethylamino)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	468 (M + H)	3
2073	N-[3-(diethylamino)propyl]-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	462 (M + H)	3
2074	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-morpholin-4-ylethyl)thiourea	462 (M + H)	3
2075	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenanthro[9,10-d][1,3]oxazol-2-ylphenyl)thiourea	642 (M + H)	3
2076	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-pyridin-3-ylthiourea	426 (M + H)	3
2077	N-(4-{(E)-[4-(dimethylamino)phenyl]diazenyl}phenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	572 (M + H)	3
2078	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3-morpholin-4-ylpropyl)thiourea	476 (M + H)	3
2079	N-(4-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
2080	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-{4-[(E)-phenyldiazenyl]phenyl}thiourea	529 (M + H)	3
2081	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(2-piperidin-1-ylethyl)thiourea	460 (M + H)	3
2082	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(1H-pyrazol-1-yl)phenyl]thiourea	491 (M + H)	3
2083	N-2,1,3-benzothiadiazol-4-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
2084	N-2,1,3-benzothiadiazol-5-yl-N'-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
2085	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylisoxazol-4-yl)thiourea	444 (M + H)	3
2086	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-[4-(1,3-oxazol-5-yl)phenyl]thiourea	492 (M + H)	3
2087	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(6-morpholin-4-ylpyridin-3-yl)thiourea	511 (M + H)	3
2088	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N'-(6-phenoxy pyridin-3-yl)thiourea	518 (M + H)	3
2089	N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	438 (M + H)	2
2090	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)urea	432 (M + H)	3
2091	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	440 (M + H)	3
2092	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea	446 (M + H)	2
2093	ethyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonyl} leucinate	470 (M + H)	3

Ex. No.	compound name	MS	class
2094	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-fluorophenyl)urea	422 (M + H)	3
2095	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-(methylthio)phenyl)urea	450 (M + H)	3
2096	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-(trifluoromethyl)phenyl)urea	472 (M + H)	3
2097	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-mesitylurea	446 (M + H)	1
2098	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)urea	418 (M + H)	3
2099	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea	506 (M + H)	2
2100	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea	637 (M + H)	1
2101	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	578 (M + H)	2
2102	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	460 (M + H)	1
2103	N-(2-chloro-6-(trifluoromethyl)phenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	506 (M + H)	3
2104	N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	452 (M + H)	3
2105	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	452 (M + H)	2
2106	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea	474 (M + H)	2
2107	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea	432 (M + H)	3
2108	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea	530 (M + H)	3
2109	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea	460 (M + H)	2
2110	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)urea	446 (M + H)	3
2111	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea	463 (M + H)	3
2112	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea	446 (M + H)	3
2113	N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	474 (M + H)	1
2114	N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	460 (M + H)	3
2115	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	452 (M + H)	3
2116	N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	518 (M + H)	3
2117	N-(4-chloro-2-(trifluoromethyl)phenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	506 (M + H)	3

Ex. No.	compound name	MS	class
2118	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	429 (M + H)	3
2119	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea	494 (M + H)	2
2120	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	510 (M + H)	1
2121	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	485 (M + H)	2
2122	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	476 (M + H)	3
2123	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	482 (M + H)	3
2124	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	480 (M + H)	3
2125	N-butyl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	384 (M + H)	3
2126	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)urea	432 (M + H)	3
2127	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate	476 (M + H)	3
2128	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea	486 (M + H)	3
2129	methyl N-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonyl}methioninate	474 (M + H)	3
2130	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-1-naphthylurea	454 (M + H)	1
2131	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea	444 (M + H)	3
2132	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)urea	496 (M + H)	3
2133	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-pentylurea	398 (M + H)	3
2134	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[1-(1-naphthyl)ethyl]urea	482 (M + H)	1
2135	methyl N-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate	490 (M + H)	2
2136	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(1-phenylethyl)urea	432 (M + H)	3
2137	1-[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	432 (M + H)	3
2138	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea	540 (M + H)	3
2139	N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	560 (M + H)	3
2140	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	486 (M + H)	3
2141	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea	464 (M + H)	3

Ex. No.	compound name	MS	class
2142	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)urea	448 (M + H)	3
2143	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-fluorobenzyl)urea	436 (M + H)	3
2144	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea	463 (M + H)	3
2145	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea	463 (M + H)	3
2146	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-methylbenzyl)urea	432 (M + H)	3
2147	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(2-nitrophenyl)urea	449 (M + H)	3
2148	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	448 (M + H)	3
2149	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea	494 (M + H)	1
2150	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	464 (M + H)	3
2151	N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	468 (M + H)	3
2152	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	550 (M + H)	3
2153	N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	496 (M + H)	3
2154	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	452 (M + H)	3
2155	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(4-fluorobenzyl)urea	436 (M + H)	3
2156	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea	448 (M + H)	3
2157	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	498 (M + H)	1
2158	N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	510 (M + H)	3
2159	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	496 (M + H)	2
2160	ethyl N-{{{[cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl]amino} carbonyl} phenylalaninate	504 (M + H)	3
2161	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	462 (M + H)	3
2162	N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	602 (M + H)	3
2163	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	518 (M + H)	3
2164	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	476 (M + H)	3
2165	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)urea	474 (M + H)	3

Ex. No.	compound name	MS	class
2166	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea	485 (M + H)	3
2167	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	498 (M + H)	3
2168	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	445 (M + H)	3
2169	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	488 (M + H)	3
2170	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	480 (M + H)	2
2171	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)thiourea	448 (M + H)	3
2172	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)thiourea	490 (M + H)	3
2173	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)thiourea	450 (M + H)	3
2174	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea	470 (M + H)	3
2175	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea	510 (M + H)	1
2176	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	480 (M + H)	3
2177	N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	513 (M + H)	2
2178	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)thiourea	448 (M + H)	3
2179	N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	389 (M + H)	3
2180	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)urea	383 (M + H)	3
2181	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	391 (M + H)	3
2182	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea	397 (M + H)	3
2183	ethyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}leucinate	421 (M + H)	3
2184	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-fluorophenyl)urea	373 (M + H)	3
2185	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-(methylthio)phenyl)urea	401 (M + H)	3
2186	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-(trifluoromethyl)phenyl)urea	445 (M + Na)	3
2187	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-mesitylurea	397 (M + H)	2
2188	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)urea	369 (M + H)	3
2189	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea	457 (M + H)	1

Ex. No.	compound name	MS	class
2190	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea	588 (M + H)	1
2191	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	529 (M + H)	1
2192	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	411 (M + H)	3
2193	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
2194	N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	403 (M + H)	3
2195	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	403 (M + H)	3
2196	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea	447 (M + Na)	3
2197	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea	383 (M + H)	3
2198	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea	481 (M + H)	3
2199	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea	411 (M + H)	3
2200	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)urea	397 (M + H)	3
2201	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea	414 (M + H)	3
2202	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea	397 (M + H)	3
2203	N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	425 (M + H)	3
2204	N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	411 (M + H)	3
2205	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	403 (M + H)	3
2206	N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	469 (M + H)	3
2207	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	457 (M + H)	3
2208	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	380 (M + H)	3
2209	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea	445 (M + H)	1
2210	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	461 (M + H)	1
2211	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	436 (M + H)	3
2212	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	427 (M + H)	3
2213	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	433 (M + H)	3

Ex. No.	compound name	MS	class
2214	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	431 (M + H)	3
2215	N-butyl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	335 (M + H)	3
2216	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)urea	383 (M + H)	3
2217	ethyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate	427 (M + H)	3
2218	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea	437 (M + H)	3
2219	methyl N-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}methioninate	425 (M + H)	3
2220	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-1-naphthylurea	405 (M + H)	3
2221	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea	395 (M + H)	3
2222	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)urea	447 (M + H)	3
2223	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-pentylurea	349 (M + H)	3
2224	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[1-(1-naphthyl)ethyl]urea	433 (M + H)	1
2225	methyl N-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate	441 (M + H)	3
2226	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(1-phenylethyl)urea	383 (M + H)	3
2227	1-[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	383 (M + H)	3
2228	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea	491 (M + H)	3
2229	N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	511 (M + H)	3
2230	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	437 (M + H)	3
2231	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	415 (M + H)	3
2232	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)urea	399 (M + H)	3
2233	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)urea	387 (M + H)	3
2234	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea	414 (M + H)	3
2235	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea	414 (M + H)	3
2236	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea	383 (M + H)	3
2237	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea	400 (M + H)	3

Ex. No.	compound name	MS	class
2238	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	399 (M + H)	3
2239	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea	445 (M + H)	1
2240	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	415 (M + H)	3
2241	N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	419 (M + H)	3
2242	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	501 (M + H)	3
2243	N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	447 (M + H)	3
2244	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	403 (M + H)	2
2245	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea	387 (M + H)	3
2246	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea	399 (M + H)	3
2247	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	449 (M + H)	1
2248	N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	461 (M + H)	3
2249	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	447 (M + H)	2
2250	ethyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate	455 (M + H)	3
2251	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	413 (M + H)	3
2252	N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	553 (M + H)	2
2253	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	469 (M + H)	2
2254	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	427 (M + H)	3
2255	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea	425 (M + H)	3
2256	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea	436 (M + H)	3
2257	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	449 (M + H)	3
2258	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	396 (M + H)	2
2259	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	439 (M + H)	3
2260	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	431 (M + H)	2
2261	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)thiourea	399 (M + H)	3

Ex. No.	compound name	MS	class
2262	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)thiourea	441 (M + H)	3
2263	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)thiourea	401 (M + H)	3
2264	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea	421 (M + H)	3
2265	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea	461 (M + H)	1
2266	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	431 (M + H)	2
2267	N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	464 (M + H)	2
2268	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)thiourea	399 (M + H)	3
2269	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)thiourea	495 (M + H)	3
2270	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)thiourea	464 (M + H)	3
2271	N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	532 (M + H)	3
2272	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)thiourea	546 (M + H)	3
2273	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea	653 (M + H)	1
2274	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)thiourea	522 (M + H)	2
2275	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea	462 (M + H)	1
2276	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)thiourea	448 (M + H)	3
2277	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	476 (M + H)	1
2278	N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	512 (M + H)	3
2279	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	468 (M + H)	3
2280	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea	462 (M + H)	3
2281	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)thiourea	462 (M + H)	3
2282	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate	478 (M + H)	3
2283	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	526 (M + H)	1
2284	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	512 (M + H)	2
2285	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	566 (M + H)	2

Ex. No.	compound name	MS	class
2286	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	468 (M + H)	3
2287	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)thiourea	484 (M + H)	3
2288	N-(2,3-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	494 (M + H)	3
2289	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea	462 (M + H)	3
2290	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	496 (M + H)	3
2291	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea	479 (M + H)	3
2292	N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	468 (M + H)	3
2293	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate	492 (M + H)	3
2294	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	522 (M + H)	3
2295	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea	452 (M + H)	3
2296	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea	464 (M + H)	3
2297	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	514 (M + H)	1
2298	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]thiourea	448 (M + H)	3
2299	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea	448 (M + H)	3
2300	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	594 (M + H)	2
2301	N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	502 (M + H)	1
2302	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)thiourea	464 (M + H)	3
2303	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea	476 (M + H)	3
2304	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	478 (M + H)	3
2305	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	464 (M + H)	3
2306	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	468 (M + H)	3
2307	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	582 (M + H)	3
2308	N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	514 (M + H)	3
2309	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea	501 (M + H)	3

Ex. No.	compound name	MS	class
2310	N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	438 (M + H)	3
2311	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4-methylthiophene-2-carboxylate	498 (M + H)	2
2312	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)thiophene-2-carboxylate	484 (M + H)	3
2313	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea	490 (M + H)	3
2314	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)thiourea	446 (M + H)	3
2315	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)thiourea	413 (M - H)	3
2316	N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	483 (M + H)	3
2317	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)thiourea	497 (M + H)	3
2318	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea	604 (M + H)	1
2319	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)thiourea	473 (M + H)	3
2320	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea	413 (M + H)	1
2321	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)thiourea	399 (M + H)	3
2322	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	427 (M + H)	3
2323	N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	463 (M + H)	3
2324	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	419 (M + H)	3
2325	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea	413 (M + H)	3
2326	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)thiourea	413 (M + H)	3
2327	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate	429 (M + H)	3
2328	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	477 (M + H)	1
2329	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	463 (M + H)	3
2330	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	3
2331	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	419 (M + H)	3
2332	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)thiourea	435 (M + H)	3

Ex. No.	compound name	MS	class
2333	N-(2,3-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	443 (M - H)	3
2334	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea	413 (M + H)	3
2335	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	447 (M + H)	3
2336	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea	428 (M - H)	3
2337	N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	419 (M + H)	3
2338	ethyl 3-({[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexylamino)carbonothioyl)amino)benzoate	441 (M - H)	3
2339	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	473 (M + H)	3
2340	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea	403 (M + H)	3
2341	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea	415 (M + H)	3
2342	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	465 (M + H)	1
2343	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]thiourea	397 (M - H)	3
2344	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)thiourea	399 (M + H)	3
2345	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	545 (M + H)	2
2346	N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	453 (M + H)	2
2347	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)thiourea	415 (M + H)	3
2348	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea	427 (M + H)	3
2349	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	429 (M + H)	3
2350	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	415 (M + H)	3
2351	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	419 (M + H)	3
2352	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	533 (M + H)	3
2353	N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	465 (M + H)	3
2354	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea	452 (M + H)	3
2355	N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea	387 (M - H)	3

Ex. No.	compound name	MS	class
2356	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)amino]carbonothioyl} amino)-4-methylthiophene-2-carboxylate	449 (M + H)	3
2357	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)amino]carbonothioyl} amino)thiophene-2-carboxylate	435 (M + H)	3
2358	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino} cyclohexyl)thiourea	441 (M + H)	3
2359	N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	452 (M + H)	3
2360	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea	446 (M + H)	3
2361	N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	454 (M + H)	3
2362	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea	460 (M + H)	2
2363	ethyl N-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]amino} carbonyl)leucinate	484 (M + H)	3
2364	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(4-fluorophenyl)urea	436 (M + H)	3
2365	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea	464 (M + H)	3
2366	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea	486 (M + H)	3
2367	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-mesitylurea	460 (M + H)	2
2368	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-methylphenyl)urea	432 (M + H)	3
2369	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea	520 (M + H)	1
2370	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea	651 (M + H)	1
2371	N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	592 (M + H)	1
2372	N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	474 (M + H)	2
2373	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	520 (M + H)	2
2374	N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	466 (M + H)	3
2375	N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]urea	466 (M + H)	3
2376	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea	488 (M + H)	1
2377	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-ethylphenyl)urea	446 (M + H)	3
2378	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino} cyclohexyl)methyl]-N'-(2-iodophenyl)urea	544 (M + H)	3

Ex. No.	compound name	MS	class
2379	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-N'-(2-isopropyl-6-methylphenyl)urea	474 (M + H)	2
2380	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea	460 (M + H)	3
2381	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea	477 (M + H)	2
2382	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea	460 (M + H)	3
2383	N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	488 (M + H)	1
2384	N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	474 (M + H)	1
2385	N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	466 (M + H)	3
2386	N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	532 (M + H)	3
2387	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	520 (M + H)	3
2388	N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	443 (M + H)	3
2389	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea	508 (M + H)	2
2390	N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	524 (M + H)	1
2391	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	499 (M + H)	3
2392	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	490 (M + H)	3
2393	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	486 (M + H)	3
2394	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	486 (M + H)	2
2395	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea	432 (M + H)	3
2396	N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	502 (M + H)	1
2397	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea	491 (M + H)	3
2398	N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	592 (M + H)	3
2399	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	486 (M + H)	3
2400	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-N'-(2-methoxy-5-methylphenyl)urea	462 (M + H)	3
2401	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea	477 (M + H)	3
2402	N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	454 (M + H)	3

Ex.No.	compound name	MS	class
2403	N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	454 (M + H)	3
2404	N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea	470 (M + H)	3
2405	N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	403 (M + H)	3
2406	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea	397 (M + H)	1
2407	N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	405 (M + H)	2
2408	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea	411 (M + H)	1
2409	ethyl N-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)leucinate	435 (M + H)	3
2410	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorophenyl)urea	387 (M + H)	2
2411	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea	415 (M + H)	3
2412	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea	435 (M - H)	3
2413	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea	411 (M + H)	1
2414	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea	383 (M + H)	3
2415	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea	471 (M + H)	1
2416	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea	602 (M + H)	1
2417	N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	543 (M + H)	1
2418	N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	425 (M + H)	1
2419	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	1
2420	N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	417 (M + H)	1
2421	N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	417 (M + H)	3
2422	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea	437 (M - H)	1
2423	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea	397 (M + H)	3
2424	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea	495 (M + H)	3
2425	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-N'-(2-isopropyl-6-methylphenyl)urea	425 (M + H)	1
2426	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea	411 (M + H)	3

Ex. No.	compound name	MS	class
2427	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea	428 (M + H)	1
2428	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea	411 (M + H)	2
2429	N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	439 (M + H)	1
2430	N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	425 (M + H)	1
2431	N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	417 (M + H)	1
2432	N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	483 (M + H)	1
2433	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	2
2434	N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	394 (M + H)	3
2435	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea	459 (M + H)	1
2436	N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	475 (M + H)	1
2437	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	450 (M + H)	1
2438	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	441 (M + H)	3
2439	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	437 (M + H)	2
2440	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	437 (M + H)	1
2441	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea	383 (M + H)	3
2442	N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	453 (M + H)	1
2443	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea	442 (M + H)	1
2444	N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	543 (M + H)	1
2445	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	437 (M + H)	1
2446	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-N'-(2-methoxy-5-methylphenyl)urea	413 (M + H)	2
2447	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea	428 (M + H)	2
2448	N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	405 (M + H)	1
2449	N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	405 (M + H)	1
2450	N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea	421 (M + H)	1

Ex. No.	compound name	MS	class
2451	N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	457 (M + H)	3
2452	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea	451 (M + H)	1
2453	N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	459 (M + H)	2
2454	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea	465 (M + H)	1
2455	ethyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)-leucinate	489 (M + H)	2
2456	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorophenyl)urea	441 (M + H)	2
2457	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea	469 (M + H)	3
2458	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea	491 (M + H)	3
2459	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea	465 (M + H)	1
2460	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea	437 (M + H)	3
2461	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea	525 (M + H)	1
2462	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea	657 (M + H)	1
2463	N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	597 (M + H)	3
2464	N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	479 (M + H)	1
2465	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]urea	525 (M + H)	1
2466	N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	1
2467	N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	3
2468	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea	493 (M + H)	1
2469	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea	451 (M + H)	3
2470	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea	549 (M + H)	3
2471	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)-urea	479 (M + H)	2
2472	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea	465 (M + H)	3

Ex. No.	compound name	MS	class
2473	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea	482 (M + H)	3
2474	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea	465 (M + H)	3
2475	N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	493 (M + H)	1
2476	N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	479 (M + H)	2
2477	N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	2
2478	N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	537 (M + H)	3
2479	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]urea	525 (M + H)	3
2480	N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	448 (M + H)	3
2481	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea	513 (M + H)	3
2482	N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	529 (M + H)	1
2483	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	504 (M + H)	3
2484	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	495 (M + H)	3
2485	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	491 (M + H)	3
2486	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	491 (M + H)	3
2487	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea	437 (M + H)	3
2488	N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	507 (M + H)	2
2489	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)-urea	496 (M + H)	2
2490	N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	597 (M + H)	1
2491	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	491 (M + H)	1
2492	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)-urea	467 (M + H)	3
2493	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea	482 (M + H)	3

Ex. No.	compound name	MS	class
2494	N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	459 (M + H)	3
2495	N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	459 (M + H)	3
2496	N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea	475 (M + H)	3

Example 2497

**2,3,4-Trifluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide
trifluoroacetate**

5 Step A: Synthesis of *cis*-(4-*tert*-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (4 g, 0.019 mol) in 50 mL CH₂Cl₂ was added DIEA (4.9 mL, 0.028 mol). The solution was cooled on an ice bath and CbzCl (2.9 mL, 0.020 mol) was added slowly. The solution was removed from the ice bath and stirring continued for an additional hour. The solvent was evaporated and the material was
10 subjected to chromatography (0-40% ethyl acetate in hexanes) to yield *cis*-(4-*tert*-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (6.2 g, 0.018 mol, 95%) as a white solid.

ESI MS *m/e* 349.0 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.34-7.28 (m, 5 H), 7.12 (d, *J* = 5.6 Hz, 1 H), 6.62 (brs, 1 H), 4.98 (s, 2 H), 3.39-3.37 (m, 2 H), 1.60-1.45 (m, 8 H), 1.37 (s, 9 H).

15

Step B: Synthesis of *cis*-(4-amino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of *cis*-(4-*tert*-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (6.2 g, 0.018 mol) in 40 mL CH₂Cl₂ was added TFA (2.7 mL, 0.36 mol). The solution was stirred at room temperature for 4 hours. The excess solvent was evaporated off and the resulting oil was
20 dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq) / NaHCO₃ (aq) solution. The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated to yield *cis*-(4-amino-cyclohexyl)-carbamic acid benzyl ester (4.3 g, 97%) as a colorless oil. The oil was carried forward without further purification.

25 ESI MS *m/e* 249.2 *M* + *H*⁺.

Step C: Synthesis of *cis*-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester.

To a solution of *cis*-(4-amino-cyclohexyl)-carbamic acid benzyl ester (0.5 g, 0.0020 mol) in 1 mL 2-propanol was added 2-chloro-4-methyl-quinoline (0.43 g, 0.0024 mol) and IEA (526 μ L, 0.0030 mol). The mixture was heated in a microwave synthesizer at 170 °C for 5 hours. The reaction was repeated 7 more times (4 g total material) and the reaction mixtures were pooled. The solvent was evaporated and the material subjected to chromatography (2-4 % 2M NH₃ in MeOH / CH₂Cl₂) to yield *cis*-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester (3.3 g, 53%) as a colorless oil.

10 ESI MS m/e 390.2 M + H⁺ ; ¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (d, J = 8 Hz, 1 H), 7.46-7.39 (m, 2 H), 7.37-7.19 (m, 7 H), 6.68 (m, 2 H), 5.01 (s, 2 H), 4.07 (m, 1 H), 3.46 (m, 1 H), 2.44 (s, 3 H), 1.79-1.71 (m, 2 H), 1.70-1.59 (m, 6 H).

Step D: Synthesis of *cis*-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine.

15 To a solution of *cis*-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester (3.3 g, 0.0085 mol) in 200 mL EtOH was added 10% Pd/C (330 mg). The reaction mixture was stirred at room temperature under H₂(g) atmosphere for 3 hours. The H₂(g) atmosphere was removed and the mixture was through a pad of celite and washed with ethyl acetate. The solvent was concentrated and the material was subjected to chromatography (2-4 % 2M NH₃ in MeOH /

20 CH₂Cl₂) to yield *cis*-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (2.0 g, 92%) as a light brown solid.

ESI MS m/e 256.4 M + H⁺ ; ¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (d, J = 8 Hz, 1 H), 7.46-7.39 (m, 2 H), 7.14-7.10 (m, 1 H), 6.69-6.68 (m, 2 H), 4.07-4.05 (m, 1 H), 2.81-2.77 (m, 1 H), 2.44 (s, 3 H), 1.78-1.71 (m, 2 H), 1.62-1.40 (m, 6 H).

Step E: Synthesis of 2,3,4-trifluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

To a solution of *cis*-*N*-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (23 mg, 0.090 mmol) in 0.5 mL DMF was added pyridine (12 μ L, 0.15 mmol) and 2,3,4-trifluorobenzoyl chloride (12.8 μ L, 0.10 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield 2,3,4-trifluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate (10.1 mg, 21%) as a white solid.

ESI MS m/e 414.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.44 (brs, 1 H), 9.27 (brs, 1 H), 8.45 (d, $J = 6.4$ Hz, 1 H), 7.98-7.93 (m, 2 H), 7.80 (t, $J = 7.6$ Hz, 1 H), 7.53 (t, $J = 8.0$ Hz, 1 H), 7.43-7.37 (m, 2 H), 7.01 (s, 1 H), 4.05 (m, 1 H), 3.97 (m, 1 H), 2.69 (s, 3 H), 1.86-1.74 (m, 8 H).

Example 2498

3,4-Difluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3,4-difluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate

Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 396.18 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.40 (brs, 1 H), 9.25 (brs, 1 H), 8.33 (d, $J = 6.0$ Hz, 1 H), 7.98-7.90 (m, 3 H), 7.80-7.76 (m, 2 H), 7.58-7.50 (m, 2 H), 7.02 (brs, 1 H), 4.09 (m, 1 H), 3.94 (m, 1 H), 2.61 (s, 3 H), 1.84-1.74 (m, 8 H).

Example 2499

4-Cyano-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 4-cyano-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate.

Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 385.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.38 (brs, 1 H), 9.27 (brs, 1 H),
5 8.51 (d, $J = 6.0$ Hz, 1 H), 8.01-7.95 (m, 6H), 7.80 (t, $J = 7.2$ Hz, 1 H), 7.54 (t, $J = 8.0$ Hz, 1 H),
7.02 (brs, 1 H), 4.09 (m, 1 H), 3.96 (m, 1 H), 2.66 (s, 3 H), 1.85-1.75 (m, 8 H).

Example 2500

10 **3-Fluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate**

Step A: Synthesis of 3-fluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate.

Using the procedure of step E of example 2497, the title compound was obtained.

15 ESI m/e 378 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.38 (brs, 1 H), 9.25 (brs, 1 H), 8.33 (d, $J = 6.0$ Hz, 1 H), 7.98-7.91 (m, 2 H), 7.80 (t, $J = 7.6$ Hz, 1 H), 7.71-7.64 (m, 2 H), 7.55-7.49 (m, 2 H), 7.41-7.36 (m, 1 H), 4.12 (m, 1 H), 4.08 (m, 1 H), 2.77 (s, 3 H), 1.85-1.74 (m, 8 H).

20 **Example 2501**

3,5-Difluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3,5-difluoro-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

25 Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 396 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.40 (brs, 1 H), 9.25 (brs, 1 H), 8.40 (d, $J = 6.0$ Hz, 1 H), 7.98-7.96 (m, 2 H), 7.80 (t, $J = 7.2$ Hz, 1 H), 7.59-7.44 (m, 4 H), 7.02 (brs, 1 H), 4.09 (m, 1 H), 3.94 (m, 1 H), 2.68 (s, 3 H), 1.85-1.74 (m, 8 H).

Example 2502

N-{*cis*-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl}-2-[4-(trifluoromethoxy)phenoxy]-
5 acetamide trifluoroacetate

Step A: Synthesis of *N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-[4-(trifluoromethoxy)phenoxy]-acetamide trifluoroacetate.

To a solution of *cis*-*N*-(4-methylquinolin-2-yl)-cyclohexane-1,4-diamine (25.5 mg, 0.1
10 mmol) in 0.5 mL DMF was added 4-(trifluoromethoxy)phenoxyacetic acid (23.6 mg, 0.1 mmol),
DIEA (0.026 mL, 0.15 mmol), and HATU (45.6 mg, 0.12 mmol). The reaction mixture was stirred
overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected
to purification by prep LCMS to yield *N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-[4-
(trifluoromethoxy)phenoxy]-acetamide trifluoroacetate (22.3 mg, 38%) as a white solid.
15 ESI MS *m/e* 474.4 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.47 (s, 1 H), 9.25 (s, 1 H), 8.00-
7.92 (m, 3 H), 7.80 (t, *J* = 7.2 Hz, 1 H), 7.53 (t, *J* = 8.0 Hz, 1 H), 7.31 (d, *J* = 8.8 Hz, 2 H), 7.04-
7.01 (m, 3 H), 4.55 (s, 2 H), 4.06 (m, 1 H), 3.84 (m, 1 H), 2.69 (s, 3 H), 1.78-1.68 (m, 8 H).

20 Example 2503

**2-(3,4-Difluorophenyl)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide
trifluoroacetate**

**Step A: Synthesis of 2-(3,4-difluorophenyl)-*N*-{*cis*-4-[(4-methylquinolin-2-
25 yl)amino]cyclohexyl}acetamide trifluoroacetate.**

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS *m/e* 410 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.42 (brs, 1 H), 9.26 (brs, 1 H), 8.09
(d, *J* = 6.4 Hz, 1 H), 7.98-7.92 (m, 2 H), 7.80 (t, *J* = 7.6 Hz, 1 H), 7.54 (t, *J* = 8.8 Hz, 1 H), 7.38-

7.27 (m, 2 H), 7.10-7.07 (m, 1 H), 7.01 (brs, 1 H), 4.02 (m, 1 H), 3.94 (m, 1 H), 2.61 (s, 3 H), 1.79-1.69 (m, 8 H).

5 Example 2504

2-(2-Bromo-4,5-dimethoxyphenyl)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide trifluoroacetate

Step A: Synthesis of 2-(2-bromo-4,5-dimethoxyphenyl)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 512.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.45 (brs, 1 H), 9.25 (brs, 1 H), 8.00-7.92 (m, 3 H), 7.80 (t, $J = 7.6$ Hz, 1 H), 7.53 (t, $J = 7.6$ Hz, 1 H), 7.09 (s, 1 H), 7.01 (brs, 1 H), 6.95 (s, 1 H), 4.10 (m, 1 H), 3.78 (m, 1 H), 3.74 (s, 3 H), 3.72 (s, 3 H), 3.53 (s, 2 H), 2.69 (s, 3 H), 1.78-1.67 (m, 8 H).

Example 2505

4-(Benzyloxy)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

20

Step A: Synthesis of 4-(benzyloxy)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 466.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.39 (brs, 1 H), 9.25 (brs, 1 H), 8.06 (d, $J = 6.0$ Hz, 1 H), 7.98-7.96 (m, 2 H), 7.84-7.76 (m, 3 H), 7.54 (t, $J = 8.0$ Hz, 1 H), 7.46 (d, $J = 7.2$ Hz, 2 H), 7.41 (t, $J = 7.2$ Hz, 2 H), 7.35-7.31 (m, 1 H), 7.08 (d, $J = 8.8$ Hz, 2 H), 7.02 (brs, 1 H), 5.17 (s, 2 H), 4.09 (m, 1 H), 3.93 (m, 1 H), 2.66 (s, 3 H), 1.84-1.72 (m, 8 H).

Example 2506

2-(2-Methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate

5

Step A: Synthesis of 2-(2-methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 420.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.50 (brs, 1 H), 9.25 (brs, 1 H),
10 7.98-7.93 (m, 2 H), 7.80-7.76 (m, 2 H), 7.53 (t, $J = 5.6$ Hz, 1 H), 7.02-6.85 (m, 5 H), 4.50 (s, 2 H),
4.07 (m, 1 H), 3.85 (m, 1 H), 3.79 (s, 3 H), 2.61 (s, 3 H), 1.84-1.69 (m, 8 H).

Example 2507

15 **2-(4-Fluorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate**

Step A: Synthesis of 2-(4-fluorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

20 Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 471.4 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.29 (dd, $J = 7.6, 2.0$ Hz, 1 H), 8.19 (dd, $J = 4.8, 2.0$ Hz, 1 H), 8.01 (d, $J = 8.0$ Hz, 1 H), 7.88 (brs, 1 H), 7.80 (t, $J = 8.4$ Hz, 1 H), 7.57 (t, $J = 8.0$ Hz, 1 H), 7.25-7.15 (m, 5 H), 6.90 (brs, 1 H), 4.20 (brs, 1 H), 4.07 (brs, 1H), 2.67 (s, 3H), 2.02-1.81 (m, 8H).

25

Example 2508

2-(4-Chlorophenoxy)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate

5 Step A: Synthesis of 2-(4-Chlorophenoxy)-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 487.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 13.0 (brs, 1 H), 9.50 (d, $J = 6.8$ Hz, 1 H), 8.35 (m, 1 H), 8.19 (m, 1 H), 8.07 (d, $J = 6.8$ Hz, 1 H), 7.93 (d, $J = 7.6$ Hz, 1 H), 7.75 (t, $J =$
10 7.2 Hz, 1 H), 7.50 (m, 3 H), 7.30 (m, 3 H), 7.10 (brs, 1 H), 4.38 (brs, 1 H), 4.01 (brs, 1 H), 2.57 (s, 3 H), 1.83 (m, 8H).

Example 2509

15 2,6-Dimethoxy-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate

Step A: Synthesis of 2,6-dimethoxy-*N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

20 Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 421.2 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 13.1 (brs, 1 H), 9.74 (d, $J = 8.0$ Hz, 1 H), 8.30 (d, $J = 8.4$ Hz, 1 H), 8.17 (d, $J = 8.4$ Hz, 1 H), 7.98 (m, 2 H), 7.60 (m, 1 H), 7.50 (t, $J =$
25 7.6 Hz, 1 H), 7.19 (brs, 1 H), 4.43 (brs, 1H), 3.94 (brs, 7H), 2.58 (s, 3H), 1.90 (m, 8 H).

Example 2510

***cis*-*N*-[4-Bromo-2-(trifluoromethoxy)benzyl]-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate**

Step A: Synthesis of *cis-N*-[4-bromo-2-(trifluoromethoxy)benzyl]-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

To a solution of *cis-N*-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (25.5 mg, 0.1 mmol) in 0.5 mL MeOH was added 4-bromo-2-trifluoromethoxybenzaldehyde (26.9 mg, 0.1 mmol). The reaction mixture was stirred for a half hour and then sodium triacetoxyborohydride (84.8 mg, 0.4 mmol) was added to the reaction. The mixture was stirred overnight and then 0.5 mL of DMSO was added. The compound was then subjected to purification by prep LCMS to yield *cis-N*-[4-bromo-2-(trifluoromethoxy)benzyl]-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate (9.6 mg, 13%) as a white solid.

ESI MS m/e 508.0 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.04 (d, $J = 8.0$ Hz, 1H), 7.84 (brs, 1 H), 7.81 (t, $J = 7.2$ Hz, 1 H), 7.69-7.63 (m, 3 H), 7.58 (t, $J = 8.0$ Hz, 1 H), 7.16 (brs, 1 H), 4.36 (s, 2 H), 4.26 (m, 1 H), 3.32-3.30 (m, 1 H), 2.71 (s, 2 H), 2.66 (s, 3 H), 2.16-1.93 (m, 8 H).

Example 2511

***cis-N*-[(5-Bromo-1H-indol-3-yl)methyl]-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate**

Step A: Synthesis of *cis-N*-[(5-bromo-1H-indol-3-yl)methyl]-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 463.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.03 (d, $J = 8.0$ Hz, 1 H), 7.92 (s, 1 H), 7.87 (brs, 1 H), 7.80-7.76 (t, $J = 7.2$ Hz, 1 H), 7.57-7.53 (m, 2 H), 7.38 (d, $J = 8.8$ Hz, 1 H), 7.31 (d, $J = 8.4$ Hz, 1 H), 7.14 (brs, 1 H), 4.47 (s, 2 H), 4.23 (m, 1 H), 3.37 (m, 1 H), 2.71 (brs, 2 H), 2.65 (s, 3 H), 2.15-1.91 (m, 8 H).

Example 2512

cis-N-(3,5-Dimethoxybenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

5 **Step A: Synthesis of *cis-N-(3,5-dimethoxybenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate*.**

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 406.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.03 (d, $J = 8.0$ Hz, 1 H), 7.88 (brs, 1 H), 7.80 (t, $J = 7.2$ Hz, 1 H), 7.57 (t, $J = 8.4$ Hz, 1 H), 7.17 (brs, 1 H), 6.71 (s, 2 H), 6.55 (s, 1 H),
10 4.24 (m, 1 H), 4.21 (s, 2 H), 3.81 (s, 6 H), 3.35 (m, 1 H), 2.70 (brs, 2 H), 2.66 (s, 3 H), 2.14-1.90 (m, 8 H).

Example 2513

15 *cis-N-(3,5-Dichlorobenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate*

Step A: Synthesis of *cis-N-(3,5-dichlorobenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate*.

20 Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 414.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.04 (d, $J = 8.4$ Hz, 1 H), 7.86 (brs, 1 H), 7.81 (t, $J = 7.2$ Hz, 1 H), 7.58-7.54 (m, 4 H), 7.16 (brs, 1 H), 4.30 (s, 2 H), 4.25 (m, 1 H), 3.41 (m, 1 H), 2.76 (brs, 2 H), 2.66 (s, 3 H), 2.12-1.92 (m, 8 H).

25

Example 2514

cis-N-(3,4-Difluorobenzyl)-N'-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of *cis*-*N*-(3,4-difluorobenzyl)-*N'*-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

- 5 ESI MS m/e 382.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.03 (d, $J = 8.0$ Hz, 1 H), 7.86 (brs, 1 H), 7.80 (t, $J = 7.2$ Hz, 1 H), 7.57-7.51 (m, 2 H), 7.39-7.37 (m, 2 H), 7.16 (brs, 1 H), 4.29 (s, 2 H), 4.25 (m, 1 H), 3.37 (m, 1 H), 2.71 (brs, 2 H), 2.66 (s, 3 H), 2.11-1.95 (m, 8 H).

10 Example 2515

***N*-(3,5-Difluorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate**

Step A: Synthesis of *N*-(3,5-difluorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-

15 yl)amino]cyclohexyl}urea trifluoroacetate.

- To a solution of *cis*-*N*-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (20 mg, 0.078 mmol) in 0.5 mL of DMSO was added 3,5-difluorophenyl isocyanate (9.3 μ L, 0.078 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield *N*-(3,5-difluorophenyl)-*N'*-
- 20 {*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate (12 mg, 29%) as a white solid. ESI MS m/e 411.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.02 (d, $J = 8.0$ Hz, 1 H), 7.87 (brs, 1 H), 7.80 (t, $J = 7.6$ Hz, 1 H), 7.56 (t, $J = 7.6$ Hz, 1 H), 7.07 (s, 1 H), 7.03 (s, 1 H), 6.97 (brs, 1 H), 6.50 (t, $J = 9.2$ Hz, 1 H), 4.02 (m, 1 H), 3.89 (m, 1 H), 2.68 (brs, 3 H), 2.66 (s, 3 H), 1.99-1.78 (m, 8 H).

Example 2516

N-[3,5-Bis(trifluoromethyl)phenyl]-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

5 **Step A: Synthesis of *N*-[3,5-bis(trifluoromethyl)phenyl]-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.**

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS *m/e* 511.2 *M* + *H*⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.02 (s, 2 H), 8.00 (s, 1 H), 7.87 (brs, 1 H), 7.80 (t, *J* = 7.2 Hz, 1 H), 7.57 (t, *J* = 8.0 Hz, 1 H), 7.49 (s, 1 H), 6.98 (brs, 1 H), 4.04 (m, 1 H),
10 3.91 (m, 1 H), 2.69 (brs, 3 H), 2.66 (s, 3 H), 2.01-1.80 (m, 8 H).

Example 2517

N-(3-Chlorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

15

Step A: Synthesis of *N*-(3-chlorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS *m/e* 409.2 *M* + *H*⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, *J* = 8.4 Hz, 1 H), 7.87 (brs, 1 H), 7.79 (t, *J* = 7.6 Hz, 1 H), 7.59 (s, 1 H), 7.56 (t, *J* = 7.6 Hz, 1 H), 7.21-7.15 (m, 2 H), 6.96 (brs, 1 H),
20 6.93-6.91 (m, 1 H), 4.01 (m, 1 H), 3.89 (t, 1 H), 2.66 (brs, 6 H), 1.99-1.78 (m, 8 H).

Example 2518

25 *N*-(3,4-Dichlorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of *N*-(3,4-dichlorophenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 443.2 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.00 (d, $J = 7.6$ Hz, 1 H), 7.87 (brs, 1 H), 7.79-7.74 (m, 2 H), 7.56 (t, $J = 7.6$ Hz, 1 H), 7.34 (d, $J = 8.4$ Hz, 1 H), 7.20 (d, $J = 8.4$ Hz, 1 H), 6.97 (brs, 1 H), 4.02 (m, 1 H), 3.88 (m, 1 H), 2.66 (brs, 6 H), 1.98-1.78 (m, 8 H).

Example 2519

10 *N*-(3-Methoxyphenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of *N*-(3-methoxyphenyl)-*N'*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

15 Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 405.4 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.00 (d, $J = 8.0$ Hz, 1 H), 7.87 (brs, 1 H), 7.79 (t, $J = 7.6$ Hz, 1 H), 7.56 (t, $J = 8.0$ Hz, 1 H), 7.14-7.10 (m, 2 H), 6.96 (brs, 1 H), 6.84 (d, $J = 8.0$ Hz, 1 H), 6.53 (d, $J = 8.4$ Hz, 1 H), 4.01 (m, 1 H), 3.89 (m, 1 H), 3.75 (s, 3 H), 2.71 (brs, 6 H), 1.99-1.78 (m, 8 H).

20

Example 2520

3-Methoxy-*N*-[*cis*-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate

25 Step A: Synthesis of *cis*-[4-(3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (2.8 g, 0.013 mol) in 40 mL CH_2Cl_2 stirring on ice was added DIEA (3.41 mL, 0.020 mol). The solution was cooled

on an ice bath and *m*-anisoyl chloride (1.84 mL, 0.013 mol) was added slowly. The solution was removed from the ice bath and stirring continued for an additional hour. The solvent was evaporated and the material was subjected to chromatography (0-40% ethyl acetate in hexanes) to yield *cis*-[4-(3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.3 g, 94 %) as
5 a white solid.

ESI MS m/e 349.0 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 8.03 (d, $J = 6.8$ Hz, 1 H), 7.42-7.32 (m, 3 H), 7.07 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.62 (brs, 1 H), 3.79 (s, 3 H), 3.77 (m, 1 H), 3.41 (m, 1 H), 1.71-1.70 (m, 4 H), 1.52-1.46 (m, 4 H), 1.38 (s, 9H).

10 Step B: Synthesis of *cis*-*N*-(4-amino-cyclohexyl)-3-methoxy-benzamide.

To a solution of *cis*-[4-(3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.3 g, 0.012 mol) in 50 mL CH_2Cl_2 was added TFA (1.84 mL, 0.024 mol). The solution was stirred for 4 hours and the solvent evaporated. The resulting oil was re-dissolved in 50 mL CH_2Cl_2 . The organic layer was extracted with 50 mL of a dilute NaOH (aq) / $NaHCO_3$ (aq) solution. The
15 aqueous layer was extracted twice more with CH_2Cl_2 and the organic layers combined, dried over $MgSO_4$, and concentrated. The resulting precipitate was crystallized in ether and hexanes to yield *cis*-*N*-(4-amino-cyclohexyl)-3-methoxy-benzamide (2.4g, 78%) as a white solid.

ESI MS m/e 249.0 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 8.10 (d, $J = 7.2$ Hz, 1 H), 7.42-7.32 (m, 3 H), 7.07 (dd, $J = 8.0, 2.4$ Hz, 1 H), 3.79 (brs, 4 H), 2.91 (m, 1 H), 1.80-1.74 (m, 2 H), 1.52-
20 1.46 (m, 6 H), 1.31 (brs, 2 H).

Step C: Synthesis of 3-methoxy-*N*-[*cis*-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate.

To a solution of *cis*-*N*-(4-amino-cyclohexyl)-3-methoxy-benzamide (28.4 mg, 0.1 mmol) in
25 0.5 mL 2-propanol was added 2-chloroquinoline (32.7 mg, 0.2 mmol) and DIEA (34.8 μ L, 0.2 mmol). The reaction mixture was heated in a microwave synthesizer at 170 °C for 10 hours. The solvent was removed and the resulting oil dissolved in 1 mL of DMSO. The compound was then

subject to purification by prep LCMS to yield 3-methoxy-*N*-[*cis*-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate (26 mg, 53%) as a colorless oil.

ESI MS m/e 376.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.85 (d, $J = 9.2$ Hz, 1 H), 7.62 (t, $J = 8.8$ Hz, 2 H), 7.50 (t, $J = 7.2$ Hz, 1 H), 7.39-7.36 (m, 3 H), 7.19 (t, $J = 7.2$ Hz, 1 H), 7.10-7.07 (m, 1 H), 6.82 (d, $J = 9.2$ Hz, 1 H), 4.18 (m, 1 H), 4.02 (m, 1 H), 3.84 (s, 3 H), 1.95-1.22 (m, 1 H).

Example 2521

3-methoxy-*N*-(*cis*-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide

10 trifluoroacetate

Step A: Synthesis of 2-chloro-4-trifluoromethyl-quinoline.

To a solution of 4-trifluoromethyl-quinolin-2-ol (1.01 g, 0.0047 mol) in 10 mL $POCl_3$ was added *N,N*-dimethylaniline (661 μ L, 0.0052 mol). The mixture was heated to reflux (125 °C) and stirred for 4 hours until the starting material completely dissolved and the solution turned dark purple in color. The solution was then cooled and poured slowly on ice (30 g; caution highly exothermic) to quench the reaction. The aqueous layer was then extracted three times with CH_2Cl_2 (25 mL). The organic layer was dried with $MgSO_4$, concentrated, and subjected to purification by chromatography (100% CH_2Cl_2) to yield 2-chloro-4-trifluoromethyl-quinoline (823 mg, 75%) as a slightly yellow solid.

ESI MS m/e 232.0 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 8.15-8.09 (m, 2 H), 8.06 (s, 1 H), 8.01-7.97 (m, 1 H), 7.88-7.85 (m, 1 H).

Step B: Synthesis of 3-methoxy-*N*-(*cis*-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

To a solution of *cis*-*N*-(4-amino-cyclohexyl)-3-methoxy-benzamide (50 mg, 0.20 mmol) in 0.5 mL 2-propanol was added 2-chloro-4-trifluoromethyl-quinoline (56 mg, 0.24 mmol), and DIEA (52.6 μ L, 0.30 mmol). The reaction mixture was heated in a microwave synthesizer at 170° C for 5

hours. The solvent was removed and the resulting oil dissolved in 1 mL of DMSO. The compound was then subjected to purification by prep LCMS to yield 3-methoxy-*N*-(*cis*-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate (71.8 mg, 64%) as a white solid.

- 5 ESI MS m/e 444.4 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 8.22 (d, $J = 6.4$ Hz, 1 H), 7.79-7.77 (m, 2 H), 7.69 (m, 1 H), 7.50 (s, 1 H), 7.44-7.34 (m, 4 H), 7.09 (dd, $J = 8.0, 2.4$ Hz 1 H), 4.14 (m, 1 H), 3.87 (m, 1 H), 3.80 (s, 3 H), 1.94-1.92 (m, 2 H), 1.82-1.72 (m, 6 H).

10 Example 2522

3-Methoxy-*N*-(*cis*-4-[(quinolin-2-ylmethyl)amino]cyclohexyl)benzamide trifluoroacetate

Step A: Synthesis of 3-methoxy-*N*-(*cis*-4-[(quinolin-2-ylmethyl)amino]cyclohexyl)benzamide trifluoroacetate.

- 15 Using the procedure of step A of example 2510, the title compound was obtained.
- ESI MS m/e 390.2 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.41 (d, $J = 8.8$ Hz, 1 H), 8.14 (d, $J = 8.4$ Hz, 1 H), 7.99 (d, $J = 8.0$ Hz, 1 H), 7.84 (t, $J = 7.2$ Hz, 1 H), 7.67 (t, $J = 7.2$ Hz, 1 H), 7.55 (d, $J = 8.4$ Hz, 1 H), 7.43-7.36 (m, 3 H), 7.12-7.10 (m, 1 H), 4.66 (s, 2 H), 4.13 (m, 1 H), 3.85 (s, 3 H), 3.46 (m, 1 H), 2.16-2.05 (m, 4 H), 2.05-1.96 (m, 2 H), 1.85-1.78 (m, 2 H).

20

Example 2523

***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide trifluoroacetate**

25

Step A: Synthesis of 2-chloro-4-dimethylamino-5-methylpyrimidine.

In 8 mL tetrahydrofuran was dissolved 2,4-dichloro-5-methylpyrimidine (0.5 g, 3.07 mmol) at 0 °C. To the reaction mixture was added dimethylamine (2M in methanol, 3.4 mL, 6.8

mmol) dropwise. The reaction mixture was stirred at 10 °C for 1.5 hour: *do not increase the reaction temperature*. The solution was concentrated and purified by flash chromatography (silica gel, 20% ethyl acetate and 5% methanol in hexanes) to give 2-chloro-4-dimethylamino-5-methylpyrimidine (307 mg, 58%) as a white solid.

5 ESI MS m/e 172 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.8 (s, 1 H), 3.18 (s, 6 H), 2.23 (s, 3 H).

Step B: Synthesis of *cis*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a suspension of 2-chloro-4-dimethylamino-5-methylpyrimidine (250mg, 1.46 mmol) in
10 2-propanol (2.5 mL) was added *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (340 mg, 1.60mmol) and DIEA (507 μL, 2.91 mmol). The reaction was performed in the Smith synthesizer for 4.5 hours at 175° C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give *cis*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (219 mg, 43 %) as a pale yellow solid.

15 ESI MS m/e 350.4 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1 H), 4.6 (brs, 1 H), 3.94 (brs, 1 H), 3.60 (brs, 1 H), 3.02 (s, 6 H), 2.18 (s, 3 H), 1.85-1.70 (m, 8 H), 1.41 (s, 9 H).

Step C: Synthesis of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-amino-cyclohexane.

20 To a suspension of *cis*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (219 mg, 0.627 mmol) in DCM (3 mL) was added trifluoroacetic acid (2mL). The reaction stirred at room temperature for 2 hours and concentrated. A few drops NaHCO₃ was added, followed by 1M NaOH until the solution was basic. The product was extracted with H₂O and CH₂Cl₂ three times. The organic layers were combined, dried over MgSO₄,
25 filtered and concentrated to give *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (115.9 mg, 74 %) as yellow oil.

ESI MS m/e 250.2 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.60 (s, 1 H), 4.95 (brs, 1 H), 3.90 (brs, 1 H), 2.98 (s, 6 H), 2.80 (brs, 1 H), 2.48 (brs, 2 H), 2.04 (s, 3 H), 1.78 (m, 2 H), 1.62 (m, 4 H), 1.4 (m, 2 H).

5 Step D: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-4-methylbenzamide trifluoroacetate.

To a suspension of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (30 mg, 0.12 mmol) was added 4-methyl-benzoyl chloride (15.8 μ L, 0.12 mmol) and DIEA (5 drops). The reaction was stirred overnight at room temperature under argon
10 gas. The solution was concentrated and the product purified using prep HPLC to give *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-4-methylbenzamide trifluoroacetate (29.1mg, 50.4 %) as a white solid.

ESI MS m/e 368 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 8.70 (s, 1 H), 7.68 (d, $J = 8.0$ Hz, 2 H), 7.24 (d, $J = 8.0$ Hz, 2 H), 6.72 (s, 1 H), 4.25 (s, 1 H), 3.23 (s, 6 H), 2.71 (s, 1 H), 2.34 (s, 3 H), 2.27
15 (s, 3 H), 1.7-1.88 (m, 8 H).

Example 2524

20 *N*-(*cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-3,4-difluorobenzamide hydrochloride

Step A: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

To a suspension of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (70 mg, 0.28 mmol) in DCM (5 mL) was added 3,4-difluorobenzoyl chloride (50 mg, 0.28 mmol) and DIEA (45 μ L, 0.28 mmol). The reaction was stirred overnight and the product was purified by column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10). The purified product was dissolved in DCM (3 mL), and 2M-HCl in ethyl ether (0.3 mL) was added.

After stirring 20 min, removal of the volatile solvent gave *N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride (26 mg, 23 %) as a white solid.

ESI MS *m/e* 390 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.8 (brs, 1 H), 8.23 (brs, 1 H), 7.80 (m, 2 H), 7.63 (m, 1 H), 7.51 (s, 1 H), 7.40 (d, *J* = 8.8 Hz, 1 H), 3.74 (brs, 2 H), 3.14 (s, 6 H), 2.11 (s, 3 H), 1.73-1.58 (m, 8 H).

Example 2525

10 3-Chloro-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)benzamide hydrochloride.

15 Using procedure of step A of example 2524, the title compound was obtained.

ESI MS *m/e* 388 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.7 (brs, 1 H), 8.22 (brs, 1 H), 7.72 (m, 2 H), 7.62 (d, *J* = 8.0 Hz, 1 H), 7.45 (s, 1 H), 7.42 (d, *J* = 8.0 Hz, 1 H), 7.32 (t, *J* = 7.6 Hz, 1 H), 3.70 (brs, 2 H), 3.10 (s, 6 H), 2.06 (s, 3 H), 1.68-1.54 (m, 8 H).

20

Example 2526

N-(*cis*-4-{{4-(Dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-3-methylbenzamide trifluoroacetate

25 Step A: Synthesis of 2-chloro-4-dimethylamino-6-methylpyrimidine.

In 100 mL tetrahydrofuran was dissolved 2,4-dichloro-6-methylpyrimidine (10 g, 61.3 mmol) at 0° C. To the reaction mixture was added dimethylamine (2M in methanol, 67.4 mL, 134.8 mmol) dropwise. The reaction mixture was stirred at 10 °C for 2.5 hours. The solution was

concentrated and purified by flash chromatography (silica gel, 20% ethyl acetate and 5% methanol in hexanes) to give 2-chloro-4-dimethylamino-6-methylpyrimidine (4.18g, 40 %) as a pale yellow solid.

ESI MS m/e 172 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 6.25 (s, 1 H), 3.2 (s, 6 H), 2.64 (s, 3 H).

5

Step B: Synthesis of *cis*-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester.

To a suspension of 2-chloro-4-dimethylamino-6-methylpyrimidine (15 mg, 0.0874 mmol) in 2-propanol (1.7 mL) was added *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (20.6 mg, 0.096 mmol) and DIEA (30.3 μ L, 0.175 mmol). The reaction was performed in the Smith synthesizer for 4.5 hours at 175 $^{\circ}$ C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH_2Cl_2) to give *cis*-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (18.9 mg, 62 %) as a pale yellow solid.

15 ESI MS m/e 350.4 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 5.65 (s, 1 H), 4.75 (brs, 1 H), 4.0 (brs, 1 H), 3.60 (brs, 1 H), 3.05 (s, 6 H), 2.22 (s, 3 H), 1.78 (m, 6 H), 1.59 (m, 2 H), 1.44 (s, 9 H).

Step C: Synthesis of *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane.

20 To a suspension of *cis*-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (617 mg, 1.77 mmol) in DCM (3 mL) was added trifluoroacetic acid (2mL). The reaction stirred at room temperature for 2 hours and concentrated. A few drops $NaHCO_3$ was added, followed by 1M NaOH until the solution was basic. The product was extracted with H_2O and CH_2Cl_2 three times. The organic layers were combined, dried over $MgSO_4$,
25 filtered and concentrated to give *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (318 mg, 72 %) as yellow oil.

ESI MS m/e 250 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 5.52 (s, 1 H), 5.10 (brs, 1 H), 3.88 (brs, 1 H), 3.20 (brs, 2 H), 2.88 (s, 6 H), 2.75 (s, 1 H), 2.04 (s, 3 H), 1.70 (m, 2 H), 1.58 (m, 4 H), 1.38 (m, 2 H).

5 Step D: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl)-3-methylbenzamide trifluoroacetate.

Using the procedure of step D of example 2523, the title compound was obtained.

ESI MS m/e 368.4 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) 9.0 (s, 1 H), 7.6 (m, 2 H), 7.22 (s, 1 H), 6.72 (s, 1 H), 5.68 (s, 1 H), 4.2 (s, 1 H), 4.12 (s, 1 H), 3.18 (s, 3 H), 3.08 (s, 3 H), 2.35 (s, 3 H), 2.29 (s, 3 H), 1.85-1.62 (m, 8 H).

Example 2527

cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]-*N*-[3-(trifluoromethyl)benzyl]-
15 cyclohexanecarboxamide

Step A: Synthesis of *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid ethyl ester.

To a suspension of 2-chloro-4-dimethylamino-6-methylpyrimidine (250 mg, 1.46 mmol) in
20 2-propanol (1.5 mL) was added *cis*-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride (330 mg, 1.59 mmol) and DIEA (0.60 mL, 3.44 mmol). The reaction was performed in the Smith synthesizer for 1 hour at 155 °C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH_2Cl_2) to give *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid ethyl ester (378.9 mg, 84.7%) as a pale yellow
25 solid.

ESI MS m/e 307 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 7.62 (brs, 1 H), 6.21 (s, 1 H), 4.04 (q, $J = 6.4$ Hz, 2 H), 3.98 (brs, 1 H), 3.15 (s, 6 H), 2.20 (s, 3 H), 1.58-1.80 (m, 8 H), 1.20 (t, $J = 6.0$ Hz, 3 H).

Step B: Synthesis of *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid.

To a suspension of *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid ethyl ester (597.6 mg, 1.95 mmol) in H₂O (10 mL) and ethanol (0.3 mL) was added KOH (547 mg, 9.75 mmol). The reaction was stirred at 70 °C for 2.5 hours until reaction was homogenous. The reaction was cooled in an ice bath and acidified with concentrated HCl. The product was purified using flash chromatography (silica gel, 0-10% MeOH in CH₂Cl₂) to give *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid (302 mg, 55%) as a white solid.

ESI MS *m/e* 279.2 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.50 (brs, 1 H), 5.79 (s, 1 H), 4.02 (brs, 1 H), 3.19 (brs, 6 H), 2.49 (brs, 1 H), 2.29 (s, 3 H), 2.05 (m, 2 H), 1.81 (m, 2 H), 1.64 (m, 4 H).

Step C: Synthesis of *cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide.

To a suspension of 3-trifluoromethylbenzylamine (14 μL, 0.0987 mmol) and *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid (25mg, 0.0898 mmol) in DCM (5 mL) was added HATU (37.5mg, 0.0987 mmol). The reaction stirred at room temperature under argon for 30 seconds and triethylamine (5 drops) was added. The reaction stirred under argon at room temperature for 16 hours. The reaction was quenched by diluting with 5 mL DCM, followed by washing twice with saturated NaHCO₃ (5mL), twice with 1M HCl (5mL) and once with H₂O (5mL). The product was purified by filtering through silica gel with 0-10% MeOH in CH₂Cl₂ to give *cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide (17.6mg, 45 %) as a white solid.

ESI MS *m/e* 436 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (brs, 1 H), 7.59 (brs, 1 H), 7.53 (m, 2 H), 7.40 (m, 2 H), 5.76 (s, 1 H), 4.50 (d, *J* = 6.4 Hz, 2 H), 4.28 (brs, 1 H), 3.19 (s, 6 H), 2.39 (m, 1 H), 2.30 (s, 3 H), 2.0 (m, 2 H), 1.87 (m, 4 H), 1.60 (m, 2 H).

Example 2528

cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[3-(propionylamino)benzyl]-cyclohexanecarboxamide

5

Step A: Synthesis of *cis*-[4-(3-nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid *tert*-butyl ester.

cis-4-(*tert*-Butoxycarbonylamino)-cyclohexanecarboxylic acid (2.0 g, 8.2 mmol) and 3-nitrobenzyl amine hydrochloride (1.54 g, 8.2 mmol) in DCM (30 mL) was reacted in the presence
10 of HATU (3.5 g, 9.02 mmol) and Et₃N (4 mL). The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. From column chromatography (silica gel, DCM/MeOH = 100:0 to 95 to 5), 2.7 g (90 %) of *cis*-[4-(3-nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid *tert*-butyl ester was isolated.

ESI MS *m/e* 378 *M* + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (brs, 1 H), 8.09 (s, 1 H), 7.60 (d, *J* = 8.0 Hz, 1 H), 7.48 (t, *J* = 7.6 Hz, 1 H), 6.17 (brs, 1 H), 4.72 (brs, 1 H), 4.53 (d, *J* = 6.0 Hz, 2 H),
15 3.74 (brs, 1 H), 2.27 (m, 1 H), 1.80-1.71 (m, 6 H), 1.65-1.59 (m, 2 H), 1.45 (s, 9 H).

Step B: Synthesis of *cis*-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride.

cis-[4-(3-Nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (2.5 g, 6.6
20 mmol) was reacted in TFA/DCM (1:2 = 23 mL) for 2 hr at room temperature. After removal of the solvents, the residue was dissolved in DCM (15 mL), and added 2M-HCl in ethyl ether (2 eq.). After stirring for 20 min at room temperature, the volatile solvent was removed to give *cis*-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride (2.0 g, 95 %) as a yellowish
25 white solid.

ESI MS *m/e* 278 *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.53 (t, *J* = 6.0 Hz, 1 H), 8.07 (d, *J* = 7.6 Hz, 1 H), 8.06 (s, 1 H), 7.84 (brs, 2 H), 7.68 (d, *J* = 7.6 Hz, 1 H), 7.59 (t, *J* = 7.6 Hz, 1 H), 4.37 (d, *J* = 6.4 Hz, 2 H), 3.13 (m, 1 H), 2.40 (m, 1 H), 1.89 (m, 2 H), 1.68 (m, 4 H), 1.57 (m, 2 H).

Step C: Synthesis of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzylamide.

2-Chloro-4-dimethylamino-5-methylpyrimidine (0.31 g, 1.8 mmol) and *cis*-4-amino-cyclohexanecarboxylic acid 3-nitro-benzylamide hydrochloride (0.52 g, 1 eq.) in IPA (2.5 mL) and DIEA (0.7 mL) was reacted in a Smith synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. The crude compound was purified from column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give 0.23 g (31 %) of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzylamide.

ESI MS *m/e* 413 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (brs, 1 H), 8.03 (d, *J* = 8.0 Hz, 1 H), 7.95 (brs, 1 H), 7.62 (d, *J* = 8.0 Hz, 1 H), 7.43 (t, *J* = 7.6 Hz, 1 H), 7.28 (s, 1 H), 4.51 (d, *J* = 5.6 Hz, 2 H), 4.33 (m, 1 H), 3.23 (s, 6 H), 2.39 (m, 1 H), 2.22 (s, 3 H), 2.02 (m, 2 H), 1.86 (m, 4 H), 1.60 (m, 2 H).

Step D: Synthesis of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide.

A solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide (0.21 g, 0.5 mmol) and 10 % Pd/C (50 mg) in EtOH (10 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH = 100:0 to 80:20) to give 0.18 g (95 %) of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide as the desired product.

ESI MS *m/e* 383 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.29 (s, 1 H), 7.03 (t, *J* = 7.6 Hz, 1 H), 6.64 (m, 2 H), 6.51 (d, *J* = 8.0 Hz, 1 H), 4.33 (d, *J* = 5.6 Hz, 2 H), 4.25 (brs, 1 H), 3.19 (s, 6 H), 2.32 (m, 1 H), 2.19 (s, 3 H), 1.97-1.78 (m, 6 H), 1.62 (m, 2 H).

Step E: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[3-(propionylamino)benzyl]cyclohexanecarboxamide.

cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide (30 mg, 0.075 mmol) and propionyl chloride (7 mg, 0.075 mmol) was reacted
5 in the presence of catalytic Et₃N (7 drops). The product was purified from column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[3-(propionylamino)benzyl]cyclohexanecarboxamide (11 mg, 32 %).

ESI MS *m/e* 439 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (brs, 1 H), 7.92 (brs, 1 H), 7.35 (s, 1 H), 7.28 (s, 1 H), 7.21 (t, *J* = 7.6 Hz, 1 H), 6.92 (d, *J* = 7.6 Hz, 1 H), 6.46 (brs, 1 H), 4.42 (d, *J* = 6.0
10 Hz, 2 H), 4.23 (m, 1 H), 3.22 (s, 6 H), 2.47 (d, *J* = 7.6 Hz, 2 H), 2.33 (m, 1 H), 2.22 (s, 3 H), 1.95-1.90 (m, 6 H), 1.63 (m, 2 H), 1.22 (t, *J* = 7.6 Hz, 3 H).

Example 2529

15 *cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[3-(isobutyrylamino)benzyl]-cyclohexanecarboxamide

Step A: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[3-(isobutyrylamino)benzyl]cyclohexanecarboxamide.

20 Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS *m/e* 453 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.80 (brs, 1 H), 8.10 (brs, 1 H), 7.93 (brs, 1 H), 7.39 (s, 1 H), 7.23 (s, 1 H), 7.18 (t, *J* = 7.6 Hz, 1 H), 6.91 (d, *J* = 7.6 Hz, 1 H), 6.69 (brs, 1 H), 4.40 (d, *J* = 5.6 Hz, 2 H), 4.22 (m, 1 H), 3.23 (s, 6 H), 2.74 (m, 1 H), 2.33 (m, 1 H), 2.20 (s, 3 H), 1.96-1.87 (m, 6 H), 1.60 (m, 2 H), 1.22 (d, *J* = 6.4 Hz, 6 H).

Example 2530

cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-{3-[(3-methylbutanoyl)amino]benzyl}cyclohexanecarboxamide.

5 Step A: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-{3-[(3-methylbutanoyl)amino]benzyl}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 467 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.62 (brs, 1 H), 8.04 (brs, 1 H), 7.91 (d, J = 7.2 Hz, 1 H), 7.35 (s, 1 H), 7.26 (s, 1 H), 7.20 (t, J = 7.6 Hz, 1 H), 6.93 (d, J = 7.6 Hz, 1 H), 6.59 (brs, 1 H), 4.42 (d, J = 5.2 Hz, 2 H), 4.22 (m, 1 H), 3.23 (s, 6 H), 2.33 (m, 1 H), 2.31 (d, J = 7.2 Hz, 2 H), 2.23 (m, 1 H), 2.21 (s, 3 H), 1.96-1.87 (m, 6 H), 1.62 (m, 2 H), 1.00 (d, J = 6.0 Hz, 6 H).

Example 2531

15 *cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-{3-[(2,2-dimethylpropanoyl)amino]benzyl}cyclohexanecarboxamide

Step A: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-{3-[(2,2-dimethylpropanoyl)amino]benzyl}cyclohexanecarboxamide.

20 Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 467 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.84 (brs, 1 H), 7.78 (d, J = 7.6 Hz, 1 H), 7.40 (s, 1 H), 7.25 (s, 1 H), 7.22 (t, J = 7.6 Hz, 1 H), 7.00 (d, J = 7.6 Hz, 1 H), 6.85 (brs, 1 H), 4.41 (d, J = 5.6 Hz, 2 H), 4.23 (m, 1 H), 3.23 (s, 6 H), 2.34 (m, 1 H), 2.22 (s, 3 H), 1.99-1.84 (m, 6 H), 1.60 (m, 2 H), 1.33 (s, 9 H).

Example 2532

cis-N-{3-[(Cyclobutylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide

5 **Step A: Synthesis of *cis-N*-{3-[(cyclobutylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.**

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 465 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.50 (brs, 1 H), 8.23 (brs, 1 H), 7.93 (d, J = 6.4 Hz, 1 H), 7.33 (s, 1 H), 7.24 (s, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.92 (d, J = 8.0 Hz, 1 H), 6.76 (brs, 1 H), 4.41 (d, J = 5.6 Hz, 2 H), 4.23 (m, 1 H), 3.33 (m, 1 H), 3.24 (s, 6 H), 2.35 (m, 4 H), 2.21 (s, 3 H), 2.18 (m, 1 H), 2.00-1.87 (m, 8 H), 1.60 (m, 2 H).

Example 2533

15 *cis-N*-{3-[(Cyclopentylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide

Step A: Synthesis of *cis-N*-{3-[(cyclopentylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

20 Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 479 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (brs, 1 H), 8.10 (brs, 1 H), 7.91 (d, J = 6.4 Hz, 1 H), 7.35 (s, 1 H), 7.26 (s, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.93 (d, J = 7.6 Hz, 1 H), 6.61 (brs, 1 H), 4.42 (d, J = 5.6 Hz, 2 H), 4.22 (m, 1 H), 3.22 (s, 6 H), 2.85 (m, 1 H), 2.33 (m, 1 H), 2.21 (s, 3 H), 2.00-1.88 (m, 10 H), 1.75 (m, 2 H), 1.60 (m, 4 H).

Example 2534

cis-N-{3-[(Cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

5 **Step A: Synthesis of *cis-N*-{3-[(cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.**

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 493 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.30 (brs, 1 H), 8.01 (brs, 1 H), 7.86 (d, J = 7.6 Hz, 1 H), 7.36 (s, 1 H), 7.26 (s, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.94 (d, J = 7.6 Hz, 1 H), 6.65
10 (brs, 1 H), 4.41 (d, J = 5.2 Hz, 2 H), 4.22 (m, 1 H), 3.22 (s, 6 H), 2.35 (m, 2 H), 2.21 (s, 3 H), 1.96-1.28 (m, 18 H).

Example 2535

15 ***cis-N*-{3-[(Cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide**

Step A: Synthesis of *cis-N*-{3-[(cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

20 Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 451 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 9.10 (brs, 1 H), 7.93 (m, 1 H), 7.36 (s, 1 H), 7.25 (s, 1 H), 7.19 (t, J = 8.0 Hz, 1 H), 6.90 (d, J = 7.2 Hz, 1 H), 6.50 (brs, 1 H), 4.43 (d, J = 6.0 Hz, 2 H), 4.23 (m, 1 H), 3.23 (s, 6 H), 2.33 (m, 1 H), 2.21 (s, 3 H), 1.96-1.88 (m, 7 H), 1.63 (m, 2 H), 1.03 (m, 2 H), 0.79 (m, 2 H).

25

Example 2536

N-[(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide.

Step A: Synthesis of {*cis*-4-[(3-nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic

5 acid *tert*-butyl ester.

A mixture of *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (1.55 g, 6.8 mmol) and 3-nitrobenzoyl chloride (1.25 g, 6.8 mmol) was stirred overnight at room temperature, diluted with DCM, washed with 1N-HCl and water, and concentrated. The crude product was preliminary purified by a short pad of silica gel with DCM/MeOH (100:0 to 90:10) to give 1.5 g
10 (75 %) of {*cis*-4-[(3-nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester.

ESI MS *m/e* 378 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.54 (t, *J* = 2.0 Hz, 1 H), 8.33 (d, *J* = 8.0 Hz, 1 H), 8.14 (d, *J* = 8.0 Hz, 1 H), 7.63 (t, *J* = 7.6 Hz, 1 H), 6.31 (brs, 1 H), 4.62 (brs, 1 H), 3.73 (brs, 1 H), 3.41 (t, *J* = 6.4 Hz, 2 H), 1.72-1.57 (m, 7 H), 1.44 (s, 9 H), 1.32 (m, 2 H).

15 Step B: Synthesis of *cis*-*N*-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride.

{*cis*-4-[(3-Nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (1.4 g, 3.7 mmol) in DCM/TFA (1:1 = 13 mL) was stirred for 2 h at room temperature. After removal of the volatile solvent, the residue was dissolved in DCM (10 mL), and 2M-HCl in ether (4 mL) was added. After stirring for 20 min at room temperature, removal of the volatile solvent gave 1.2 g
20 (82 %) of *cis*-*N*-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride as the desired product.

ESI MS *m/e* 278 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.91 (t, *J* = 5.6 Hz, 1 H), 8.65 (m, 1 H), 8.36 (d, *J* = 2.0 Hz, 1 H), 8.29 (d, *J* = 8.0 Hz, 1 H), 7.97 (brs, 2 H), 7.74 (t, *J* = 8.0 Hz, 1 H), 3.25 (t, *J* = 6.8 Hz, 2 H), 3.13 (brs, 1 H), 1.77 (m, 1 H), 1.65-1.61 (m, 4 H), 1.51 (m, 4 H).

25

Step C: Synthesis of *cis*-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3-nitro-benzamide.

A solution of 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25 g, 1.46 mmol) and *cis*-*N*-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride (0.46 g) in IPA (2 mL) and DIEA (0.46 mL) was reacted for 1 hr 10 min. at 155 °C in a Smith synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. The crude
5 compound was purified from column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give 0.23 g (38 %) of *cis*-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3-nitro-benzamide.

ESI MS *m/e* 413.2 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.73 (t, *J* = 2.0 Hz, 1 H), 8.34 (d, *J* = 7.6 Hz, 1 H), 8.28 (d, *J* = 8.0 Hz, 1 H), 8.20 (brs, 1 H), 7.60 (t, *J* = 7.6 Hz, 1 H), 7.35 (brs, 1 H), 7.25
10 (s, 1 H), 4.18 (m, 1 H), 3.48 (t, *J* = 4.8 Hz, 2 H), 3.24 (s, 6 H), 2.21 (s, 3 H), 1.89-1.57 (m, 9 H).

Step D: Synthesis of *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide.

A solution of *cis*-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-
15 cyclohexylmethyl]-3-nitro-benzamide (0.22 g, 0.53 mmol) and 10 % Pd/C (30 mg) in EtOH (15 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH = 100:0 to 80:20) to give 0.19 g (95 %) as yellowish oil. 17 mg (0.04 mmol) of this oil was reacted with isovaleryl chlorides (5 mg, 0.04 mmol) using the
20 procedure of step E of example 2528 to give *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide (9 mg, 47 %).

ESI MS *m/e* 467.6 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.11 (brs, 1 H), 8.22 (d, *J* = 7.2 Hz, 1 H), 8.04 (s, 1 H), 7.55 (d, *J* = 7.6 Hz, 1 H), 7.34 (t, *J* = 7.6 Hz, 1 H), 7.30 (s, 1 H), 6.42 (m, 1 H), 4.14 (m, 1 H), 3.43 (t, *J* = 4.8 Hz, 2 H), 3.19 (s, 6 H), 2.33 (d, *J* = 6.8 Hz, 2 H), 2.25 (m, 1 H), 2.20 (s, 3
25 H), 1.94 (m, 2 H), 1.72~1.59 (m, 7 H), 1.02 (d, *J* = 6.4 Hz, 6 H).

Example 2537

N-[(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(propionylamino)benzamide

5 **Step A: Synthesis of *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-(propionylamino)benzamide.**

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS *m/e* 439 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.10 (brs, 1 H), 8.23 (d, *J* = 7.2 Hz, 1 H), 8.02 (s, 1 H), 7.55 (d, *J* = 8.0 Hz, 1 H), 7.35 (t, *J* = 7.6 Hz, 1 H), 7.29 (s, 1 H), 6.36 (m, 1 H), 4.16 (brs, 1 H), 3.47 (m, 2 H), 3.21 (s, 6 H), 2.50 (q, *J* = 7.6 Hz, 2 H), 2.21 (s, 3 H), 1.95 (m, 2 H), 1.72-1.61 (m, 7 H), 1.25 (t, *J* = 7.2 Hz, 3 H).

Example 2538

15 ***N*-[(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(isobutyrylamino)benzamide**

Step A: Synthesis of *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-(isobutyrylamino)benzamide

20 Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS *m/e* 453 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.09 (brs, 1 H), 8.23 (d, *J* = 6.8 Hz, 1 H), 8.07 (s, 1 H), 7.55 (d, *J* = 7.6 Hz, 1 H), 7.34 (t, *J* = 7.6 Hz, 1 H), 7.29 (s, 1 H), 6.38 (m, 1 H), 4.16 (brs, 1 H), 3.45 (m, 2 H), 3.21 (s, 6 H), 2.73 (m, 1 H), 2.20 (s, 3 H), 1.95 (m, 2 H), 1.72-1.61 (m, 7 H), 1.26 (d, *J* = 6.8 Hz, 6 H).

Example 2539

3-[(Cyclopropylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

5 Step A: Synthesis of 3-[(cyclopropylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 451 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 9.60 (brs, 1 H), 8.22 (d, $J = 6.8$ Hz, 1 H), 8.03 (s, 1 H), 7.56 (brs, 1 H), 7.55 (d, $J = 7.6$ Hz, 1 H), 7.32 (t, $J = 7.6$ Hz, 1 H), 7.28 (s, 1 H), 6.41 (m, 1 H), 4.15 (brs, 1 H), 3.45 (m, 2 H), 3.21 (s, 6 H), 2.20 (s, 3 H), 1.95 (m, 2 H), 1.89 (m, 1 H), 1.72~1.61 (m, 7 H), 1.05 (m, 2 H), 0.82 (m, 2 H).

Example 2540

15 3-[(Cyclobutylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Step A: Synthesis of 3-[(cyclobutylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

20 Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 465 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.90 (brs, 1 H), 8.21 (d, $J = 6.8$ Hz, 1 H), 8.04 (s, 1 H), 7.54 (d, $J = 8.0$ Hz, 1 H), 7.34 (t, $J = 7.6$ Hz, 1 H), 7.31 (s, 1 H), 6.41 (m, 1 H), 4.14 (brs, 1 H), 3.43 (t, $J = 5.2$ Hz, 2 H), 3.34 (m, 1 H), 3.19 (s, 6 H), 2.41 (m, 2 H), 2.23 (m, 1 H), 2.20 (s, 3 H), 2.02-1.88 (m, 4 H), 1.72-1.55 (m, 8 H).

Example 2541

3-[(Cyclopentylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

5 **Step A: Synthesis of 3-[(cyclopentylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.**

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 479 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 9.14 (brs, 1 H), 8.22 (d, $J = 7.2$ Hz, 1 H), 8.07 (s, 1 H), 7.54 (d, $J = 8.0$ Hz, 1 H), 7.33 (t, $J = 8.0$ Hz, 1 H), 7.29 (s, 1 H), 6.43 (m, 1 H), 4.14
10 (brs, 1 H), 3.44 (t, $J = 5.2$ Hz, 2 H), 3.19 (s, 6 H), 2.91 (m, 1 H), 2.20 (s, 3 H), 1.98-1.59 (m, 17 H).

Example 2542

3-[(Cyclohexylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide
15

Step A: Synthesis of 3-[(cyclohexylcarbonyl)amino]-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using the procedure of step D of example 2536, the title compound was obtained.

20 ESI MS m/e 479 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.94 (brs, 1 H), 8.17 (d, $J = 7.2$ Hz, 1 H), 8.05 (s, 1 H), 7.54 (d, $J = 8.0$ Hz, 1 H), 7.33 (t, $J = 8.0$ Hz, 1 H), 7.30 (s, 1 H), 6.44 (m, 1 H), 4.13 (brs, 1 H), 3.42 (t, $J = 5.2$ Hz, 2 H), 3.19 (s, 6 H), 2.42 (m, 1 H), 2.20 (s, 3 H), 1.98-1.52 (m, 15 H), 1.29 (m, 4 H).

25

Examples 2543-2553

Compounds 2543 to 2553 were prepared in a similar manner as described in Example 2497 using the appropriate acid chloride and amine intermediate from Step D.

Examples 2554-2557

Compounds 2554 to 2557 were prepared in a similar manner as described in Example 2502 using the appropriate carboxylic acid and amine intermediate from Example 2497 Step D.

5

Examples 2558-2561

Compounds 2558 to 2561 were prepared in a similar manner as described in Example 2515 using the appropriate isocyanate and amine intermediate from Example 2497 Step D.

10 **Examples 2562 and 2563**

Compounds 2562 and 2563 were prepared in a similar manner as described in Example 2523 using the appropriate acid chloride and amine intermediate from Step C.

Examples 2564-2570

15 Compounds 2564 to 2570 were prepared in a similar manner as described in Example 2526 using the appropriate acid chloride and amine intermediate from Step C.

Examples 2571-2587

20 Compounds 2571 to 2587 were prepared in a similar manner as described in Example 2527 using the appropriate benzyl amine and carboxylic acid intermediate from Step B.

Ex. No.	compound name	MS	class
2543	3-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	374.2 (M + H)	1
2544	4-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	374.2 (M + H)	1
2545	4-fluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	378.2 (M + H)	1
2546	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3-(trifluoromethyl)benzamide	428 (M + H)	3
2547	3-chloro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	394.2 (M + H)	1
2548	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide	496.2 (M + H)	1
2549	3-methoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	390.4 (M + H)	1
2550	3-cyano-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	385.2 (M + H)	1
2551	2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide	424.2 (M + H)	1
2552	3,4,5-trimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	450.4 (M + H)	1
2553	3,5-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide	420.2 (M + H)	1
2554	2-(3-methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide	420.2 (M + H)	1
2555	(2R)-2-(3-chlorophenyl)-2-hydroxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide	424.2 (M + H)	1
2556	2-(3-methylphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide	404.2 (M + H)	1
2557	5-bromo-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-furamide	428 (M + H)	1
2558	N-[4-(benzyloxy)phenyl]-N'-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea	481.2 (M + H)	2
2559	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N'-(4-phenoxyphenyl)urea	467.4 (M + H)	1
2560	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N'-(3-phenoxyphenyl)urea	467.4 (M + H)	2
2561	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N'-(2-phenoxyphenyl)urea	467.4 (M + H)	1
2562	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	368.2 (M + H)	1
2563	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	384.2 (M + H)	1
2564	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	384.2 (M + H)	1
2565	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide	368.2 (M + H)	1
2566	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388.2 (M + H)	1

Ex. No.	compound name	MS	class
2567	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388.4 (M + H)	1
2568	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	390.2 (M + H)	1
2569	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	438.2 (M + H)	3
2570	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	372.2 (M + H)	1
2571	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide	494.2 (M + H)	1
2572	cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436.2 (M + H)	1
2573	cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436.2 (M + H)	1
2574	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarboxamide	382.2 (M + H)	1
2575	cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436.2 (M + H)	1
2576	cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	428.2 (M + H)	1
2577	cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	402.2 (M + H)	1
2578	cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	504.2 (M + H)	1
2579	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide	398.2 (M + H)	1
2580	cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	402.2 (M + H)	1
2581	cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436.2 (M + H)	1
2582	cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404.2 (M + H)	1
2583	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404.2 (M + H)	1
2584	cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404.2 (M + H)	1
2585	cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	464.2 (M + H)	1
2586	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide	382.4 (M + H)	1
2587	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide	452.2 (M + H)	1

Example 2588

N-(*cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride

5 Step A: Synthesis of N-(*cis*-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (2.18 g, 10 mmol) in anhydrous benzene (25 mL) was slowly added 3,5-bistrifluoromethyl benzoyl chloride (2.8 g, 1 eq.) and followed by Et₃N (~3mL) at room temperature under N₂ atmosphere: formation of solid
10 salts makes stirring difficult. The reaction was stirred vigorously for an additional 2 h at room temperature, washed with sat.-NaHCO₃ (3x) and water (1x), dried with MgSO₄, and concentrated to give [*cis*-4-[(3,5-bistrifluoromethyl-benzoylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.5 g, 99 %), which was used for the next reaction without further purification. ESI MS *m/e* 455 (M + H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (s, 2 H), 7.98 (s, 1 H), 6.12 (bs, 1 H), 4.58 (bs, 1 H),
15 4.11 (m, 1 H), 3.69 (bs, 1 H), 1.95~1.65 (m, 8 H), 1.44 (s, 9 H).

[*cis*-4-[(3,5-Bistrifluoromethyl-benzoylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.5 g, 10 mmol) was dissolved in DCM (20 mL), and TFA (10 mL) was added to the reaction. After 1.5 h stirring at room temperature, removal of the volatile solvent gave the crude *N*-(*cis*-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate as a sticky oil. With addition
20 of water (~50 mL) to the crude product, shaking for 5 to 10 min provided formation of precipitates. The precipitates were filtered, washed with water, and dried. 3.98 (82 %) of *N*-(*cis*-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate was isolated as a white powder. ESI MS *m/e* 355 (M + H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.62 (bd, 1 H, J = 4.8 Hz), 8.47 (s, 2 H), 8.29 (s, 1 H), 7.84 (bs, 3 H), 3.91 (bs, 1 H), 3.16 (bs, 1 H), 1.94 (m, 2 H), 1.75~1.66 (m, 6 H).

25

Step B: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25 g, 1.45

mmol), N-(*cis*-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate (0.68 g, 1 eq.), DIEA (0.5 mL, 2 eq.), and *tert*-BuOH (2.5 mL) was reacted for 2 h at 180 °C in a Smith microwave synthesizer: over 95 % conversion was observed by LC-MS. The reaction was diluted with DCM, washed with diluted-HCl and water, dried, and concentrated. 0.35 g (48 %) of N-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-bistrifluoromethyl-benzamide was isolated by column chromatography (silica gel; DCM:MeOH = 100:0 to 95:5).

To a solution of this neutral compound in DCM (10 mL) was added 4M-HCl in dioxane (0.4 mL, 2 eq.). After 30 min stirring at room temperature, removal of the volatile solvent provided N-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino] cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride as a white powder. ESI MS *m/e* 490 (M + H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.1 (bs, 1 H), 8.78 (bd, 1 H, J = 5.6 Hz), 8.48 (s, 2 H), 8.28 (s, 1 H), 8.05 (bd, 1 H, J = 6.4 Hz), 7.62 (s, 1 H), 3.91 (bs, 2 H), 3.26 (s, 6 H), 2.23 (s, 3 H), 1.87 (m, 2 H), 1.73 (bs, 6 H).

15

Example 2589

N-[(*cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride

20 Step A: Synthesis of N-(*cis*-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (1.1 g, 4.8 mmol) in dry benzene (15 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (1.33 g, 1 eq.) and followed by Et₃N (2 mL) at room temperature under N₂. The reaction was stirred for an additional 2 h at room temperature, washed with sat.-NaHCO₃ (3x) and water (1x), dried with MgSO₄, and concentrated. The crude {*cis*-4-[(3,5-bistrifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester was used for the next reaction without further purification.

To a solution of {*cis*-4-[(3,5-bistrifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (2.1 g, 4.5 mmol) in DCM (10 mL) was added TFA (5 mL) at room temperature. After 1.5 h stirring at ambient temperature, removal of the volatile solvent gave the crude N-(*cis*-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate as a sticky oil. After addition of water (~40 mL) to the crude product, 5 ~ 10 min shaking provided formation of precipitates. The ppts were filtered, washed with water, and dried. 1.40 (61 %) of N-(*cis*-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 369 ($M + H$)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.97 (bs, 1 H), 8.47 (s, 2 H), 8.29 (s, 1 H), 7.78 (bs, 3 H), 3.29 (t, 2 H, $J = 6.8$ Hz), 3.15 (bs, 1 H), 1.78 (bs, 1 H), 1.66 (m, 4 H), 1.52 (m, 4 H).

Step B: Synthesis of N-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-5-methylpyrimidine (0.21 g, 1.2 mmol), N-(*cis*-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate (0.6 g, 1 eq.), DIEA (0.45 mL, 2 eq.), and *tert*-BuOH (2.5 mL) was reacted for 1.6 h at 185 °C in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with diluted HCl and water, dried, and concentrated. The crude product was purified by column chromatography (silica gel; DCM:MeOH = 100:0 to 95:5). 0.3 g (50 %) of N-[(*cis*-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide was isolated.

To a solution of neutral compound in DCM (10 mL) was added 4M-HCl in dioxane (0.3 mL, 2 eq.). After 30 min stirring at ambient temperature, removal of the volatile solvent provided N-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride as a white powder. ESI MS m/e 504 ($M + H$)⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.5 (bs, 1 H), 8.79 (d, 1 H, $J = 8.0$ Hz), 8.43 (s, 2 H), 7.93 (s, 1 H), 7.50 (bs, 1 H), 7.15 (d, 1 H, $J = 4.4$ Hz), 4.23 (bs, 1 H), 3.51 (bs, 2 H), 3.27 (s, 6 H), 2.23 (s, 3 H), 1.89~1.82 (m, 5 H), 1.66~1.60 (m, 4 H).

Example 2590

N-[(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-5-methyl pyrimidine (0.4 g, 2.3 mmol), *cis*-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (0.61 g, 1 eq.), DIEA (0.8 mL, 2 eq.), and *t*-BuOH (2.5 mL), were reacted in a Smith microwave synthesizer for 6500 sec at 185 °C. Completion of the reaction was confirmed by LC-MS. The combined reaction was diluted with DCM, washed with 1N-HCl (2 x) and water (1 x), and dried with anhydrous MgSO₄. The organic was concentrated and purified by column chromatography (silica gel; hexane: DCM: MeOH = 1:5:0 to 0:95:5). Removal of the solvent gave 3.2 g (58 %) of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester. ESI MS *m/z* 398 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (bs, 1 H), 7.36 (m, 6 H), 5.10 (s, 3 H, NH-was overlapped), 4.12 (bs, 1 H), 3.24 (s, 6 H), 3.14 (t, 2 H, *J* = 6.4 Hz), 2.22 (s, 3 H), 1.88~1.50 (m, 9 H).

Step B: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl] amine.

The heterogenous mixture of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (3.0 g, 7.5 mmol) and 10 % Pd/C (0.12 g) in EtOH (20 mL) was stirred overnight under H₂ atmosphere at room temperature. Cbz of all starting material was cleaved, which was confirmed by ESI MS. The reaction was filtered through a pad of celite, and the organic was concentrated and purified by column chromatography (silica gel, DCM:MeOH = 100:0 to 80:20). 1.5 g (75 %) of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-

ylamino)-cyclohexylmethyl] amine was isolated as a yellowish powder.

ESI MS m/z 264 ($M + H$)⁺; ¹H NMR (400 MHz, DMSO- d_6) (7.70 (bs, 2 H), 7.60 (s, 1 H), 6.05 (d, 1 H, $J = 6.4$ Hz), 3.89 (bs, 1 H), 2.96 (s, 6 H), 2.71 (d, 2 H, $J = 6.8$ Hz), 2.08 (s, 3 H), 1.70~1.45 (m, 9 H).

5

Step C: Synthesis of *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate.

To a solution of *N*-[(*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl] amine (25 mg, 0.01 mmol) in DCM (1.0 mL) was added 4-trifluoromethoxybenzoyl chloride (21 mg, 1 eq.), and followed by Et₃N (30 L). The reaction was stirred for 4h at room temperature, concentrated, and purified by prep-HPLC. 20 mg (38 %) of *N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/z 452 ($M + H$)⁺; ¹H NMR (400 MHz, CDCl₃) (13.9 (bs, 1 H), 8.36 (bd, 1 H, $J = 6.4$ Hz), 7.88 (d, 2 H, $J = 8.4$ Hz), 7.27 (s, 1 H), 7.23 (d, 2 H, $J = 8.4$ Hz), 7.08 (bs, 1 H), 4.17 (bs, 1 H), 3.42 (t, 2 H, $J = 5.6$ Hz), 3.28 (s, 6 H), 2.23 (s, 3 H), 1.91~1.78 (m, 3 H), 1.65~1.55 (m, 6 H).

15

Example 2591

3,5-Dichloro-*N*-[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-methyl)cyclohexyl]benzamide trifluoroacetate

20

Step A: Synthesis of *N*-*cis*-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-5-methyl pyrimidine (0.4 g, 2.3 mmol), *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (0.53 g, 1 eq.), DIEA (0.7 mL, 2 eq.), and *t*-BuOH (2 mL), were reacted in a Smith microwave synthesizer for 7000 sec at 185 °C. ESI MS confirmed that all starting material was consumed. The reactions were

25

combined, diluted with DCM and washed with 1N-HCl (2 x) and water (1 x). The organic was concentrated and carried to the next step without a further purification.

The crude *N*-{*cis*-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester was dissolved in DCM (15 mL), and TFA (10 mL) was added. After 1.5 h stirring, removal of the volatile solvent gave *N*-*cis*-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine trifluoroacetate as a sticky oil. The sticky oil was treated with sat. NaOH (15 mL), and the basic aqueous layer was extracted with DCM (2 x) to remove nonpolar organic impurity, and the aqueous was concentrated to give a solid residue. The solid residue was extracted several times with DCM/MeOH (3/1), and removal of the solvent provided neutral *N*-*cis*-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (1.5 g, 41 %) as a yellowish powder.

ESI MS 264 (M + H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, 1 H), 5.05 (bs, 1 H), 3.29 (t, 2 H, J = 6.4 Hz), 3.03 (s, 7 H, CH₂-NH₂ was overlapped), 2.54 (bs, 2 H), 2.13 (s, 3 H), 1.72 (bm, 1 H), 1.59~1.45 (m, 8 H).

Step B: Synthesis of 3,5-dichloro-*N*-[*cis*-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide trifluoroacetate.

To a solution of *N*-*cis*-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (28 mg, 0.01 mmol) in benzene/DCM (2/1, 1.5 mL) was added 3,5-dichlorobenzoyl chloride (22 mg, 1eq.), and followed by Et₃N (30 μL). The reaction was stirred for 3h at room temperature, concentrated, and purified by prep-HPLC. 30 mg (51 %) of 3,5-dichloro-*N*-[*cis*-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 436 (M + H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.7 (bs, 1 H), 8.71 (bs, 1 H), 7.61 (d, 2 H, J = 1.6 Hz), 7.44 (t, 1 H, J = 1.6 Hz), 7.29 (s, 1 H), 6.59 (d, 1 H, J = 6.4 Hz), 4.23 (bm, 1 H), 3.36 (t, 2 H, J = 6.0 Hz), 3.29 (s, 6 H), 2.24 (s, 3 H), 1.81 (m, 3 H), 1.68 (m, 4 H), 1.45 (m, 2 H).

Example 2592

N-[*cis*-4-({[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

5 **Step A: Synthesis of *N*-*cis*-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine.**

Six sealed tubes, each containing 2-chloro-4-dimethylamino-6-methyl pyrimidine (0.4 g, 2.3 mmol), *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (0.53 g, 1 eq.), DIEA (0.7 mL, 2 eq.), and *t*-BuOH (2 mL), were reacted in a Smith microwave synthesizer for 6500 sec
10 at 185 °C. The reaction was monitored by LC-MS. The combined reaction was diluted with DCM and washed with 1N-HCl (2 x) and water (1 x). The organic was concentrated and performed deprotection without a further purification.

To a solution of *N*-{*cis*-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester in DCM (15 mL) was added TFA (10 mL). The reaction was stirred
15 for 1.5 h at room temperature, and removal of the volatile solvent gave *N*-*cis*-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine trifluoroacetate as a sticky oil. The sticky oil was treated with sat. NaOH (15 mL), and the basic aqueous layer was extracted with DCM (2 x), and the aqueous was concentrated to give a solid residue. The solid residue was extracted several times with DCM/MeOH (3/1), and removal of the solvent provided neutral *N*-*cis*-
20 4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (2.1 g, 57 %) as a yellowish powder.

ESI MS *m/e* 264 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 5.91 (bs, 1 H), 5.65 (s, 1 H), 3.33 (t, 2 H, *J* = 6.4 Hz), 3.06 (s, 6 H), 2.97 (m, 1 H), 2.27 (bs, 2 H), 2.11 (s, 3 H), 1.70 (m, 1 H), 1.59~1.45 (m, 8 H).

25

Step B: Synthesis of *N*-[*cis*-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

To a solution of *N*-*cis*-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-

cyclohexylamine (20 mg, 0.008 mmol) in benzene/DCM (2/1, 1.5 mL) was added 3,5-bistrifluoromethylbenzoyl chloride (21 mg, 1eq.), and followed by Et₃N (30 μ L). The reaction was stirred for 3h at room temperature, concentrated, and purified by prep-HPLC. 25 mg (53 %) of *N*-[*cis*-4-({4-(dimethylamino)-6-methylpyrimidin-2-yl}amino) methyl)cyclohexyl]-3,5-

5 bis(trifluoromethyl)benzamide trifluoroacetate was isolated as a white powder.

ESI MS *m/e* 504 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.9 (bs, 1 H), 8.86 (bs, 1 H), 8.25 (s, 2 H), 7.96 (s, 1 H), 7.30 (d, 1 H, *J* = 6.4 Hz), 5.74 (s, 1 H), 4.40 (bm, 1 H), 3.42 (t, 2 H, *J* = 6.0 Hz), 3.26 (s, 3 H), 3.13 (s, 3 H), 2.33 (s, 3 H), 1.91~1.60 (m, 9 H).

10

Example 2593

4-Chloro-*N*-[*cis*-4-{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino)cyclohexyl]-methyl]benzamide trifluoroacetate

15 **Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.**

Six sealed tubes, each containing 2-chloro-4-dimethylamino-6-methyl pyrimidine (0.4 g, 2.3 mmol), *cis*-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (0.61 g, 1 eq.), DIEA (0.8 mL, 2 eq.), and *t*-BuOH (2.5 mL), were reacted in a Smith microwave synthesizer for 6500 sec at
20 180 °C. The combined reaction was diluted with DCM, washed with 1N-HCl (2 x) and water (1 x), dried with MgSO₄, and concentrated. Purification by column chromatography (silica gel; hexane: DCM: MeOH = 1:5:0 to 0:95:5) gave 4.8 g (86 %) of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

ESI MS *m/z* 398 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.40 (bs, 1 H), 7.38 (m, 5 H), 5.70 (s, 1
25 H), 5.10 (s, 3 H, NH-was overlapped), 4.17 (bs, 1 H), 3.14 (bs, 6 H), 3.12 (t, 2 H, *J* = 6.0 Hz), 2.32 (s, 3 H), 1.90~1.50 (m, 9 H).

Step B: Synthesis of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-

cyclohexylmethyl] amine.

The heterogenous solution of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (4.5 g, 11.3 mmol) and 10 % Pd/C (0.20 g) in EtOH (25 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered
 5 through a pad of celite, and the organic was concentrated and purified by column chromatography (silica gel, DCM:MeOH = 100:0 to 80:20). 2.2 g (76 %) of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl] amine was isolated as a yellowish powder.

ESI MS *m/e* 264 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (bs, 1 H), 5.72 (s, 1 H), 4.40 (bs, 2 H), 4.15 (bm, 1 H), 3.16 (s, 6 H), 2.84 (d, 2 H, *J* = 6.8 Hz), 2.32 (s, 3 H), 1.80 (m, 2 H), 1.70~1.45
 10 (m, 7 H).

Step C: Synthesis of 4-chloro-*N*-[(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl) methyl]benzamide trifluoroacetate.

To a solution of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl] amine (25 mg, 0.01 mmol) in DCM/benzene (3/1, 1.0 mL) was added 4-
 15 chlorobenzoyl chloride (17 mg, 1eq.), and followed by Et₃N (30 μL). The reaction was stirred for 4h at room temperature, concentrated, and purified by prep-HPLC. 25 mg (51 %) of 4-chloro-*N*-[(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino} cyclohexyl)methyl]benzamide trifluoroacetate was isolated as a white powder.

20 ESI MS *m/e* 402 (*M* + *H*)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1 H), 8.60 (bd, 1 H, *J* = 6.4 Hz), 7.78 (d, 2 H, *J* = 8.4 Hz), 7.35 (d, 2 H, *J* = 8.4 Hz), 7.03 (bm, 1 H), 5.71 (s, 1 H), 4.20 (bs, 1 H), 3.42 (t, 2 H, *J* = 6.0 Hz), 3.22 (s, 3 H), 3.10 (s, 3 H), 2.31 (s, 3 H), 1.91~1.78 (m, 3 H), 1.65~1.55 (m, 6 H).

25

Example 2594

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-*N*-[(1*S*)-1-(4-methyl-phenyl)ethyl]cyclohexanecarboxamide hydrochloride

Step A: Synthesis of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid ethyl ester.

A sealed tube containing a suspension of 2-chloro-4-dimethylamino-5-methylpyrimidine (0.28 g, 1.6 mmol), *cis*-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride (0.33 g, 1 eq.), DIEA (0.65 mL, 2 eq.) in IPA (2 mL) was reacted in a Smith microwave synthesizer for 1 hour at 155° C. The solution was diluted with DCM, washed with 1N-HCl and water, concentrated, and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid ethyl ester (0.3 g, 60 %) as a pale yellow solid.

ESI MS *m/e* 307 (M + H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 1 H), 4.72 (bd, 1 H, J = 6.8 Hz), 4.13 (q, 2 H, J = 6.8 Hz), 3.96 (bs, 1 H), 3.01 (s, 6 H), 2.44 (m, 1 H), 2.13 (s, 3 H), 1.89 (m, 2H), 1.72 (m, 6 H), 1.25 (t, 3 H, J = 6.8 Hz).

Step B: Synthesis of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid.

A suspension of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid ethyl ester (0.25 g, 0.8 mmol) in 4N-HCl (10 mL) was stirred for 4 h at 85 °C. Progress of the reaction was monitored by LC-MS. The reaction was cooled to room temperature and completely removed the volatile solvent under a vacuum to give *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid (0.2 g, 90 %) as a white powder.

ESI MS *m/e* 279 (M + H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (bs, 1 H), 7.43 (s, 1 H), 3.94 (bs, 1 H), 3.28 (bs, 6 H), 2.49 (bs, 1 H), 2.25 (s, 3 H), 2.04 (m, 2 H), 1.82 (m, 2 H), 1.73 (m, 4 H), COOH was not observed.

Step C: Synthesis of *cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1*S*)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide hydrochloride.

To a suspension of (*S*)-1-(4-methylphenyl)-ethylamine (12 mg, 1 eq.) and *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexanecarboxylic acid (24 mg, 0.09 mmol) in DCM (2 mL) was added HATU (36 mg, 1.1 eq.). The reaction stirred for 30 seconds at room temperature under argon, and triethylamine (5 drops) was added. The reaction stirred overnight at room temperature. The reaction was diluted with DCM, washed with saturated NaHCO₃ (2x) and H₂O (1x), and concentrated. Purification by column chromatography (silica gel; DCM:MeOH = 100:0 to 94:6) gave *cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid (*S*)-(1-*p*-tolyl-ethyl)-amide (15 mg, 43 %). To a solution of the amide in DCM (1 mL) was added 4M-HCl in dioxane (50 μ L). The reaction was stirred for 30 min at room temperature, and removal of the volatile solvent gave *cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}-N-[(1*S*)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide hydrochloride as a white powder.

ESI MS *m/e* 396 (*M* + *H*)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.0 (bs, 1 H), 8.14 (d, 1 H, *J* = 8.4 Hz), 7.68 (bs, 1 H), 7.54 (s, 1 H), 7.14 (d, 2 H, *J* = 8.0 Hz), 7.07 (d, 2 H, *J* = 8.0 Hz), 4.84 (m, 1 H), 4.01 (bs, 1 H), 3.24 (s, 6 H), 2.27 (m, 1 H), 2.25 (s, 3 H), 2.22 (s, 3 H), 1.80~1.54 (m, 8 H), 1.29 (d, 3 H, *J* = 6.8 Hz).

Example 2595

2,2-Difluoro-N-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate

Step A: Synthesis of 2,2-difluoro-N-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate.

2-(3,5-Dimethoxy-4-formyl)phenoxy ethyl polystyrene resin (1.0 gram; 0.94mmol/gram) and methylamine (0.0122 mol) in 15 mL of CH₂Cl₂ was suspended in a fritted synthesis flask. To this suspension was added a solution of NaBH(OAc)₃ (0.0122 mol) in CH₂Cl₂ (15 mL). After shaking the mixture overnight in a rotary shaker, the solution was removed by filtration. The

resulting resin bound N-methylamine was washed sequentially with CH₂Cl₂, DMF, and MeOH. The washing sequence was repeated four times. The resin bound N-methylamine was dried under vacuum for 20 minutes.

The resin bound Nmethylamine was suspended in DMF (10 mL). To the resin suspension
5 was added 2,4-dichloro-5-methyl-pyrimidine (1.41 mmol) followed by triethylamine (0.393 mL, 2.82 mmol). The reaction mixture was shaken at 40 °C overnight. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂ and MeOH. The wash sequence was repeated four times. The resulting resin bound intermediate was dried under vacuum for 20 minutes

The resin bound intermediate was divided up into three portions and each portion was
10 transferred into a 5ml Smith synthesizer reaction vessel. The resins (0.282 mmol) were separately suspended in a 1:1 solution of IPA/H₂O (3 mL). To each suspension was added *cis*-1,4-diamino-cyclohexane (0.85 mmol) and DIEA (0.295ml; 1.69 mmol). The reactions were heated in a microwave synthesizer at 180°C for 4.5 hours. The resins were pooled together; and the solution removed by filtration. The resin was sequentially washed with IPA, H₂O, MeOH, CH₂Cl₂, and
15 MeOH. The washing sequence was repeated three times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

The resin bound intermediate was suspended in DMF (10ml). To the resin suspension was added the 2,2- difluoro-benzo[1,3]dioxole 5-carbonyl chloride (0.94 mmol) and triethylamine (0.256 mL; 1.88 mol). The reaction was shaken in a rotary mixer at room temperature for 45
20 minutes. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂, MeOH. The wash sequence repeated three times.

After drying under vacuum for 20 minutes, the resin was treated with 15 mL of TFA solution (TFA /CH₂Cl₂ /H₂O 20:20:1 v/v). The reaction was shaken for 2 hours and the TFA solution was collected after filtration. The TFA was removed by rotary evaporation and the
25 compound subjected to purification by preparative HPLC to give 2,2-difluoro-*N*-(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino} cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate (8.6 mg, 5%) as a white solid.

ESI MS *m/e* 420.5 M+H⁺; ¹H NMR (400MHz, CD₃OD) δ 8.21 (d, *J* = 4 Hz, 1H), 7.75-7.67 (m,

2H), 7.41 (s, 1H), 7.28 (d, $J = 8$ Hz, 1H), 3.99 (m, 2H), 3.05 (s, 3H), 1.99 (s, 3H), 1.95-1.71 (m, 8H).

5 **Example 2596**

5-Bromo-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-2-furamide trifluoroacetate

Step A: Synthesis of 5-bromo-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-2-furamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 408.2 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 7.41 (s, 1H), 7.10 (s, 1H), 6.60 (s, 1H), 4.08-3.97 (m, 2H), 3.05 (s, 3H), 1.99 (s, 3H), 1.95-1.71 (m, 8H).

15

Example 2597

3,5-Dibromo-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-benzamide trifluoroacetate

Step A: Synthesis of 3,5-dibromo-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 496.2 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 8.37 (m, $J = 4$ Hz, 1H), 8.02-7.91 (m, 3H) 7.41 (s, 1H), 4.12-3.97 (m, 2H), 3.05 (s, 3H), 1.99 (s, 3H), 1.95-1.71 (m, 8H).

25

Example 2598

3-Fluoro-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-5-

(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 3-fluoro-*N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-5-(trifluoromethyl)benzamide trifluoroacetate.

5 Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 426.4 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 8.02 (m, 1H), 7.98 (d, $J=4$ Hz, 1H), 7.68 (d, $J=4$ Hz, 1H), 7.43-7.41 (s, 1H), 4.31-3.81 (m, 2H), 3.05 (s, 3H), 1.87 (s, 3H), 1.87-1.73 (m, 8H).

10

Example 2599

***N*-(*cis*-4-{{5-Methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate**

15 **Step A: Synthesis of *N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate.**

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 424.3 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 8.34 (d, $J=4$ Hz, 1H), 7.85 (d, $J=8$ Hz, 1H), 7.72-7.55 (s, 1H), 7.47-7.31 (m, 3H), 4.31-3.82 (m, 2H), 3.05 (s, 3H), 1.98 (s, 3H), 1.96-1.72 (m, 8H).

20

Example 2600

***N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride**

25

Step A: Synthesis of *N*-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride.

To a solution of (2-chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (200mg, 1.27 mmol) in 1mL 2-propanol was added *cis-N*-(4-amino-cyclohexyl)-3,5-bis-trifluoromethyl-benzamide (676mg, 1.91mmol) and DIEA (2.54mmol). The mixture was heated in a microwave synthesizer at 180 °C for 2 hours. The solvent was evaporated and the material subjected to chromatography (70 ~ 95% ethyl acetate/ hexanes). The combined compound in CH₂Cl₂ was added 2 M HCl in diethyl ether (1.5ml, 0.38mmol). The solvents were removed in vacuo to yield *N*-(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride (385.5mg, 0.75mmol, 59 %) as a white solid.

ESI MS 476.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.7 (s, 1H), 8.64 (s, 1H), 8.35 (s, 2H), 8.14 (s, 1H), 8.09 (bs, 1H), 8.00 (bs, 1H), 7.45 (s, 1H), 3.83 (bs, 1H), 3.75 (bs, 1H), 3.20 (s, 3H), 2.77-2.76 (d, *J* = 4 Hz, 3H), 1.76 (m, 2H), 1.58 (m, 6H).

Example 2601

N-(*cis*-4-{[4-(Ethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Step A: Synthesis of *N*-(*cis*-4-{[4-(ethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS *m/e* 390.4 M+H⁺; ¹H NMR (400MHz, CD₃OD) δ 8.22 (d, *J* = 4 Hz, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.42 (s, 1H), 7.38 (m, 1H), 4.22-3.99 (m, 2H), 3.63-3.56 (quartet, *J* = 4 Hz, 2H), 1.99 (s, 3H), 1.93-1.81 (m, 8H), 1.29-1.19 (t, *J* = 8 Hz, 3H).

Example 2602

3,4-Difluoro-*N*-(*cis*-4-{[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide trifluoroacetate

Step A: Synthesis of 3,4-difluoro-N-(*cis*-4-{[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

- 5 ESI MS m/e 404.4 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 8.10 (m, 1H), 7.80-7.75(m, 1H), 7.68 (m, 1H), 7.42 (s, 1H), 7.39-7.34 (m, 1H), 4.28-4.07 (m, 3H), 2.03 (s, 3H), 1.99-1.79 (m, 8H), 1.31-1.26 (d, J = 12 Hz, 6H).

10 **Example 2603**

N-(*cis*-4-{[4-(cyclopropylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Step A: Synthesis of N-(*cis*-4-{[4-(cyclopropylamino)-5-methylpyrimidin-2-yl]amino}-
15 **cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.**

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 402.2 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 7.78-7.73 (m, 1H), 7.69-7.66 (m, 1H), 7.42 (s, 1H), 7.40-7.33 (m, 1H), 4.26-3.88 (m, 2H), 3.02-2.96 (m, 1H), 1.97-1.81 (m, 11H), 0.90-0.85 (m, 2H), 0.72-0.68 (m, 2H).

20

Example 2604

3,4-Difluoro-N-(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide trifluoroacetate

25

Step A: Synthesis of 3,4-difluoro-N-(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 376.2 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 7.80-7.75 (m, 1H), 7.68 (m, 1H), 7.43-7.35 (m, 2H), 4.31-4.06 (m, 2H), 3.05 (s, 3H), 2.04 (s, 3H), 1.99-1.75 (m, 8H).

5 **Example 2605**

2-(3,4-Dichlorophenoxy)-N-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-(3,4-dichlorophenoxy)-N-(*cis*-4-{{5-methyl-4-(methylamino)-pyrimidin-2-yl}amino}cyclohexyl)acetamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 438.3 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 7.45-7.40 (m, 2H), 7.20 (s, 1H), 6.97-6.94 (m, 1H), 4.55 (s, 2H), 3.92-3.34 (s, 2H) 3.04 (s, 3H), 1.98 (s, 3H), 1.53-1.71 (m, 8H).

15

Example 2606

2-(2,3-Dichlorophenoxy)-N-(*cis*-4-{{5-methyl-4-(methylamino)pyrimidin-2-yl}amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-(2,3-dichlorophenoxy)-N-(*cis*-4-{{5-methyl-4-(methylamino)-pyrimidin-2-yl}amino}cyclohexyl)acetamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 438.3 $M+H^+$; 1H NMR (400MHz, CD_3OD) δ 7.42 (s, 1H), 7.31-6.92 (m, 3H), 4.65 (s, 2H), 4.07-3.95 (m, 2H), 3.05 (s, 3H), 1.98 (s, 3H), 1.93-1.69 (m, 8H).

25

Example 2607

N-(*cis*-4-{{4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl}amino}cyclohexyl)benzamide

trifluoroacetate**Step A: Synthesis of 2,4-dichloro-5,6-dimethyl-pyrimidine.**

To a suspension of 2,4-dihydroxy-5,6-dimethylpyrimidine (6.2 g, 0.044 mol) in POCl₃ (25 mL) was slowly added *N,N*-dimethylaniline (6.18 mL, 0.049 mol). The mixture was then refluxed at 125 °C for 3 hours. After this time, the starting material completely dissolved indicating that the reaction was completed. The reaction mixture was cooled and then poured slowly onto ice to quench the POCl₃ (caution exothermic!). A precipitate formed, which was filtered and washed with ice-cold water. The precipitate was dried under high vacuum overnight to yield 2,4-dichloro-5,6-dimethyl-pyrimidine (7.2 g, 0.041 mol, 92 %) as a yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 2.56 (s, 3H), 2.36 (s, 3H).

Step B: Synthesis of (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-5,6-dimethyl-pyrimidine (0.2 g, 0.0011 mol) in 1 mL 2-propanol was added DIEA (268 uL, 0.0017 mol) and dimethylamine (514 uL, 0.0010 mol). The mixture was then heated in a microwave at 170 °C for 10 minutes. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (0-50% ethyl acetate in hexanes) to yield (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine (75 mg, 0.40 mmol, 40%) as a white solid.

ESI MS 186.0 M+H⁺ ; ¹H NMR (400 MHz, CDCl₃) δ 3.03 (s, 6H), 2.37 (s, 3H), 2.15 (s, 3H).

Step C: Synthesis of *cis*-[4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine (0.5 g, 0.0027 mol) in 2 mL 2-propanol was added DIEA (514 uL, 0.0040 mol) and *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (635 mg, 0.0030 mol). The mixture was then heated in a microwave at 170 °C for 1 hour. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (0-100% ethyl acetate in hexanes) to yield *cis*-[4-(4-dimethylamino-5,6-

dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (875 mg, 2.4 mmol, 89 %) as a white solid.

ESI MS 364.6 M+H⁺ ; ¹H NMR (400 MHz, CD₃OD) δ 3.97 (m, 1H), 3.53 (m, 1H), 2.95 (s, 6H), 2.23 (s, 3H), 2.09 (s, 3H), 1.78-1.55 (m, 8H), 1.48 (s, 9H).

5

Step D: Synthesis of *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane.

To a solution of *cis*-[4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (3.4 g, 0.0094 mol) in 40 mL CH₂Cl₂ was added TFA (1.4 mL, 0.019 mol). The solution was stirred at room temperature for 4 hours (or until the reaction was complete as judged by TLC). The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq) / NaHCO₃ (aq) solution (the aqueous layer was confirmed to remain basic during the extraction using pH paper indicator). The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers
15 combined, dried over MgSO₄, and concentrated to yield *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (2.2 g, 0.0084 mol, 90%) as a white solid.

ESI MS 264.2 M+H⁺ ; ¹H NMR (400 MHz, CD₃OD) δ 3.99 (m, 1H), 2.95 (s, 6H), 2.80 (m, 1H), 2.23 (s, 3H), 2.09 (s, 3H), 1.84-1.67 (m, 6H), 1.52-1.49 (m, 2H).

20 **Step E: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}-cyclohexyl)benzamide trifluoroacetate.**

To a solution of *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (30 mg, 0.11 mmol) in 0.5 mL DMF was added pyridine (13.8 uL, 0.17 mmol) and benzoyl chloride (12.6 uL, 0.11 mmol). The reaction mixture was stirred overnight and then
25 0.5 mL of DMSO was added to the mixture. The compound was then subject to purification by prep LCMS to yield *N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate (27 mg, 0.056 mmol, 52%) as a white solid TFA salt.

ESI MS m/e 368.2 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.85-7.83 (m, 2H), 7.58-7.54 (m, 1H), 7.51-7.47 (m, 2H), 4.15 (m, 1H), 4.03 (m, 1H), 3.28 (s, 6H), 2.34 (s, 3H), 2.19 (s, 3H), 2.00-1.80 (m, 8H).

5

Example 2608

N-(*cis*-4-{{4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl}amino}cyclohexyl)-3-(trifluoromethyl)benzamide trifluoroacetate

- 10 **Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl}amino}-cyclohexyl)-3-(trifluoromethyl)benzamide trifluoroacetate.**

Using the procedure of Example 2607, the title compound was obtained as a white solid TFA salt.

- ESI MS m/e 436.4 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.16 (s, 1H), 8.12 (d, 1H, $J = 7.6$ Hz),
15 7.89 (d, 1H, $J = 8.0$ Hz), 7.71 (t, 1H, $J = 8.0$ Hz), 4.16 (m, 1H), 4.05 (m, 1H), 3.28 (s, 6H), 2.34 (s, 3H), 2.20 (s, 3H), 2.00-1.82 (m, 8H).

Example 2609

- 20 *N*-(*cis*-4-{{4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl}amino}cyclohexyl)-2-hydroxynicotinamide trifluoroacetate

Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl}amino}-cyclohexyl)-2-hydroxynicotinamide trifluoroacetate.

- 25 To a solution of *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (30 mg, 0.11 mmol) in 0.5 mL DMF was added 2-hydroxynicotinic acid (15 mg, 0.11 mmol), DIEA (29.8 μ L, 0.17 mmol), and HATU (52 mg, 0.14 mmol). The reaction mixture was stirred overnight and then 0.5 mL DMSO was added to the mixture. The compound was then subject to

purification by prep LCMS to yield *N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy nicotinamide trifluoroacetate (17 mg, 0.034 mmol, 31 %) as a white solid.

ESI MS m/e 385.2 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 8.53 (dd, 1H, $J_1 = 7.2$ Hz, $J_2 = 2.0$ Hz),
5 7.70 (dd, 1H, $J_1 = 6.4$ Hz, $J_2 = 2.0$ Hz), 6.61 (t, 1H, $J = 6.8$ Hz), 4.17 (m, 1H), 4.01 (m, 1H), 3.28 (s, 6H), 2.33 (s, 3H), 2.19 (s, 3H), 1.98-1.72 (m, 8H).

Example 2610

10 **5-Bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide trifluoroacetate**

Step A: Synthesis of 5-Bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino} cyclohexyl)-2-furamide trifluoroacetate.

15 Using a similar procedure of Example 2609, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 436.2 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.15 (d, 1H, $J = 3.6$ Hz), 6.63 (d, 1H, $J = 3.2$ Hz), 4.16 (m, 1H), 3.99 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.19 (s, 3H), 1.98-1.95 (m, 2H),
1.89-1.76 (m, 6H).

20

Example 2611

***N*²-{*cis*-4-[(3,5-Dimethoxybenzyl)amino]cyclohexyl}-*N*⁴,*N*⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate**

25

Step A: Synthesis of *N*²-{*cis*-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-*N*⁴,*N*⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate.

To a solution of *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-

aminocyclohexane (26.3 mg, 0.1 mmol) in 0.5 mL MeOH was added 3,5-dimethoxybenzaldehyde (15.0 mg, 0.09 mmol). The mixture was stirred at room temperature for a half an hour and then sodium triacetoxyborohydride (84.8 mg, 0.4 mmol) was added. The mixture was stirred at room temperature overnight and then 0.5 mL of DMSO was added to the mixture. The compound was
5 then subjected to purification by prep LCMS to yield N^2 -{*cis*-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}- $N^4,N^4,5,6$ -tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate (24 mg, 0.037 mmol, 42%) as a white solid TFA salt.
ESI MS m/e 414.6 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 6.71 (d, 2H, $J=2.0$ Hz), 6.59 (t, 1H, $J=2.0$ Hz), 4.28 (m, 1H), 4.21 (s, 2H), 3.84 (s, 6H), 3.28 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.19 (s,
10 3H), 2.10-2.08 (m, 4H), 1.85-1.83 (m, 4H).

Example 2612

N^2 -{*cis*-4-[(3-Bromobenzyl)amino]cyclohexyl}- $N^4,N^4,5,6$ -tetramethylpyrimidine-2,4-diamine
15 bis-trifluoroacetate

Step A: Synthesis of N^2 -{*cis*-4-[(3-bromobenzyl)amino]cyclohexyl}- $N^4,N^4,5,6$ -tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate.

Using the procedure of Example 2611, the title compound was obtained as a white solid
20 TFA salt.

ESI MS m/e 432.4 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.78 (s, 1H), 7.68 (d, 1H, $J=8.0$ Hz), 7.54 (d, 1H, $J=7.6$ Hz), 7.45 (t, 1H, $J=4$ Hz), 4.29 (m, 3H), 3.28 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.20 (s, 3H), 2.11-2.09 (m, 4H), 1.87-1.82 (m, 4H).

25

Example 2613

N -(*cis*-4-{[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)- N' -(3-methoxyphenyl)urea trifluoroacetate

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}-cyclohexyl)-*N'*-(3-methoxyphenyl)urea trifluoroacetate.

To a solution of *cis*-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (26.3 mg, 0.1 mmol) in 0.5 mL DMSO was added 3-methoxyphenyl isocyanate (13.1 μ L, 0.1 mmol). The mixture was stirred at room temperature overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subject to purification by prep LC MS to yield *N*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidin-2-yl]amino}cyclohexyl)-*N'*-(3-methoxyphenyl)urea trifluoroacetate (28 mg, 0.053 mmol, 53%) as a white solid.

ESI MS m/e 413.6 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.18 (m, 2H), 6.86 (dd, 1H, $J_1 = 8.0$ Hz, $J_2 = 2.0$ Hz), 6.58 (dd, 1H, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz), 4.03 (m, 1H), 3.82 (m, 1H), 3.79 (s, 3H), 3.27 (s, 6H), 2.33 (s, 3H), 2.19 (s, 3H), 1.92-1.73 (m, 8H).

Example 2614

***N*-(3,5-Difluorophenyl)-*N'*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate**

Step A: Synthesis of *N*-(3,5-difluorophenyl)-*N'*-(*cis*-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate.

Using the procedure of Example 2613, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 419.3 $M+H^+$; 1H NMR (400 MHz, CD_3OD) δ 7.08-7.03 (m, 2H), 6.55-6.49 (m, 1H), 4.04 (m, 1H), 3.81 (m, 1H), 3.28 (s, 6H), 2.33 (s, 3H), 2.20 (s, 3H), 1.93-1.73 (m, 8H).

Example 2615

1-(4-Chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(4-chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate.

To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (35 mg, 0.14 mmol), 1-(4-chlorophenyl)-cyclobutanecarboxylic acid (30 mg, 1 eq.) in DCM (2 mL) was added HATU (58 mg, 1.1 eq.) and followed by Et₃N (40 μ L, 2 eq.). The reaction was stirred at room temperature for 4 h, and completion of the reaction was confirmed by LCMS. After removal of the volatile solvent, the residue was purified by prep-HPLC to give 32 mg (41 %) of 1-(4-chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate as a white solid.

ESI MS m/e 442 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.6 (bs, 1 H), 8.38 (d, 1 H, J = 7.2 Hz), 7.32-7.22 (m, 5 H), 5.76 (d, 1 H, J = 8.8 Hz), 4.09 (bs, 1 H), 3.81 (m, 1 H), 3.26 (s, 6 H), 2.77 (m, 2 H), 2.44 (m, 2 H), 2.22 (s, 3 H), 2.02 (m, 1 H), 1.86 (m, 1 H), 1.65~1.50 (m, 8 H).

Example 2616

2-(4-Chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate

Step A: Synthesis of 2-(4-chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 430 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.3 (bs, 1 H), 8.21 (d, 1 H, J = 7.6 Hz), 7.28 (bs, 4 H), 7.22 (m, 1 H), 5.67 (d, 1 H, J = 8.4 Hz), 4.09 (bs, 1 H), 3.85 (m, 1 H), 3.26 (s, 6 H), 2.22 (s, 3 H), 1.71~1.61 (m, 6 H), 1.54 (s, 6 H), 1.50 (m, 2 H).

Example 2617

2-[3,5-bis(Trifluoromethyl)phenyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate

5

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 532 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.9 (bs, 1 H), 8.68 (d, 1 H, $J = 7.6$ Hz),
10 7.78 (s, 2 H), 7.72 (s, 1 H), 7.21 (d, 1 H, $J = 4.4$ Hz), 6.14 (d, 1 H, $J = 8.4$ Hz), 4.20 (bs, 1 H), 3.93
(m, 1 H), 3.26 (s, 6 H), 2.22 (s, 3 H), 1.77~1.56 (m, 8 H), 1.61 (s, 6 H).

Example 2618

15 2-[3,5-bis(Trifluoromethyl)phenyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate.

20 Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 504 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.8 (bs, 1 H), 8.51 (d, 1 H, $J = 7.8$ Hz),
7.78 (s, 2 H), 7.73 (s, 1 H), 7.22 (m, 1 H), 5.87 (d, 1 H, $J = 8.0$ Hz), 4.15 (bs, 1 H), 3.96 (m, 1 H),
3.62 (s, 2 H), 3.28 (s, 6 H), 2.24 (s, 3 H), 1.80~1.65 (m, 8 H).

25

Example 2619

1-(4-Chlorophenyl)-*N*-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate.

To a solution of *cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (36 mg, 0.14 mmol), 1-(4-chlorophenyl)-cyclopropanecarboxylic acid (31 mg, 1 eq.) in DCM (2 mL) was added HATU (60 mg, 1.1 eq.) and followed by Et₃N (40 µL, 2 eq.). The reaction was stirred at room temperature for 4 h, and completion of the reaction was confirmed by ESI MS. After removal of the volatile solvent, the residue was purified by prep-HPLC to give 45 mg (72 %) of 1-(4-Chlorophenyl)-N-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropane carboxamide trifluoroacetate as a white solid.

ESI MS *m/e* 428 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.4 (bs, 1 H), 8.61 (d, 1 H, *J* = 7.2 Hz), 7.32 (m, 4 H), 5.70 (s, 1 H), 5.46 (d, 1 H, *J* = 8.0 Hz), 4.04 (bs, 1 H), 3.79 (m, 1 H), 3.21 (s, 3 H), 3.10 (s, 3 H), 2.31 (s, 3 H), 1.68~1.47 (m, 9 H), 1.22 (m, 1 H), 1.00 (m, 2H).

15

Example 2620

1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate

20 Step A: Synthesis of 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate.

Using the procedure of Example 2619, the title compound was obtained.

ESI MS *m/e* 442 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.1 (bs, 1 H), 8.41 (d, 1 H, *J* = 7.6 Hz), 7.28 (s, 4 H), 5.95 (d, 1 H, *J* = 8.8 Hz), 5.72 (s, 1 H), 4.14 (bs, 1 H), 3.82 (m, 1 H), 3.21 (s, 3 H), 3.11 (s, 3 H), 2.77 (m, 2 H), 2.44 (m, 2 H), 2.31 (s, 3 H), 2.01 (m, 1 H), 1.83 (m, 1 H), 1.70~1.50 (m, 8 H).

25

Example 2621

1-(2,4-Dichlorophenyl)-N-(cis-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate

- 5 **Step A: Synthesis of 1-(2,4-dichlorophenyl)-N-(cis-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate.**

Using the procedure of Example 2619, the title compound was obtained.

ESI MS m/e 462 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.4 (bs, 1 H), 8.54 (bs, 1 H), 7.43 (s, 1 H), 7.28 (d, 1 H, $J = 8.4$ Hz), 7.26 (d, 1 H, $J = 8.0$ Hz), 5.70 (s, 1 H), 5.39 (d, 1 H, $J = 8.0$ Hz),
10 4.06 (bs, 1 H), 3.84 (m, 1 H), 3.20 (s, 3 H), 3.10 (s, 3 H), 2.30 (s, 3 H), 1.69~1.62 (m, 8 H), 1.50 (m, 2 H), 1.01 (m, 2H).

Example 2622

- 15 **2-[3,5-bis(Trifluoromethyl)phenyl]-N-(cis-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-2-methylpropanamide trifluoroacetate**

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

- 20 Using the procedure of Example 2619, the title compound was obtained.

ESI MS m/e 532 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.8 (bs, 1 H), 8.80 (d, 1 H, $J = 8.4$ Hz), 7.79 (s, 2 H), 7.72 (s, 1 H), 6.20 (d, 1 H, $J = 8.4$ Hz), 5.70 (s, 1 H), 4.24 (bs, 1 H), 3.94 (bm, 1 H), 3.22 (s, 3 H), 3.10 (s, 3 H), 2.30 (s, 3 H), 1.79~1.60 (m, 8 H), 1.61 (s, 6 H).

25

Example 2623

2-(3,4-difluorophenyl)-N-(cis-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-hydroxyacetamide hydrochloride

Step A: 2-(3,4-difluorophenyl)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide hydrochloride.

- To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (43 mg, 0.17 mmol), 3,4-difluoro mandelic acid (34 mg, 1 eq.) in DCM (2 mL) was added HATU (68 mg, 1.1 eq.) and followed by Et₃N (50 μL, 2 eq.). The reaction was stirred at room temperature for 4 h and quenched. After removal of the volatile solvent, the residue was purified by column chromatography (DCM : MeOH = 100 : 0 to 94 : 6). 28 mg (39 %) of the product was isolated and converted into HCl salt.
- ESI MS *m/e* 420 *M* + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, 1 H, *J* = 8.0 Hz), 7.39~7.20 (m, 3 H), 7.04 (m, 1H), 5.05 (s, 1 H), 4.08 (bs, 1 H), 3.89 (bs, 1 H), 3.26 (s, 6 H), 2.22 (s, 3 H), 1.78~1.60 (m, 8 H), two exchangeable protons (-NH- and -OH) were not detected.

Example 2624

***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide**

- Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide.**

- Using the procedure of Example 2623, the title compound was obtained.
- ESI MS *m/e* 452 *M* + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (bs, 1 H), 7.22 (s, 1 H), 7.65 (d, 1 H, *J* = 8.0 Hz), 7.51 (d, 1 H, *J* = 8.0 Hz), 7.42 (t, 1 H, *J* = 8.0 Hz), 7.22 (s, 1 H), 7.00 (d, 1 H, *J* = 8.0 Hz), 5.10 (s, 1 H), 4.04 (bs, 1 H), 3.89 (bs, 1 H), 3.20 (s, 6 H), 2.18 (s, 3 H), 1.78~1.64 (m, 8 H), one exchangeable proton (-OH) was not detected.

Example 2625

N-(*cis*-4-{{4-(Dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide

Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}-
5 cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 414 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.72 (d, 1 H, $J = 6.8$ Hz), 7.31 (d, 2 H, $J = 8.4$ Hz), 7.22 (s, 1 H), 6.83 (d, 2 H, $J = 8.4$ Hz), 6.78 (d, 1 H, $J = 7.6$ Hz), 4.98 (s, 1 H), 4.06 (bs, 1 H), 3.90 (bs, 1 H), 3.76 (s, 3 H), 3.25 (s, 6 H), 2.20 (s, 3 H), 1.78~1.64 (m, 8 H).

10

Example 2626

2-(3-Chlorophenyl)-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-
2-hydroxyacetamide

15

Step A: Synthesis of 2-(3-chlorophenyl)-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-hydroxyacetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 418 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.63 (bs, 1 H), 7.44 (s, 1 H), 7.33 (m, 1 H),
20 7.21 (m, 2 H), 7.12 (bs, 1 H), 5.03 (s, 1 H), 4.08 (bs, 1 H), 3.88 (bs, 1 H), 3.24 (s, 6 H), 2.19 (s, 3 H), 1.78~1.63 (m, 8 H).

Example 2627

25 2-(2,3-Difluorophenyl)-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-hydroxyacetamide

Step A: Synthesis of 2-(2,3-difluorophenyl)-N-(cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-2-hydroxyacetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 420 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.26 (s, 1 H), 7.14 (m, 1H), 7.06 (m, 2 H),
5 6.73 (d, 1 H, $J = 8.0$ Hz), 5.32 (s, 1 H), 4.06 (bs, 1 H), 3.93 (bs, 1 H), 3.22 (s, 6 H), 2.20 (s, 3 H),
1.78~1.64 (m, 8 H).

Example 2628

10 **N-(cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride**

Step A: Synthesis of N-(cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride.

15 To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (45 mg, 0.18 mmol) in IPA (2 mL) was added 2-trifluoromethyl benzenesulfonyl chloride (44 mg, 1 eq.) and followed by DIEA (50 μ L, 2 eq.). The reaction was stirred at room temperature for 1.5 h under an inert atmosphere, and the progress of the reaction was monitored by ESI MS. The reaction was diluted with DCM (7 mL), washed with saturated
20 $NaHCO_3$ (1 x 5 mL) and water (1 x 5 mL), and concentrated. The crude product was purified by column chromatography (DCM : MeOH = 100 : 0 to 95 : 5). 31 mg (38 %) of the product was isolated and converted into HCl salt.

ESI MS m/e 458 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 12.2 (bs, 1 H), 8.13 (m, 2 H), 8.06 (d, 1 H, $J = 6.0$ Hz), 7.93 (d, 1 H, $J = 8.0$ Hz), 7.87 (t, 1 H, $J = 7.6$ Hz), 7.79 (t, 1 H, $J = 7.6$ Hz), 7.62
25 (bs, 1 H), 3.78 (bs, 1 H), 3.22 (s, 6 H), 3.21 (bs, 1 H), 2.20 (s, 3 H), 1.78~1.54 (m, 8 H).

Example 2629

4-Chloro-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-benzenesulfonamide hydrochloride

Step A: Synthesis of 4-chloro-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)benzenesulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 424 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.9 (bs, 1 H), 7.92 (bs, 1 H), 7.83 (s, 1 H, overlapped with the doublet of 7.81 ppm), 7.81 (d, 2 H, $J = 8.4$ Hz), 7.64 (d, 2 H, $J = 8.4$ Hz), 7.58 (bs, 1 H), 3.74 (bs, 1 H), 3.21 (s, 6 H), 3.08 (bs, 1 H), 2.20 (s, 3 H), 1.70~1.44 (m, 8 H).

10

Example 2630

2-Bromo-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-benzenesulfonamide hydrochloride

15

Step A: Synthesis of 2-bromo-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)benzenesulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 468 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.9 (bs, 1 H), 8.00 (d, 1 H, $J = 7.2$ Hz), 7.92 (bs, 1 H), 7.82 (d, 2 H, $J = 7.6$ Hz), 7.59~7.48 (m, 3 H), 3.73 (bs, 1 H), 3.21 (s, 6 H), 3.20 (bs, 1 H), 2.20 (s, 3 H), 1.72 (m, 2 H), 1.58 (m, 6 H).

Example 2631

***N*-(*cis*-4-{{4-(Dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)thiophene-2-sulfonamide hydrochloride**

25

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)thiophene-2-sulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 396 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.1 (bs, 1 H), 7.99 (bs, 1 H), 7.92 (bs, 1 H), 7.88 (d, 1 H, $J = 4.8$ Hz), 7.60 (bs, 1 H), 7.57 (d, 1 H, $J = 2.8$ Hz), 7.14 (t, 1 H, $J = 4.8$ Hz), 3.75 (bs, 1 H), 3.22 (s, 6 H), 3.17 (bs, 1 H), 2.20 (s, 3 H), 1.70~1.51 (m, 8 H).

Example 2632

10 ***N*⁴,*N*⁴,5-Trimethyl-*N*²-(*cis*-4-{[3-(trifluoromethyl)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate**

Step A: Synthesis of *N*⁴,*N*⁴,5-trimethyl-*N*²-(*cis*-4-{[3-(trifluoromethyl)benzyl]amino}-cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate.

15 A solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (31 mg, 0.12 mmol) and 3-trifluoromethyl benzaldehyde (22 mg, 1 eq.) in MeOH (1.5 mL) was stirred at room temperature for 4 h. NaBH(OAc)₃ (85 mg, ~ 4 eq.) was added into the reaction, and the reaction was stirred overnight. The reaction was quenched with water, extracted with DCM, concentrated, and purified by prep-HPLC. 35 mg (54 %) of *N*⁴,*N*⁴,5-trimethyl-*N*²-(*cis*-4-{[3-(trifluoromethyl)benzyl]amino} cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate was isolated as a white powder.

20 ESI MS m/e 408 $M + H^+$; 1H NMR (400 MHz, CDCl₃) δ 13.7 (bs, 1 H), 9.70 (bs, 2 H), 8.60 (d, 1 H, $J = 8.8$ Hz), 7.70 (m, 2 H), 7.59 (d, 1 H, $J = 8.0$ Hz), 7.48 (t, 1 H, $J = 8.4$ Hz), 4.31 (m, 1 H), 4.23 (s, 2 H), 3.30 (m, 1 H), 3.29 (s, 6 H), 2.25 (s, 3 H), 2.05 (m, 2 H), 1.93 (m, 4 H), 1.64 (m, 2 H).

25

Example 2633

***N*²-(*cis*-4-{[4-(Difluoromethoxy)benzyl]amino}cyclohexyl)-*N*⁴,*N*⁴,5-trimethylpyrimidine-2,4-**

diamine bistrifluoroacetate

Step A: Synthesis of N^2 -(*cis*-4-{[4-(difluoromethoxy)benzyl]amino}cyclohexyl)- $N^4,N^4,5$ -trimethylpyrimidine-2,4-diamine bistrifluoroacetate.

5 Using the procedure of Example 2632, the title compound was obtained.

ESI MS m/e 406 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.8 (bs, 1 H), 9.60 (bs, 1 H), 8.60 (d, 1 H, $J = 8.8$ Hz), 7.46 (d, 2 H, $J = 8.8$ Hz), 7.24 (s, 1 H), 7.07 (d, 2 H, $J = 8.8$ Hz), 6.48 (t, 1 H, $J_{F-H} = 73.6$ Hz), 4.31 (m, 1 H), 4.15 (s, 2 H), 3.40 (bs, 1 H), 3.29 (s, 6 H), 2.24 (s, 3 H), 2.05 (m, 2 H), 1.90 (m, 4 H), 1.63 (m, 2 H).

10

Example 2634

N^2 -(*cis*-4-{(3-Bromo-4-methoxybenzyl)amino}cyclohexyl)- $N^4,N^4,5$ -trimethylpyrimidine-2,4-diamine bistrifluoroacetate

15

Step A: Synthesis of N^2 -(*cis*-4-{(3-bromo-4-methoxybenzyl)amino}cyclohexyl)- $N^4,N^4,5$ -trimethylpyrimidine-2,4-diamine bistrifluoroacetate.

Using the procedure of Example 2632, the title compound was obtained.

ESI MS m/e 448 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.8 (bs, 1 H), 9.44 (bs, 1 H), 8.57 (d, 1 H, $J = 8.0$ Hz), 7.58 (d, 1 H, $J = 2.4$ Hz), 7.41 (dd, 1 H, $J = 8.8$ and 2.0 Hz), 7.24 (s, 1 H), 6.86 (d, 1 H, $J = 8.0$ Hz), 4.29 (m, 1 H), 4.07 (s, 2 H), 3.86 (s, 3 H), 3.28 (s, 6 H), 3.25 (bs, 1 H), 2.24 (s, 3 H), 2.05~1.85 (m, 6 H), 1.64 (m, 2 H).

25 **Example 2635**

N^2 -(3,4-Dichlorophenyl)- N -(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)- N^2 -methylglycinamide bistrifluoroacetate

Step A: Synthesis of 2-bromo-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide.

cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (3.5 g, 14.0 mmol) was dissolved in 20 mL of methylene chloride, and cooled to 0°C in an ice bath. Bromo-acetyl bromide (1.26 mL, 14.0 mmol) was added dropwise into the stirring solution over the ice bath. The reaction mixture was stirred at room temperature for 10 minutes. Methylene chloride was evaporated off to yield 2-bromo-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide as a pinkish crude solid. (6.1g, 95%).

ESI MS m/z 370.1 ($M + H^+$) ; 1H NMR (400 MHz, $CDCl_3$) δ 12.20 (s, 1H), 8.21 (d, $J = 7.2$ Hz, 1H), 6.85 (d, $J = 6.8$ Hz, 1H), 4.15 (s, 1H), 3.97-3.89 (m, 3H), 3.31 (s, 6H), 2.27 (s, 3H), 1.93-1.72 (m, 8H).

Step B: Synthesis of *N*²-(3,4-dichlorophenyl)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-*N*²-methylglycinamide bistrifluoroacetate.

2-Bromo-*N*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide (50 mg, 0.135 mmol) and (3,4-dichloro-phenyl)-methyl-amine (48 mg, 0.270 mmol) were dissolved in 0.8 mL of DMF. The reaction mixture was heated via Smith Synthesizer at 180°C for 50 minutes. The crude was purified by HPLC to give *N*²-(3,4-dichlorophenyl)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-*N*²-methylglycinamide bistrifluoroacetate as a white solid. (12.8 mg, 18%)

ESI MS m/z 465.3 ($M + H^+$) ; 1H NMR (400 MHz, $CDCl_3$) δ 8.75 (d, $J = 6.0$ Hz, 1H), 6.80 (d, $J = 2.8$ Hz, 1H), 6.67-6.65 (m, 1H), 6.57 (dd, $J = 9.0, 3.0$ Hz, 1H), 4.13 (s, 1H), 3.98 (s, 1H), 3.86 (s, 2H), 3.29 (s, 6H), 3.06 (s, 3H), 2.25 (s, 3H), 1.73-1.62 (m, 8H).

Example 2636

N-[[(1*R*,3*S*)-3-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate

Step A: Synthesis of (3-[(2-Chloro-pyridine-3-carbonyl)-amino]-methyl)-cyclopentyl)-carbamic acid tert-butyl ester.

(3-Aminomethyl-cyclopentyl)-carbamic acid *tert*-butyl ester (0.050 g, 0.23 mmol), 2-chloronicotinoyl chloride (0.041 g, 0.23 mmol), and diisopropylethylamine (0.061 mL, 0.34 mmol) were combined in dichloromethane (2.00 mL) at ambient temperature and stirred 18 hrs. The mixture was concentrated and purified by flash silica chromatography (5% methanol in ethyl acetate) to give (3-[(2-chloro-pyridine-3-carbonyl)-amino]-methyl)-cyclopentyl)-carbamic acid *tert*-butyl ester (0.035 g, 43%) as a solid.

ESI MS m/e 354, $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (dd, $J_{aa} = 1.5$ Hz, $J_{ab} = 4.7$ Hz, 1 H), 8.11 (dd, $J_{aa} = 1.5$ Hz, $J_{ab} = 7.6$ Hz, 1 H), 7.35 (dq, $J_{aa} = 1.2$ Hz, $J_{ab} = 4.8$ Hz, $J_{ac} = 7.6$ Hz, 1 H), 6.56 (bs, 1 H), 4.59 (bs, 1 H), 3.97 (m, 1 H), 3.48 (m, 2 H), 2.27 (m, 2 H), 1.94 (m, 2 H), 1.49 (m, 1 H), 1.44 (s, 9 H), 1.25 (m, 2 H).

Step B: Synthesis of *N*-(3-Amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide.

(3-[(2-Chloro-pyridine-3-carbonyl)-amino]-methyl)-cyclopentyl)-carbamic acid *tert*-butyl ester (0.23 mmol), 4-fluorophenol (0.026 g, 0.23 mmol), cesium carbonate (0.152 g, 0.46 mmol), and dioxane (2.00 mL) were combined and heated to 180°C for 1 hr. utilizing a SmithSynthesizer microwave apparatus. Trifluoroacetic acid (3.00 mL) was added and the mixture stirred 18 hrs.

Then it was concentrated, neutralized with saturated aqueous $NaHCO_3$, extracted with dichloromethane, and concentrated to give *N*-(3-amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide as the crude product.

ESI MS m/e 330, $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.52 (dd, $J_{aa} = 1.0$ Hz, $J_{ab} = 7.6$ Hz, 1 H), 8.19 (dd, $J_{aa} = 1.9$ Hz, $J_{ab} = 3.9$ Hz, 1 H), 8.06 (t, $J = 5.8$ Hz, 1 H), 6.91 (t, $J = 8.2$ Hz, 1 H), 6.77 (dd, $J_{aa} = 3.6$ Hz, $J_{ab} = 3.2$ Hz, 1 H), 3.62 (m, 2 H), 2.26 (m, 2 H), 2.05 (m, 1 H), 1.81 (m, 2 H), 1.62 (m, 1 H), 1.48 (m, 2 H).

Step C: Synthesis of *N*-[((1*R*,3*S*)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-

amino} cyclopentyl) methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate.

- 5-Methyl-4-dimethylamino-2-chloropyrimidine (0.040 g, 0.23 mmol), *N*-(3-amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide (0.23 mmol), diisopropyl-ethylamine (0.061 mL, 0.34 mmol), and isopropanol (2.00 mL) were combined and heated to 180°C for 2 hrs. utilizing a SmithSynthesizer microwave apparatus. The mixture was then purified by prep LCMS (gradient: 15-95% acetonitrile-water with 0.05% TFA) to give *N*-[[(1*R*,3*S*)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} cyclopentyl) methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate as a white solid (0.018 g, 13.5% over two steps).
- 10 ESI MS *m/e* 465, *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.63 (bs, 1 H), 8.44 (t, *J* = 5.7 Hz, 1 H), 8.16 (dd, *J*_{aa} = 1.9 Hz, *J*_{ab} = 4.8 Hz, 1 H), 8.04 (dd, *J*_{aa} = 1.8 Hz, *J*_{ab} = 7.4 Hz, 1 H), 7.98 (bs, 1 H), 7.53 (s, 1 H), 7.25-7.19 (m, 2 H), 4.08 (bs, 1 H), 3.22 (s, 6 H), 2.53 (s, 3 H), 2.19 (m, 2 H), 1.95 (m, 1 H), 1.71 (m, 1 H), 1.54 (m, 2 H), 1.46 (m, 2 H), 1.22 (m, 2 H).

15

Example 2637

***N*-[[(1*R*,3*S*)-3-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate**

- 20 **Step A: Synthesis of (3-{[(6-Chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid *tert*-butyl ester.**

- (3-Aminomethyl-cyclopentyl)-carbamic acid *tert*-butyl ester (0.050 g, 0.23 mmol), 6-chloronicotinoyl chloride (0.041 g, 0.23 mmol), and diisopropylethylamine (0.061 mL, 0.34 mmol) were combined in dichloromethane (2.00 mL) at ambient temperature and stirred 18 hrs. The mixture was concentrated and purified by flash silica chromatography (5% methanol in ethyl acetate) to give an orange gel.
- 25

ESI MS *m/e* 354, *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, *J* = 2.1 Hz, 1 H), 8.09 (dd, *J*_{aa} = 1.8 Hz, *J*_{ab} = 8.3 Hz, 1 H), 7.41 (d, *J* = 8.3 Hz, 1 H), 6.48 (bs, 1 H), 4.65 (d, *J* = 8 Hz, 1 H), 3.92

(m, 1 H), 3.46 (m, 2 H), 2.25 (m, 2 H), 1.98 (m, 2 H), 1.81 (m, 1 H), 1.47 (s, 9 H), 1.18 (m, 2 H).

Step B: Synthesis of *N*-[[(1*R*,3*S*)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate.

5 (3-[[[6-Chloro-pyridine-3-carbonyl)-amino]-methyl]-cyclopentyl)-carbamic acid tert-butyl ester (0.23 mmol), 2-methoxyphenol (0.029 g, 0.23 mmol), cesium carbonate (0.152 g, 0.46 mmol), and dioxane (2.00 mL) were combined and heated to 180°C for 1 hr. utilizing a SmithSynthesizer microwave apparatus. Trifluoroacetic acid (3.00 mL) was added and the mixture stirred 18 hrs. Then it was concentrated, neutralized with saturated aqueous NaHCO₃, extracted with
10 dichloromethane, and concentrated to give a foam. 5-Methyl-4-dimethylamino-2-chloropyrimidine (0.040 g, 0.23 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol), and isopropanol (2.00 mL) were added and the combined mixture was heated to 180 °C for 2 hrs utilizing a Smith synthesizer microwave apparatus. The mixture was then purified by prep-LCMS (gradient: 15-95% acetonitrile-water with 0.05% TFA) to give *N*-[[(1*R*,3*S*)-3-{[4-(dimethylamino)-5-
15 methylpyrimidin-2-yl]amino} cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate as a white solid (0.011 g, 8.1% over four steps).

ESI MS *m/e* 477, *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.05 (bs, 1 H), 8.63 (s, 1 H), 8.16 (dd, *J*_{aa} = 2.2 Hz, *J*_{ab} = 8.6 Hz, 1 H), 7.58 (bs, 1 H), 7.23 (s, 1 H), 7.19 (d, *J* = 6.2 Hz, 1 H), 7.16 (dd, *J*_{aa} = 1.5 Hz, *J*_{ab} = 7.7 Hz, 1 H), 7.00 (t, *J* = 8.8 Hz, 1 H), 6.91 (d, *J* = 12 Hz, 1 H), 4.25 (bs, 1 H),
20 3.75 (s, 3 H), 3.66 (m, 1 H), 3.29 (s, 6 H), 3.11 (m, 2 H), 2.52 (m, 2 H), 2.23 (s, 3 H), 2.10 (m, 2 H), 1.78 (m, 1 H), 1.62 (m, 2 H).

Example 2638

25 *N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-

bromoacetamide.

To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (150 mg, 0.6 mmol) in DCM (10 mL) was added dropwise bromoacetyl bromide (120 mg, 1 eq.) at 0 °C under an inert atmosphere. After 5 min stirring, DIEA (0.1 mL, 1 eq.) was added into the reaction. The reaction was stirred for an additional 3 h at below 15 °C, quenched, and purified by column chromatography. 0.12 g (55 %) of the product was isolated.

Step B: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-2-(3-fluorophenoxy)acetamide.

A sealed tube containing a heterogenous solution of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-bromoacetamide (30 mg, 0.08 mmol), 3-fluorophenol (27 mg, 3 eq.), and Cs₂CO₃ (30 mg, 1.1 eq.) in dioxane (~0.7 mL) was reacted in a Smith microwave synthesizer for 3000 sec at 180 °C. The reaction was diluted with DCM, washed with sat.-NaHCO₃ (2 x) and water (1 x), concentrated, and purified by column chromatography to give 11 mg (34 %) of the product.

ESI MS *m/e* 402 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1 H), 7.26 (m, 1 H), 6.74~6.63 (m, 3 H), 6.51 (d, 1 H, *J* = 8.0 Hz), 5.15 (bs, 1 H), 4.45 (s, 2 H), 4.01 (m, 1 H), 3.97 (bs, 1 H), 3.05 (s, 6 H), 2.15 (s, 3 H), 1.82~1.61 (m, 8 H).

Example 2639

2-[(5-Chloropyridin-3-yl)oxy]-*N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)acetamide

Step A: Synthesis of 2-[(5-chloropyridin-3-yl)oxy]-*N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)acetamide.

Using the procedure of Example 2638, the title compound was obtained.

ESI MS m/e 419 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.25 (m, 2 H), 7.53 (s, 1 H), 7.27 (t, 1 H, $J = 2.4$ Hz), 6.56 (d, 1 H, $J = 7.6$ Hz), 5.57 (bs, 1 H), 4.50 (s, 2 H), 4.01 (bs, 2 H), 3.08 (s, 6 H), 2.16 (s, 3 H), 1.83~1.64 (m, 8 H).

5

Example 2640

N-(*cis*-4-{{4-(Dimethylamino)-5-ethylpyrimidin-2-yl}amino}cyclohexyl)-3,4-difluorobenzamide

10 **Step A: Synthesis of 2,4-dichloro-5-ethylpyrimidine.**

To a suspension of 5-ethyluracil (1 g, 7.1 mmol) in $POCl_3$ (4.5 mL) was slowly added *N,N*-dimethylaniline (1 mL). The reaction was heated at reflux (~ 120 °C) for 5 h until the starting material was completely dissolved and the entire solution turned a purple color. The mixture was allowed to cool and poured very slowly into ice (~ 40 g). The resulting ppt was filtered and washed
15 with ice water. The ppt was dissolved with a minimal amount of DCM and poured onto a short column of silica gel, and the product (1.2 g, ~ 100 %) was obtained by column chromatography with DCM.

1H NMR (400 MHz, $CDCl_3$) δ 8.42 (s, 1 H), 2.75 (q, 2 H, $J = 7.6$ Hz), 1.29 (t, 3 H, $J = 7.6$ Hz).

20 **Step B: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5-ethylpyrimidin-2-yl}amino}cyclohexyl)-3,4-difluorobenzamide.**

A solution of 2,4-dichloro-5-ethylpyrimidine (1.2 g, 6.8 mmol), in THF (15 mL) was cooled to 5 °C in an ice bath, and 2M-dimethylamine (7 mL, 2 eq.) was slowly added. The reaction was stirred for 2 h at around 10 °C, and the volatile solvent was removed. The residue was purified
25 by column chromatography (hexane:DCM = 50:50 to 10:90) to give 0.89 g (70 %) of 2-chloro-4-dimethylamino-5-ethylpyrimidine: ESI MS $m/e = 186 M + H^+$.

A sealed tube containing 2-chloro-4-dimethylamino-5-ethylpyrimidine (35 mg, 0.019 mmol), *cis*-(4-amino-cyclohexyl)-3,4-difluoro-benzamide (48 mg, 1 eq.), DIEA (50 mg, 2 eq.), and

IPA (1 mL) was reacted in a Smith microwave synthesizer for 2 h at 180 °C. The reaction was diluted with DCM, washed with 1-N HCl and water, concentrated, and purified from column chromatography (DCM:MeOH = 100:0 to 95:5) to give 11 mg (14 %) of the product.

ESI MS m/e 404 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.68 (s, 1 H), 7.61 (m, 1 H), 7.48 (m, 1 H),

5 7.19 (m, 1 H), 5.99 (d, 1 H, $J = 7.2$ Hz), 4.38 (d, 1 H, $J = 6.0$ Hz), 4.20 (m, 1 H), 4.12 (m, 1 H),
3.10 (s, 6 H), 2.29 (q, 2 H, $J = 7.2$ Hz), 1.96~1.64 (m, 8 H), 1.18 (t, 3 H, $J = 7.6$ Hz).

Example 2641

10 *N*-[*cis*-4-({4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide hydrochloride

Step A: Synthesis of *N*-[*cis*-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide hydrochloride.

15 A solution of 2,4-dichloro-5-methylpyrimidine (2.6 g, 16 mmol) and ethyl methylamine (2.7 mL, 2 eq.) in THF (20 mL) was stirred at < 10 °C for 4 h. After removal of the volatile solvent, the residue was purified by column chromatography. 1.3 g (45 %) of 2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine was isolated.

ESI MS m/e 186 $M + H^+$.

20 A sealed tube containing 2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine (80 mg, 0.019 mmol), *cis*-(4-amino-cyclohexyl)-3,4-difluoro-benzamide (100 mg, 1 eq.), DIEA (0.14 mL, 2 eq.), and IPA (1 mL) was reacted in a Smith microwave synthesizer for 2 h at 180 °C. The reaction was diluted with DCM, washed with 1-N HCl and water, concentrated, and purified by column chromatography (DCM:MeOH = 100:0 to 95:5) to give 35 mg (20 %) of the product, which was
25 converted to HCl salt.

ESI MS m/e 404 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 12.0 (bs, 1 H), 8.36 (bs, 1 H), 7.97 (d, 1 H, $J = 6.0$ Hz), 7.90 (m, 1 H), 7.73 (m, 1 H), 7.63 (s, 1 H), 7.51 (m, 1 H), 3.85 (bm, 2 H), 3.65 (q, 2 H, $J = 7.2$ Hz), 3.25 (s, 3 H), 2.22 (s, 3 H), 1.84 (m, 2 H), 1.69 (m, 6 H), 1.18 (t, 3 H, $J = 7.2$ Hz).

Example 2642

N-(*cis*-4-{{4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl}amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine.

To a solution of 2,4-dichloro-5-trifluoromethylpyrimidine (1 g, 4.6 mmol) in THF (15 mL) was added 2M-dimethylamine (4.6 mL, 2 eq.) at 0 °C. The reaction was stirred for an additional 1.5 h at < 5 °C, concentrated, and purified by column chromatography (DCM:hexane:MeOH = 90:10:0 to 95:0:5). 0.49 g (47 %) of 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine was isolated.

ESI MS *m/e* 226 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.36 (s, 1 H), 3.21 (s, 6 H).

Step B: Synthesis of *cis*-[4-(4-Dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

A sealed tube containing 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine (0.49 g, 2.0 mmol), *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (0.47 g, 1 eq.), DIEA (0.7 mL, 2 eq.) in IPA (2.5 mL) was reacted in a Smith microwave synthesizer for 2 h at 175 °C. The solution was concentrated and purified by column chromatography (DCM:MeOH = 100:0 to 96:4). 0.57 g (65 %) of *cis*-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester was isolated.

ESI MS *m/e* 404 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1 H), 5.10 (bs, 1 H), 4.53 (bs, 1 H), 3.94 (bs, 1 H), 3.61 (bs, 1 H), 3.09 (s, 6 H), 1.78~1.49 (m, 8 H), 1.44 (s, 9 H).

Step C: Synthesis of *cis-N*-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine.

To a solution of *cis*-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-

cyclohexyl]-carbamic acid tert-butyl ester (0.55g, 1.3 mmol) in DCM (10 mL) was added TFA (7 mL). The reaction was stirred at room temperature for 2 h and concentrated. The residue was neutralized with sat-NaOH, and the aqueous layer was extracted with DCM (3 x). The combined organic layers were washed with water, dried, and concentrated to give 0.25 g (65 %) of *cis-N*-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine.

ESI MS m/e 304 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.16 (s, 1 H), 5.42 (bs, 1 H), 3.98 (bs, 1 H), 3.09 (s, 6 H), 2.87 (bs, 1 H), 1.81 (m, 2 H), 1.73~1.65 (m, 4 H), 1.43 (m, 4 H).

Step D: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

To a solution of *cis-N*-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine (30 mg, 0.01 mmol) in dry benzene (2 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (27 mg, 1 eq.) and followed by Et_3N (20 μ L, 2.5 eq). The reaction was stirred overnight, concentrated, and purified by prep-HPLC. 32 mg (49 %) of *N*-(*cis*-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino} cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 544 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 9.35 (d, 1 H, $J = 8.0$ Hz), 8.47 (s, 1 H), 8.32 (s, 2 H), 8.07 (s, 1 H), 7.61 (d, 1 H, $J = 8.4$ Hz), 4.31 (bs, 1 H), 4.20 (bs, 1 H), 3.33 (s, 6 H), 1.93~1.79 (m, 8 H).

Example 2643

***N*-(*cis*-4-{[4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate.

Using the procedure of Example 2642, the title compound was obtained.

ESI MS m/e 492 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 9.45 (d, 1 H, $J = 8.0$ Hz), 8.05 (s, 1 H), 7.88 (d, 2 H, $J = 8.8$ Hz), 7.24 (m, 2 H, overlapped with solvent), 7.04 (d, 1 H, $J = 8.4$ Hz), 4.27 (bs, 1 H), 4.18 (bs, 1 H), 3.31 (s, 6 H), 1.89~1.77 (m, 8 H).

5

Example 2644

N-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide hydrochloride

10 Step A: Synthesis of (3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester.

A solution of ethyl bromoacetate (0.65g, 3.2 mmol), 3-trifluoromethyl thiophenol (0.88 g, 1.5 eq.), and Et_3N (1.5 mL) in THF (15 mL) was stirred for 2 h at 62 °C. The mixture was diluted with DCM, washed with sat.- $NaHCO_3$ (3x) and water, dried with $MgSO_4$, and concentrated. The crude product (0.73 g, 85 %) was used to next reaction without a further purification.

15 1H NMR (400 MHz, $CDCl_3$) δ 7.62 (s, 1 H), 7.55 (d, 1 H, $J = 8.0$ Hz), 7.46~7.37 (m, 2 H), 4.16 (q, 2 H, $J = 7.2$ Hz), 3.66 (s, 2 H), 1.22 (t, 3 H, $J = 7.2$ Hz).

Step B: Synthesis of (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester.

To a solution of (3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester (0.5 g, 1.9 mmol) in DCM (10 mL) was added 77 %-MCPBA (0.42 g, 1 eq.) under Ar atmosphere at 0 °C. The reaction was stirred for an additional 3 h, diluted with DCM, washed with sat.- $NaHCO_3$ and water, and concentrated. (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester (0.34 g, 64 %) and (3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester (0.15 g, 27 %) were isolated by column chromatography (hexane:EtOAc = 95:5 to 80:20).

25 (3-Trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester:

1H NMR (400 MHz, $CDCl_3$) δ 7.95 (s, 1 H), 7.87 (d, 1 H, $J = 8.0$ Hz), 7.78 (d, 1 H, $J = 8.0$ Hz), 7.67 (t, 1 H, $J = 8.0$ Hz), 4.15 (q, 2 H, $J = 7.2$ Hz), 3.86 (d, 1 H, $J = 14.0$ Hz), 3.70 (d, 1 H, $J = 14.0$ Hz), 1.22 (t, 3 H, $J = 7.2$ Hz).

(3-Trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester:

^1H NMR (400 MHz, CDCl_3) δ 8.20 (s, 1 H), 8.14 (d, 1 H, $J = 7.6$ Hz), 7.94 (d, 1 H, $J = 7.6$ Hz), 7.74 (t, 1 H, $J = 7.6$ Hz), 4.15 (s, 2 H), 4.14 (q, 2 H, $J = 7.6$ Hz), 1.20 (t, 3 H, $J = 7.2$ Hz).

5 **Step C: Synthesis of (3-trifluoromethyl-phenylsulfinyl)-acetic acid.**

To a heterogenous solution of (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester (0.2 g, 0.7 mmol) in H_2O (5 mL)/EtOH (0.5 mL) was added KOH (120 mg, 3 eq.). The reaction was stirred for 2 h at 85 °C, concentrated to about half of the reaction volume, and acidified with conc-HCl at an ice bath. (3-Trifluoromethyl-phenylsulfinyl)-acetic acid (100 mg, 56 %) was

10 filtered and dried.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.05 (s, 1 H), 8.01 (d, 1 H, $J = 8.0$ Hz), 7.92 (d, 1 H, $J = 8.0$ Hz), 7.81 (t, 1 H, $J = 8.0$ Hz), 4.16 (d, 1 H, $J = 14.4$ Hz), 3.87 (d, 1 H, $J = 14.4$ Hz).

Step D: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-

15 **cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide hydrochloride.**

To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (60 mg, 0.024 mmol) in DCM (5 mL) was added (3-trifluoromethyl-phenylsulfinyl)-acetic acid (60 mg, 1 eq.), followed by HATU (85 mg, 1.1 eq.), and Et_3N (30 μL).

The reaction was stirred for 16 h at room temperature and concentrated. The residue was purified

20 by column chromatography to give *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl} acetamide (52 mg, 45%), which was converted to HCl salt with 4M-HCl in dioxane.

ESI MS m/e 484 $\text{M} + \text{H}^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.7 (bs, 1 H), 8.08 (d, 1 H, $J = 6.4$ Hz), 7.99 (m, 2 H), 7.92 (d, 1 H, $J = 8.0$ Hz), 7.90 (bs, 1 H), 7.82 (t, 1 H, $J = 8.0$ Hz), 7.59 (s, 1 H),
25 3.94 (d, 1 H, $J = 12.8$ Hz), 3.86 (d, 1 H, $J = 12.8$ Hz), 3.80 (bs, 1 H), 3.68 (bs, 1 H), 3.25 (s, 6 H), 2.23 (s, 3 H), 1.70~1.50 (m, 8 H).

Example 2645

2-[(3,4-Dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide hydrochloride

- 5 **Step A: Synthesis of 2-[(3,4-dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethyl amino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide hydrochloride.**

Using the procedure of Example 2644, the title compound was obtained.

- ESI MS m/e 484 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.9 (bs, 1 H), 8.13 (d, 1 H, $J = 6.8$ Hz), 7.98 (bs, 1 H), 7.87 (s, 1 H), 7.86 (d, 1 H, $J = 8.8$ Hz), 7.65 (d, 1 H, $J = 8.8$ Hz), 7.61 (bs, 1 H),
10 3.93 (d, 1 H, $J = 12.8$ Hz), 3.87 (d, 1 H, $J = 12.8$ Hz), 3.81 (bs, 1 H), 3.64 (bs, 1 H), 3.25 (s, 6 H),
2.23 (s, 3 H), 1.70~1.50 (m, 8 H).

Example 2646

- 15 **N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide hydrochloride**

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide hydrochloride.

- 20 (3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester was obtained from step B in Example 2644. The ester was hydrolyzed to (3-trifluoromethyl-phenylsulfonyl)-acetic acid using the procedure of step C in Example 2644.

1H NMR (400 MHz, DMSO- d_6) δ 8.22 (d, 1 H, $J = 8.0$ Hz), 8.21 (s, 1 H), 8.14 (d, 1 H, $J = 8.0$ Hz),
7.90 (t, 1 H, $J = 8.0$ Hz), 4.69 (s, 2 H).

- 25 To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (56 mg, 0.023 mmol) in DCM (5 mL) was added (3-trifluoromethyl-phenylsulfonyl)-acetic acid (60 mg, 1 eq.), followed by HATU (85 mg, 1.1 eq.), and Et_3N (30 μ L). The reaction was stirred for 16 h at room temperature and concentrated. The residue was purified

by column chromatography to give *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl] sulfonyl}acetamide (50 mg, 45%), which was converted to HCl salt with 4M HCl in dioxane.

ESI MS m/e 500 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.6 (bs, 1 H), 8.22 (d, 1 H, $J = 6.4$ Hz), 8.17~8.12 (m, 3 H), 7.90 (t, 1 H, $J = 7.6$ Hz), 7.87 (bs, 1 H), 7.57 (s, 1 H), 4.45 (s, 2 H), 3.79 (bs, 1 H), 3.61 (bs, 1 H), 3.25 (s, 6 H), 2.23 (s, 3 H), 1.70~1.47 (m, 8 H).

Example 2647

10 *N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride

Step A: Synthesis of 2-chloro-*N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide.

15 To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (0.6 g, 2.4 mmol) in DCM (20 mL) was added 2-chloronicotinoyl chloride (0.44 g, 1.01 eq.) and followed by DIEA (0.4 mL, ~ 1.1 eq.). The reaction was stirred overnight at room temperature, washed with sat-NaHCO₃ (2x) and water (1x), dried with MgSO₄, and concentrated. The crude residue was purified by column chromatography to give 2-chloro-*N*-[*cis*-4-(4-

20 dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (0.57 g, 65 %).

ESI MS m/e 389 $M + H^+$; 1H NMR (400 MHz, CDCl₃) δ 8.72 (bs, 1 H), 8.47 (d, 1 H, $J = 5.0$ Hz), 7.98 (d, 1 H, $J = 7.0$ Hz), 7.32 (dd, 1 H, $J = 8.0$ and 5.0 Hz), 7.28 (s, 1 H), 6.88 (d, 1 H, $J = 8.0$ Hz), 4.18 (m, 2 H), 3.27 (s, 6 H), 2.23 (s, 3 H), 1.90~1.80 (m, 8 H).

25 **Step B: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride.**

A sealed tube containing 2-chloro-*N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (0.35 g, 0.9 mmol), 4-fluorophenol (0.25 g, 2.5 eq.), Cs₂CO₃

(0.33 g, 1.1 eq.), and dioxane (3 mL) was reacted in a Smith microwave synthesizer for 1 h at 180 °C. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3x) and water (1x), dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH = 100:0 to 95:5) to give *N*-[*cis*-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-
5 phenoxy)-nicotinamide (0.33 g, 80 %). The neutral compound was dissolved in DCM (5 mL), and 4M-HCl (0.45 mL, 2.5 eq.) in dioxane was added. After 20 min stirring, removal of the volatile solvent gave *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride.

ESI MS *m/e* 465 *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.1 (bs, 1 H), 8.34 (d, 1 H, *J* = 7.2
10 Hz), 8.15 (dd, 1 H, *J* = 5.2 and 2.0 Hz), 8.06 (d, 1 H, *J* = 6.8 Hz), 8.01 (d, 1 H, *J* = 7.6 Hz), 7.63 (s, 1 H), 7.26~7.18 (m, 5 H), 3.94 (bs, 1 H), 3.88 (bs, 1 H), 3.25 (s, 6 H), 2.21 (s, 3 H), 1.72 (bs, 8 H).

Example 2648

15 **2-(2-Bromophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride**

Step A: Synthesis of 2-(2-bromophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

20 Using the procedure of Example 2647, the title compound was obtained.

ESI MS *m/e* 525 *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.8 (bs, 1 H), 8.20 (d, 1 H, *J* = 7.6 Hz), 8.16~8.11 (m, 2 H), 7.96 (bs, 1 H), 7.70 (dd, 1 H, *J* = 8.0 and 1.6 Hz), 7.60 (s, 1 H), 7.47~7.38 (m, 2 H), 7.25~7.19 (m, 2 H), 3.97 (bs, 1 H), 3.89 (bs, 1 H), 3.24 (s, 6 H), 2.22 (s, 3 H), 1.74 (bs, 8 H).

25

Example 2649

2-(4-Bromophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-

yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-(4-bromophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

5 Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 525 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.9 (bs, 1 H), 8.28 (d, 1 H, $J = 7.0$ Hz), 8.12 (dd, 1 H, $J = 4.4$ and 1.6 Hz), 7.97 (d, 1 H, $J = 7.6$ Hz), 7.91 (bs, 1 H), 7.56 (bs, 1 H), 7.54 (d, 2 H, $J = 8.8$ Hz), 7.17 (m, 1 H), 7.14 (d, 2 H, $J = 8.8$ Hz), 3.87 (bs, 1 H), 3.81 (bs, 1 H), 3.19 (s, 6 H), 2.16 (s, 3 H), 1.65 (bs, 8 H).

10

Example 2650

2-(4-Chlorophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

15

Step A: Synthesis of 2-(4-chlorophenoxy)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 481 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.8 (bs, 1 H), 8.27 (d, 1 H, $J = 6.6$ Hz), 8.12 (dd, 1 H, $J = 4.8$ and 1.6 Hz), 7.97 (dd, 1 H, $J = 7.0$ and 1.6 Hz), 7.86 (bs, 1 H), 7.55 (s, 1 H), 7.41 (d, 2 H, $J = 8.8$ Hz), 7.20 (d, 2 H, $J = 8.8$ Hz), 7.17 (m, 1 H), 3.88 (bs, 1 H), 3.81 (bs, 1 H), 3.19 (s, 6 H), 2.16 (s, 3 H), 1.65 (bs, 8 H).

25 **Example 2651**

2-[(5-chloropyridin-3-yl)oxy]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 482 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.6 (bs, 1 H), 8.46 (s, 1 H), 8.31 (d, 1 H, $J = 1.6$ Hz), 8.01 (bm, 1 H), 7.83 (t, 1 H, $J = 2.0$ Hz), 7.56 (d, 1 H, $J = 5.2$ Hz), 7.49 (bm, 1 H), 7.25 (bs, 1 H), 6.07 (bs, 1 H), 5.74 (s, 1 H), 4.51 (bs, 1 H), 4.00 (bs, 1 H), 3.23 (s, 6 H), 2.19 (s, 3 H), 1.90 (m, 2 H), 1.75 (m, 4 H), 1.39 (m, 2 H).

10 Example 2652

2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide hydrochloride

15 Step A: Synthesis of 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

A sealed tube containing 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (70 mg, 0.018 mmol), 2-methyl-2-propanethiol (80 mg, 5 eq.), CS_2CO_3 (60 mg, 1.1 eq) in dioxane (0.8 mL) was reacted in a Smith microwave synthesizer for 1.5 h at 180 °C. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3x) and water (1x),
20 dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH = 100:0 to 95:5) to give 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} cyclohexyl)nicotinamide (50 mg, 62 %), which was converted to HCl salt.

ESI MS m/e 443 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.2 (bs, 1 H), 8.47 (dd, 1 H, $J = 4.8$ and 1.6 Hz), 8.40 (d, 1 H, $J = 6.0$ Hz), 8.00 (bm, 1 H), 7.62 (s, 1 H), 7.56 (dd, 1 H, $J = 7.6$ and 1.6
25 Hz), 7.15 (m, 1 H), 3.90 (bs, 2 H), 3.25 (s, 6 H), 2.21 (s, 3 H), 1.80~1.65 (m, 8 H), 1.49 (s, 9 H).

Example 2653

N-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-(propylthio)nicotinamide hydrochloride

- 5 **Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-(propylthio)nicotinamide hydrochloride.**

Using the procedure of Example 2652, the title compound was obtained.

ESI MS m/e 429 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.4 (bs, 1 H), 8.44 (m, 2 H), 8.04 (d, 1 H, $J = 6.8$ Hz), 7.63 (d, 2 H, $J = 6.4$ Hz), 7.12 (m, 1 H), 3.85 (bs, 2 H), 3.24 (s, 6 H), 3.06 (t, 2 H, $J = 6.8$ Hz), 2.21 (s, 3 H), 1.83~1.65 (m, 8 H), 1.62 (m, 2 H), 0.95 (t, 3 H, $J = 7.2$ Hz).

Example 2654

N-(*cis*-4-{{4-(Dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)-2-(isopropylthio)nicotinamide hydrochloride

Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}-cyclohexyl)-2-(isopropylthio)nicotinamide hydrochloride.

Using the procedure of Example 2652, the title compound was obtained.

20 ESI MS m/e 429 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.2 (bs, 1 H), 8.46 (dd, 1 H, $J = 4.8$ and 1.6 Hz), 8.42 (bs, 1 H), 8.02 (d, 1 H, $J = 6.4$ Hz), 7.62 (m, 2 H), 7.12 (m, 1 H), 3.95 (sept, 1 H, $J = 6.4$ Hz), 3.83 (bs, 2 H), 3.25 (s, 6 H), 2.21 (s, 3 H), 1.82~1.65 (m, 8 H), 1.30 (d, 6 H, $J = 6.8$ Hz).

25

Example 2655

2-(*tert*-Butylsulfinyl)-*N*-(*cis*-4-{{4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)nicotinamide

Step A: Synthesis of 2-(*tert*-butylsulfinyl)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide.

To a solution of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-
5 *tert*-butyl sulfanyl-nicotinamide (30 mg, 0.07 mmol) in DCM (5 mL) was added MCPBA (16 mg,
1.1 eq) at 0 °C. The reaction was stirred for an additional 2 h at < 10 °C with monitoring the
progress by ESI MS. The reaction was diluted with DCM, washed with sat.-NaHCO₃ (2x) and
water (1x), dried, concentrated, and purified by column chromatography (DCM:MeOH = 100:0 to
94:6). 26 mg (85 %) of 2-(*tert*-butylsulfinyl)-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-
10 yl]amino}cyclohexyl)nicotinamide was isolated.

ESI MS *m/e* 459 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.71 (dd, 1 H, *J* = 4.8 and 1.6 Hz), 8.54 (d,
1 H, *J* = 6.8 Hz), 8.20 (d, 1 H, *J* = 8.0 Hz), 7.61 (s, 1 H), 7.43 (dd, 1 H, *J* = 8.0 and 4.0 Hz), 5.03 (d,
1 H, *J* = 6.0 Hz), 4.12 (bs, 1 H), 3.98 (bs, 1 H), 2.99 (s, 6 H), 2.12 (s, 3 H), 1.87~1.75 (m, 8 H),
1.23 (s, 9 H).

15

Example 2656

**2-[(3,4-Difluorophenyl)sulfonyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-
yl]amino}cyclohexyl)nicotinamide hydrochloride**

20

**Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-
2-(3,4-difluorophenyl)-sulfanyl-nicotinamide.**

A sealed tube containing 2-chloro-*N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-
ylamino)-cyclohexyl]-nicotinamide (100 mg, 0.025 mmol), 3,4-difluorothiophenol (90 mg, 2.5 eq.),
25 Cs₂CO₃ (150 mg, 2 eq), and dioxane (2 mL) was reacted in a Smith microwave synthesizer for 1.0
h at 180 °C. The reaction was diluted with DCM, washed with sat.-NaHCO₃ (3x) and water (1x),
dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH =
100:0 to 95:5) to give *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-

(3,4-difluorophenyl)-sulfanyl-nicotinamide (70 mg, 55 %).

ESI MS m/e 499 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.34 (dd, 1 H, $J = 4.8$ and 1.6 Hz), 7.79 (dd, 1 H, $J = 7.2$ and 2.0 Hz), 7.62 (s, 1 H), 7.35 (m, 1 H), 7.25 (m, 1 H), 7.16 (m, 1 H), 7.08 (dd, 1 H, $J = 7.6$ and 4.8 Hz), 6.28 (d, 1 H, $J = 7.2$ Hz), 4.71 (d, 1 H, $J = 7.2$ Hz),
5 4.18 (m, 1 H), 3.97 (m, 1 H), 3.02 (s, 6 H), 2.13 (s, 3 H), 1.92~1.85 (m, 4 H), 1.80~1.74 (m, 4 H).

Step B: Synthesis of 2-[(3,4-difluorophenyl)sulfonyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

To a solution of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-
10 2-(3,4-difluorophenyl)-sulfanyl-nicotinamide (45 mg, 0.09 mmol) in DCM (6 mL) was added MCPBA (77 %, 31 mg, 2 eq.) at 0 °C under Ar atmosphere. The reaction was stirred overnight, washed with sat.- $NaHCO_3$ (2 x) and water, concentrated, and purified by column chromatography (DCM:MeOH = 100:0 to 94:6). 25 mg (53 %) of 2-[(3,4-difluorophenyl)sulfonyl]-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino} cyclohexyl)nicotinamide was isolated and
15 converted to its HCl salt.

ESI MS m/e 531 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 11.8 (bs, 1 H), 8.70 (m, 2 H), 8.04 (m, 1 H), 7.95 (dd, 1 H, $J = 7.6$ and 1.6 Hz), 7.89 (m, 1 H), 7.78~7.70 (m, 2 H), 7.60 (s, 1 H), 3.95 (bs, 1 H), 3.87 (bs, 1 H), 3.25 (s, 6 H), 2.22 (s, 3 H), 1.76 (bs, 8 H).

20

Example 2657

***N*-(3,4-Difluorophenyl)-*N'*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-*N*-methylurea trifluoroacetate**

25 **Step A: Synthesis of ethyl 3,4-difluorophenylcarbamate.**

3,4-Difluoroaniline (2.8 mL, 28 mmol) and *N,N'*-diisopropylethylamine (5.4 mL, 31 mmol) were dissolved in 10 mL of anhydrous THF, and cooled to 0°C in an ice bath. Ethyl chloroformate (5.4 mL, 31 mmol) was added slowly into the stirring solution over the ice bath.

The solution was allowed to warm up to room temperature and stir for 30 minutes. The solvent was removed via vacuo and the crude solid was purified by column chromatography using ethyl acetate and hexane mixture (3:97) to yield ethyl 3,4-difluorophenylcarbamate as an off-white solid. (5.59 g, 99%)

- 5 ESI MS m/z 202.1 ($M + H^+$) ; 1H NMR (400 MHz, DMSO- d_6) δ 9.79 (s, 1H), 7.55-7.50 (m, 1H), 7.29-7.22 (m, 1H), 7.16-7.15 (m, 1H), 4.10 (q, $J = 7.2$ Hz, 2H), 1.22 (t, $J = 7.2$ Hz, 3H).

Step B: Synthesis of (3,4-difluoro-phenyl)-methyl-amine.

- Lithium aluminum hydride (2.2 g, 56 mmol) was placed in a 500 mL round bottom flask.
- 10 THF (100 mL) was syringed into the flask under argon. The solution was cooled to 0°C in an ice bath. To the ice-cold solution, 3,4-difluorophenylcarbamate (5.59 g, 28 mmol) was added slowly into the flask. The solution was refluxed for 3 hours. After cooling the reaction mixture to 0°C, H₂O (3 mL), 1 N NaOH (3 mL), and then more H₂O (15 mL) were added for quenching. The precipitate was filtered off and THF was evaporated from the filtrate. The crude was dissolved in
- 15 150 mL of ethyl acetate, washed with water, and dried over Na₂SO₄. The organic solvent was removed via vacuo to yield (3,4-difluoro-phenyl)-methyl-amine as a light brown oil. (2.86 g, 71%)
- ESI MS m/z 144.2 ($M + H^+$) ; 1H NMR (400 MHz, CDCl₃) δ 7.04-6.97 (m, 1H), 6.45-6.39 (m, 1H), 6.32-6.28 (m, 1H), 3.69 (b, 1H), 2.86 (s, 3H).

20 **Step C: Synthesis of *N*-(3,4-difluorophenyl)-*N'*-(*cis*-4-{[4-(dimethylamino)-5-methyl-pyrimidin-2-yl]amino}cyclohexyl)-*N*-methylurea trifluoroacetate.**

- cis*-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino) cyclohexyl]-carbamic acid *tert*-butyl ester (100 mg, 0.402 mmol) and 1,1'-carbonyldiimidazole (78.1 mg, 0.482 mmol) were dissolved in 1 mL of methylene chloride and allowed to stir at room temperature overnight. To the vial, (3,4-
- 25 difluoro-phenyl)-methyl-amine (88 mg, 0.603 mmol) was added. The solution was heated via Smith Synthesizer at 130°C for 15 minutes. The solvent was evaporated, and 1 mL of methanol was added to the crude. The crude was purified by HPLC to yield *N*-(3,4-difluorophenyl)-*N'*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-*N*-methylurea trifluoroacetate

as a white solid. (47.8 mg, 22%)

ESI MS m/z 419.3 ($M + H^+$) ; 1H NMR (400 MHz, $CDCl_3$) δ 14.0 (s, 1H), 8.62 (d, $J = 6.4$ Hz, 1H), 7.29-7.21 (m, 2H), 7.13-7.01 (m, 2H), 4.61 (bs, 1H), 4.10 (m, 1H), 3.78 (m, 1H), 3.46-3.29 (b, 3H), 3.24 (s, 6H), 2.24 (s, 3H), 1.77-1.56 (m, 8H).

5

Example 2658

N-[(*cis*-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride

10

Step A: Synthesis of *N*-(*cis*-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (1.1 g, 4.8 mmol) in dry benzene (15 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (1.33 g, 1 eq.) and followed by Et_3N (~2 mL) at room temperature under N_2 . The reaction was stirred for an additional 2 h at room temperature, washed with sat.- $NaHCO_3$ (3x) and water (1x), dried with $MgSO_4$, and concentrated. The crude {*cis*-{4-[(3,5-Bis-trifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester was pure enough to use for the next deprotection without a further purification.

{*cis*-{4-[(3,5-Bis-trifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (2.1 g, 4.5 mmol) was dissolved in DCM (10 mL), and TFA (5 mL) was added to the reaction. After 1.5 h stirring at room temperature, removal of the volatile solvent gave crude *N*-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide trifluoroacetate as a sticky oil. Addition of water (~40 mL) to the crude product and shaking well for 5 ~ 10 min provided formation of precipitates, and the ppts were filtered, washed with water, and dried; 1.40 (61 %) of *N*-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide trifluoroacetate was isolated as a white powder.

25

ESI MS m/e 369 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 8.97 (bs, 1 H), 8.47 (s, 2 H), 8.29 (s, 1

H), 7.78 (bs, 3 H), 3.29 (t, 2 H, $J = 6.8$ Hz), 3.15 (bs, 1 H), 1.78 (bs, 1 H), 1.66 (m, 4 H), 1.52 (m, 4 H).

Step B: Synthesis of *N*-[(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-6-methylpyrimidine (0.21 g, 1.2 mmol), *N*-(*cis*-4-amino-cyclohexylmethyl)-3,5-bis(trifluoromethyl)-benzamide trifluoroacetate (0.6 g, 1 eq.), DIEA (0.45 mL, 2 eq.), and *tert*-BuOH (2.5 mL) was reacted for 1.6 h at 185 °C in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with diluted-HCl and water, dried, and concentrated. The crude product was purified by column chromatography (silica gel; DCM:MeOH = 100:0 to 95:5). 0.3 g (50 %) of *N*-[(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide was isolated and converted to HCl-salt.

ESI MS m/e 504 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 12.8 (bs, 1 H), 8.72 (d, 1 H, $J = 8.0$ Hz), 8.39 (s, 2 H), 7.93 (s, 1 H), 7.43 (bs, 1 H), 5.70 (s, 1 H), 4.24 (bm, 1 H), 3.49 (t, 2 H, $J = 4.4$ Hz), 3.22 (s, 3 H), 3.11 (s, 3 H), 2.31 (s, 3 H), 1.91~1.79 (m, 5 H), 1.64~1.56 (m, 4 H).

Example 2659

***N*²-[*cis*-4-({6-[(3,4-Difluorophenyl)sulfinyl]pyrazin-2-yl}amino)cyclohexyl]-*N*⁴,*N*⁴,5-trimethylpyrimidine-2,4-diamine**

Step A: Synthesis of *cis*-[1-(6-chloro-pyrazin-2-ylamino)-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)]-cyclohexane.

A sealed tube containing *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane hydrochloride (0.2 g, 0.7 mmol), 2,6-dichloropyrazine (0.1 g, 1 eq.), DIEA (0.3 mL, 2 eq.), and IPA (2 mL) was reacted for 1.5 h at 170 °C in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, concentrated, and purified by

column chromatography (DCM:MeOH = 100:0 to 96:4). 0.15 g (61 %) of *cis*-[1-(6-chloro-pyrazin-2-ylamino)-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)]-cyclohexane was isolated.

ESI MS m/e 362 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.70 (bs, 1 H), 7.76 (s, 1 H), 7.71 (s, 1 H),
 5 7.29 (s, 1 H), 5.32 (bs, 1 H), 4.11 (bs, 1 H), 4.00 (bs, 1 H), 3.27 (s, 6 H), 2.23 (s, 3 H), 1.80 (m, 8 H).

Step B: Synthesis of *cis*-{1-[6-(3,4-difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)}-cyclohexane.

10 A sealed tube containing *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-(6-chloro-pyrazin-2-ylamino)-cyclohexane (0.1 g, 0.27 mmol), 3,4-difluorothiophenol (0.1 g, 2.5 eq.), CS_2CO_3 (0.15 g, 2 eq.), and dioxane (2 mL) was reacted for 1 h at 180 °C in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with sat- $NaHCO_3$ (3x) and water, concentrated, and purified by column chromatography to give 85 mg (65 %) of *cis*-{1-[6-(3,4-
 15 difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)}-cyclohexane.

ESI MS m/e 472 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.60 (s, 1 H), 7.48 (s, 1 H), 7.42 (m, 2 H), 7.29 (m, 1 H), 7.15 (m, 1 H), 6.70 (bs, 1 H), 5.15 (d, 1 H, $J = 7.6$ Hz), 4.03 (bs, 1 H), 3.67 (bm, 1 H), 3.16 (s, 6 H), 2.19 (s, 3 H), 1.81~1.61 (m, 8 H).

20

Step C: Synthesis of N^2 -[*cis*-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino)-cyclohexyl]- $N^4, N^4, 5$ -trimethylpyrimidine-2,4-diamine.

To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-[6-(3,4-difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-cyclohexane (35 mg, 0.07 mmol) in DCM (5 mL)
 25 was added MCPBA (33 mg, 2 eq.) at room temperature under an Ar atmosphere. The reaction was stirred overnight, washed with sat- $NaHCO_3$ (2x) and water, concentrated, and purified by column chromatography (DCM:MeOH = 100:0 to 95:5). 12 mg (33 %) of N^2 -[*cis*-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino) cyclohexyl]- $N^4, N^4, 5$ -trimethylpyrimidine-2,4-diamine

was isolated.

ESI MS m/e 488 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.25 (s, 1 H), 7.87 (s, 1 H), 7.63 (m, 1 H), 7.57 (s, 1 H), 7.53 (m, 1 H), 7.26 (m, 1 H), 5.36 (bs, 1 H), 5.14 (d, 1 H, $J = 6.8$ Hz), 4.01 (bs, 1 H), 3.82 (bm, 1 H), 3.06 (s, 6 H), 2.15 (s, 3 H), 1.87~1.60 (m, 8 H).

5

Example 2660

cis-N-[1-(4-Bromophenyl)ethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide hydrochloride

10

Step A: Synthesis of *cis-N*-[1-(4-bromophenyl)ethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide hydrochloride.

To a solution of *cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid obtained from step B of Example 2594 (24 mg, 0.08 mmol) in DCM (3
15 mL) was added 1-(4-bromophenyl)-ethylamine (18 mg, 1 eq.), and followed by HATU (36 mg, 1.1 eq.) and Et_3N (20 μ L). The reaction was stirred overnight, concentrated, and purified by column chromatography (DCM:MeOH = 100:0 to 95:5). 16 mg (41 %) of *cis-N*-[1-(4-bromophenyl)ethyl]-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexanecarboxamide was isolated and converted to HCl salt.

20 ESI MS m/e 460 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 11.0 (bs, 1 H), 8.20 (d, 1 H, $J = 7.6$ Hz), 7.66 (bs, 1 H), 7.50 (s, 1 H), 7.43 (d, 2 H, $J = 8.4$ Hz), 7.18 (d, 2 H, $J = 8.4$ Hz), 4.79 (m, 1 H), 3.95 (bs, 1 H), 3.19 (s, 6 H), 2.23 (bs, 1 H), 2.16 (s, 3 H), 1.70~1.50 (m, 8 H), 1.24 (d, 3 H, $J = 7.2$ Hz).

25

Example 2661

N-[(*cis*-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine.

2,4- Dichloro-5-methylpyrimidine (3.8g, 23.4mmol) in 20ml in CH_2Cl_2 was added 2.0 M methylamine in methyl alcohol (14.05ml, 28.1mmol) at 0 °C. The reaction mixture was stirred overnight and then the excess solvent was evaporated off and the material subjected to chromatography (50% hexanes in ethyl acetate) to yield (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (968.7mg, 6.17mmol, 26%) as a white solid.

ESI MS 158.0 $\text{M}+\text{H}^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.86 (s, 1H), 7.39 (s, 1H), 2.93-2.92 (d, J = 4 Hz, 3H), 2.04 (s, 3H).

Step B: Synthesis of *N*-[(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamidehydrochloride.

To a solution of (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (200mg, 1.27mmol) in 1mL 2-propanol was added *cis-N*-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide in TFA salt (736mg, 1.52mmol) and DIEA (2.54mmol). The mixture was heated in a microwave synthesizer at 180°C for 2 hours. The solvent was evaporated and the material subjected to chromatography (70 ~ 95% ethyl acetate/ hexanes). The combined compound was dissolved in CH_2Cl_2 and was added 2 M HCl in diethyl ether (5.6ml, 1.42mmol) to yield *N*-[(*cis*-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino} cyclohexyl)methyl]-3,5-

bis(trifluoromethyl)benzamidehydrochloride (443mg, 0.84mmol, 66%) as a white solid.

ESI MS 490.4 $\text{M}+\text{H}^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.5 (s, 1H), 8.86-8.83 (t, J = 4 Hz, 8 Hz, 1H), 8.32 (s, 2H), 8.11 (s, 1H), 8.03 (bs, 1H), 7.97 (bs, 1H), 7.40 (s, 1H), 3.90 (bs, 1H), 3.24 (s, 3H), 3.06-3.04 (d, J = 8 Hz, 2H), 2.72-2.71 (d, J = 4 Hz, 3H), 1.54 (bs, 4H), 1.42 (m, 4H), 1.20 (2H).

Example 2662

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-*N*-[(1*R*)-1-(3-

methoxyphenyl)ethyl]cyclohexanecarboxamide hydrochloride

Step A: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[(1*R*)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide hydrochloride.

5 Using the procedure of Example 2660, the title compound was obtained.

ESI MS m/e 412 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 10.9 (bs, 1 H), 7.98 (d, 1 H, $J = 8.0$ Hz), 7.53 (bs, 1 H), 6.98 (t, 1 H, $J = 8.0$ Hz), 6.63 (d, 1 H, $J = 7.4$ Hz), 6.62 (s, 1 H), 6.54 (d, 2 H, $J = 8.0$ Hz), 4.64 (m, 1 H), 3.79 (bs, 1 H), 3.50 (s, 3 H), 3.03 (s, 6 H), 2.08 (bs, 1 H), 1.97 (s, 3 H), 1.60~1.30 (m, 8 H), 1.10 (d, 3 H, $J = 6.8$ Hz).

10

Example 2663

***cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[(1*R*)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide hydrochloride**

15

Step A: Synthesis of *cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-*N*-[(1*R*)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide hydrochloride.

Using the procedure of Example 2660, the title compound was obtained.

ESI MS m/e 432 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 11.1 (bs, 1 H), 8.39 (d, 1 H, $J = 8.0$ Hz), 8.09 (d, 1 H, $J = 8.0$ Hz), 7.94 (m, 1 H), 7.82 (d, 1 H, $J = 8.0$ Hz), 7.73 (bs, 1 H), 7.56~7.49 (m, 5 H), 5.69 (m, 1 H), 4.01 (bs, 1 H), 3.25 (s, 6 H), 2.33 (bs, 1 H), 2.23 (s, 3 H), 1.85~1.55 (m, 8 H), 1.49 (d, 3 H, $J = 6.8$ Hz).

25 **Example 2664**

***N*-(*cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)-3-methylbenzamide hydrochloride**

Step A: Synthesis of *N*-(*cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]-cyclohexyl)-3-methylbenzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 368 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.2 (bs, 1 H), 8.28 (bs, 1 H), 7.98 (bd, 1 H, $J = 6.0$ Hz), 7.64 (m, 3 H), 7.31 (s, 1 H), 7.30 (s, 1 H), 3.91 (bs, 1 H), 3.85 (bs, 1 H), 3.25 (s, 6 H), 2.35 (s, 3 H), 2.22 (s, 3 H), 1.85 (bs, 2 H), 1.70 (bs, 6 H).

Example 2665

10 *N*-{*cis*-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of *cis*-*N*-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide.

To a solution of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.2 g, 0.015 mol) in CH_2Cl_2 (50 mL) was added DIEA (3.9 mL, 0.022 mol). The mixture was cooled on an ice bath and 3,5-bis(trifluoromethyl)benzoyl chloride (2.9 mL, 0.015 mol) was slowly added. The mixture was brought to room temperature and stirred for 1 hour. After this time, the solvent and excess DIEA was evaporated in vacuo. The resulting oil was re-dissolved in CH_2Cl_2 (30 mL) and extracted with H_2O (30 mL), 1M NaOH (30 mL), and brine (30 mL). The brine layer was twice back extracted with CH_2Cl_2 and the organic layers were combined, dried over $MgSO_4$, and concentrated. The resulting precipitate was re-dissolved in CH_2Cl_2 (50 mL) and TFA (4.6 mL, 0.060 mol) was added. The solution was stirred at room temperature for 4 hours (or until the reaction was complete as judged by TLC). The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH_2Cl_2 . The organic layer was extracted with 30 mL of a dilute NaOH (aq) / $NaHCO_3$ (aq) solution (the aqueous layer was confirmed to remain basic during the extraction using pH paper indicator). The aqueous layer was back extracted twice with CH_2Cl_2 and the organic layers combined, dried over $MgSO_4$, and concentrated. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield *cis*-*N*-(4-

amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (4.0 g, 0.011 mol, 77%) as a white solid.

ESI MS 355.0 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 2H), 8.18 (s, 1H), 4.04 (m, 1H), 3.00 (m, 1H), 1.89-1.84 (m, 2H), 1.79-1.74 (m, 4H), 1.74-1.64 (m, 2H).

5 **Step B Synthesis of *N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride.**

To a solution of 2-chloro-4-methyl-quinoline (326 mg, 1.84 mmol) in 2 mL *t*-BuOH was added DIEA (369 μL, 2.12 mmol) and *cis*-*N*-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (500 mg, 1.41 mmol). The mixture was then heated in a microwave at 180 °C for 12 hours. The
10 reaction mixture was cooled and concentrated and the resulting oil was purified by column (<5 % MeOH in CH₂Cl₂). The organic solvents were evaporated and the resulting oil was re-dissolved into 4 mL CH₂Cl₂ and HCl (1.4 mL, 2.82 mol) was added. The reaction was stirred for 30 minutes and the solvent was removed. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield *N*-{*cis*-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-
15 3,5-bis(trifluoromethyl)benzamide hydrochloride (620 mg, 1.17 mmol, 83%).

ESI MS 496.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.47 (s, 2H), 8.21 (s, 1H), 8.05 (d, 1H, *J* = 8.0 Hz), 7.93 (bs, 1H), 7.82 (t, 1H, *J* = 7.8 Hz), 7.59 (t, 1H, *J* = 8.2 Hz), 7.09 (bs, 1H), 4.17 (m, 1H), 4.15 (m, 1H), 2.73 (s, 3H), 2.08-1.95 (m, 8H).

20

Example 2666

N-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide hydrochloride

25 **Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide hydrochloride.**

Using the procedure of example 2523, the title compound was obtained.

ESI MS *m/e* 438 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.9 (bs, 1 H), 8.59 (bd, 1 H, *J* = 6.8 Hz),

7.69 (s, 1 H), 7.68 (d, 1 H, $J = 8.4$ Hz), 7.43 (t, 1 H, $J = 8.0$ Hz), 7.30 (d, 1 H, $J = 7.6$ Hz), 7.20 (d, 1 H, $J = 5.2$ Hz), 6.55 (d, 1 H, $J = 8.0$ Hz), 4.17 (bs, 1 H), 4.10 (bs, 1 H), 3.29 (s, 6 H), 2.24 (s, 3 H), 1.98~1.83 (m, 6 H), 1.73 (m, 2 H).

5

Example 2667

N-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

- 10 **Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.**

Using the procedure of example 2523, the title compound was obtained.

- ESI MS m/e 438 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 12.3 (bs, 1 H), 8.54 (bd, 1 H, $J = 6.8$ Hz), 7.86 (d, 2 H, $J = 8.8$ Hz), 7.22 (d, 2 H, $J = 8.8$ Hz), 7.21 (s, 1 H), 6.68 (d, 1 H, $J = 8.0$ Hz), 4.17 (bs, 1 H), 4.10 (bs, 1 H), 3.28 (s, 6 H), 2.24 (s, 3 H), 1.95~1.85 (m, 6 H), 1.72 (m, 2 H).

15

Example 2668

- 20 **3-Chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride**

Step A: Synthesis of 3-chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

- 25 ESI MS m/e 472 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 12.5 (bs, 1 H), 8.37 (bd, 1 H, $J = 7.2$ Hz), 8.06 (s, 1 H), 7.86 (d, 1 H, $J = 8.4$ Hz), 7.51 (d, 1 H, $J = 8.4$ Hz), 7.30 (d, 1 H, $J = 8.0$ Hz), 7.24 (s, 1 H), 4.17 (bs, 1 H), 4.08 (bm, 1 H), 3.28 (s, 6 H), 2.23 (s, 3 H), 1.92~1.85 (m, 6 H), 1.71 (m, 2 H).

Example 2669

4-Chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide hydrochloride

5

Step A: Synthesis of 4-chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 456 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 12.8 (bs, 1 H), 8.58 (bd, 1 H, $J = 6.8$ Hz),
10 8.19 (s, 1 H), 7.90 (d, 1 H, $J = 8.4$ Hz), 7.54 (d, 1 H, $J = 8.4$ Hz), 7.19 (bd, 1 H, $J = 5.2$ Hz), 6.76 (d,
1 H, $J = 8.4$ Hz), 4.19 (bs, 1 H), 4.10 (bm, 1 H), 3.29 (s, 6 H), 2.24 (s, 3 H), 1.94~1.83 (m, 6 H),
1.72 (m, 2 H).

15 **Example 2670**

3,5-Dichloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3,5-dichloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

20 Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 12.1 (bs, 1 H), 8.50 (bs, 1 H), 8.02 (bd,
1 H, $J = 5.2$ Hz), 7.86 (d, 2 H, $J = 1.6$ Hz), 7.77 (t, 1 H, $J = 1.6$ Hz), 7.63 (s, 1 H), 3.90 (bs, 1 H),
3.85 (bs, 1 H), 3.25 (s, 6 H), 2.22 (s, 3 H), 1.85 (bs, 2 H), 1.70 (bs, 6 H).

25

Example 2671

3,4-Dichloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2yl]amino}cyclohexyl)-

benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

5 Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.2 (bs, 1 H), 8.47 (bs, 1 H), 8.09 (d, 1 H, $J = 2.0$ Hz), 8.05 (d, 1 H, $J = 6.4$ Hz), 7.82 (dd, 1 H, $J = 8.0$ and 1.6 Hz), 7.71 (d, 1 H, $J = 8.4$ Hz), 7.63 (s, 1 H), 3.90 (bs, 1 H), 3.85 (bs, 1 H), 3.25 (s, 6 H), 2.22 (s, 3 H), 1.85 (bs, 2 H), 1.70 (bs, 6 H).

10

Example 2672

5-Bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide

15

Step A: Synthesis of 5-bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.64 (s, 1 H), 7.02 (d, 1 H, $J = 3.6$ Hz), 6.41 (d, 1 H, $J = 3.6$ Hz), 6.23 (bs, 1 H), 4.77 (bs, 1 H), 4.08 (bs, 1 H), 3.96 (bs, 1 H), 3.02 (s, 6 H), 2.14 (s, 3 H), 1.88~1.60 (m, 8 H).

20

Example 2673

25 ***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(methylsulfonyl)benzamide**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(methylsulfonyl)benzamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.02 (d, 1 H, $J = 7.6$ Hz), 7.69 (t, 1 H, $J = 8.0$ Hz), 7.59 (t, 2 H, $J = 7.6$ Hz), 6.39 (d, 1 H, $J = 8.0$ Hz), 6.34 (bs, 1 H), 4.10 (bs, 2 H), 3.33 (s, 3 H), 3.25 (s, 6 H), 2.25 (s, 3 H), 1.93~1.71 (m, 8 H).

Example 2674

10 ***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)benzamide**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)benzamide.

15 Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.40 (s, 1 H), 8.18 (d, 1 H, $J = 7.6$ Hz), 8.08 (d, 1 H, $J = 7.6$ Hz), 7.67 (t, 1 H, $J = 7.6$ Hz), 7.34 (s, 1 H), 6.99 (d, 1 H, $J = 8.0$ Hz), 6.57 (bd, 1 H, $J = 6.4$ Hz), 4.17 (bm, 2 H), 3.32 (s, 6 H), 3.16 (s, 3 H), 2.27 (s, 3 H), 1.90~1.71 (m, 8 H).

20

Example 2675

***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(methylsulfonyl)benzamide**

25 **Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-4-(methylsulfonyl)benzamide.**

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.04 (d, 2 H, $J = 8.4$ Hz), 7.98 (d, 2 H, $J =$

8.4 Hz), 7.28 (s, 1 H), 6.86 (d, 1 H, $J = 8.4$ Hz), 6.41 (d, 1 H, $J = 7.6$ Hz), 4.14 (bm, 2 H), 3.32 (s, 6 H), 3.07 (s, 3 H), 2.27 (s, 3 H), 1.90~1.71 (m, 8 H).

5 **Example 2676**

Methyl 2-{[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoate

Step A: Synthesis of methyl 2-{[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}benzoate.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 428 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.10 (bs, 1 H), 7.87 (d, 1 H, $J = 7.6$ Hz), 7.52 (t, 1 H, $J = 7.6$ Hz), 7.46 (m, 2 H), 7.30 (s, 1 H), 6.56 (d, 1 H, $J = 8.0$ Hz), 4.13 (bm, 2 H), 3.87 (s, 3 H), 3.24 (s, 6 H), 2.22 (s, 3 H), 1.93~1.75 (m, 8 H).

15

Example 2677

Methyl 3-{[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoate

20

Step A: Synthesis of methyl 3-{[(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}benzoate.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 428 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.48 (s, 1 H), 8.17 (bs, 1 H), 8.14 (d, 1 H, $J = 7.6$ Hz), 8.08 (d, 1 H, $J = 7.6$ Hz), 7.51 (t, 1 H, $J = 8.0$ Hz), 7.31 (s, 1 H), 7.16 (d, 1 H, $J = 7.6$ Hz), 4.14 (bm, 2 H), 3.94 (s, 3 H), 3.26 (s, 6 H), 2.23 (s, 3 H), 1.93~1.73 (m, 8 H).

25

Example 2678

2-[[*(cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl]benzoic acid hydrochloride

- 5 **Step A: Synthesis of 2-[[*(cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl]benzoic acid hydrochloride.**

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 398 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.5 (bs, 2 H), 8.32 (bs, 1 H), 8.04 (d, 1 H, $J = 6.4$ Hz), 7.80 (d, 1 H, $J = 7.6$ Hz), 7.68 (s, 1 H), 7.58 (m, 1 H), 7.51 (t, 1 H, $J = 7.6$ Hz),
10 7.39 (d, 1 H, $J = 7.6$ Hz), 3.89 (bs, 2 H), 3.28 (s, 6 H), 2.25 (s, 3 H), 1.85~1.70 (m, 8 H).

Example 2679

- 3-[[*(cis*-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl]benzoic acid hydrochloride**
- 15

Step A: Synthesis of 3-[[*(cis*-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl]benzoic acid hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

- 20 ESI MS m/e 398 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 13.2 (bs, 1 H), 12.3 (bs, 1 H), 8.59 (bs, 1 H), 8.47 (m, 1 H), 8.16~8.11 (m, 3 H), 7.72 (s, 1 H), 7.64 (t, 1 H, $J = 8.0$ Hz), 3.95 (bs, 2 H), 3.32 (s, 6 H), 2.29 (s, 3 H), 1.93 (bs, 2 H), 1.78 (bs, 6 H).

25 **Example 2680**

***N*-(*cis*-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 390 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.7 (bs, 1 H), 8.37 (bs, 1 H),
5 7.93~7.88 (m, 2 H), 7.73 (m, 1 H), 7.51 (dd, 1 H, $J = 18.8$ and 8.4 Hz), 6.26 (s, 1 H), 3.96 (bs, 1 H),
3.84 (bs, 1 H), 3.17 (s, 3 H), 3.13 (s, 3 H), 2.25 (s, 3 H), 1.85 (bm, 2 H), 1.70 (bs, 6 H).

Example 2681

10 ***N*-(*cis*-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid.

15 To a solution of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (242 mg, 1.41 mmol) in 2 mL *t*-BuOH was added DIEA (369 μ L, 2.12 mmol) and *cis*-*N*-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (500 mg, 1.41 mmol). The mixture was then heated in a microwave at 180 °C for 1.7 hours. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (<5 % MeOH in CH_2Cl_2). The organic solvents were
20 evaporated and the resulting oil was re-dissolved into 4 mL CH_2Cl_2 and HCl (1.4 mL, 2.82 mol) was added. The reaction was stirred for 30 minutes and the solvent was removed. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield *N*-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid (653 mg, 1.24 mmol, 88%).
25 ESI MS 490.4 $M + H^+$; 1H NMR (400 MHz, CD_3OD) δ 12.58 (bs, 1H), 8.81 (d, 1H, $J = 6.4$ Hz), 8.50 (s, 2H), 8.30 (s, 1H), 7.89 (bs, 1H), 6.28 (s, 1H), 4.00 (m, 1H), 3.90 (m, 1H), 3.18 (s, 3H), 3.12 (s, 3H), 2.25 (s, 3H), 1.87-1.71 (m, 8H).

Example 2682

N-(*cis*-4-{{4-(Dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

5

Step A: Synthesis of *N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS *m/e* 438 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.0 (bs, 1 H), 8.52 (bd, 1 H, *J* = 7.6 Hz),
10 7.87 (d, 2 H, *J* = 8.8 Hz), 7.23 (d, 2 H, *J* = 8.8 Hz), 6.84 (d, 1 H, *J* = 8.0 Hz), 5.72 (s, 1 H), 4.22
(bm, 1 H), 4.11 (bm, 1 H), 3.24 (s, 3 H), 3.12 (s, 3 H), 2.34 (s, 3 H), 1.95~1.85 (m, 6 H), 1.72 (m, 2
H).

15 **Example 2683**

3-Chloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

20

Using the procedure of example 2526, the title compound was obtained.

ESI MS *m/e* 472 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.9 (bs, 1 H), 8.52 (d, 1 H, *J* = 7.6 Hz),
7.96 (d, 1 H, *J* = 2.4 Hz), 7.73 (dd, 1 H, *J* = 8.8 and 2.0 Hz), 7.34 (d, 1 H, *J* = 8.4 Hz), 6.59 (d, 1 H,
J = 8.0 Hz), 5.72 (s, 1 H), 4.22 (bm, 1 H), 4.10 (bm, 1 H), 3.24 (s, 3 H), 3.12 (s, 3 H), 2.34 (s, 3 H),
25 1.95~1.83 (m, 6 H), 1.72 (m, 2 H).

Example 2684

4-Chloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-benzamide hydrochloride

Step A: Synthesis of 4-chloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 388 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.1 (bs, 1 H), 8.57 (bd, 1 H, $J = 8.0$ Hz), 7.73 (d, 2 H, $J = 8.4$ Hz), 7.37 (d, 2 H, $J = 8.4$ Hz), 6.46 (d, 1 H, $J = 6.0$ Hz), 5.71 (s, 1 H), 4.20 (bs, 1 H), 4.10 (bs, 1 H), 3.24 (s, 3 H), 3.12 (s, 3 H), 2.34 (s, 3 H), 1.94~1.82 (m, 6 H), 1.73 (m, 2 H).

10

Example 2685

3,4-Dichloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-benzamide hydrochloride

15

Step A: Synthesis of 3,4-dichloro-*N*-(*cis*-4-{{4-(dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 422 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 13.0 (bs, 1 H), 8.51 (d, 1 H, $J = 7.6$ Hz), 7.94 (d, 1 H, $J = 2.0$ Hz), 7.64 (dd, 1 H, $J = 8.4$ and 2.0 Hz), 7.47 (d, 1 H, $J = 8.4$ Hz), 6.88 (d, 1 H, $J = 8.8$ Hz), 5.72 (s, 1 H), 4.22 (bm, 1 H), 4.09 (bm, 1 H), 3.24 (s, 3 H), 3.13 (s, 3 H), 2.34 (s, 3 H), 1.94~1.82 (m, 6 H), 1.72 (m, 2 H).

25 **Example 2686**

***N*-(*cis*-4-{{4-(Dimethylamino)-6-methylpyrimidin-2-yl}amino}cyclohexyl)-3,5-dimethoxybenzamide**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 414 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 6.88 (d, 2 H, $J = 2.0$ Hz), 6.57 (t, 1 H, $J = 2.0$ Hz), 6.15 (d, 1 H, $J = 7.6$ Hz), 5.69 (s, 1 H), 5.10 (bs, 1 H), 4.06 (bm, 2 H), 3.82 (s, 6 H), 3.04 (s, 6 H), 2.21 (s, 3 H), 1.90~1.81 (m, 6 H), 1.67 (m, 2 H).

Example 2687

5-Bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide hydrochloride

Step A: Synthesis of 5-bromo-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 433.2 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 12.2 (s, 1H), 8.85 (d, $J = 4$ Hz, 1H), 8.73 (d, $J = 4$ Hz, 1H), 8.51 (bs, 1H), 8.34-8.33 (m, 1H), 7.55 (bs, 1H), 3.76 (bs, 2H), 3.14 (bs, 6H), 2.10 (s, 3 H), 1.74-1.59 (m, 8H).

Example 2688

***N*-(*cis*-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride**

Step A: Synthesis of *N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 520.4 $M + H^+$; 1H NMR (400 MHz, $DMSO-d_6$) δ 12.0 (s, 1H), 8.84 (s, 1H), 8.36 (bs, 1H),

7.91 (bs, 1H), 7.88 (d, $J = 8$ Hz, 2H), 7.73-7.71 (d, $J = 8$ Hz, 2H), 7.60 (s, 1H), 3.85 (bs, 2H), 3.23 (s, 6H), 2.20 (s, 3H), 1.82 (m, 2H), 1.68 (m, 6H).

5 Example 2689

3-Bromo-4-chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3-bromo-4-chloro-*N*-(*cis*-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 466.0 $M+H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.0 (s, 1H), 8.32-8.31 (d, $J = 4$ Hz, 1H), 8.08-8.07 (d, $J = 2$ Hz, 1H), 7.88-7.86 (d, $J = 8$ Hz, 1H), 7.73-7.70 (dd, $J_1 = 4$ Hz, $J_2 = 4$ Hz, 1H), 7.57-7.55 (d, $J = 8$ Hz, 1H), 7.49 (s, 1H), 3.76-3.69 (m, 2H), 3.16 (s, 6H), 2.07 (s, 3H), 1.70 (bs, 2H), 1.55 (bs, 6H).

Examples 2690-2711

Compounds 2690 to 2711 were prepared in a similar manner as described in Example 2590 using the appropriate acid chloride and amine intermediate from Step B.

Examples 2712-2731

Compounds 2712 to 2731 were prepared in a similar manner as described in Example 2591 using the appropriate acid chloride and amine intermediate from Step A.

Examples 2732-2750

Compounds 2732 to 2750 were prepared in a similar manner as described in Example 2592 using the appropriate acid chloride and amine intermediate from Step A.

Examples 2751-2770

Compounds 2751 to 2770 were prepared in a similar manner as described in Example 2593 using the appropriate acid chloride and amine intermediate from Step B.

5

Examples 2771-2794

Compounds 2771 to 2794 were prepared in a similar manner as described in Example 2594 using the appropriate amine and the carboxylic acid intermediate from Step B.

10 **Examples 2795-2823**

Compounds 2795 to 2823 were prepared in a similar manner as described in Example 2527 using the appropriate amine and the carboxylic acid intermediate from Step B.

Examples 2824-2864

15 Compounds 2824 to 2864 were prepared in a similar manner as described in Example 2607 using the appropriate acid chloride and the amine intermediate from Step D.

Examples 2865-2866

Compounds 2865 and 2866 were prepared in a similar manner as described in Example 2611 using the appropriate benzaldehyde and the amine from Step A.

20

Examples 2867-2869

Compounds 2867 to 2869 were prepared in a similar manner as described in Example 2613 using the appropriate isocyanate and the amine from Step A.

25

Examples 2870-2875

Compounds 2870 to 2875 were prepared in a similar manner as described in Example 2615 using the appropriate carboxylic acid and the amine from Step A.

Example 2876

Compound 2876 was prepared in a similar manner as described in Example 2623 using the appropriate 4-chloro mandelic acid and the amine of Step A.

5

Examples 2877-2879

Compounds 2877 to 2879 were prepared in a similar manner as described in Example 2638 using the appropriate phenol and the bromoacetamide intermediate of Step B.

10 **Examples 2880-2884**

Compounds 2880 to 2884 were prepared in a similar manner as described in Example 2644 using the appropriate thiophenol.

Examples 2885-2895

15 Compounds 2885 to 2895 were prepared in a similar manner as described in Example 2647 using the appropriate phenol and the chloropyridyl intermediate of Step A.

Examples 2896-2940

Compounds 2896 to 2940 were prepared in a similar manner as described in Example 2523
20 using the appropriate acid chloride and the amine of Step C.

Examples 2941-2948

Compounds 2941 to 2948 were prepared in a similar manner as described in Example 2635 using the appropriate *N*-methylaniline and the bromoacetamide intermediate from step A.

25

Examples 2949-2950

Compounds 2949 and 2950 were prepared in a similar manner as described in Example 2619 using the appropriate carboxylic acid and the amine of Step A.

Examples 2951-2994

Compounds 2951 to 2994 were prepared in a similar manner as described in Example 2526 using the appropriate acid chloride and the amine of Step C.

5

Example 2995

Compound 2995 was prepared in a similar manner as described in Example 2628 using phenylsulfonyl chloride and the amine of Step A.

10 **Examples 2996-3004**

Compounds 2996 to 3004 were prepared in a similar manner as described in Example 2632 using the appropriate benzaldehyde and the amine of Step A.

Example 3005

15 Compound 3005 was prepared in a similar manner as described in Example 2632 using 3-trifluoromethoxy benzaldehyde and the amine from step C of Example 2526.

Example 3006

Compound 3006 was prepared in a similar manner as described in Example 2642 using
20 3,4-difluorobenzoyl chloride and the amine from Step C.

Examples 3007-3011

Compounds 3007 to 3011 were prepared in a similar manner as described in Example 2637 using the appropriate phenol and the chloropyridyl intermediate from Step A.

25

Examples 3012-3020

Compounds 3012 to 3020 were prepared in a similar manner as described in Example 2636 using the appropriate phenol and the chloropyridyl intermediate of Step A.

Examples 3021-3029

Compounds 3021 to 3029 were prepared in a similar manner as described in Example 2657 using the appropriate *N*-methylaniline and the intermediate prepared in Step C.

5

Example 3030

Compound 3030 was prepared in a similar manner as described in Example 2595 using 3,4-dichlorobenzoyl chloride and the amine of Step A.

10 Specific compounds as shown in the Examples and in the Tables herein are represented as a mono or di-salt, for example, trifluoroacetate, hydrochloride, and the like; or as a free base. It is understood that these specific representations of the compounds in no way limit the scope of the invention to the respective salt or free base. For example, a trifluoroacetate salt can be readily converted to the corresponding free amine by treatment with a sufficient amount of base and if
15 desired converted to another salt, for example, a pharmaceutically acceptable salt as described herein.

It is understood that the present invention embraces compounds, as disclosed herein, as free bases, inorganic salts, and organic salts; and as solvates, and hydrates thereof.

Compounds in the subsequent table are listed specifically as the free base and may have
20 been specifically isolated as a trifluoroacetate, hydrochloride, or like salt as dictated by the specific synthetic procedure.

Ex. No.	compound name	MS	class
2690	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	368 (M + H)	3
2691	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methylbenzamide	382 (M + H)	3
2692	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide	404 (M + H)	2
2693	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methoxybenzamide	398 (M + H)	3
2694	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide	428 (M + H)	1
2695	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide	400 (M + H)	2
2696	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide	400 (M + H)	2
2697	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide	436 (M + H)	1
2698	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethyl)benzamide	436 (M + H)	3
2699	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide	452 (M + H)	2
2700	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide	452 (M + H)	2
2701	4-cyano-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	393 (M + H)	2
2702	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	446 (M + H)	1
2703	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	460 (M + H)	1
2704	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	420 (M + H)	1
2705	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-(trifluoromethyl)benzamide	454 (M + H)	2
2706	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	436 (M + H)	1
2707	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	436 (M + H)	1
2708	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide	448 (M + H)	2
2709	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide	444 (M + H)	3
2710	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	402 (M + H)	2
2711	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide	428 (M + H)	2
2712	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	368 (M + H)	3

Ex. No.	compound name	MS	class
2713	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-methylbenzamide	382 (M + H)	3
2714	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide	404 (M + H)	3
2715	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-methoxybenzamide	398 (M + H)	3
2716	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide	428 (M + H)	2
2717	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-fluoro-4-methylbenzamide	400 (M + H)	3
2718	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-fluoro-3-methylbenzamide	400 (M + H)	2
2719	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-(trifluoromethyl)benzamide	436 (M + H)	3
2720	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-(trifluoromethyl)benzamide	436 (M + H)	3
2721	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-(trifluoromethoxy)benzamide	452 (M + H)	3
2722	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-(trifluoromethoxy)benzamide	452 (M + H)	3
2723	4-cyano-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	393 (M + H)	3
2724	4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	446 (M + H)	3
2725	4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-methylbenzamide	460 (M + H)	2
2726	3-chloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-fluorobenzamide	420 (M + H)	2
2727	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-fluoro-4-(trifluoromethyl)-benzamide	454 (M + H)	3
2728	3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	436 (M + H)	2
2729	3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	436 (M + H)	3
2730	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide	448 (M + H)	3
2731	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide	504 (M + H)	2
2732	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	368 (M + H)	3
2733	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-methylbenzamide	382 (M + H)	3
2734	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide	404 (M + H)	3
2735	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-methoxybenzamide	398 (M + H)	3

Ex. No.	compound name	MS	class
2736	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide	428 (M + H)	3
2737	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-fluoro-4-methylbenzamide	400 (M + H)	3
2738	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-fluoro-3-methylbenzamide	400 (M + H)	3
2739	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-(trifluoromethyl)benzamide	436 (M + H)	3
2740	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-(trifluoromethyl)benzamide	436 (M + H)	3
2741	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-(trifluoromethoxy)benzamide	452 (M + H)	3
2742	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-(trifluoromethoxy)benzamide	452 (M + H)	3
2743	4-cyano-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	393 (M + H)	3
2744	4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	446 (M + H)	2
2745	4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-methylbenzamide	460 (M + H)	2
2746	3-chloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-4-fluorobenzamide	420 (M + H)	3
2747	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-fluoro-4-(trifluoromethyl)-benzamide	454 (M + H)	3
2748	3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	436 (M + H)	2
2749	3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide	436 (M + H)	2
2750	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide	448 (M + H)	3
2751	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	368 (M + H)	3
2752	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methylbenzamide	382 (M + H)	3
2753	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide	404 (M + H)	3
2754	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-methoxybenzamide	398 (M + H)	3
2755	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide	400 (M + H)	2
2756	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide	400 (M + H)	3
2757	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide	436 (M + H)	3
2758	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethyl)benzamide	436 (M + H)	2

Ex. No.	compound name	MS	class
2759	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide	452 (M + H)	3
2760	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide	452 (M + H)	3
2761	4-cyano-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	393 (M + H)	3
2762	4-bromo-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	446 (M + H)	1
2763	4-bromo-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide	460 (M + H)	1
2764	3-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide	420 (M + H)	1
2765	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-(trifluoromethyl)-benzamide	454 (M + H)	2
2766	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	436 (M + H)	2
2767	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	436 (M + H)	2
2768	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-difluoro-1,3-benzodioxole-5-carboxamide	448 (M + H)	
2769	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide	444 (M + H)	
2770	4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide	402 (M + H)	2
2771	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-phenylethyl]cyclohexanecarboxamide	382 (M + H)	2
2772	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide	396 (M + H)	1
2773	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide	400 (M + H)	1
2774	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide	400 (M + H)	2
2775	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	1
2776	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	1
2777	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	1
2778	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	416 (M + H)	1
2779	cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	460 (M + H)	1
2780	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide	427 (M + H)	1
2781	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide	427 (M + H)	2

Ex. No.	compound name	MS	class
2782	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide	432 (M + H)	1
2783	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide	432 (M + H)	1
2784	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-fluorophenyl)cyclohexanecarboxamide	372 (M + H)	2
2785	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(4-propylphenyl)cyclohexanecarboxamide	396 (M + H)	2
2786	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(4-methoxyphenyl)cyclohexanecarboxamide	384 (M + H)	3
2787	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide	384 (M + H)	1
2788	cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	388 (M + H)	1
2789	cis-N-(2-bromophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	432 (M + H)	3
2790	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide	394 (M + H)	1
2791	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide	422 (M + H)	1
2792	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[2-(methylthio)phenyl]cyclohexanecarboxamide	400 (M + H)	2
2793	N2-[cis-4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexyl]-N4,N4,5-trimethylpyrimidine-2,4-diamine	394 (M + H)	3
2794	cis-N-(4-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-methylcyclohexanecarboxamide	402 (M + H)	
2795	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide	396 (M + H)	1
2796	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	2
2797	cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	416 (M + H)	1
2798	cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	368 (M + H)	2
2799	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-fluorobenzyl)cyclohexanecarboxamide	386 (M + H)	2
2800	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(2-fluorobenzyl)cyclohexanecarboxamide	386 (M + H)	2
2801	cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404 (M + H)	1
2802	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	1
2803	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide	412 (M + H)	1
2804	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide	400 (M + H)	2
2805	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	416 (M + H)	1

Ex. No.	compound name	MS	class
2806	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide	494 (M + H)	1
2807	cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436 (M + H)	1
2808	cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436 (M + H)	1
2809	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarboxamide	382 (M + H)	1
2810	cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436 (M + H)	1
2811	cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	428 (M + H)	1
2812	cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	402 (M + H)	1
2813	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide	436 (M + H)	2
2814	cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	504 (M + H)	1
2815	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide	398 (M + H)	1
2816	cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	402 (M + H)	1
2817	cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	436 (M + H)	1
2818	cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404 (M + H)	1
2819	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404 (M + H)	1
2820	cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	404 (M + H)	1
2821	cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide	464 (M + H)	1
2822	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide	382 (M + H)	1
2823	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide	452 (M + H)	1
2824	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	398 (M + H)	1
2825	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dihydroxyisonicotinamide	401 (M + H)	3
2826	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)pyrazine-2-carboxamide	370 (M + H)	3
2827	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-6-hydroxynicotinamide	385 (M + H)	3
2828	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-3-carboxamide	373 (M + H)	2
2829	2-(3,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide	434 (M + H)	2

Ex. No.	compound name	MS	class
2830	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,3-oxazole-4-carboxamide	373 (M + H)	2
2831	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methylnicotinamide	383 (M + H)	3
2832	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide	429 (M + H)	1
2833	3-amino-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)pyrazine-2-carboxamide	385 (M + H)	2
2834	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-ethoxynicotinamide	413 (M + H)	3
2835	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)pyridine-2-carboxamide	369 (M + H)	3
2836	3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	393 (M + H)	1
2837	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	382 (M + H)	1
2838	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	402 (M + H)	1
2839	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	446 (M + H)	1
2840	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide	428 (M + H)	1
2841	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide	504 (M + H)	1
2842	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	436 (M + H)	1
2843	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	452 (M + H)	2
2844	4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	393 (M + H)	1
2845	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide	382 (M + H)	1
2846	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	386 (M + H)	1
2847	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	402 (M + H)	1
2848	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide	398 (M + H)	2
2849	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide	446 (M + H)	1
2850	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	436 (M + H)	1
2851	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide	412 (M + H)	3
2852	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	460 (M + H)	1
2853	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide	400 (M + H)	1

Ex. No.	compound name	MS	class
2854	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	400 (M + H)	1
2855	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide	396 (M + H)	2
2856	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide	452 (M + H)	1
2857	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide	447 (M + H)	1
2858	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylthiophene-2-carboxamide	388 (M + H)	1
2859	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-6-(trifluoromethyl)nicotinamide	437 (M + H)	2
2860	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide	456 (M + H)	1
2861	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide	412 (M + H)	1
2862	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide	426 (M + H)	1
2863	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-6-hydroxypyridine-2-carboxamide	385 (M + H)	3
2864	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	404 (M + H)	1
2865	N4,N4,5,6-tetramethyl-N2-(cis-4-{[3-(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine	438 (M + H)	3
2866	N2-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N4,N4,5,6-tetramethylpyrimidine-2,4-diamine	390 (M + H)	2
2867	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea	433 (M + H)	1
2868	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)urea	427 (M + H)	1
2869	N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea	489 (M + H)	3
2870	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-cyclopropanecarboxamide	428 (M + H)	1
2871	1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-cyclopropanecarboxamide	462 (M + H)	1
2872	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	402 (M + H)	1
2873	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)-cyclopropanecarboxamide	408 (M + H)	1
2874	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)propanamide	416 (M + H)	1

Ex. No.	compound name	MS	class
2875	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)-cyclopropanecarboxamide	424 (M + H)	1
2876	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide	418 (M + H)	1
2877	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide	414 (M + H)	1
2878	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide	452 (M + H)	1
2879	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	418 (M + H)	1
2880	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]-sulfinyl}acetamide	484 (M + H)	1
2881	2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	450 (M + H)	1
2882	2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	494 (M + H)	1
2883	2-[(3,4-difluorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	452 (M + H)	2
2884	2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	468 (M + H)	
2885	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide	461 (M + H)	1
2886	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide	465 (M + H)	1
2887	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide	477 (M + H)	1
2888	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide	477 (M + H)	1
2889	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide	573 (M + H)	1
2890	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide	477 (M + H)	1
2891	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide	465 (M + H)	1
2892	2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide	481 (M + H)	1
2893	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide	481 (M + H)	1
2894	2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide	525 (M + H)	1
2895	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]-nicotinamide	515 (M + H)	1
2896	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	422 (M + H)	1

Ex. No.	compound name	MS	class
2897	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide	372 (M + H)	1
2898	3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	432 (M + H)	1
2899	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	372 (M + H)	1
2900	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide	414 (M + H)	1
2901	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide	390 (M + H)	1
2902	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5-difluorobenzamide	390 (M + H)	1
2903	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide	408 (M + H)	1
2904	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	354 (M + H)	2
2905	4-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	410 (M + H)	1
2906	4-butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	410 (M + H)	
2907	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388 (M + H)	1
2908	3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	379 (M + H)	1
2909	4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	379 (M + H)	1
2910	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide	384 (M + H)	3
2911	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	432 (M + H)	1
2912	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	422 (M + H)	1
2913	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxybenzamide	384 (M + H)	3
2914	2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	432 (M + H)	3
2915	2-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388 (M + H)	3
2916	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-fluorobenzamide	372 (M + H)	3
2917	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylbenzamide	368 (M + H)	3
2918	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)benzamide	422 (M + H)	3
2919	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide	440 (M + H)	1
2920	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	446 (M + H)	1

Ex. No.	compound name	MS	class
2921	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide	398 (M + H)	2
2922	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	397 (M + H)	
2923	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	386 (M + H)	1
2924	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide	386 (M + H)	1
2925	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide	382 (M + H)	1
2926	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide	434 (M + H)	1
2927	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide	398 (M + H)	2
2928	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide	412 (M + H)	2
2929	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide	442 (M + H)	1
2930	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide	440 (M + H)	1
2931	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide	440 (M + H)	3
2932	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	406 (M + H)	3
2933	3,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	510 (M + H)	1
2934	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethylbenzamide	382 (M + H)	1
2935	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	402 (M + H)	1
2936	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide	452 (M + H)	1
2937	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	368 (M + H)	1
2938	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide -	384 (M + H)	1
2939	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide	368 (M + H)	1
2940	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388 (M + H)	1
2941	N-2~(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide	431 (M + H)	1
2942	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methyl-N2-(3-methylphenyl)-glycinamide	411 (M + H)	1

Ex. No.	compound name	MS	class
2943	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-fluorophenyl)-N2-methylglycinamide	415 (M + H)	1
2944	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(4-fluorophenyl)-N2-methylglycinamide	415 (M + H)	1
2945	N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide	431 (M + H)	1
2946	N2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide	433 (M + H)	1
2947	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-methoxyphenyl)-N2-methylglycinamide	427 (M + H)	1
2948	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(4-methoxyphenyl)-N2-methylglycinamide	427 (M + H)	2
2949	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide	430 (M + H)	1
2950	2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide	504 (M + H)	2
2951	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	354 (M + H)	3
2952	4-butyl-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	410 (M + H)	3
2953	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide	372 (M + H)	2
2954	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	422 (M + H)	1
2955	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide	384 (M + H)	3
2956	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxybenzamide	384 (M + H)	3
2957	3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	379 (M + H)	1
2958	4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	379 (M + H)	1
2959	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide	414 (M + H)	1
2960	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide	440 (M + H)	2
2961	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide	440 (M + H)	1
2962	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide	440 (M + H)	1
2963	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	406 (M + H)	1
2964	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide	386 (M + H)	1

Ex. No.	compound name	MS	class
2965	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide	386 (M + H)	1
2966	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	422 (M + H)	1
2967	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide	438 (M + H)	1
2968	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide	390 (M + H)	1
2969	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	446 (M + H)	1
2970	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide	382 (M + H)	3
2971	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide	398 (M + H)	3
2972	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide	422 (M + H)	2
2973	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	432 (M + H)	1
2974	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethylbenzamide	382 (M + H)	2
2975	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide	442 (M + H)	1
2976	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide	398 (M + H)	2
2977	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide	412 (M + H)	1
2978	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide	433 (M + H)	1
2979	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide	422 (M + H)	1
2980	5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide	378 (M + H)	1
2981	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide	452 (M + H)	2
2982	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide	456 (M + H)	1
2983	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide	368 (M + H)	1
2984	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide	384 (M + H)	1
2985	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide	368 (M + H)	1
2986	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388 (M + H)	1
2987	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	388 (M + H)	1
2988	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	390 (M + H)	1

Ex. No.	compound name	MS	class
2989	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	438 (M + H)	3
2990	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide	372 (M + H)	1
2991	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide	444 (M + H)	1
2992	N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide	399 (M + H)	1
2993	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide	444 (M + H)	1
2994	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide	422 (M + H)	1
2995	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzenesulfonamide	390 (M + H)	3
2996	N4,N4,5-trimethyl-N2-{cis-4-[(4-methylbenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine	354 (M + H)	3
2997	N2-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	376 (M + H)	3
2998	N2-{cis-4-[(3-chlorobenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	374 (M + H)	3
2999	N2-{cis-4-[(3-bromobenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	418 (M + H)	3
3000	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	400 (M + H)	2
3001	N2-{cis-4-[(3,5-dichlorobenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	408 (M + H)	3
3002	N2-{cis-4-[(3,4-dichlorobenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	408 (M + H)	3
3003	N2-{cis-4-[(4-methoxy-3-methylbenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine	384 (M + H)	3
3004	N4,N4,5-trimethyl-N2-(cis-4-{[3-(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine	424 (M + H)	3
3005	N4,N4,6-trimethyl-N2-(cis-4-{[3-(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine	424 (M + H)	3
3006	N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide	444 (M + H)	3
3007	N-[(1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(3-fluorophenoxy)nicotinamide	465 (M + H)	
3008	6-(3-chlorophenoxy)-N-[(1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]nicotinamide	481 (M + H)	
3009	N-[(1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(3-methoxyphenoxy)-nicotinamide	477 (M + H)	
3010	N-[(1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)-nicotinamide	477 (M + H)	

Ex. No.	compound name	MS	class
3011	N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-6-(2-fluorophenoxy)nicotinamide	465 (M + H)	
3012	2-(4-bromophenoxy)-N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)nicotinamide	525 (M + H)	2
3013	N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-2-(2-methoxyphenoxy)-nicotinamide	477 (M + H)	1
3014	2-(2-bromophenoxy)-N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)nicotinamide	525 (M + H)	3
3015	N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-2-(2-fluorophenoxy)nicotinamide	465 (M + H)	1
3016	N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-2-(4-methoxyphenoxy)-nicotinamide	477 (M + H)	
3017	N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-2-(3-fluorophenoxy)nicotinamide	465 (M + H)	3
3018	2-(3-chlorophenoxy)-N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)nicotinamide	481 (M + H)	3
3019	2-(3-chloro-4-fluorophenoxy)-N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-nicotinamide	499 (M + H)	2
3020	2-(4-chloro-3-fluorophenoxy)-N-(((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl)-nicotinamide	499 (M + H)	3
3021	N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea	417 (M + H)	1
3022	N-(3,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea	451 (M + H)	1
3023	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea	397 (M + H)	1
3024	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea	397 (M + H)	1
3025	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea	401 (M + H)	1
3026	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea	401 (M + H)	1
3027	N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea	417 (M + H)	1
3028	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea	413 (M + H)	1
3029	N'-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea	413 (M + H)	1
3030	3,4-dichloro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide	408 (M + H)	3

Example 3031**3,4-Difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride****Step A: Synthesis of (*cis*-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.**

- 5 To a suspension of *cis*-cyclohexane-1,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr. Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was
- 10 extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give (*cis*-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.
- ESI MS *m/e* 405, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.40 (m, 10 H), 5.07 (s, 4 H),
- 15 4.70-5.00 (m, 2 H), 3.52-3.80 (m, 2 H), 1.60-1.80 (m, 4 H), 1.45-1.60 (m, 4 H).

Step B: Synthesis of (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester.

- To a solution of (*cis*-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was
- 20 stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtered through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)₂O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 1.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was
- 25 dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in

MeOH (660 mL) was added a solution of (Boc)₂O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 10 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give

- 5 *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)₂O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for
- 10 3.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (5.01 g, 10% based on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a
- 15 solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)₂O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 13 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.53 g, 7% based on the
- 20 starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (11.1 g) as a colorless oil.

ESI MS *m/e* 215, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.30-4.82 (m, 1 H), 3.50-3.80 (m, 1 H), 2.78-2.95 (m, 1 H), 1.44 (s, 9H), 1.20-1.80 (m, 8 H).

25

Step C: Synthesis of (*cis*-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-carbamic acid *tert*-butyl ester.

To a solution of 3,4-difluoro-benzoic acid (4.10 g, 25.9 mmol) and (*cis*-4-amino-cyclohexyl)-

carbamic acid *tert*-butyl ester (5.05 g, 23.6 mmol) in DMF (50 mL) were added Et₃N (90 mL, 56.7 mmol), HOBt-H₂O (5.41 g, 35.3 mmol), and EDC-HCl (4.97 g, 25.9 mmol). The reaction mixture was stirred at ambient temperature for 17 hr. To the reaction mixture was added water (200 mL) and the suspension was stirred at ambient temperature for 10 min. The precipitated was collected by
5 filtration, washed with H₂O and EtOH, and dried at 80 °C under reduced pressure to give (*cis*-4-
{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-carbamic acid *tert*-butyl ester (5.20 g, 62.3%) as a white solid.
ESI MS *m/e* 377, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9 H), 1.53-1.95 (m, 8 H), 3.60-3.74 (m, 1 H), 4.00-4.16 (m, 1 H), 4.50-4.68 (m, 1 H), 5.95-6.09 (m, 1 H), 7.15-7.28 (m, 1 H), 7.43-7.68
10 (m, 2 H).

Step D: Synthesis of *N*-(*cis*-4-amino-cyclohexyl)-3,4-difluoro-benzamide.

A solution of (*cis*-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-
15 carbamic acid *tert*-butyl ester (5.20 g, 14.7 mmol) in EtOAc (52 mL) was cooled on an ice-bath and
4 M hydrogen chloride in EtOAc (104 mL) was added. The mixture was stirred at ambient
temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the
aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over
MgSO₄, filtered, concentrated, and dried at 60 °C under reduced pressure to give *N*-(*cis*-4-amino-
20 cyclohexyl)-3,4-difluoro-benzamide (3.00 g, 80%) as a white solid.
ESI MS *m/e* 255, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.15-1.52 (m, 3 H), 1.59-1.89 (m, 5 H),
2.94-3.06 (m, 1 H), 4.06-4.20 (m, 1 H), 6.01-6.18 (m, 1 H), 7.13-7.26 (m, 1 H), 7.43-7.50 (m, 1 H),
7.57-7.67 (m, 1 H).

25 Step E: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

A mixture of 2-chloro-quinoline (200 mg, 1.22 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-3,4-difluoro-benzamide (342 mg, 1.34 mmol) in butanol (1 mL) was stirred at 130 °C for

- 60 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added
- 5 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et₂O, and dried at 80 °C under reduced pressure to give 3,4-difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (189 mg, 37%) as a white solid.
- 10 ESI MS *m/e* 382, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.09 (m, 8 H), 3.96-4.24 (m, 2 H), 6.90-7.03 (m, 2 H), 7.14-7.25 (m, 1 H), 7.41-7.48 (m, 1 H), 7.57-7.64 (m, 1 H), 7.69-7.79 (m, 4 H), 8.18 (d, *J* = 9.6 Hz, 1 H), 9.73-9.76 (m, 1 H).

15 Example 3032

2-Phenoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of *N*-(*cis*-4-amino-cyclohexyl)-2-phenoxy-nicotinamide.

- To a solution of (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of
- 20 example 3031 (6.00 g, 27.8 mmol) in CHCl₃ (60 mL) was added *i*-Pr₂NEt (9.67 mL, 55.6 mmol). The mixture was cooled on an ice-bath and 2-phenoxy-nicotinoyl chloride (6.50 g, 27.8 mmol) was added. The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. To a solution of the above material
- 25 in EtOAc (100 mL) and CHCl₃ (40 mL) was added 4 M hydrogen chloride in EtOAc (100 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid

chromatography (NH-silica gel, 0.2% to 1% MeOH in CHCl₃) to give *N*-(*cis*-4-amino-cyclohexyl)-2-phenoxy-nicotinamide (3.51 g, 41%) as a pale yellow oil.

ESI MS *m/e* 312, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.39 (m, 3 H), 1.65-1.94 (m, 5 H), 2.80-2.91 (m, 1 H), 4.18-4.30 (m, 1 H), 7.13-7.22 (m, 3 H), 7.25-7.33 (m, 1 H), 7.41-7.51 (m, 2 H),
5 8.04-8.14 (m, 1 H), 8.22 (dd, *J* = 4.7, 2.1 Hz, 1 H), 8.62 (dd, *J* = 7.6, 2.0 Hz, 1 H).

Step B: Synthesis of 2-phenoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

A mixture of 2-chloro-quinoline (200 mg, 1.22 mmol) and *cis*-*N*-(4-amino-cyclohexyl)-2-phenoxy-nicotinamide (418 mg, 1.34 mmol) in butanol (1 mL) was stirred at 130 °C for
10 6 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% to 16% EtOAc in hexane). To a solution of the above material in EtOAc (10 mL) was added
15 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 2-phenoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride (138 mg, 37%) as a white solid.

20 ESI MS *m/e* 461, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.87-2.10 (m, 8 H), 3.83-3.97 (m, 1 H) 4.12-4.24 (m, 1 H), 6.90 (d, *J* = 9.5 Hz, 1 H), 7.12 (dd, *J* = 7.6, 4.5 Hz, 1 H), 7.20-7.32 (m, 3 H), 7.37-7.50 (m, 3 H), 7.66-7.80 (m, 3 H), 7.95 (d, *J* = 7.0 Hz, 1 H) 8.13 (d, *J* = 9.6 Hz, 1 H), 8.21 (dd, *J* = 4.6, 2.2 Hz, 1 H), 8.53 (dd, *J* = 7.6, 1.9 Hz, 1 H), 9.77-9.92 (m, 1 H).

25

Example 3033

3-Methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine.

A mixture of 2-chloro-quinoline (16.0 g, 97.8 mol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (23.0 g, 107.5 mol) in butanol (16 mL) was stirred at 130 °C for 3 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the
5 aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (160 mL) was added 4 M hydrogen chloride in EtOAc (80 mL). The mixture was stirred at ambient temperature for 12 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the
10 aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 5% MeOH in CHCl₃) to give *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine (6.30 g, 27%) as pale yellow solid.

ESI MS *m/e* 242, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.53 (m, 4 H), 1.65-1.93 (m, 6 H),
15 2.84-2.98 (m, 1 H), 4.04-4.16 (m, 1 H), 4.78-4.91 (m, 1 H), 6.61 (d, *J* = 9.0 Hz, 1 H), 7.17 (ddd, *J* = 8.0, 6.9, 1.2 Hz, 1 H), 7.46-7.58 (m, 2 H), 7.61-7.66 (m, 1 H), 7.79 (d, *J* = 8.9 Hz, 1 H).

Step B: Synthesis of 3-methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

20 To a solution of *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine (300 mg, 1.24 mmol) in CHCl₃ (2 mL) were added *i*-Pr₂NEt (0.45 mL, 2.60 mmol) and 3-methyl-benzoyl chloride (210 mg, 1.36 mmol) in CHCl₃ (1 mL). The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by
25 medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The

precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 3-methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (294 mg, 60%) as a white solid.

ESI MS *m/e* 382, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.07 (m, 8 H), 2.40 (s, 3 H),
5 3.93-4.04 (m, 1 H), 4.08-4.26 (m, 1 H), 6.49-6.58 (m, 1 H), 6.94 (d, *J* = 9.5 Hz, 1 H), 7.25-7.32 (m, 2 H), 7.40-7.48 (m, 1 H), 7.56-7.66 (m, 2 H), 7.67-7.81 (m, 3 H) 8.17 (d, *J* = 9.5 Hz, 1 H), 9.74-9.87 (m, 1 H).

10 Example 3034

3-Methoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

15 Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS *m/e* 398, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.09 (m, 8 H), 3.86 (s, 3 H),
3.94-4.06 (m, 1 H), 4.08-4.25 (m, 1 H), 6.63 (d, *J* = 8.6 Hz, 1 H), 6.91-7.05 (m, 2 H), 7.28-7.48 (m,
4 H), 7.68-7.80 (m, 3 H), 8.17 (d, *J* = 9.3 Hz, 1 H), 9.75-9.84 (m, 1 H).

20

Example 3035

3-Chloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide

25 **hydrochloride.**

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS *m/e* 402, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.10 (m, 8 H), 3.96-4.07 (m,
1 H), 4.09-4.26 (m, 1 H), 6.75 (d, *J* = 7.8 Hz, 1 H), 6.96 (d, *J* = 9.3 Hz, 1 H), 7.33-7.49 (m, 3 H),

7.66-7.79 (m, 4 H), 7.83-7.88 (m, 1 H), 8.19 (d, $J = 9.3$ Hz, 1 H), 9.80 (d, $J = 8.5$ Hz, 1 H).

Example 3036

5 5-Nitro-thiophene-3-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

10 To a solution of 5-nitro-thiophene-3-carboxylic acid (516 mg, 2.98 mmol) and *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (600 mg, 2.48 mmol) in DMF (6 mL) were added Et₃N (0.83 mL, 5.95 mmol), HOBt-H₂O (570 mg, 3.72 mmol), and EDC-HCl (571 g, 2.98 mmol). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature
15 for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% to 50% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the
20 suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 5-nitro-thiophene-3-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride (329 mg, 60%) as a yellow solid. ESI MS *m/e* 419, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.18 (m, 8 H), 3.96-4.25 (m, 2 H), 6.97 (d, $J = 9.3$ Hz, 1 H), 7.39-7.53 (m, 2 H), 7.67-7.80 (m, 3 H), 8.20 (d, $J = 9.4$ Hz, 1 H),
25 8.26-8.30 (m, 1 H), 8.39-8.42 (m, 1 H), 9.59 (d, $J = 8.6$ Hz, 1 H).

Example 3037**2-Chloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride****Step A: Synthesis of 2-chloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide****5 hydrochloride.**

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 403, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.84-2.17 (m, 8 H), 3.93-4.05 (m, 1 H), 4.13-4.30 (m, 1 H), 6.89-7.02 (m, 2 H), 7.30-7.50 (m, 2 H), 7.67-7.81 (m, 3 H), 7.96 (d, *J* = 7.5 Hz, 1 H), 8.19 (d, *J* = 9.6 Hz, 1 H), 8.44-8.50 (m, 1 H), 9.73-9.87 (m, 1 H).

10

Example 3038**3-Chloro-4-fluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride****15 Step A: Synthesis of 3-chloro-4-fluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.**

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS *m/e* 420, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.08 (m, 8 H), 3.95-4.06 (m, 1 H), 4.07-4.23 (m, 1 H), 6.68-6.78 (m, 1 H), 6.95 (d, *J* = 9.6 Hz, 1 H), 7.18 (t, *J* = 8.6 Hz, 1 H),
20 7.41-7.48 (m, 1 H), 7.68-7.79 (m, 4 H), 7.95 (dd, *J* = 7.0, 2.2 Hz, 1 H), 8.18 (d, *J* = 9.6 Hz, 1 H), 9.79 (d, *J* = 8.4 Hz, 1 H).

Example 3039**25 3,5-Dimethoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride****Step A: Synthesis of 3,5-dimethoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.**

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 428, M (free) + Na⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.14 (m, 8 H), 3.85 (s, 6 H), 3.95-4.26 (m, 2 H), 6.53-6.66 (m, 2 H), 6.89-7.01 (m, 3 H), 7.40-7.51 (m, 1 H), 7.68-7.82 (m, 3 H), 8.18 (d, *J* = 9.6 Hz, 1 H), 9.76-9.85 (m, 1 H).

5

Example 3040

3,4-Dichloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

10 **Step A: Synthesis of 3,4-dichloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.**

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 436, M (free) + Na⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.15 (m, 8 H), 3.98-4.25 (m, 2 H), 6.87-7.00 (m, 2 H), 7.42-7.52 (m, 2 H), 7.65-7.80 (m, 4 H), 7.98 (d, *J* = 2.0 Hz, 1 H), 8.19 (d, 15 *J* = 9.5 Hz, 1 H), 9.87 (d, *J* = 8.6 Hz, 1 H).

Example 3041

Benzo[2,1,3]oxadiazole-5-carboxylic acid-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide

20 **hydrochloride**

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

25 ESI MS m/e 388, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.23 (m, 8 H), 3.98-4.31 (m, 2 H), 6.97 (d, *J* = 9.5 Hz, 1 H), 7.38-7.50 (m, 2 H), 7.70-7.78 (m, 3 H), 7.88 (ddd, *J* = 14.3, 9.3, 1.2 Hz, 2 H), 8.20 (d, *J* = 9.5 Hz, 1 H), 8.41 (t, *J* = 1.2 Hz, 1 H), 9.75 (d, *J* = 8.1 Hz, 1 H).

Example 3042

1-Methyl-4-nitro-1*H*-pyrrole-2-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

5

Step A: Synthesis of 1-methyl-4-nitro-1*H*-pyrrole-2-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 394, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.14 (m, 8 H), 3.91-4.15 (m, 5 H), 6.96 (d, *J* = 9.4 Hz, 1 H), 7.09 (d, *J* = 9.0 Hz, 1 H), 7.28-7.31 (m, 1 H), 7.41-7.54 (m, 2 H), 7.67-7.79 (m, 3 H), 8.19 (d, *J* = 9.6 Hz, 1 H), 9.66 (m, 1 H).

Example 3043

15 **9*H*-Xanthene-9-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride**

Step A: Synthesis of 9*H*-Xanthene-9-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

20 ESI MS *m/e* 472, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-1.89 (m, 8 H), 3.76-3.94 (m, 2 H), 5.99-6.09 (m, 1 H), 6.87 (d, *J* = 10.1 Hz, 1 H), 7.05-7.18 (m, 4 H), 7.24-7.47 (m, 5 H), 7.65-7.79 (m, 3 H), 8.13 (d, *J* = 9.6 Hz, 1 H), 9.62 (d, *J* = 7.6 Hz, 1 H).

25 **Example 3044**

5-(4-Chloro-phenyl)-furan-2-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Step A: Synthesis of 5-(4-chloro-phenyl)-furan-2-carboxylic acid[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 468, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.13 (m, 8 H), 3.93-4.07 (m, 1 H), 4.10-4.28 (m, 1 H), 6.65-7.03 (m, 3 H), 7.12-7.23 (m, 1 H), 7.32-7.52 (m, 3 H), 7.63-7.85 (m, 5 H), 8.12-8.26 (m, 1 H), 9.74-9.94 (m, 1 H).

Example 3045

10 3-Nitro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-nitro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

15 ESI MS *m/e* 413, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.30 (m, 8 H), 3.99-4.10 (m, 1 H), 4.13-4.31 (m, 1 H), 6.97 (d, *J* = 9.5 Hz, 1 H), 7.24-7.33 (m, 1 H), 7.42-7.51 (m, 1 H), 7.63 (t, *J* = 7.9 Hz, 1 H), 7.70-7.79 (m, 3 H), 8.17-8.24 (m, 2 H), 8.30-8.35 (m, 1 H), 8.75-8.77 (m, 1 H), 9.76 (d, *J* = 7.3 Hz, 1 H).

20

Example 3046

4-Fluoro-3-methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-fluoro-3-methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-

25 **benzamide hydrochloride.**

To a solution of *cis-N*-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (250 mg, 1.04 mmol) in CHCl₃ (5 mL) were added Et₃N (0.3 mL, 2.15 mmol) and 4-fluoro-3-methyl-benzoyl chloride (197 mg, 1.14 mmol). The mixture was stirred at ambient

temperature for 12 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M
5 hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 6 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give 4-fluoro-3-methyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (363 mg, 85%) as a white solid.

10 ESI MS *m/e* 400, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.10 (m, 8 H), 2.32 (d, *J* = 1.9 Hz, 3 H), 3.96-4.07 (m, 1 H), 4.09-4.27 (m, 1 H), 6.62-6.72 (m, 1 H), 6.96 (d, *J* = 9.5 Hz, 1 H), 7.04 (t, *J* = 8.9 Hz, 1 H), 7.40-7.51 (m, 1 H), 7.61-7.83 (m, 5 H) 8.19 (d, *J* = 9.6 Hz, 1 H), 9.71-9.85 (m, 1 H).

15

Example 3047**3-Bromo-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride****Step A: Synthesis of 3-bromo-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide**20 **hydrochloride.**

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS *m/e* 446, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8 H), 3.96-4.08 (m, 1 H), 4.09-4.27 (m, 1 H), 6.84 (d, *J* = 7.8 Hz, 1 H), 6.96 (d, *J* = 9.6 Hz, 1 H), 7.30 (t, *J* = 7.9 Hz, 1 H), 7.41-7.50 (m, 1 H), 7.57-7.64 (m, 1 H), 7.69-7.80 (m, 4 H), 8.01 (t, *J* = 1.6 Hz, 1 H), 8.19 (d, *J*
25 = 9.3 Hz, 1 H), 9.71 (m, 1 H).

Example 3048

2-(2-Bromo-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride**Step A: Synthesis of 2-(2-bromo-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.**

5 To a solution of 2-bromo-phenol (453 mg, 2.62 mmol) in DMA (4 mL) was added 60% NaH in oil (210 mg, 5.24 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide obtained in step A of example 3037 (1.00 g, 2.62 mmol) in DMA (2 mL). The mixture was stirred at 120 °C for 3 hr and the reaction was quenched with water. The aqueous layer was extracted with CHCl₃ (three times). The
10 combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 1% to 2% MeOH in CHCl₃) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at
15 ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 2-(2-bromo-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride (262 mg, 18%) as a white solid.

ESI MS *m/e* 517, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.89-2.17 (m, 8 H), 3.81-3.98 (m, 1 H), 4.14-4.30 (m, 1 H), 6.92 (d, *J* = 9.5 Hz, 1 H), 7.11-7.20 (m, 2 H), 7.34-7.47 (m, 3 H), 7.63-7.80
20 (m, 4 H), 7.92-8.00 (m, 1 H), 8.10-8.20 (m, 2 H), 8.54 (dd, *J* = 7.5, 2.0 Hz, 1 H), 9.71-9.88 (m, 1 H).

Example 3049**3-Cyano-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride**

25

Step A: Synthesis of 3-cyano-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 393, $M(\text{free}) + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.80-2.17 (m, 8 H), 3.98-4.30 (m, 2 H), 6.97 (d, $J = 9.3$ Hz, 1 H), 7.07-7.18 (m, 1 H), 7.42-7.50 (m, 1 H) 7.56 (t, $J = 7.8$ Hz, 1 H), 7.70-7.80 (m, 4 H), 8.08 (d, $J = 7.9$ Hz, 1 H), 8.17-8.25 (m, 2 H), 9.69-9.84 (m, 1 H).

5

Example 3050

N-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide

10 **hydrochloride.**

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 436, $M(\text{free}) + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.77-2.13 (m, 8 H), 3.97-4.09 (m, 1 H), 4.12-4.33 (m, 1 H), 6.92-7.05 (m, 2 H), 7.41-7.50 (m, 1 H), 7.57 (t, $J = 7.7$ Hz, 1 H), 7.69-7.79 (m, 4 H), 8.02 (d, $J = 8.1$ Hz, 1 H), 8.13-8.26 (m, 2 H), 9.72-9.85 (m, 1 H).

15

Example 3051

N-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-acetamide hydrochloride

20 **Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-acetamide hydrochloride.**

To a solution of *m*-tolylloxy-acetic acid (189 mg, 1.14 mmol) and *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3036 (250 mg, 1.04 mmol) in DMF (15 mL) were added Et_3N (0.35 mL, 2.50 mmol), $\text{HOBT} \cdot \text{H}_2\text{O}$ (238 mg, 1.56 mmol), and $\text{EDC} \cdot \text{HCl}$ (219 g, 1.14 mmol). The reaction mixture was stirred at ambient temperature for 13 hr. To the reaction mixture was added water (30 mL) and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 1% to 5% MeOH in CHCl_3) to give a colorless oil.

25

To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to
5 give *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-acetamide hydrochloride (140 mg, 32%) as a white solid.

ESI MS *m/e* 412, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.06 (m, 8 H), 2.33 (s, 3 H), 3.88-4.12 (m, 2 H), 4.44 (s, 2 H), 6.72-6.96 (m, 5 H), 7.18 (t, *J* = 8.0 Hz, 1 H), 7.39-7.47 (m, 1 H), 7.68-7.81 (m, 3 H), 8.17 (d, *J* = 9.3 Hz, 1 H), 9.72-9.89 (m, 1 H).

10

Example 3052

2,2-Diphenyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

15 **Step A: Synthesis of 2,2-diphenyl-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.**

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS *m/e* 458, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-1.97 (m, 8 H), 3.84-4.10 (m, 2 H), 4.87 (s, 1 H), 6.16-6.25 (m, 1 H), 6.90 (d, *J* = 9.5 Hz, 1 H), 7.20-7.36 (m, 10 H), 7.39-7.48 (m,
20 1 H), 7.67-7.79 (m, 3 H), 8.15 (d, *J* = 9.2 Hz, 1 H), 9.63-9.77 (m, 1 H).

Example 3053

5-Bromo-furan-2-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

25

Step A: Synthesis of 5-bromo-furan-2-carboxylic acid [*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 436, $M(\text{free}) + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.84-2.09 (m, 8 H), 3.92-4.18 (m, 2 H), 6.42 (d, $J = 3.5$ Hz, 1 H), 6.61 (d, $J = 8.6$ Hz, 1 H), 6.95 (d, $J = 8.2$ Hz, 1 H), 7.05 (d, $J = 3.5$ Hz, 1 H), 7.42-7.48 (m, 1 H), 7.69-7.83 (m, 3 H), 8.19 (d, $J = 9.5$ Hz, 1 H), 9.85 (d, $J = 8.6$ Hz, 1 H).

5

Example 3054**2-(4-Fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride****Step A: 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester.**

10 To a solution of 2-fluoro-phenol (3.02 g, 26.9 mmol) in DMA (20 mL) was added 60% NaH in oil (1.08 mg, 26.9 mmol). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added 2-chloro-nicotinic acid ethyl ester (5.00 g, 26.9 mmol) in DMA (5 mL). The mixture was stirred at 120 °C for 2 hr and the reaction was quenched with saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried
15 over MgSO_4 , filtered, and concentrated. The residue was suspended in 10% Et_2O in hexane (50 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with hexane, and dried at 70 °C under reduced pressure to give 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester (3.08 g, 44%) as a white solid.
ESI MS m/e 284, $M + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.40 (td, $J = 7.1, 1.6$ Hz, 3 H), 4.41 (qd,
20 $J = 7.1, 1.6$ Hz, 2 H), 6.99-7.21 (m, 5 H), 8.23-8.29 (m, 2 H).

Step B: Synthesis of 2-(4-fluoro-phenoxy)-nicotinic acid.

To a solution of 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester (3.00 g, 11.5 mmol) in EtOH (90 mL) was added 2 M aqueous NaOH (6 mL). The mixture was stirred at ambient temperature for
25 4 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, and concentrated. The residue was suspended in 10% Et_2O in hexane (80 mL) and the suspension was stirred at ambient temperature for 1 hr. The

precipitate was collected by filtration, washed with hexane, and dried at 70 °C under reduced pressure to give 2-(4-fluoro-phenoxy)-nicotinic acid (2.39 g, 89%) as a white solid.

ESI MS m/e 233, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.05-7.25 (m, 5 H), 8.32 (dd, J = 4.8, 2.0 Hz, 1 H), 8.49 (dd, J = 7.6, 2.0 Hz, 1 H).

5

Step C: Synthesis of 2-(4-fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 479, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.83-2.14 (m, 8 H), 3.88-4.01 (m, 10 1 H), 4.13-4.30 (m, 1 H), 6.93 (d, J = 9.3 Hz, 1 H), 7.11-7.20 (m, 3 H), 7.25-7.31 (m, 2 H), 7.43 (t, J = 7.9 Hz, 1 H), 7.67-7.81 (m, 3 H), 7.93 (d, J = 7.2 Hz, 1 H), 8.16 (d, J = 9.2 Hz, 1 H), 8.21 (dd, J = 4.8, 2.0 Hz, 1 H), 8.54 (dd, J = 7.6, 2.0 Hz, 1 H), 9.81-9.94 (m, 1 H).

15 Example 3055

2-(3,4-Difluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenoxy)-nicotinic acid.

20 To a solution of 3,4-difluoro-phenol (3.77 g, 28.9 mmol) in DMA (20 mL) was added 60% NaH in oil (1.16 mg, 28.9 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-nicotinic acid ethyl ester (5.36 g, 28.9 mmol) in DMA (5 mL). The mixture was stirred at 120 °C for 2.5 hr and the reaction was quenched with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer
25 was dried over $MgSO_4$, filtered, and concentrated. The residue was suspended in 10% Et_2O in hexane (150 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitate was filtered, washed with hexane, and dried at 70 °C under reduced pressure to give a white solid. To a solution of the above material in EtOH (150 mL) was added 2 M aqueous NaOH (15.2 mL). The mixture was

stirred at ambient temperature for 12 hr. To the mixture was added 1 M aqueous HCl (46 mL, pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 10% Et₂O in hexane (150 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with hexane, and dried at 70 °C under reduced pressure to give 2-(3,4-difluoro-phenoxy)-nicotinic acid (4.85 g, 67) as a white solid.

ESI MS *m/e* 251, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 6.90-7.30 (m, 4 H), 8.30-8.35 (m, 1 H), 8.46-8.52 (m, 1 H).

10

Step B: Synthesis of 2-(3,4-difluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 475, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.13 (m, 8 H), 3.91-4.03 (m, 1 H), 4.13-4.29 (m, 1 H), 6.94 (d, *J* = 9.6 Hz, 1 H), 7.11-7.34 (m, 4 H), 7.40-7.47 (m, 1 H), 7.67-7.85 (m, 4 H), 8.17 (d, *J* = 9.5 Hz, 1 H), 8.22 (dd, *J* = 4.8, 2.0 Hz, 1 H), 8.53 (dd, *J* = 7.6, 2.0 Hz, 1 H), 9.84-9.98 (m, 1 H).

20 **Example 3056**

***N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-2-*p*-tolylxy-nicotinamide hydrochloride**

Step A: Synthesis of 2-*p*-tolylxy-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS *m/e* 229, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.40 (s, 3 H) 7.05-7.31 (m, 5 H), 8.30-8.35 (m, 1 H), 8.52-8.57 (m, 1 H).

Step B: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-2-*p*-tolylxy-nicotinamide

hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 475, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.86-2.13 (m, 3 H), 2.36 (s, 3 H),
3.86-3.98 (m, 1 H), 4.11-4.29 (m, 1 H), 6.86-7.00 (m, 1 H), 7.07-7.31 (m, 5 H), 7.43 (t, $J = 7.6$ Hz,
5 1 H), 7.64-7.82 (m, 3 H), 7.92-8.28 (m, 3 H), 8.53 (d, $J = 7.0$ Hz, 1 H), 9.74-9.87 (m, 1 H).

Example 3057**2-(4-Chloro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride**

10

Step A: Synthesis of 2-(4-chloro-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 250, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.10-7.21 (m, 3 H), 7.36-7.45 (m, 2 H),
8.30-8.36 (m, 1 H), 8.45-8.51 (m, 1 H).

15

Step B: Synthesis of 2-(4-chloro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 473, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.83-2.13 (m, 8 H), 3.87-4.04 (m, 1 H),
20 4.10-4.33 (m, 1 H), 6.87-7.01 (m, 1 H), 7.10-7.35 (m, 3 H), 7.38-7.50 (m, 3 H), 7.65-7.93 (m, 4 H),
8.10-8.26 (m, 2 H), 8.53 (d, $J = 6.4$ Hz, 1 H), 9.78-9.97 (m, 1 H).

Example 3058**25 2-(4-Bromo-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride****Step A: 2-(4-bromo-phenoxy)-nicotinic acid**

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 294, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.05-7.12 (m, 2 H), 7.18 (dd, $J = 7.6, 4.8$ Hz, 1 H), 7.52-7.62 (m, 2 H), 8.31-8.35 (m, 1 H), 8.48 (dd, $J = 7.6, 2.0$ Hz, 1 H).

5 Step B: Synthesis of 2-(4-bromo-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 517, $M(\text{free}) + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.80-2.11 (m, 8 H), 3.87-4.02 (m, 1 H), 4.12-4.30 (m, 1 H), 6.86-7.01 (m, 1 H), 7.09-7.29 (m, 3 H), 7.38-7.48 (m, 1 H), 7.51-7.62 (m, 2 H), 7.64-7.93 (m, 4 H), 8.11-8.25 (m, 2 H), 8.53 (d, $J = 7.6$ Hz, 1 H), 9.78-9.96 (m, 1 H).

Example 3059

**2-(4-Methoxy-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-
15 nicotinamide hydrochloride**

Step A: Synthesis of 2-(4-methoxy-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 245, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 6.94-7.01 (m, 2 H), 7.09-7.20 (m, 3 H),
20 8.31-8.35 (m, 1 H), 8.50-8.55 (m, 1 H).

Step B: Synthesis of 2-(4-methoxy-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

25 ESI MS m/e 491, $M(\text{free}) + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.85-2.12 (m, 8 H), 3.81 (brs, 3 H), 3.86-3.99 (m, 1 H), 4.12-4.30 (m, 1 H), 6.84-7.29 (m, 6 H), 7.37-7.49 (m, 1 H), 7.64-7.82 (m, 3 H), 7.96-8.28 (m, 3 H), 8.48-8.60 (m, 1 H), 9.71-9.86 (m, 1 H).

Example 3060

2-(3-Chloro-4-fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

5

Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 268, $M + H^+$; 1H NMR (200 MHz, $CDCl_3$) δ 7.03-7.32 (m, 4 H), 8.29-8.37 (m, 1 H), 8.44-8.53 (m, 1 H).

10

Step B: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 491, $M(\text{free}) + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.83-2.10 (m, 8 H), 3.88-4.04 (m, 1
15 H), 4.11-4.27 (m, 1 H), 6.92 (d, $J = 9.6$ Hz, 1 H) 7.16 (dd, $J = 7.6, 4.8$ Hz, 1 H), 7.21-7.46 (m, 4 H),
7.67-7.81 (m, 4 H), 8.15 (d, $J = 9.5$ Hz, 1 H), 8.20 (dd, $J = 4.8, 2.0$ Hz, 1 H), 8.52 (dd, $J = 7.6, 2.0$
Hz, 1 H), 9.83-9.95 (m, 1 H).

20 **Example 3061**

***N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-nicotinamide hydrochloride**

Step A: Synthesis of 2-*m*-tolylloxy-nicotinic acid

Using the procedure for the step A of example 3055, the title compound was obtained.

25 ESI MS m/e 229, M^+ ; 1H NMR (200 MHz, $CDCl_3$) δ 2.40 (s, 3 H), 6.95-7.41 (m, 5 H), 8.33 (dd, J
= 4.8, 1.8 Hz, 1 H), 8.54 (dd, $J = 7.7, 1.9$ Hz, 1 H).

Step B: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-nicotinamide

hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 475, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.87-2.07 (m, 8 H), 2.40 (s, 3 H), 3.85-3.98 (m, 1 H), 4.10-4.25 (m, 1 H), 6.88-6.99 (m, 1 H), 7.01-7.18 (m, 4 H), 7.33 (t, $J = 7.8$ Hz, 1 H), 7.42 (t, $J = 7.5$ Hz, 1 H), 7.66-7.81 (m, 3 H), 7.93-8.03 (m, 1 H), 8.12-8.20 (m, 1 H), 8.23 (dd, $J = 4.7, 1.9$ Hz, 1 H), 8.52 (dd, $J = 7.5, 1.9$ Hz, 1 H), 9.71-9.83 (m, 1 H).

Example 3062**10 2-(3-Methoxy-phenoxy)-N-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride****Step A: Synthesis of (3-methoxy-phenoxy)-acetic acid ethyl ester.**

To a solution of 3-methoxy-phenol (3.54 g, 28.5 mmol) in DMA (20 mL) was added 60% NaH in oil (1.14 g, 28.5 mmol). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added bromo-acetic acid ethyl ester (4.53 g, 28.5 mmol) in DMA (10 mL). The mixture was stirred at ambient temperature for 1.5 hr and the reaction was quenched with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (3-methoxy-phenoxy)-acetic acid ethyl ester (5.19 g, 91%) as a colorless oil.

ESI MS m/e 233, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.30 (t, $J = 7.1$ Hz, 3 H), 3.79 (s, 3 H), 4.27 (q, $J = 7.1$ Hz, 2 H), 4.60 (s, 2 H), 6.44-6.61 (m, 3 H), 7.15-7.23 (m, 1 H).

Step B: Synthesis of (3-methoxy-phenoxy)-acetic acid.

To a solution of (3-methoxy-phenoxy)-acetic acid ethyl ester (5.06 g, 24.1 mmol) in EtOH (100 mL) was added 1 M aqueous NaOH (25.3 mL). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with $CHCl_3$ (three times). The combined

organic layer was dried over MgSO_4 , filtered, and concentrated to give (3-methoxy-phenoxy)-acetic acid (4.05 g, 92%) as a white solid.

ESI MS m/e 182, M^+ ; ^1H NMR (300 MHz, DMSO-d_6) δ 3.73 (s, 3 H), 4.65 (s, 2 H), 6.45-6.57 (m, 3 H), 7.13-7.23 (m, 1 H), 12.97 (brs, 1 H).

5

Step C: Synthesis of 2-(3-methoxy-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 406, $M(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.79-2.05 (m, 8 H), 3.82 (s, 3 H),
10 3.90-4.11 (m, 2 H), 4.46 (s, 2 H), 6.52-6.61 (m, 3 H), 6.80-6.87 (m, 1 H), 6.93 (d, $J = 9.5$ Hz, 1 H),
7.16-7.24 (m, 1 H), 7.41-7.48 (m, 1 H), 7.69-7.82 (m, 3 H), 8.17 (d, $J = 9.5$ Hz, 1 H) 9.78-9.88 (m, 1 H).

15 Example 3063

2-(3-Chloro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of (3-chloro-phenoxy)-acetic acid ethyl ester.

Using the procedure for the step A of example 3062, the title compound was obtained.

20 ESI MS m/e 237, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.30 (t, $J = 7.2$ Hz, 3 H), 4.28 (q, $J = 7.2$ Hz, 2 H), 4.60 (s, 2 H), 6.73-7.02 (m, 3 H), 7.14-7.30 (m, 1 H).

Step B: Synthesis of (3-chloro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

25 ESI MS m/e 187, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 4.73 (d, $J = 1.2$ Hz, 2 H), 6.87-6.94 (m, 1 H), 6.98-7.05 (m, 2 H), 7.27-7.35 (m, 1 H), 13.07 (s, 1 H).

Step C: Synthesis of 2-(3-chloro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-

acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 410, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.78-2.07 (m, 8 H), 3.90-4.14 (m, 2 H), 4.45 (s, 2 H) 6.74-6.84 (m, 1 H), 6.86-7.03 (m, 4 H), 7.20-7.29 (m, 1 H), 7.40-7.49 (m, 1 H),
5 7.69-7.82 (m, 3 H), 8.18 (d, $J=9.3$ Hz, 1 H), 9.79-9.93 (m, 1 H).

Example 3064**2-(3-Chloro-4-fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide****10 hydrochloride****Step A: Synthesis of (3-chloro-4-fluoro-phenoxy)-acetic acid ethyl ester.**

Using the procedure for the step A of example 3062, the title compound was obtained.

ESI MS m/e 233, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.30 (t, $J=7.1$ Hz, 3 H), 4.28 (q, $J=7.1$
15 Hz, 2 H), 4.58 (s, 2 H), 6.75-6.82 (m, 1 H), 6.95 (dd, $J=5.9, 3.1$ Hz, 1 H), 7.01-7.11 (m, 1 H).

Step B: Synthesis of (3-chloro-4-fluoro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

ESI MS m/e 205, $M + H^+$; 1H NMR (300 MHz, $DMSO-d_6$) δ 4.72 (s, 2 H), 6.92-6.97 (m, 1 H), 7.17
20 (dd, $J=6.1, 3.1$ Hz, 1 H), 7.34 (t, $J=9.1$ Hz, 1 H), 13.08 (brs, 1 H).

Step C: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

25 ESI MS m/e 450, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.76-2.08 (m, 8 H), 3.91-4.13 (m, 2 H), 4.42 (s, 2 H), 6.73-6.97 (m, 3 H), 7.00-7.14 (m, 2 H), 7.41-7.49 (m, 1 H), 7.70-7.80 (m, 3 H), 8.18 (d, $J=9.5$ Hz, 1 H), 9.79-9.90 (m, 1 H).

Example 3065**2-(3,4-Dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride****5 Step A: Synthesis of (3,4-dichloro-phenoxy)-acetic acid ethyl ester.**

Using the procedure for the step A of example 3062, the title compound was obtained.

CI MS m/e 249, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.30 (t, $J = 7.1$ Hz, 3 H), 4.28 (q, $J = 7.1$ Hz, 2 H), 4.59 (s, 2 H), 6.78 (dd, $J = 9.0, 2.9$ Hz, 1 H), 7.01 (d, $J = 2.8$ Hz, 1 H), 7.34 (d, $J = 9.1$ Hz, 1 H).

10 Step B: Synthesis of (3,4-dichloro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

ESI MS m/e 221, $M + H^+$; 1H NMR (300 MHz, $DMSO-d_6$) δ 4.76 (s, 2 H), 6.96 (dd, $J = 8.9, 2.9$ Hz, 1 H), 7.24 (d, $J = 2.9$ Hz, 1 H), 7.53 (d, $J = 8.9$ Hz, 1 H), 13.12 (brs, 1 H).

15 Step C: Synthesis of 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 466, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.75-2.07 (m, 8 H), 3.92-4.13 (m, 2 H), 4.44 (s, 2 H), 6.78 (d, $J = 8.1$ Hz, 1 H), 6.86-6.97 (m, 2 H), 7.10 (d, $J = 2.9$ Hz, 1 H), 7.37 (d, $J = 8.9$ Hz, 1 H), 7.41-7.49 (m, 1 H), 7.67-7.82 (m, 3 H), 8.18 (d, $J = 9.5$ Hz, 1 H), 9.80-9.90 (m, 1 H).

Example 3066**25 C-(Methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride****Step A: Synthesis of (methyl-phenyl-amino)-acetic acid ethyl ester.**

To a solution of bromo-acetic acid ethyl ester (5.00 g, 29.9 mmol) in IPA (10 mL) were added *i*-Pr₂NEt (4.06 g, 31.4 mmol) and methyl-phenyl-amine (3.37 g, 31.4 mmol). The mixture was stirred at reflux for 2.5 hr and the reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄,
5 filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (methyl-phenyl-amino)-acetic acid ethyl ester (5.61 g, 97%) as a yellow oil. ESI MS *m/e* 216, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.24 (t, *J* = 7.1 Hz, 3 H), 3.07 (s, 3 H), 4.05 (s, 2 H), 4.17 (q, *J* = 7.1 Hz, 2 H), 6.63-6.79 (m, 3 H), 7.18-7.29 (m, 2 H).

10 Step B: Synthesis of (methyl-phenyl-amino)-acetic acid.

To a solution of (methyl-phenyl-amino)-acetic acid ethyl ester (5.48 g, 28.4 mmol) in EtOH (100 mL) was added 1 M aqueous NaOH (29.8 mL). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined
15 organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (methyl-phenyl-amino)-acetic acid (1.73 g, 37%) as a yellow oil. ESI MS *m/e* 165, *M*⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3 H), 4.07 (s, 2 H), 6.65-6.85 (m, 3 H), 7.18-7.30 (m, 2 H), 8.62 (brs, 1 H).

20

Step C: Synthesis of *C*-(methyl-phenyl-amino)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained. ESI MS *m/e* 411, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-1.99 (m, 8 H), 3.05-3.16 (m,
25 3 H), 3.79-4.02 (m, 4 H), 6.82-7.00 (m, 4 H), 7.06-7.49 (m, 5 H), 7.65-7.80 (m, 3 H), 8.15 (d, *J* = 9.9 Hz, 1 H), 9.57-9.68 (m, 1 H).

Example 3067**2-(3,4-Dichloro-phenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride****5 Step A: Synthesis of (3,4-dichloro-phenylamino)-acetic acid ethyl ester.**

Using the procedure for the step A of example 3066, the title compound was obtained.

CI MS m/e 248, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J = 7.1 Hz, 3 H), 3.85 (d, J = 5.4 Hz, 2 H), 4.26 (q, J = 7.1 Hz, 2 H), 4.33-4.42 (m, 1 H), 6.45 (dd, J = 8.7, 2.8 Hz, 1 H), 6.66 (d, J = 2.8 Hz, 1 H), 7.21 (d, J = 8.7 Hz, 1 H).

10

Step B: Synthesis of (3,4-dichloro-phenylamino)-acetic acid.

Using the procedure for the step B of example 3054, the title compound was obtained.

ESI MS m/e 220, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.84 (s, 2 H), 6.37 (brs, 1 H), 6.57 (dd, J = 8.8, 2.7 Hz, 1 H), 6.76 (d, J = 2.6 Hz, 1 H), 7.26 (d, J = 8.8 Hz, 1 H), 12.67 (brs, 1 H).

15

Step C: Synthesis of 2-(3,4-dichloro-phenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 465, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.72-2.05 (m, 8 H), 3.80 (s, 2 H),
20 3.87-4.10 (m, 2 H), 6.48-6.57 (m, 1 H), 6.73 (brs, 1 H), 6.86-7.05 (m, 2 H), 7.18 (d, J = 8.7 Hz, 1 H),
7.39-7.50 (m, 1 H), 7.66-7.80 (m, 3 H), 8.11-8.24 (m, 1 H), 9.55-9.68 (m, 1 H).

Example 3068**25 3,4-Difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride****Step A: Synthesis of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester.**

A suspension of *cis*-4-amino-cyclohexanecarboxylic acid (244 g, 1.70 mol) in MeOH (2.45

L) was cooled to -8°C . Thionyl chloride (45.0 mL, 617 mmol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in CHCl_3 (3.00 L) were added triethylamine (261 mL, 1.87 mol) and $(\text{Boc})_2\text{O}$ (409 g, 1.87 mol) successively. The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (silica gel, CHCl_3 only to 10% MeOH in CHCl_3) to give a colorless oil (531 g). To a suspension cooled at -4°C of lithium aluminum hydride (78.3 g, 2.06 mol) in Et_2O (7.9 L) was added a solution of the above oil (530.9 g) in Et_2O (5.3 L) below 0°C . The resulting suspension was stirred at ambient temperature for 2 hr. The reaction mixture was cooled on an ice-bath, quenched with cold water, and filtrated through a pad of celite. The filtrate was dried over MgSO_4 , filtrated, and concentrated. The precipitate was suspended in hexane (300 mL), filtrated, washed with hexane, and dried under reduced pressure to give (*cis*-4-hydroxymethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (301 g, 77%) as a white solid.

15 ESI MS m/e 252, $\text{M} + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.16-1.36 (m, 2 H), 1.45 (s, 9 H), 1.52-1.77 (m, 7 H), 3.51 (d, $J = 6.2$ Hz, 2 H), 3.75 (brs, 1 H), 4.30-4.82 (m, 1 H).

Step B: Synthesis of [*cis*-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester.

20 To a solution of (*cis*-4-hydroxymethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added triphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% diethyl azodicarboxylate (DEAD) in toluene (33.6 mL, 74.1 mmol) was added over 1 hr. The reaction mixture was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash

25 chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of the above solid (27.5 g) in EtOH (275 mL) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHCl_3 (three times). The

combined organic layer was dried over MgSO_4 , filtrated, and concentrated. To a solution of the above residue in CHCl_3 (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0 °C and ZnCl_2 (14.4 g, 84.4 mmol) was added below 5 °C. The reaction mixture was stirred at ambient temperature for 16 hr and poured into saturated aqueous NaHCO_3 . The aqueous layer was
5 extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCl_3) to give [*cis*-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (25.3 g, 91%) as a colorless oil.

ESI MS m/e 385, $M + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.13-1.31 (m, 2 H), 1.44 (s, 9 H), 1.48-1.75
10 (m, 7 H), 3.10 (t, $J = 6.4$ Hz, 2 H), 3.72 (brs, 1 H), 4.42-4.76 (m, 1 H), 4.76-4.92 (m, 1 H), 5.09 (s, 2 H), 7.27-7.38 (m, 5 H).

Step C: Synthesis of (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of [*cis*-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid
15 *tert*-butyl ester (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtrated, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (five times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and dried under reduced pressure to give (*cis*-4-amino-
20 cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

ESI MS m/e 263, $M + \text{H}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.36-1.98 (m, 9 H), 2.96-3.32 (m, 3 H), 5.12 (brs, 3 H), 7.36 (s, 5 H).

Step D: Synthesis of (*cis*-4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine.

25 A mixture of 2-chloro-quinoline (10.0 g, 61.1 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (17.6 g, 67.2 mmol) in butanol (10 mL) was stirred at reflux for 2 days. The reaction mixture was poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 ,

filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (100 mL) was added 10% Pd/C (1.00 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by
5 medium-pressure liquid chromatography (NH-silica gel, 2% MeOH in CHCl₃) to give (*cis*-4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine (6.20 g, 40%) as a pale yellow solid.
ESI MS *m/e* 256, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.51 (m, 4 H), 1.59-1.93 (m, 5 H), 2.60 (d, *J* = 6.2 Hz, 2 H), 4.08-4.20 (m, 1 H), 4.94 (d, *J* = 7.4 Hz, 1 H), 6.65 (d, *J* = 9.0 Hz, 1 H), 7.18 (ddd, *J* = 7.9, 6.8, 1.1 Hz, 1 H) 7.47-7.59 (m, 2 H), 7.61-7.67 (m, 1 H) 7.81 (d, *J* = 8.9 Hz, 1 H).

10

Step E: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride.

To a solution of *cis*-(4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine (300 mg, 1.17 mmol) and 3,4-difluoro-benzoic acid (223 mg, 1.41 mmol) in DMF (3 mL) were added Et₃N (0.40 mL, 2.87
15 mmol), HOBT-H₂O (270 mg, 1.76 mmol), and EDC-HCl (270 mg, 1.41 mmol). The reaction mixture was stirred at ambient temperature for 16 hr. To the reaction mixture was added water (20 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added
20 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 2 hr, filtered, washed with Et₂O, and dried at 80 °C under reduced pressure to give 3,4-difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride (390 mg, 77%) as a white solid.

ESI MS *m/e* 418, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.08 (m, 9 H), 3.48-3.56 (m, 2 H), 3.98-4.09 (m, 1 H), 6.92-7.07 (m, 2 H), 7.18-7.29 (m, 1 H), 7.39-7.47 (m, 1 H), 7.67-7.76 (m, 3 H), 7.81-7.93 (m, 2 H), 8.15 (d, *J* = 9.6 Hz, 1 H), 9.86-9.95 (m, 1 H).

25

Example 3069**2-Phenoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide hydrochloride**

Step A: Synthesis of 2-phenoxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide hydrochloride.

Using the procedure for the step E of example 3068, the title compound was obtained.

ESI MS *m/e* 475, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-2.02 (m, 9 H), 3.42-3.52 (m, 2 H), 3.91-4.05 (m, 1 H), 6.91 (d, *J* = 9.5 Hz, 1 H), 7.10-7.20 (m, 3 H), 7.23-7.31 (m, 1 H), 7.38-7.50 (m, 3 H), 7.65-7.82 (m, 3 H), 8.06-8.17 (m, 2 H), 8.20 (dd, *J* = 4.7, 2.0 Hz, 1 H) 8.60 (dd, *J* = 7.7, 1.9 Hz, 1 H), 9.65-9.78 (m, 1 H).

Example 3070***N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

15

Step A: Synthesis of *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine.

A mixture of 2-Chloro-4-methyl-quinoline (10.0 g, 56.3 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (13.3 g, 62.1 mmol) in IPA (10 mL) was stirred at reflux for 7 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (150 mL) was added 4 M hydrogen chloride in EtOAc (150 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (3.41 g, 24%) as pale yellow solid.

ESI MS m/e 256, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.19-1.55 (m, 4 H), 1.67-1.94 (m, 4 H), 2.56 (s, 3 H), 2.85-2.98 (m, 1 H), 4.03-4.15 (m, 1 H), 4.77 (d, $J = 6.8$ Hz, 1 H), 6.49 (s, 1 H), 7.17-7.25 (m, 1 H), 7.47-7.55 (m, 1 H), 7.62-7.68 (m, 1 H), 7.72-7.77 (m, 1 H).

5 Step B: Synthesis of *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (300 mg, 1.17 mmol) in $CHCl_3$ (2 mL) were added Et_3N (0.45 mL, 2.60 mmol) and 2-phenoxy-nicotinoyl chloride (411 mg, 1.76 mmol) in $CHCl_3$ (1 mL). The mixture was stirred at ambient temperature for 14 hr. The reaction was quenched with saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et_2O , and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (85 mg, 15%) as a white solid.

ESI MS m/e 453, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.85-2.12 (m, 8 H), 2.70 (s, 3 H), 3.83-4.00 (m, 1 H), 4.11-4.28 (m, 1 H), 6.74 (s, 1 H), 7.08-7.18 (m, 1 H), 7.19-7.34 (m, 3 H), 7.38-7.53 (m, 3 H), 7.63-7.85 (m, 3 H), 7.91-7.99 (m, 1 H), 8.20-8.24 (m, 1 H), 8.54 (d, $J = 7.4$ Hz, 1 H).

25 Example 3071

3,4-Difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of 3,4-difluoro-benzoic acid (222 mg, 1.40 mmol) and *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in DMF (3 mL) were added Et₃N (0.39 mL, 2.80 mmol), HOBT-H₂O (268 mg, 1.76 mmol), and EDC-HCl (268 g, 1.40 mmol). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give a yellow oil. To a solution of the above material in EtOAc (8 mL) was added 4 M hydrogen chloride in EtOAc (0.5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 3,4-difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (377 mg, 75%) as a white solid.

ESI MS *m/e* 396, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.17 (m, 8 H), 2.73 (s, 3 H), 3.95-4.26 (m, 2 H), 6.71 (d, *J* = 7.1 Hz, 1 H), 6.79 (s, 1 H), 7.14-7.28 (m, 1 H), 7.41-7.51 (m, 1 H), 7.54-7.64 (m, 1 H), 7.66-7.79 (m, 3 H), 7.85 (d, *J* = 8.2 Hz, 1 H), 9.57-9.67 (m, 1 H).

Example 3072

1-(2,3-Dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride.

To a solution of *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-

benzene (242 mg, 1.29 mmol). The mixture was stirred at ambient temperature for 5 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane) and flash chromatography (silica gel, 2% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above
5 material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride (421 mg, 68%) as a white solid.

10 ESI MS *m/e* 465, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.76-2.17 (m, 8 H), 2.70 (s, 3 H), 3.69-4.08 (m, 2 H), 6.65-6.83 (m, 2 H), 6.95-7.17 (m, 2 H), 7.41 (t, *J* = 8.1 Hz, 1 H), 7.54-7.89 (m, 4 H), 8.05-8.17 (m, 1 H), 9.13-9.27 (m, 1 H).

15 Example 3073

3-Chloro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

20 To a solution of *N*-(*cis*-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in CHCl₃ (3 mL) were added Et₃N (0.35 mL, 2.51 mmol) and 3-chloro-benzoyl chloride (226 mg, 1.29 mmol). The mixture was stirred at ambient temperature for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered,
25 concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature

for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give 3-chloro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (441 mg, 87%) as a white solid.

ESI MS *m/e* 416, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.11 (m, 8 H), 2.72 (s, 3 H),
5 3.92-4.29 (m, 2 H), 6.78 (s, 1 H), 6.94 (d, *J* = 9.0 Hz, 1 H), 7.33-7.50 (m, 3 H), 7.68-7.76 (m, 3 H),
7.83-7.88 (m, 2 H), 9.58 (d, *J* = 9.0 Hz, 1 H).

Example 3074

10 5-Nitro-thiophene-3-carboxylic acid [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

15 Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS *m/e* 411, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.14 (m, 8 H), 2.73 (s, 3 H),
3.97-4.26 (m, 2 H), 6.79 (s, 1 H), 7.41-7.57 (m, 2 H), 7.68-7.76 (m, 2 H), 7.85 (d, *J* = 8.2 Hz, 1 H),
8.26 (d, *J* = 1.4 Hz, 1 H), 8.38 (d, *J* = 1.4 Hz, 1 H), 9.41 (d, *J* = 9.0 Hz, 1 H).

20

Example 3075

3-Methyl-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methyl-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide
25 **hydrochloride.**

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS *m/e* 374, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.10 (m, 8 H), 2.41 (s, 3 H), 2.72
(d, *J* = 0.8 Hz, 3 H), 3.94-4.05 (m, 1 H), 4.08-4.25 (m, 1 H), 6.62 (d, *J* = 8.1 Hz, 1 H), 6.78 (s, 1 H),

7.28-7.36 (m, 2 H), 7.42-7.49 (m, 1 H), 7.58-7.66 (m, 2 H), 7.67-7.79 (m, 2 H), 7.84 (d, $J = 8.1$ Hz, 1 H), 9.62 (d, $J = 8.1$ Hz, 1 H).

5 Example 3076

3-Methoxy-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methoxy-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

- 10 Using the procedure for the step B of example 3070, the title compound was obtained.
- ESI MS m/e 390, $M(\text{free}) + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.66-2.10 (m, 8 H), 2.72 (s, 3 H), 3.87 (s, 3 H), 3.94-4.26 (m, 2 H), 6.69-6.81 (m, 2 H), 6.99-7.07 (m, 1 H), 7.28-7.51 (m, 4 H), 7.66-7.79 (m, 2 H), 7.84 (d, $J = 7.9$ Hz, 1 H), 9.55-9.68 (m, 1 H).

15

Example 3077

4-Cyano-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-cyano-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide

20 **hydrochloride.**

- Using the procedure for the step B of example 3070, the title compound was obtained.
- ESI MS m/e 385, $M(\text{free}) + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.79-2.16 (m, 8 H), 2.73 (d, $J = 0.9$ Hz, 3 H), 3.99-4.29 (m, 2 H), 6.79 (s, 1 H), 7.20-7.28 (m, 1 H), 7.42-7.51 (m, 1 H), 7.69-7.76 (m, 4 H), 7.86 (d, $J = 8.2$ Hz, 1 H), 7.95-8.02 (m, 2 H), 9.54 (d, $J = 8.9$ Hz, 1 H).

25

Example 3078

3,4-Dichloro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Using the procedure for the step B of example 3070, the title compound was obtained.

- 5 ESI MS m/e 428, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.80-2.14 (m, 8 H), 2.73 (d, J = 0.6 Hz, 3 H), 3.95-4.24 (m, 2 H), 6.75-6.87 (m, 2 H), 7.42-7.52 (m, 2 H), 7.64-7.76 (m, 3 H), 7.85 (d, J = 8.2 Hz, 1 H), 7.98 (d, J = 1.9 Hz, 1 H), 9.60 (d, J = 7.9 Hz, 1 H).

10 **Example 3079**

3-Chloro-4-fluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-4-fluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-

15 **benzamide hydrochloride.**

Using the procedure for the step B of example 3070, the title compound was obtained.

- ESI MS m/e 412, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.79-2.14 (m, 8 H), 2.73 (d, J = 0.8 Hz, 3 H), 3.96-4.26 (m, 2 H), 6.70-6.82 (m, 2 H), 7.18 (t, J = 8.6 Hz, 1 H), 7.42-7.51 (m, 1 H), 7.68-7.78 (m, 3 H), 7.85 (d, J = 8.2 Hz, 1 H), 7.96 (dd, J = 7.0, 2.2 Hz, 1 H), 9.61 (d, J = 8.4 Hz, 1 H).
- 20 H).

Example 3080

4-Fluoro-3-methyl-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide
25 **hydrochloride**

Step A: Synthesis of 4-fluoro-3-methyl-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 414, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-2.10 (m, 8 H), 2.33 (d, *J* = 1.9 Hz, 3 H), 2.72 (s, 3 H), 3.95-4.25 (m, 2 H), 6.45-6.54 (m, 1 H), 6.78 (s, 1 H), 7.00-7.08 (m, 1 H), 7.42-7.50 (m, 1 H), 7.60-7.80 (m, 4 H), 7.84 (d, *J* = 8.6 Hz, 1 H), 9.58-9.70 (m, 1 H).

5

Example 3081

1-Methyl-4-nitro-1*H*-pyrrole-2-carboxylic acid-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

10

Step A: Synthesis of 1-methyl-4-nitro-1*H*-pyrrole-2-carboxylic acid- [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 408, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.11 (m, 8 H), 2.72 (s, 3 H), 3.94-4.14 (m, 5 H), 6.77 (s, 1 H), 7.09-7.16 (m, 1 H), 7.26-7.29 (m, 1 H), 7.41-7.55 (m, 2 H), 7.67-7.78 (m, 2 H), 7.84 (d, *J* = 8.2 Hz, 1 H), 9.51-9.63 (m, 1 H).

15

Example 3082

9*H*-Xanthene-9-carboxylic acid-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

20

Step A: Synthesis of 9*H*-xanthene-9-carboxylic acid [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

25

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 486, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-1.91 (m, 8 H), 2.68 (s, 3 H), 3.75-3.97 (m, 2 H), 4.88 (s, 1 H), 6.14-6.27 (m, 1 H), 6.69 (brs, 1 H), 7.03-7.18 (m, 4 H), 7.23-7.49 (m, 5 H), 7.62-7.86 (m, 3 H), 9.34-9.47 (m, 1 H).

Example 3083

**5-Bromo-furan-2-carboxylic acid-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-
amide hydrochloride**

Step A: Synthesis of 5-bromo-furan-2-carboxylic acid [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

10 ESI MS m/e 428, $M(\text{free}) + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.62-2.08 (m, 8 H), 2.72 (s, 3 H), 3.90-4.19 (m, 2 H), 6.42 (d, $J = 3.6$ Hz, 1 H), 6.67-6.80 (m, 2 H), 7.05 (d, $J = 3.6$ Hz, 1 H), 7.41-7.51 (m, 1 H), 7.67-7.81 (m, 2 H), 7.85 (d, $J = 8.4$ Hz, 1 H), 9.59-9.72 (m, 1 H).

15 **Example 3084**

***N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-acetamide hydrochloride**

Step A: Synthesis of *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-acetamide hydrochloride.

20 Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 426, $M(\text{free}) + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.75-2.07 (m, 8 H), 2.34 (s, 3 H), 2.72 (s, 3 H), 3.86-4.14 (m, 2 H), 4.46 (s, 2 H), 6.70-6.95 (m, 5 H), 7.15-7.24 (m, 1 H), 7.41-7.50 (m, 1 H), 7.67-7.88 (m, 3 H), 9.58-9.69 (m, 1 H).

25

Example 3085

Benzo[2,1,3]oxadiazole-5-carboxylic acid-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid [*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

- 5 ESI MS *m/e* 402, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.28 (m, 8 H), 2.73 (s, 3 H), 3.98-4.11 (m, 1 H), 4.12-4.32 (m, 1 H), 6.79 (s, 1 H), 7.37-7.50 (m, 2 H), 7.71 (s, 1 H), 7.72 (s, 1 H), 7.81-7.96 (m, 3 H), 8.40 (s, 1 H), 9.56 (d, *J* = 8.7 Hz, 1 H).

10 **Example 3086**

3-Bromo-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-bromo-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

- 15 Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS *m/e* 438, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8 H), 2.72 (s, 3 H), 3.96-4.06 (m, 1 H), 4.08-4.26 (m, 1 H), 6.75-6.85 (m, 2 H), 7.26-7.34 (m, 1 H), 7.42-7.50 (m, 1 H), 7.57-7.64 (m, 1 H), 7.66-7.79 (m, 3 H), 7.85 (d, *J* = 8.2 Hz, 1 H), 8.01 (s, 1 H), 9.55-9.66 (m, 1 H).

20

Example 3087

3-Cyano-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-cyano-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-

- 25 **benzamide hydrochloride.**

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS *m/e* 385, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.18 (m, 8 H), 2.73 (s, 3 H), 3.98-4.29 (m, 2 H), 6.80 (s, 1 H), 7.13-7.22 (m, 1 H), 7.43-7.60 (m, 2 H), 7.68-7.79 (m, 3 H), 7.85 (d,

$J = 8.1$ Hz, 1 H), 8.08 (d, $J = 7.2$ Hz, 1 H), 8.22 (s, 1 H), 9.49-9.62 (m, 1 H).

Example 3088

5 *N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride.

10 Using the procedure for the step A of example 3073, the title compound was obtained.
ESI MS m/e 428, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.81-2.14 (m, 8 H), 2.73 (s, 3 H), 3.95-4.09 (m, 1 H), 4.12-4.31 (m, 1 H), 6.79 (s, 1 H), 6.85-6.99 (m, 1 H), 7.43-7.50 (m, 1 H), 7.57 (t, $J = 7.8$ Hz, 1 H), 7.64-7.79 (m, 3 H), 7.85 (d, $J = 8.2$ Hz, 1 H), 8.01 (d, $J = 7.8$ Hz, 1 H), 8.15 (s, 1 H), 9.56-9.68 (m, 1 H).

15

Example 3089

N-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide hydrochloride

20 **Step A: Synthesis of *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide hydrochloride.**

Using the procedure for the step A of example 3073, the title compound was obtained.
ESI MS m/e 472, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.56-2.10 (m, 8 H), 2.51-2.87 (m, 3 H), 3.81-4.16 (m, 2 H), 4.94 (s, 1 H), 6.40-6.88 (m, 2 H), 7.17-7.51 (m, 11 H), 7.63-7.89 (m, 3 H),
25 9.44 (brs, 1 H).

Example 3090

2-(4-Fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 493, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.12 (m, 8 H), 2.71 (s, 3 H), 3.87-4.00 (m, 1 H), 4.11-4.30 (m, 1 H), 6.76 (brs, 1 H), 7.09-7.21 (m, 3 H), 7.24-7.35 (m, 2 H), 7.44 (t, J = 7.1 Hz, 1 H), 7.65-7.99 (m, 4 H), 8.19-8.25 (m, 1 H), 8.54 (d, J = 6.2 Hz, 1 H), 9.60-9.73 (m, 1 H).

Example 3091

2-(3,4-Difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 511, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8 H), 2.71 (s, 3 H), 3.90-4.03 (m, 1 H), 4.13-4.30 (m, 1 H), 6.76 (s, 1 H), 7.10-7.51 (m, 5 H), 7.65-7.88 (m, 4 H), 8.18-8.27 (m, 1 H), 8.50-8.58 (m, 1 H), 9.67-9.81 (m, 1 H).

Example 3092

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-

nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 489, $M(\text{free}) + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.83-2.15 (m, 8 H), 2.36 (s, 3 H),
2.71 (s, 3 H), 3.78-4.03 (m, 1 H), 4.10-4.32 (m, 1 H), 6.67-6.84 (m, 1 H), 7.06-7.51 (m, 6 H),
5 7.62-7.90 (m, 3 H), 7.95-8.08 (m, 1 H), 8.19-8.30 (m, 1 H), 8.48-8.61 (m, 1 H), 9.62 (brs, 1 H).

Example 3093

2-(4-Chloro-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide

10 **hydrochloride**

Step A: Synthesis of 2-(4-chloro-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

15 ESI MS m/e 487, $M(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.58-2.13 (m, 8 H), 2.71 (s, 3 H),
3.87-4.02 (m, 1 H), 4.10-4.31 (m, 1 H), 6.75 (brs, 1 H), 7.15 (dd, $J = 7.5, 4.8$ Hz, 1 H), 7.22-7.33 (m,
2 H), 7.37-7.49 (m, 3 H), 7.64-7.92 (m, 4 H), 8.21 (dd, $J = 4.8, 2.0$ Hz, 1 H), 8.53 (dd, $J = 7.6, 2.0$
Hz, 1 H), 9.63-9.78 (m, 1 H).

20

Example 3094

2-(4-Bromo-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide

hydrochloride

25 **Step A: Synthesis of 2-(4-bromo-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.**

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 531, $M(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.81-2.20 (m, 8 H), 2.72 (s, 3 H),

3.83-4.31 (m, 2 H), 6.66-6.85 (m, 1 H), 7.03-7.93 (m, 10 H), 8.16-8.28 (m, 1 H), 8.46-8.61 (m, 1 H), 9.55-9.61 (m, 1 H).

5 Example 3095

2-(4-Methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-

10 cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 483, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.84-2.19 (m, 8 H), 2.71 (s, 3 H), 3.74-4.00 (m, 4 H), 4.12-4.28 (m, 1 H), 6.68-6.82 (m, 1 H), 6.91-7.30 (m, 5 H), 7.38-7.50 (m, 1 H), 7.63-7.88 (m, 3 H), 7.96-8.09 (m, 1 H), 8.17-8.33 (m, 1 H), 8.48-8.61 (m, 1 H), 9.50-9.70 (m, 1 H).

15

Example 3096

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

20

Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 505, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.13 (m, 8 H), 2.71 (s, 3 H), 25 3.89-4.02 (m, 1 H), 4.13-4.29 (m, 1 H), 6.76 (brs, 1 H), 7.17 (dd, J = 7.6, 4.8 Hz, 1 H), 7.22-7.49 (m, 4 H), 7.65-7.87 (m, 4 H), 8.21 (dd, J = 4.8, 2.0 Hz, 1 H), 8.52 (dd, J = 7.6, 2.0 Hz, 1 H), 9.65-9.77 (m, 1 H).

Example 3097

***N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-nicotinamide hydrochloride**

5 Step A: Synthesis of *N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-*m*-tolylloxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 467, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.85-2.10 (m, 8 H), 2.40 (s, 3 H), 2.70 (s, 3 H), 3.84-3.98 (m, 1 H), 4.10-4.24 (m, 1 H), 6.76 (brs, 1 H), 7.00-7.21 (m, 4 H), 7.28-7.48 (m, 2
10 H), 7.62-7.87 (m, 3 H), 7.94-8.06 (m, 1 H), 8.21-8.29 (m, 1 H), 8.53 (d, $J = 6.4$ Hz, 1 H), 9.51-9.64 (m, 1 H).

Example 3098

15 2-(3-Methoxy-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3-methoxy-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

20 Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 442, M (free) + Na^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.71-2.06 (m, 8 H), 2.72 (s, 3 H), 3.82 (s, 3 H), 3.89-4.11 (m, 2 H), 4.46 (s, 3 H), 6.52-6.61 (m, 3 H), 6.75 (s, 1 H) 6.84-6.92 (m, 1 H), 7.16-7.24 (m, 1 H), 7.41-7.49 (m, 1 H), 7.67-7.80 (m, 1 H), 7.84 (d, $J = 8.2$ Hz, 1 H), 9.57-9.70 (m,
1 H).

25

Example 3099

2-(3-Chloro-phenoxy)-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide

hydrochloride

Step A: Synthesis of 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

5 Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 446, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.06 (m, 8 H), 2.72 (s, 3 H), 3.91-4.13 (m, 2 H), 4.45 (s, 2 H), 6.73-7.03 (m, 5 H), 7.19-7.28 (m, 1 H), 7.41-7.50 (m, 1 H), 7.67-7.87 (m, 3 H), 9.58-9.72 (m, 1 H).

10

Example 3100

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

15 **Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.**

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 464, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.70-2.07 (m, 8 H), 2.72 (s, 3 H), 3.91-4.14 (m, 2 H), 4.42 (s, 2 H), 6.76 (s, 1 H), 6.83-6.95 (m, 2 H), 6.99-7.16 (m, 2 H), 7.42-7.50 (m, 20 1 H), 7.67-7.80 (m, 2 H), 7.84 (d, J = 7.9 Hz, 1 H), 9.59-9.70 (m, 1 H).

Example 3101

2-(3,4-Dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide
25 **hydrochloride**

Step A: Synthesis of 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 480, $M(\text{free}) + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.78-2.13 (m, 8 H), 2.72 (s, 3 H), 3.91-4.14 (m, 2 H), 4.44 (s, 2 H), 6.76 (brs, 1 H), 6.84-6.93 (m, 2 H), 7.09 (d, $J = 2.8$ Hz, 1 H), 7.37 (d, $J = 8.9$ Hz, 1 H), 7.42-7.49 (m, 1 H), 7.67-7.80 (m, 2 H), 7.84 (d, $J = 8.1$ Hz, 1 H), 9.54-9.72 (m, 1 H).

Example 3102

C-(Methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 403, $M(\text{free}) + \text{H}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.67-1.99 (m, 8 H), 2.70 (s, 3 H), 3.11 (s, 3 H), 3.76-4.06 (m, 4 H), 6.63-7.01 (m, 4 H), 7.08-7.50 (m, 4 H), 7.60-7.92 (m, 3 H), 9.34-9.51 (m, 1 H).

Example 3103

2-(3,4-Dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of 2-(3,4-dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 479, $M(\text{free}) + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.75-2.02 (m, 8 H), 2.71 (s, 3 H), 3.74-4.08 (m, 4 H), 6.45-6.56 (m, 1 H), 6.67-6.78 (m, 2 H), 7.04-7.19 (m, 2 H), 7.39-7.50 (m, 1 H),

7.62-7.87 (m, 3 H), 9.31-9.46 (m, 1 H).

Example 3104

5 3,4-Difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride

Step A: Synthesis of (*cis*-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine.

A mixture of 2-chloro-4-methyl-quinoline (10.0 g, 56.3 mmol) and (*cis*-4-amino-
10 cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (17.7 g, 67.6 mmol) in butanol (10 mL) was stirred at reflux for 5 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by
medium-pressure liquid chromatography (NH-silica gel, 10% to 20% EtOAc in hexane and silica gel,
15 2% to 10% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above oil in MeOH (140 mL) was added 10% Pd/C (1.40 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 10% MeOH in CHCl₃) to give (*cis*-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine (5.74 g, 38%) as a pale yellow
20 solid.

ESI MS *m/e* 470, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.14-1.51 (m, 4 H), 1.60-1.94 (m, 5 H), 2.56 (s, 3 H), 2.60 (d, *J* = 6.4 Hz, 2 H), 4.08-4.22 (m, 1 H), 4.82-4.92 (m, 1 H), 6.52 (s, 1 H), 7.17-7.24 (m, 1 H), 7.47-7.54 (m, 1 H), 7.62-7.67 (m, 1 H), 7.72-7.77 (m, 1 H).

25 Step B: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride.

To a solution of (*cis*-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine (300 mg, 0.90 mmol) in CHCl₃ (2 mL) were added *i*-Pr₂NEt (0.33 mL, 1.89 mmol) and 3,4-difluoro-benzoyl

chloride (175 mg, 0.99 mmol) in CHCl_3 (1 mL). The mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 25% EtOAc in
5 hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et_2O , and dried at 60 °C under reduced pressure to give 3,4-difluoro-*N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-
10 cyclohexylmethyl]-benzamide hydrochloride (289 mg, 72%) as a white solid.
ESI MS m/e 432, $\text{M}(\text{free}) + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.56-2.05 (m, 9 H), 2.70 (s, 3 H), 3.49-3.54 (m, 2 H), 3.97-4.09 (m, 1 H), 6.75 (s, 1 H), 6.89-6.98 (m, 1 H), 7.19-7.30 (m, 1 H), 7.40-7.47 (m, 1 H), 7.66-7.75 (m, 2 H), 7.79-7.93 (m, 3 H), 9.72-9.85 (m, 1 H).

15

Example 3105

***N*-[*cis*-4-(4-Methyl-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide
hydrochloride**

20 **Step A: Synthesis of *N*-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.**

Using the procedure for the step C of example 3104, the title compound was obtained.

ESI MS m/e 467, $\text{M}(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.61-2.14 (m, 9 H), 2.69 (s, 3 H), 3.42-3.50 (m, 2 H), 3.92-4.04 (m, 1 H), 6.73 (brs, 1 H), 7.10-7.32 (m, 4 H), 7.38-7.49 (m, 3 H),
25 7.64-7.84 (m, 3 H), 8.06-8.15 (m, 1 H), 8.19-8.24 (m, 1 H), 8.57-8.63 (m, 1 H), 9.49-9.62 (m, 1 H).

Example 3106

1-(2,3-Dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of (*cis*-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine obtained in step B of example 3014 (300 mg, 1.11 mmol) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (230 mg, 1.22 mmol). The mixture was stirred at ambient temperature for 21 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (247 mg, 45%) as a white solid.

ESI MS *m/e* 479, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.51-2.18 (m, 9 H), 2.71 (d, *J* = 0.8 Hz, 3 H), 3.37-3.44 (m, 2 H), 4.04-4.14 (m, 1 H), 6.78 (s, 1 H), 6.89-7.13 (m, 3 H), 7.42-7.50 (m, 1 H), 7.70-7.76 (m, 2 H), 7.84 (d, *J* = 8.1 Hz, 1 H), 8.13-8.22 (m, 2 H), 9.38 (d, *J* = 9.2 Hz, 1 H), 13.95 (brs, 1 H).

Example 3107

***N*-[*cis*-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

Step A: Synthesis of 5,6,7,8-tetrahydro-quinazoline-2,4-diol.

To a solution of 2-oxo-cyclohexanecarboxylic acid ethyl ester (61.5 g, 361 mmol) in EtOH

(61.5 mL) was added urea (73.8 g, 1.23 mol). The mixture was stirred at reflux for 10.5 days and stirred at ambient temperature for 30 min. The precipitate was filtrated, washed with acetone, and dried. A suspension of the above solid in H₂O(100 mL) stirred on an ice-bath for 1 hr. The precipitate was filtrated, washed with hexane, and dried under reduced pressure to give

5 5,6,7,8-tetrahydro-quinazoline-2,4-diol (21.0 g, 35%) as a pale yellow solid.

CI MS m/e 167, M + H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.48-1.71 (m, 4 H), 2.09-2.19 (m, 2 H), 2.24-2.34 (m, 2 H), 10.41-10.98 (m, 2 H).

Step B: Synthesis of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine.

10 A suspension of 5,6,7,8-tetrahydro-quinazoline-2,4-diol (20.9 g, 100 mmol) in POCl₃ (105 mL) was stirred at reflux for 2 hr and the reaction mixture was concentrated. The residue was poured into ice water. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. To the solution of residue (7.00 g) in THF (70 mL) was added 50% aqueous Me₂NH (7.77 g, 86.2 mmol) and the mixture stirred at ambient
15 temperature for 2 hr. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (silica gel, 20% EtOAc in hexane) to give (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (6.08 g, 64%) as a white solid.
ESI MS m/e 234, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-1.90 (m, 4 H), 2.59 (t, J = 6.0 Hz, 2
20 H), 2.76 (t, J = 6.6 Hz, 2 H), 3.06 (s, 6 H).

Step C: Synthesis of (cis-4-amino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of (cis-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (75.0 g, 350 mmol) in CHCl₃ (750 mL) were added Et₃N (53.7 mL, 385 mmol) and
25 benzyl chloroformate (55 mL, 385 mmol). The mixture was stirred at ambient temperature for 20 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by flash chromatography (silica gel, 0.4% to 5% MeOH in CHCl₃) to give a pale yellow oil.

To a solution of the residue in EtOAc (200 mL) was added 4 M hydrogen chloride in EtOAc (200 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl_3 (three time). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified flash chromatography (silica gel, 25% to 50% EtOAc in hexane) to give (*cis*-4-amino-cyclohexyl)-carbamic acid benzyl ester (37.6 g, 43%) as a pale brown oil.

ESI MS m/e 249, $\text{M}^+ + \text{H}^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.13-1.83 (m, 8 H), 2.77-2.97 (m, 1 H), 3.63-3.83 (m, 1 H), 4.92-5.20 (m, 3 H), 7.25-7.47 (m, 5 H).

10 Step D: Synthesis of N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

A mixture of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (16.0 g, 75.7 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid benzyl ester (18.8 g, 75.7 mmol) in butanol (21 mL) was stirred at reflux for 6 days. The reaction mixture was poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three-times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (270 mL) was added 10% Pd/C (2.70 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl_3) to give N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine (15.8 g, 72%) as a pale yellow solid.

FAB MS m/e 290, $\text{M}^+ + \text{H}^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.00-1.90 (m, 14 H), 2.49 (t, $J = 5.9$ Hz, 2 H), 2.61 (t, $J = 6.6$ Hz, 2 H), 2.71-3.00 (m, 7 H), 3.93-4.07 (m, 1 H), 4.67-4.80 (m, 1 H).

25

Step E: Synthesis of N -[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

To a solution of N^2 -(*cis*-4-amino-cyclohexyl)- N^4,N^4 -dimethyl-5,6,7,8-tetrahydro-

quinazolin-2,4-diamine (300 mg, 1.04 mmol) in CHCl_3 (3 mL) were added Et_3N (0.31 mL, 2.22 mmol) and 2-phenoxy-nicotinoyl chloride (266 mg, 1.14 mmol). The mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 ,
5 filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et_2O , and dried at 80 °C under
10 reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (159 mg, 29%) as a white solid.
ESI MS m/e 487, $\text{M}(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.61-1.98 (m, 12 H), 2.54 (t, $J = 5.9$ Hz, 2 H), 2.74 (t, $J = 6.5$ Hz, 2 H), 3.20 (s, 6 H), 4.02-4.20 (m, 2 H), 7.12 (dd, $J = 7.5, 4.8$ Hz, 1 H), 7.21-7.30 (m, 3 H), 7.42-7.50 (m, 2 H), 7.87-7.93 (m, 1 H), 8.21 (dd, $J = 4.8, 2.2$ Hz, 1 H), 8.25-8.32
15 (m, 1 H), 8.52 (dd, $J = 7.6, 2.0$ Hz, 1 H), 13.18 (s, 1 H).

Example 3108

3-Chloro-*N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-
20 4-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

25 ESI MS m/e 468, $\text{M}(\text{free}) + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.61-2.00 (m, 12 H), 2.51-2.61 (m, 2 H), 2.68-2.81 (m, 2 H), 3.23 (s, 6 H), 4.02-4.26 (m, 2 H), 6.73-6.90 (m, 1 H), 7.13-7.23 (m, 1 H), 7.65-7.82 (m, 1 H), 7.96 (d, $J = 6.8$ Hz, 1 H), 8.22-8.44 (m, 1 H), 12.63-12.89 (m, 1 H).

Example 3109

N-[*cis*-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride

5

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS *m/e* 448, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.60-2.04 (m, 12 H), 2.27-2.36 (m, 3 H), 2.50-2.61 (m, 2 H), 2.65-2.84 (m, 2 H), 3.23 (s, 6 H), 4.03-4.27 (m, 2 H), 6.42-6.58 (m, 1 H), 6.96-7.11 (m, 1 H), 7.56-7.75 (m, 2 H), 8.25-8.47 (m, 1 H).

10

Example 3110

N-[*cis*-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride

15

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

20

ESI MS *m/e* 476, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.04 (m, 12 H), 2.51-2.62 (m, 2 H), 2.66-2.86 (m, 2 H), 3.23 (s, 6 H), 3.85 (s, 6 H), 4.04-4.27 (m, 2 H), 6.50-6.70 (m, 2 H), 6.95 (brs, 2 H), 8.19-8.47 (m, 1 H).

25

Example 3111

Benzo[2,1,3]oxadiazole-5-carboxylic acid- [*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid- [*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

5 ESI MS *m/e* 458, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.01 (m, 12 H), 2.56 (t, *J* = 5.8 Hz, 2 H), 2.71 (t, *J* = 6.5 Hz, 2 H), 3.23 (s, 6 H), 4.04-4.27 (m, 2 H), 7.71 (d, *J* = 8.2 Hz, 1 H), 7.85 (dd, *J* = 9.5, 1.1 Hz, 1 H), 7.91-7.96 (m, 1 H), 8.27 (d, *J* = 8.1 Hz, 1 H), 8.42 (t, *J* = 1.2 Hz, 1 H).

10 Example 3112

***N*-[*cis*-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3-nitro-benzamide hydrochloride**

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-

15 **2-ylamino)-cyclohexyl]-3-nitro-benzamide hydrochloride.**

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS *m/e* 461, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.04 (m, 12 H), 2.50-2.85 (m, 4 H), 3.24 (s, 6 H), 4.11-4.29 (m, 2 H), 7.04-7.20 (m, 1 H), 7.56-7.68 (m, 1 H), 8.13-8.38 (m, 3 H), 8.72-8.79 (m, 1 H).

20

Example 3113

***N*-[*cis*-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride**

25

Step A: Synthesis of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

A mixture of (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C

of example 3068 (3.10 g, 11.8 mmol) and (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 3107 (2.00 g, 9.44 mmol) in butanol (3 mL) was stirred at reflux for 19 hr. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, 5 concentrated, and purified by flash chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil (2.48 g) in MeOH (25 mL) was added 10% Pd/C (248 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 8 hr. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give N²-(*cis*-4-aminomethyl- 10 cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine (1.70 g, 59%) as a pale yellow solid.

FAB MS m/e 304, M (free) + H⁺

Step B: Synthesis of N-[*cis*-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)- 15 cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 501, M (free) + H⁺

Example 3114

20 N-[*cis*-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of 2,4-dichloro-quinoline.

A suspension of quinoline-2,4-diol (150 g, 931 mmol) in POCl₃ (975 mL, 10.4 mol) was 25 stirred at reflux for 6 hr and the reaction mixture was concentrated. The residue was diluted with CHCl₃ (500 mL) and the solution was poured into ice water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 20% EtOAc in hexane) to give 2,4-dichloro-quinoline

(177 g, 96%) as a pale brown solid.

EI MS m/e 197, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.50 (s, 1 H), 7.65 (ddd, $J = 8.3, 7.0, 1.3$ Hz, 1 H), 7.79 (ddd, $J = 8.5, 7.0, 1.3$ Hz, 1 H), 8.00-8.06 (m, 1 H), 8.16-8.21 (m, 1 H).

5 Step B: Synthesis of (2-chloro-quinolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-quinoline (177 g, 894 mmol) in THF (2.1 L) was added 50% aqueous Me_2NH (234 mL, 2.23 mol). The mixture was stirred at ambient temperature for 68 hr. To the mixture was added 50% aqueous Me_2NH (47 mL, 448 mmol) and stirred at ambient temperature for 3 hr. The solution was poured into saturated aqueous $NaHCO_3$ and the aqueous layer was
10 extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtrated, concentrated, and purified by flash chromatography (NH-silica, 1% to 3% EtOAc in hexane) to give (2-chloro-quinolin-4-yl)-dimethyl-amine (75.9 g, 41%) as a pale yellow oil and (4-chloro-quinolin-2-yl)-dimethyl-amine (28.0 g, 15%) as a pale yellow oil.

(2-chloro-quinolin-4-yl)-dimethyl-amine;

15 ESI MS m/e 207, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 3.06 (s, 6 H), 6.71 (s, 1 H), 7.45 (ddd, $J = 8.4, 7.0, 1.2$ Hz, 1 H), 7.63 (ddd, $J = 8.4, 6.9, 1.5$ Hz, 1 H), 7.91-7.93 (m, 1 H), 7.97-8.03 (m, 1 H).

(4-chloro-quinolin-2-yl)-dimethyl-amine;

ESI MS m/e 207, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 3.18 (s, 6 H), 6.97 (brs, 1 H), 7.18-7.31 (m, 1 H), 7.49-7.63 (m, 1 H), 7.66-7.72 (m, 1 H), 7.95-8.00 (m, 1 H).

20

Step C: Synthesis of N^2 -(*cis*-4-amino-cyclohexyl)- N^4, N^4 -dimethyl-quinoline-2,4-diamine.

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine (15.6 g, 75.7 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid benzyl ester obtained in step C of example 3107 (18.8 g, 75.7 mmol) in butanol (20 mL) was stirred at reflux for 6 days. The reaction mixture was poured into
25 saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (170 mL) was added 10% Pd/C (1.70 g). The mixture was stirred at ambient

temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine (11.7 g, 55%) as a pale yellow solid.

- 5 FAB MS *m/e* 285, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.19-1.96 (m, 10 H), 2.81-3.03 (m, 7 H), 4.02-4.17 (m, 1 H), 4.66-4.83 (m, 1 H), 6.03 (s, 1 H), 7.06-7.21 (m, 1 H), 7.39-7.52 (m, 1 H), 7.55-7.67 (m, 1 H), 7.80-7.90 (m, 1 H).

Step D: Synthesis of *N*-[*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-

10 2-phenoxy-nicotinamide hydrochloride.

- To a solution of *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine (300 mg, 1.05 mmol) in CHCl₃ (3 mL) were added Et₃N (0.31 mL, 2.22 mmol) and 2-phenoxy-nicotinoyl chloride (271 mg, 1.16 mmol). The mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three
15 times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by
20 filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (160 mg, 29%) as a white solid.

- ESI MS *m/e* 482, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.15 (m, 8 H), 3.21 (s, 6 H), 3.73-3.88 (m, 1 H), 4.06-4.27 (m, 1 H), 5.79 (s, 1 H), 7.12 (dd, *J* = 7.6, 4.8 Hz, 1 H), 7.19-7.33 (m, 4 H), 7.41-7.71 (m, 4 H), 7.81-7.97 (m, 2 H), 8.21 (dd, *J* = 4.8, 2.0 Hz, 1 H), 8.52 (dd, *J* = 7.6, 2.0 Hz, 1 H), 8.94-9.08 (m, 1 H), 13.81 (brs, 1 H).

Example 3115***N*-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride****Step A: Synthesis of *N*-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-****5 nicotinamide hydrochloride.**

A mixture of 2,4-dichloro-quinoline obtained in step A of example 3114 (1.5 g, 7.57 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 2 (2.3 g, 7.57 mmol) in butanol (2 mL) was stirred at 130 °C for 3 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times).

10 The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil.

To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The

15 precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (295 mg, 8%) as a white solid and *N*-[*cis*-4-(2-chloro-quinolin-4-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (283 mg, 7%) as a white solid.

N-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride;

20 ESI MS *m/e* 495, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.86-2.10 (m, 8 H), 3.82-3.96 (m, 1 H), 4.13-4.28 (m, 1 H), 7.04 (s, 1 H), 7.10-7.34 (m, 4 H), 7.41-7.55 (m, 3 H), 7.71-7.84 (m, 2 H), 7.92-8.11 (m, 2 H), 8.20-8.26 (m, 1 H), 8.50-8.59 (m, 1 H), 9.83 (brs, 1 H).

N-[*cis*-4-(2-chloro-quinolin-4-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride;

ESI MS *m/e* 495, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.72-2.37 (m, 8 H), 3.64-3.84 (m, 1 H), 4.36 (brs, 1 H), 6.33 (brs, 1 H), 7.05-7.60 (m, 8 H), 8.06-8.66 (m, 6 H).

Example 3116**3,4-Difluoro-*N*-[*cis*-4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride****Step A: Synthesis of 2-chloro-quinolin-4-ol.**

- 5 A mixture of 2,4-dichloro-quinoline obtained in step A of example 3114 (3.00 g, 15.1 mmol) and MeOH (485 mg, 15.1 mmol) in butanol (3 mL) was stirred at reflux for 3 hr. The reaction mixture was suspended in CHCl₃ (15 mL) and stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with CHCl₃, and dried at 50 °C under reduced pressure to give 2-chloro-quinolin-4-ol (1.47 g, 54%) as a pale yellow solid.
- 10 ESI MS *m/e* 179, M⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 6.83 (s, 1 H), 7.27-7.43 (m, 2 H), 7.60-7.67 (m, 1 H), 7.86 (d, *J* = 7.9 Hz, 1 H), 12.05 (brs, 1 H).

Step B: Synthesis of 2-chloro-4-methoxy-quinoline.

- To a solution of 2-chloro-quinolin-4-ol (500 mg, 2.78 mmol) in DMF (5 mL) were added
- 15 K₂CO₃ (462 mg, 3.37 mmol) and MeI (210 μL, 3.37 mmol). The mixture was stirred at 50°C for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% EtOAc in hexane) to give 2-chloro-4-methoxy-quinoline (440 mg, 82%) as a white solid.
- 20 ESI MS *m/e* 194, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.71 (s, 3 H), 6.89 (s, 1 H), 7.27-7.43 (m, 2 H), 7.60-7.69 (m, 1 H), 8.01 (d, *J* = 8.1 Hz, 1 H).

Step C: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

- 25 A mixture of 2-chloro-4-methoxy-quinoline (250 mg, 1.29 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (361 mg, 1.42 mmol) in butanol (1 mL) was stirred at 130 °C for 5 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three

times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL).

The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was

5 suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et_2O , and dried at 80 °C under reduced pressure to give *cis*-3,4-difluoro-*N*-[4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (79 mg, 14%) as a white solid.

ESI MS m/e 434, M (free) + Na^+ ; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 1.58-2.09 (m, 8 H), 3.55-3.72 (m, 10 4 H), 3.88-4.06 (m, 1 H), 5.93 (s, 1 H), 7.03-8.09 (m, 7 H), 8.25-8.45 (m, 2 H).

Example 3117

N-[*cis*-4-(4-Chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

15

Step A: Synthesis of *N*-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3115, the title compound was obtained.

N-[*cis*-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride;

20 ESI MS m/e 416, M (free) + H^+ ; ^1H NMR (300 MHz, CDCl_3) δ 1.82-2.22 (m, 8 H), 3.93-4.28 (m, 2 H), 6.65-6.77 (m, 1 H), 7.08 (s, 1 H), 7.14-7.29 (m, 1 H), 7.48-7.64 (m, 2 H), 7.68-7.88 (m, 3 H), 8.09 (d, J = 8.1 Hz, 1 H), 9.82-9.90 (m, 1 H).

N-[*cis*-4-(2-chloro-quinolin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride;

ESI MS m/e 438, M (free) + Na^+ ; ^1H NMR (300 MHz, CDCl_3) δ 1.72-2.37 (m, 8 H), 3.76-3.95 (m, 25 1 H), 4.49-4.65 (m, 1 H), 6.37 (brs, 1 H), 6.94-7.12 (m, 1 H), 7.18-7.33 (m, 1 H), 7.39-7.55 (m, 1 H), 7.60-7.76 (m, 1 H), 7.85-7.95 (m, 1 H), 8.06-8.20 (m, 2 H), 8.46-8.58 (m, 1 H), 8.70-8.87 (m, 1 H).

Example 3118***N*-[*cis*-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride****5 Step A: Synthesis of [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.**

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine obtained in step B of example 3114 (23.6 g, 114 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (36.0 g, 137 mmol) in butanol (31 mL) was stirred at reflux for 14 days. The
10 reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 14% to 66% EtOAc in hexane) to give [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 39%) as a pale yellow solid.

15 ESI MS *m/e* 433, M (free) + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.12-1.97 (m, 9 H), 2.94 (s, 6 H), 3.13 (t, *J* = 6.4 Hz, 2 H), 4.06-4.26 (m, 1 H), 4.62-4.94 (m, 2 H), 5.11 (s, 2 H), 6.04 (s, 1 H), 7.14 (ddd, *J* = 8.4, 7.0, 1.3 Hz, 1 H), 7.29-7.40 (m, 5 H), 7.45 (ddd, *J* = 8.4, 6.8, 1.5 Hz, 1 H), 7.57-7.64 (m, 1 H), 7.84 (dd, *J* = 8.4, 1.3 Hz, 1 H).

20 Step B: Synthesis of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine.

To a solution of [*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 44.6 mmol) in MeOH (200 mL) was added 5% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue in
25 methanol (200 mL) was 10% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 day. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 5% to 14% 7 M NH₃/MeOH in CHCl₃) to give *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine (12.7 g, 95%) as a

pale yellow solid.

FAB MS m/e 299, $M^+ + H^+$; 1H NMR (200 MHz, $CDCl_3$) δ 1.08-1.99 (m, 11 H), 2.60 (d, $J = 6.2$ Hz, 2 H), 2.94 (s, 6 H), 4.04-4.22 (m, 1 H), 4.77-4.93 (m, 1 H), 6.06 (s, 1 H), 7.14 (ddd, $J = 8.4, 7.0, 1.3$ Hz, 1 H), 7.45 (ddd, $J = 8.4, 6.8, 1.5$ Hz, 1 H), 7.61 (s, 1 H), 7.84 (dd, $J = 8.4, 1.3$ Hz, 1 H).

5

Step C: Synthesis of *N*-[*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of 2-Phenoxy-nicotinic acid (190 mg, 1.20 mmol) and *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinoline-2,4-diamine (300 mg, 1.00 mmol) in DMF (3 mL) were added Et₃N (0.33 mL, 2.40 mmol), HOBt-H₂O (230 mg, 1.50 mmol), and EDC-HCl (230 g, 1.20 mmol). The reaction mixture was stirred at ambient temperature for 20 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride (164 mg, 31%) as a white solid.

ESI MS m/e 496, M (free) + H^+

Example 3119

***N*-[*cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide hydrochloride**

Step A: Synthesis of 2-chloro-4-dimethylamino-5-methylpyrimidine.

To the solution of 2,4-dichloro-5-methylpyrimidine (20.0 g, 123 mmol) in THF (200 mL) was added 50% aqueous Me_2NH (13.3 g, 143 mol) and the mixture was stirred at ambient temperature for 5 days. To the reaction was added saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified flash chromatography (NH-silica gel, 2% EtOAc in hexane) to give 2-chloro-4-dimethylamino-5-methylpyrimidine (19.9 g, 94 %) as a white solid and 4-chloro-2-dimethylamino-5-methylpyrimidine (1.53 g, 7%) as a white solid.

2-chloro-4-dimethylamino-5-methylpyrimidine;

ESI MS m/e 172, $\text{M} + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 2.27 (s, 3 H), 3.15 (s, 6 H), 7.82 (s, 1 H).

4-chloro-2-dimethylamino-5-methylpyrimidine;

ESI MS m/e 194, $\text{M} + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 2.14 (s, 3 H), 3.15 (s, 6 H), 8.06 (s, 1 H).

Step B: Synthesis of [*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

A mixture of 2-chloro-4-dimethylamino-5-methylpyrimidine (7.00 g, 40.8 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (9.61 g, 44.8 mmol) in butanol (7 mL) was stirred at 130 °C for 26 hr. The reaction mixture was poured into saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 3% to 50% EtOAc in hexane) to give [*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid *tert*-butyl ester (5.90 g, 42%) as a colorless oil.

ESI MS m/e 350, $\text{M} + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.40-1.84 (m, 17 H), 2.14 (d, $J = 0.8$ Hz, 3 H), 3.02 (s, 6 H), 3.53-3.71 (m, 1 H), 3.85-3.99 (m, 1 H), 4.51-4.64 (m, 1 H), 4.68-4.78 (m, 1 H), 7.66 (s, 1 H).

Step C: Synthesis of N^2 -(*cis*-4-amino-cyclohexyl)-5, N^4 , N^4 -trimethyl-pyrimidine-2,4-diamine.

A solution of [*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-

carbamic acid *tert*-butyl ester (5.71 g, 16.3 mmol) in EtOAc (60 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (120 mL) was added. The mixture was stirred at ambient temperature for 1.5 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over 5 MgSO₄, filtered, concentrated, and dried under reduced pressure to give *N*²-(*cis*-4-amino-cyclohexyl)-5,*N*⁴,*N*⁴-trimethyl-pyrimidine-2,4-diamine (3.99 g, 98%) as a pale yellow oil. ESI MS *m/e* 250, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.39-1.91 (m, 8 H), 2.12 (s, 3 H), 2.79-2.97 (m, 1 H), 3.00 (s, 6 H), 3.86-4.05 (m, 1 H), 4.71-4.92 (m, 1 H), 7.66 (s, 1 H).

10 **Step D: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.**

To a solution of *N*²-(*cis*-4-amino-cyclohexyl)-5,*N*⁴,*N*⁴-trimethyl-pyrimidine-2,4-diamine (200 mg, 0.80 mmol) in CHCl₃ (4 mL) were added Et₃N (0.25 mL, 1.79 mmol) and 1,3-difluoro-benzoyl chloride (156 mg, 0.88 mmol). The mixture was stirred at ambient temperature 15 for 22 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 3% MeOH in CHCl₃). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient 20 temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (56 mg, 16%) as a white solid. 25 ESI MS *m/e* 412, *M*(free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-1.99 (m, 8 H), 2.26 (s, 3 H), 3.30 (s, 6 H), 4.02-4.25 (m, 2 H), 6.65-6.74 (m, 1 H), 7.13-7.26 (m, 2 H), 7.53-7.62 (m, 1 H), 7.67-7.79 (m, 1 H), 8.55-8.65 (m, 1 H).

Example 3120

N-[*cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

5

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step D of example 3119, the title compound was obtained.

ESI MS *m/e* 447, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-1.97 (m, 8 H), 2.23 (s, 3 H), 3.28
10 (s, 6 H), 4.01-4.21 (m, 2 H), 7.13 (dd, *J* = 7.6, 4.8 Hz, 1 H), 7.19-7.32 (m, 4 H), 7.42-7.52 (m, 2 H),
7.86-7.95 (m, 1 H), 8.21 (dd, *J* = 4.8, 2.0 Hz, 1 H), 8.39-8.48 (m, 1 H), 8.53 (dd, *J* = 7.6, 2.0 Hz, 1
H).

15 **Example 3121**

N-[*cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methyl-benzamide
hydrochloride

**Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-
20 3-methyl-benzamide hydrochloride.**

Using the procedure for the step D of example 3119, the title compound was obtained.

ESI MS *m/e* 390, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.01 (m, 8 H), 2.25 (s, 3 H),
2.41 (s, 3 H), 3.30 (s, 6 H), 4.04-4.22 (m, 2 H), 6.41-6.52 (m, 1 H), 7.19-7.34 (m, 3 H), 7.56-7.66 (m,
2 H), 8.53-8.63 (m, 1 H), 13.04 (s, 1 H).

25

Example 3122

N-[*cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methoxy-benzamide

hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methoxy-benzamide hydrochloride.

- 5 Using the procedure for the step D of example 3119, the title compound was obtained.
- ESI MS *m/e* 406, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-1.99 (m, 8 H), 2.25 (s, 3 H), 3.30 (s, 6 H), 3.86 (s, 3 H), 4.06-4.23 (m, 2 H), 6.72-6.81 (m, 1 H), 6.98-7.05 (m, 1 H), 7.20-7.43 (m, 4 H), 8.47-8.57 (m, 1 H).

10

Example 3123

***N*-[*cis*-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride**

- 15 **Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride.**

- To a solution of 4-fluoro-phenol (317 mg, 2.83 mmol) in DMA (4 mL) was added 60% NaH in oil (226 mg, 5.56 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-*N*-[*cis*-4-(dimethylamino-methyl-pyrimidin-2-ylamino)-cyclohexyl]-
- 20 nicotinamide (1.10 g, 2.83 mmol) in DMA (3 mL). The mixture was stirred at 120 °C for 2 hr and the reaction was quenched with water (60 mL). The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride
- 25 in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-

(4-fluoro-phenoxy)-nicotinamide hydrochloride (154 mg, 11%) as a white solid.

ESI MS m/e 487, $M(\text{free}) + \text{Na}^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.61-2.02 (m, 8 H), 2.24 (s, 3 H), 3.28 (s, 6 H), 4.03-4.25 (m, 2 H), 7.06-7.33 (m, 6 H), 7.79-7.91 (m, 1 H), 8.16-8.23 (m, 1 H), 8.46-8.59 (m, 2 H).

5

Example 3124

2-(2-Bromo-phenoxy)-*N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

10

Step A: Synthesis of 2-(2-bromo-phenoxy)-*N*-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3123, the title compound was obtained.

ESI MS m/e 547, $M(\text{free}) + \text{Na}^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.72-2.02 (m, 8 H), 2.23 (s, 3 H), 3.28 (s, 6 H), 3.97-4.27 (m, 2 H), 7.09-7.48 (m, 5 H), 7.66 (dd, $J=7.9, 1.3$ Hz, 1 H), 7.84-7.95 (m, 1 H), 8.13-8.19 (m, 1 H), 8.31-8.43 (m, 1 H), 8.53 (dd, $J=7.4, 2.2$ Hz, 1 H), 13.32 (s, 1 H).

Example 3125

1-(2,3-Dichloro-phenyl)-3-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-5,*N*⁴,*N*⁴-trimethyl-pyrimidine-2,4-diamine.

A mixture of 2-chloro-4-dimethylamino-5-methylpyrimidine obtained in step A of example 3119 (3.00 g, 17.4 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (5.48 g, 20.9 mmol) in butanol (3 mL) was stirred at reflux for 70 hr. The reaction mixture was poured into saturated aqueous NaHCO_3 and the aqueous layer was extracted

with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (30 mL) was added 10% Pd/C (600 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was

5 filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% MeOH in CHCl_3) to give N^2 -(*cis*-4-aminomethyl-cyclohexyl)-5, N^4 , N^4 -trimethyl-pyrimidine-2,4-diamine (1.03 g, 22%) as a pale yellow solid.

ESI MS m/e 264, $M(\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 1.15-1.89 (m, 11 H), 2.13 (s, 3 H), 2.59 (d, $J = 6.4$ Hz, 2 H), 3.02 (s, 6 H), 4.03-4.13 (m, 1 H), 4.77-4.85 (m, 1 H), 7.67 (s, 1 H).

10

Step B: Synthesis of 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of N^2 -(*cis*-4-aminomethyl-cyclohexyl)-5, N^4 , N^4 -trimethyl-pyrimidine-2,4-diamine (300 mg, 1.14 mmol) in DMSO (3 mL) was added

15 1,2-dichloro-3-isocyanato-benzene (236 mg, 1.25 mmol). The mixture was stirred at ambient temperature for 16 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 3% MeOH in CHCl_3) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture

20 was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et_2O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et_2O , and dried at 60 °C under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[*cis*-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (326 mg, 59%) as a white solid.

25 ESI MS m/e 473, $M(\text{free}) + \text{Na}^+$; ^1H NMR (200 MHz, CDCl_3) δ 1.45-1.99 (m, 9 H), 2.24 (s, 3 H), 3.30 (s, 6 H), 3.32-3.43 (m, 2 H), 4.22-4.38 (m, 2 H), 6.85-7.15 (m, 3 H), 7.22 (brs, 1 H), 8.14-8.26 (m, 2 H), 8.49-8.62 (m, 1 H), 12.14 (s, 1 H).

Example 3126

N-[*cis*-4-(4-Dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

5

Step A: Synthesis of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine.

To the solution of 2,4-dichloro-6-methylpyrimidine (20.0 g, 123 mmol) in THF (200 mL) was added 50% aqueous Me₂NH (13.3 g, 147 mmol) and the mixture was stirred at ambient temperature for 24 hr. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (NH-silica gel, 5% to 16% EtOAc in hexane) to give (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (14.4 g, 68 %) as a pale yellow solid and (4-chloro-6-methyl-pyrimidin-2-yl)-dimethyl-amine (6.57 g, 31%) as a pale yellow solid.

(2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine;

15 ESI MS m/e 194, M⁺ + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.34 (s, 3 H), 3.10 (s, 6 H), 6.16 (s, 1 H).

(4-chloro-6-methyl-pyrimidin-2-yl)-dimethyl-amine;

CI MS m/e 172, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.29 (s, 3 H), 3.16 (s, 6 H), 6.34 (s, 1 H).

20 **Step B: Synthesis of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.**

A mixture of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (300 mg, 1.75 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 3032 (598 mg, 1.92 mmol) in butanol (1 mL) was stirred at 130 °C for 40 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was

suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et₂O, and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (549 mg, 65%) as a white solid.

- 5 ESI MS *m/e* 447, *M*(free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.05 (m, 8 H), 2.34 (s, 3 H), 3.12 (s, 3 H), 3.23 (s, 3 H), 4.03-4.22 (m, 2 H), 5.71 (s, 1 H), 7.13 (dd, *J* = 7.5, 4.8 Hz, 1 H), 7.21-7.32 (m, 3 H), 7.41-7.51 (m, 2 H), 7.84-7.95 (m, 1 H), 8.21 (dd, *J* = 4.7, 2.1 Hz, 1 H), 8.45-8.57 (m, 2 H), 13.43 (brs, 1 H).

10

Example 3127

N-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

- 15 **Step A: Synthesis of *N*²-(*cis*-4-amino-cyclohexyl)-6,*N*⁴,*N*⁴-trimethyl-pyrimidine-2,4-diamine.**

- A mixture of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (6.00 g, 35.0 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (8.30 g, 38.5 mmol) in butanol (6 mL) was stirred at 130 °C for 48 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The
- 20 combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 16% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (60 mL) was added 4 M hydrogen chloride in EtOAc (60 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined
- 25 organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 10% MeOH in CHCl₃) to give *N*²-(*cis*-4-amino-cyclohexyl)-6,*N*⁴,*N*⁴-trimethyl-pyrimidine-2,4-diamine (2.29 g, 26%) as a pale yellow oil.

ESI MS m/e 250, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.18-1.50 (m, 4 H), 1.58-1.93 (m, 6 H), 2.19 (s, 3 H), 2.76-2.87 (m, 1 H), 3.03 (s, 6 H), 3.96-4.06 (m, 1 H), 4.78-4.89 (m, 1 H), 5.67 (s, 1 H).

Step B: Synthesis of *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-

5 3,4-difluoro-benzamide hydrochloride

To a solution of *N*²-(*cis*-4-amino-cyclohexyl)-6,*N'*,*N'*-trimethyl-pyrimidine-2,4-diamine (300 mg, 1.20 mmol) in $CHCl_3$ (2 mL) were added *i*-Pr₂NEt (0.44 mL, 2.52 mmol) and 3,4-difluoro-benzoyl chloride (233 mg, 1.32 mmol) in $CHCl_3$ (1 mL). The mixture was stirred at ambient temperature for 15 hr. The reaction was quenched with saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (359 mg, 70%) as a white solid.

ESI MS m/e 390, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.64-2.00 (m, 8 H), 2.35 (d, $J = 0.6$ Hz, 3 H), 3.14 (s, 3 H), 3.26 (s, 3 H), 4.03-4.29 (m, 2 H), 5.74 (d, $J = 0.7$ Hz, 1 H), 6.61-6.72 (m, 1 H), 7.14-7.26 (m, 1 H), 7.53-7.62 (m, 1 H), 7.67-7.78 (m, 1 H), 8.59 (d, $J = 7.8$ Hz, 1 H).

Example 3128

25 3-Chloro-*N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-*N*-[*cis*-4-(4-dimethylamino-6-methyl-pyrimidin-

2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3127, the title compound was obtained.

ESI MS m/e 410, $M(\text{free}) + \text{Na}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.67-2.00 (m, 8 H), 2.35 (s, 3 H), 3.13 (s, 3 H), 3.25 (s, 3 H), 4.04-4.26 (m, 2 H), 5.75 (s, 1 H), 6.53 (d, $J = 8.6$ Hz, 1 H), 7.32-7.48 (m, 2 H), 7.64-7.70 (m, 1 H), 7.83 (t, $J = 1.9$ Hz, 1 H), 8.60 (d, $J = 7.9$ Hz, 1 H), 13.11 (brs, 1 H).

Example 3129***N*-[*cis*-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide****10 hydrochloride****Step A: Synthesis of (2-chloro-pyrimidin-4-yl)-dimethyl-amine.**

To a solution of 2,4-dichloro-pyrimidine (15.0 g, 10.15 mmol) in THF (150 mL) was added 50% aqueous MeNH_2 (22.7 g, 25.2 mmol). The mixture was stirred at ambient temperature for 2 hr.

15 The solution was poured into saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-dimethyl-amine (8.66 g, 55%) as a white solid and (4-chloro-pyrimidin-2-yl)-dimethyl-amine (0.87 g, 6%) as a white solid.

20 (2-chloro-pyrimidin-4-yl)-dimethyl-amine;

CI MS m/e 158, $M + \text{H}^+$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.12 (s, 6 H), 6.32 (d, $J = 6.1$ Hz, 1 H), 8.00 (d, $J = 6.1$ Hz, 1 H).

(4-chloro-pyrimidin-2-yl)-dimethyl-amine;

ESI MS m/e 157, M^+ ; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.21 (s, 6 H), 6.50 (d, $J = 5.1$ Hz, 1 H), 8.18 (d, 25 $J = 5.1$ Hz, 1 H).

Step B: Synthesis of [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid

***tert*-butyl ester.**

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine (1.50 g, 9.52 mmol) and (*cis*-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 3031 (2.24 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130 °C for 22 hr in a sealed tube. The reaction mixture was
 5 poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane) to give [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (1.34 g, 42%) as a white solid.

10 ESI MS *m/e* 358, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9 H), 1.48 (s, 8 H), 3.03 (s, 6 H), 3.61 (brs, 1 H), 3.89-4.04 (m, 1 H), 4.47-4.63 (m, 1 H), 4.77-4.89 (m, 1 H), 5.80 (d, *J* = 6.1 Hz, 1 H), 7.84 (d, *J* = 6.1 Hz, 1 H).

Step C: Synthesis of *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine.

15 To a solution of [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (1.26 g, 3.76 mmol) in EtOAc (15 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was alkalized with 1 M aqueous NaOH. The aqueous layer was extracted with CHCl₃ (six times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give
 20 *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine (923 mg, quant.) as a pale yellow oil.

ESI MS *m/e* 250, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29-1.51 (m, 2 H), 1.61-1.91 (m, 6 H), 2.80-2.92 (m, 1 H), 3.03 (s, 6 H), 3.96-4.04 (m, 1 H), 4.85-4.98 (m, 1 H), 5.79 (d, *J* = 6.1 Hz, 1 H), 7.84 (d, *J* = 6.1 Hz, 1 H).

25

Step D: Synthesis of *N*-[*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of *N*²-(*cis*-4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine (300

mg, 1.20 mmol) in CHCl_3 (3 mL) were added Et_3N (0.35 mL, 2.51 mmol) and 2-phenoxy-nicotinoyl chloride (309 mg, 1.32 mmol). The mixture was stirred at ambient temperature for 22 hr. The reaction was quenched with saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and
5 purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 3% MeOH in CHCl_3). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et_2O , and dried
10 at 80 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (150 mg, 26%) as a white solid.
ESI MS *m/e* 433, *M*(free) + H^+

15 Example 3130

3,4-Difluoro-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride.

20

A mixture of 2-chloro-4-trifluoromethyl-pyrimidine (200 mg, 1.09 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (306 mg, 1.20 mmol) in butanol (1 mL) was stirred at 130 °C for 12 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three
25 times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was

suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give 3,4-difluoro-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride (123 mg, 26%) as a white solid.

5 ESI MS m/e 423, M⁺ (free) + Na⁺

Example 3131

3,4-Difluoro-*N*-[*cis*-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

10

Step A: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 385, M (free) + Na⁺

15

Example 3132

***N*-[*cis*-4-(4,6-Dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride**

20

Step A: Synthesis of *N*-[*cis*-4-(4,6-dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 415, M (free) + Na⁺

25

Example 3133

2-Phenoxy-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide

hydrochloride

Step A: Synthesis of 2-phenoxy-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide hydrochloride.

- 5 A mixture of 2-chloro-4-trifluoromethyl-pyrimidine (200 mg, 1.10 mmol) and *N*-(*cis*-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 3032 (375 mg, 1.20 mmol) in butanol (1 mL) was stirred at 130 °C for 3 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by
- 10 medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60 °C under reduced
- 15 pressure to give 2-phenoxy-*N*-[*cis*-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide hydrochloride (111 mg, 21%) as a white solid.

ESI MS *m/e* 480, M(free) + Na⁺

20 **Example 3134**

***N*-[*cis*-4-(4-Methoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

- Step A: Synthesis of *N*-[*cis*-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-**
- 25 **nicotinamide hydrochloride.**

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS *m/e* 442, M(free) + Na⁺

Example 3135

***N*-[*cis*-4-(4,6-Dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

5

Step A: Synthesis of *N*-[*cis*-4-(4,6-dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS *m/e* 472, M (free) + Na⁺

10

Example 3136

***N*-[*cis*-4-(4-Dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

15 **Step A: Synthesis of (5-bromo-2-chloro-pyrimidin-4-yl)-dimethyl-amine.**

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS *m/e* 236, M + H⁺

Step B: Synthesis of (2-chloro-5-phenyl-pyrimidin-4-yl)-dimethyl-amine.

20 To a solution of (5-bromo-2-chloro-pyrimidin-4-yl)-dimethyl-amine (2.00 g, 8.46 mmol) in toluene (30 mL) were added 2 M aqueous K₂CO₃ (15 mL), phenylboronic acid (1.03 g, 8.45mmol), and tetrakis-(triphenylphosphine)-palladium (977 mg, 0.845 mmol). The reaction mixture was stirred at reflux for 8 hr. The mixture was poured into water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified

25 by flash chromatography (NH-silica gel, 3% EtOAc in hexane) to give (2-chloro-5-phenyl-pyrimidin-4-yl)-dimethyl-amine (1.44 g, 73%).

ESI MS *m/e* 256, M + Na⁺

Step C: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 531, M (free) + Na⁺

5

Example 3137

***N*-[*cis*-4-(5-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

10 Step A: Synthesis of (2,5-dichloro-pyrimidin-4-yl)-dimethyl-amine.

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS m/e 191, M⁺

15 Step B: Synthesis of *N*-[*cis*-4-(5-chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 467, M (free) + H⁺

Example 3138

20 *N*-[*cis*-4-(4-Dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

25 Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 474, M (free) + Na⁺

Example 3139

***N*-[*cis*-4-(5-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride**

- 5 **Step A: Synthesis of *N*-[*cis*-4-(5-chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.**

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 432, $M(\text{free}) + \text{Na}^+$

10

Example 3140

***N*-[*cis*-4-(4-Dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

- 15 **Step A: Synthesis of (2-chloro-5-fluoro-pyrimidin-4-yl)-dimethyl-amine.**

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS m/e 176, $M + \text{H}^+$

- 20 **Step B: Synthesis of *N*-[*cis*-4-(4-dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.**

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 451, $M(\text{free}) + \text{H}^+$

- 25 **Example 3141**

***N*-[*cis*-4-(5-Bromo-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

Step A: Synthesis of *N*-[*cis*-4-(5-bromo-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS *m/e* 533, M (free) + Na⁺

5

Example 3142

***N*-[*cis*-4-(4,6-Dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride**

10

Step A: Synthesis of *N*-[*cis*-4-(4,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS *m/e* 383, M (free) + Na⁺

15

Example 3143

***N*-[*cis*-4-(4,6-Dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride**

20

Step A: Synthesis of *N*-[*cis*-4-(4,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS *m/e* 440, M (free) + Na⁺

25

Example 3144

3,4-Difluoro-*N*-[*cis*-4-(pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-*N*-[*cis*-4-(pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

5 ESI MS *m/e* 355, *M* (free) + Na⁺

Example 3145

***N*-[*cis*-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide**
10 **hydrochloride**

Step A: Synthesis of [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step A of example 3129
15 (1.50 g, 9.52 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (2.75 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130 °C for 22 hr in a sealed tube.

The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in
20 hexane to EtOAc) to give [*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (816 mg, 22%) as a pale yellow oil.

ESI MS *m/e* 406, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.22-1.92 (m, 9 H), 3.03 (s, 6 H), 3.11 (t, *J* = 6.2 Hz, 2 H), 4.02-4.15 (m, 1 H), 4.82-4.93 (m, 2 H), 5.10 (s, 2 H), 5.79 (d, *J* = 6.1 Hz, 1 H), 7.28-7.42 (m, 5 H), 7.83 (d, *J* = 6.1 Hz, 1 H).

25

Step B: Synthesis of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine.

Using the procedure for the step B of example 3118, the title compound was obtained.

ESI MS m/e 250, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 1.40-1.88 (m, 9 H), 2.87 (d, $J = 5.9$ Hz, 2 H), 3.03 (s, 6 H), 4.11 (brs, 1 H), 5.63 (brs, 1 H), 5.78 (d, $J = 6.2$ Hz, 1 H), 7.08 (brs, 2 H), 7.82 (d, $J = 6.2$ Hz, 1 H).

5 **Step C: Synthesis of *N*-[*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.**

To a solution of *N*²-(*cis*-4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-pyrimidine-2,4-diamine (400 mg, 1.60 mmol) in $CHCl_3$ (2 mL) were added *i*-Pr₂NEt (0.56 mL, 3.36 mmol) and 2-phenoxy-nicotinoyl chloride (523 mg, 2.24 mmol) in $CHCl_3$ (2 mL). The mixture was stirred at
10 ambient temperature for 5 hr. The reaction was quenched with saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at
15 ambient temperature for 1 hr and concentrated. The residue was suspended in Et_2O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et_2O , and dried at 60 °C under reduced pressure to give *N*-[*cis*-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride (199 mg, 26%) as a white solid.

20 ESI MS m/e 469, M (free) + Na^+

Example 3146

3-Hydroxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

25

Step A: Synthesis of 3-hydroxy-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 362, M (free) + H^+ ; 1H NMR (300 MHz, DMSO- d_6) δ 1.60-2.09 (m, 8 H), 3.83-4.02 (m, 1 H), 4.22-4.49 (m, 1 H), 6.79-7.02 (m, 1 H), 7.12-7.59 (m, 5 H), 7.67-8.45 (m, 5 H), 9.40-9.78 (m, 2 H), 12.91-13.17 (m, 1 H).

5

Example 3147

N-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 404, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.54-2.12 (m, 8 H), 3.89-4.31 (m, 5 H), 6.89-7.05 (m, 2 H), 7.41-7.58 (m, 2 H), 7.68-7.82 (m, 3 H), 8.00-8.22 (m, 3 H), 8.46-8.51 (m, 1 H), 9.66-9.85 (m, 1 H).

15

Example 3148

N-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride

20

Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 482, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 1.75-2.27 (m, 8 H), 4.00-4.32 (m, 2 H), 6.97 (d, J = 9.4 Hz, 1 H), 7.42-7.65 (m, 2 H), 7.69-7.80 (m, 3 H), 7.96-8.02 (m, 1 H), 8.20 (d, J = 9.3 Hz, 1 H), 8.35-8.42 (m, 2 H), 9.69-9.79 (m, 1 H).

25

Example 3149***N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride**

Step A: Synthesis of *N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-

5 benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS *m/e* 430, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.33 (m, 8 H), 3.96-4.29 (m, 2 H), 6.88-7.03 (m, 2 H), 7.29-7.51 (m, 3 H), 7.69-7.82 (m, 5 H), 8.19 (d, *J* = 9.5 Hz, 1 H), 9.73-9.86 (m, 1 H).

10

Example 3150***N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid**

15 Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester.

To a solution of isophthalic acid monomethyl ester (435 mg) and *cis*-*N*-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (500 mg) in DMF (5 mL) were added Et₃N (0.96 mL), HOBT-H₂O (476 mg), and EDC-HCl (437 mg). The reaction mixture was stirred at
20 ambient temperature for 18 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane) to give *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (740 mg) as a white solid.

25 ESI MS *m/e* 404, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-2.05 (m, 8 H), 3.96 (s, 3 H), 4.10-4.28 (m, 2 H), 4.80-4.90 (m, 1 H), 6.16-6.26 (m, 1 H), 6.66 (d, *J* = 8.8 Hz, 1 H), 7.18-7.20 (m, 1 H), 7.49-7.68 (m, 4 H), 7.84 (d, *J* = 8.3 Hz, 1 H), 8.03-8.10 (m, 1 H), 8.15-8.22 (m, 1 H), 8.35-8.38 (m, 1 H).

Step B: Synthesis of *N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid.

To a solution of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (400 mg) in EtOH (12 mL) was added 2 M aqueous NaOH (0.52 mL). The reaction mixture was stirred at ambient temperature for 11 hr. To the reaction mixture was added 1 M aqueous HCl (0.6 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (silica gel, 1% to 5% MeOH in CHCl₃) to give a white solid. The suspension of above solid in Et₂O (20 mL) was stirred at ambient temperature for 1 hr and filtered to give *N*-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid (183 mg) as a white solid. ESI MS *m/e* 412, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.63-2.09 (m, 8 H), 3.84-4.18 (m, 2 H), 6.83-6.91 (m, 2 H), 7.07-7.17 (m, 1 H), 7.39-7.64 (m, 4 H), 7.83 (d, *J* = 9.0 Hz, 1 H), 8.03-8.13 (m, 2 H), 8.39-8.53 (m, 2 H).

15

Example 3151***C*-(Ethyl-phenyl-amino)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride**

Step A: Synthesis of *C*-(ethyl-phenyl-amino)-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

20

Using the procedure for the step A of example 3036, the title compound was obtained. ESI MS *m/e* 403, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.18-1.36 (m, 3 H), 1.54-2.15 (m, 8 H), 3.39-3.65 (m, 3 H), 3.68-4.11 (m, 3 H), 6.80-7.20 (m, 3 H), 7.29-7.86 (m, 8 H), 8.07-8.23 (m, 1 H), 9.48-9.68 (m, 1 H).

25

Example 3152**3,5-Difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride**

Step A: Synthesis of 3,5-Difluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

- 5 ESI MS *m/e* 404, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.71-2.02 (m, 8 H), 3.87-4.13 (m, 1 H), 4.24-4.53 (m, 1 H), 7.21-8.01 (m, 7 H), 8.18-8.60 (m, 3 H), 9.48-9.81 (m, 1 H), 13.09-13.28 (m, 1 H).

10 **Example 3153**

4-Chloro-3-fluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide- hydrochloride

Step A: Synthesis of 4-chloro-3-fluoro-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

- 15 Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 398, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.10 (m, 8 H), 3.97-4.27 (m, 2 H), 6.88-7.03 (m, 2 H), 7.39-7.50 (m, 2 H), 7.54-7.62 (m, 1 H), 7.66-7.83 (m, 4 H), 8.19 (d, *J* = 9.4 Hz, 1 H), 9.65-9.82 (m, 1 H).

20

Example 3154

***C*-[(4-Chloro-phenyl)-ethyl-amino]-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride**

- 25 **Step A: Synthesis of *C*-[(4-chloro-phenyl)-ethyl-amino]-*N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.**

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS *m/e* 459, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 0.99-1.19 (m, 3 H), 1.42-1.96 (m,

8 H), 3.30-3.55 (m, 2 H), 3.71-3.87 (m, 1 H), 3.94 (s, 2 H), 4.29-4.51 (m, 1 H), 6.57-6.77 (m, 2 H), 7.02-7.58 (m, 4 H), 7.65-8.04 (m, 3 H), 8.15-8.44 (m, 2 H), 9.61-9.85 (m, 1 H), 13.17-13.42 (m, 1 H).

5 Example 3155

N-[*cis*-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride

Step A: Synthesis of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride.

- 10 To a solution of *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamide acid obtained in step B of example 3150 (160 mg) in DMF (2 mL) were added 28% aqueous NH₃ (30 mg), Et₃N (0.14 mL), HOBt-H₂O (94 mg), and EDC-HCl (95 mg). The reaction mixture was stirred at ambient temperature for 16 hr. To the reaction mixture was added water (20 mL) and the aqueous layer extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered,
- 15 concentrated under reduced pressure, purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). The solution of above purified material in EtOH (3 mL) was added 4 M hydrogen chloride in EtOAc (0.3 mL). The mixture was stirred at ambient temperature for 2 hr, filtered, and dried under reduced pressure to give *N*-[*cis*-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride (9 mg) as a white solid.
- 20 ESI MS *m/e* 411, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.70-2.06 (m, 8 H), 3.89-4.08 (m, 1 H), 4.19-4.39 (m, 1 H), 7.17-7.60 (m, 4 H), 7.71-8.46 (m, 8 H), 12.84-12.97 (m, 1 H).

Example 3156

- 25 3,4-Difluoro-*N*-{*cis*-4-[(quinolin-2-ylmethyl)-amino]-cyclohexyl}-benzamide dihydrochloride

Step A: Synthesis of 3,4-difluoro-*N*-{*cis*-4-[(quinolin-2-ylmethyl)-amino]-